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ABSTRACT 
 
Hypertrophic cardiomyopathy (HCM) is an autosomal dominantly inherited primary cardiac disease. 
The primary features of HCM are left ventricular hypertrophy, myocardial disarray, fibrosis and an 
increased risk of sudden cardiac death. To date, more than 264 HCM-causing mutations, occurring in 
thirteen genes, have been identified. As the vast majority of HCM-causing mutations occur in 
components of the cardiac sarcomere, HCM has been considered a disease of the cardiac sarcomere. 
Functional analyses of HCM-causing mutations in sarcomeric protein-encoding genes revealed that 
HCM-causing mutations have a vast array of effects on contractile function. The discovery of HCM-
causing mutations in the gamma two subunit of adenosine monophosphate activated protein kinase 
highlighted the fact that mutations in non-sarcomeric proteins can also cause HCM and supports a 
hypothesis that HCM-causing mutations may result in energy wastage leading to energy depletion. 
 
Mutations in the cardiac myosin binding protein C (cMyBPC) gene (MYBPC3) are the second most 
prevalent cause of HCM. cMyBPC is a modular protein that forms an integral part of the sarcomeric 
thick filament, where it acts as a regulator of thick filament structure and cardiac contractility. 
Although cMyBPC has been studied extensively, the mechanisms through which it fulfill these 
functions have remained elusive, largely due to a lack of a comprehensive understanding of its 
interactions with other sarcomeric components and its quaternary structure.  
 
The aims of the present study were, firstly, to screen MYBPC3 for HCM-causing mutations in a 
panel of HCM-affected individuals and, secondly, to identify the ligands of domains of cMyBPC in 
which HCM-causing mutations were found. 
 iv
A panel of deoxyribonucleic acid (DNA) samples obtained from unrelated HCM-affected individuals 
was screened for HCM-causing mutations in MYBPC3, using polymerase chain reaction (PCR)-
based single-strand conformation polymorphism method, as well as restriction enzyme digestion, 
DNA sequencing and reverse transcription PCR techniques. In order to identify the ligands of 
domains in which HCM-causing mutations were found, yeast two-hybrid (Y2H) candidate-ligand- 
and library-assays were performed.  
 
Three novel and two previously described putative HCM-causing mutations were identified in 
MYBPC3. Data generated in this and other studies, however, suggest that two of these “mutations” 
are likely to be either polymorphisms, or disease-modifying factors, rather than main-locus HCM-
causing mutations. 
 
Recent findings showed a specific interaction between domains C5 and C8 of cMyBPC. This finding 
identified domains C6 or C10 as candidate ligands of domain C7. Y2H-assays revealed a specific 
C7:C10 interaction. Additional Y2H assays also identified C-zone titin as a ligand of domain C7 and 
domain C10 as a ligand of domain C3. Several other Y2H assays, however, yielded no known 
sarcomeric ligands of the N-terminal region of cMyBPC. 
 
Identification of the ligands of specific domains of cMyBPC led to the development of detailed 
models of cMyBPC quaternary structure when cMyBPC is both unphosphorylated and fully 
phosphorylated. The integration of these models into an existing model of thick filament quaternary 
structure allows new insights into the functioning of cMyBPC as a regulator of both thick filament 
structure and cardiac contractility, as well as the pathophysiology of cMyBPC-associated HCM. 
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OPSOMMING 
Hipertrofiese kardiomiopatie (HKM) is ‘n outsosomaal dominante primêre hartsiekte. Die primêre 
kenmerke van HKM is linker ventrikulêre hipertrofie, miokardiale wanorde, fibrose en ‘n verhoogde 
risiko van skielike dood. Tot dusver is 260 HKM-veroorsakende mutasies in 13 gene geïdentifiseer. 
Aangesien die oorgrote meerderheid van HKM-veroorsakende mutasies in komponente van die 
kardiale sarkomeer voorkom, is HKM as ‘n siekte van die kardiale sarkomeer beskryf. Funksionele 
analise van HKM-veroorsakende mutasies in sarkomeriese protein-koderende gene het aan die lig 
gebring dat hierdie mutasies ‘n wye spektrum van gevolge op kontraktiele funksie het. Die 
ontdekking van HKM-veroorsakende mutasies in die gamma-twee subeenheid van adenosien 
monofosfaat-geaktiveerde proteïen kinase het die feit dat mutasies nie-sarkomeriese proteïene ook 
HKM kan veroorsaak onderstreep en ondersteun ‘n hipotese dat HKM-veroorsakende mutasies 
energievermorsing en energie uitputting tot gevolg het. 
 
Mutasies in die kardiale miosien-bindingsproteïen C (kMiBPC) geen (MYBPC3) is die tweede mees 
algemene oorsaak van HKM. kMiBPC is ‘n modulêre protein wat ‘n integrale deel van die 
sarkomeriese dik filament vorm, waar dit die struktuur van die dik filament en kardiale kontraktiliteit 
reguleer. Nieteenstaande die feit dat kMiBPC intensief bestudeer is, word die meganismes hoe 
hierdie funksies vervul word swak verstaan, grotendeels weens die afwesigheid van ‘n in diepte 
begrip van sy interaksies met ander komponente van die sarkomeer asook sy kwaternêre struktuur. 
 
Die doelstellings van hierdie studie was, eerstens, om MYBPC3 vir HKM-veroorsakende mutasies in 
‘n paneel van HKM-geaffekteerde individue te deursoek en tweedens, om die ligande van domeine 
van kMiBPC waarin HKM-veroorsakende mutasies gevind is te identifiseer. 
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‘n Paneel van deoksiribonukleïensuur (DNS) monsters verkry van onverwante HKM-geaffekteerde 
individue is deursoek vir HKM-veroorsakende mutasies in MYBPC3, deur middel van die polimerase 
ketting-reaksie (PKR)-gebasseerde enkelstrand konformasie polimorfisme metode, sowel as 
restriksie ensiem vertering, DNS volgordebepaling en terugtranskripsie PKR tegnieke. Die ligande 
van domeine van kMiBPC waarin HKM-veroorsakende mutasies gevind is, is geïdentifiseer deur 
middel van gis twee-hibried (G2H) kandidaat-ligand en biblioteek-siftings eksperimente. 
 
Drie onbeskryfde en twee voorheen beskryfde vermeende HKM-veroorsakende mutasies in 
MYPBC3 is geïdentifiseer. Data gegenereer in hierdie en ander studies dui daarop dat twee van 
hierdie “mutasies” eerder polimorfismes, of siekte-modifiserende faktore, as hoof-lokus HKM-
veroorsakende mutasies is. 
 
Onlangse bevindings het ‘n spesifieke interaksie tussend die C5 en C8 domeine van kMiBPC getoon. 
Hierdie bevindings het óf domein C6, óf C10, as kandidaat-ligande van domein C7 geïdentifiseer. 
G2H eksperimente het ‘n spesifieke interaksie tussen domains C7 en C10 getoon. Addisionele G2H 
eksperimente het ook C-zone titin as ‘n ligand van domein C7 sowel as domein C10 as ‘n ligand van 
domein C3 geïdentifiseer. Verdere G2H eksperimente het egter geen sarkomeriese ligande van die 
N-terminale gedeelte van kMiBPC geïdentifiseer nie. 
 
Die identifikasie van ligande van spesifieke domeins van kMiBPC het gelei tot die ontwikkelling van 
‘n gedetaileerde model van kMiBPC kwaternêre struktuur wanneer kMiBPC beide ongefosforileerd 
en ten volle gefosforileerd is. Die intergrasie van hierdie modelle in bestaande modelle van dik 
filament kwaternêre struktuur werp nuwe lig op die funksionering van kMiBPC as ‘n reguleerder van 
beide dik filament struktuur en kardiale kontraktiliteit, sowel as die patofisiologie van kMiBPC-
geassosieerde HKM. 
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CHAPTER I: INTRODUCTION 
 
I.1. HYPERTROPHIC CARDIOMYOPATHY 
 
Hypertrophic cardiomyopathy (HCM) is a primary cardiac disease, which is inherited in an 
autosomal dominant fashion (Spirito et al., 1997). It has been estimated that this disease, which is the 
most prevalent cause of sudden death in apparently healthy young individuals (Fananapazir and 
Epstein, 1991), affects about one in five hundred people in the general population (Maron et al., 
1995; Seidman and Seidman, 2001). The primary features of HCM are left ventricular hypertrophy 
(LVH) in the absence of other aetiologies, myocardial disarray, fibrosis, diastolic dysfunction and an 
increased risk of both sudden cardiac death (SCD) and congestive heart failure (Fananapazir and 
Epstein, 1994; Davies and McKenna, 1995). 
 
As the symptoms with which patients suffering from HCM present, such as angina, dyspnoea, 
palpitations, presyncope and syncope, are characteristic of several diseases, a positive diagnosis of 
HCM can only be made following electrocardiographic (ECG) and echocardiographic evaluation, if 
LVH, in the absence of other aetiologies, is present (Fananapazir and Epstein, 1989; Fananapazir et 
al., 1989; Fananapazir and Epstein, 1991; Fananapazir et al., 1992; Maron and Fananapazir, 1992). 
Diagnosis of HCM is further confounded by the fact that HCM shows reduced penetrence, rendering 
asymptomatic mutation carriers clinically undiagnosable (Maron et al., 1984; Davies and McKenna, 
1995). Due to these difficulties in the clinical diagnosis of HCM, combined with the fact that 
clinically unaffected mutation carriers remain at risk of SCD (Watkins et al., 1995b; Moolman et al.,  
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1997; Moolman-Smook et al., 2000), molecular diagnosis of HCM may be advantageous, as it 
facilitates counselling and patient management. 
 
I.1.1. MOLECULAR GENETICS OF HCM 
 
To date, more than 264 different HCM-causing mutations, occurring in eleven different genes, have 
been identified (FHC Mutation Database, available at: 
http://morgan.angis.su.oz.au/Databases/Heart/heartbreak.html). The vast majority of these mutations 
occur in genes encoding components of the cardiac sarcomere, namely, the β-myosin heavy chain 
gene (MYH7) (Geisterfer-Lowrance et al., 1990), the cardiac troponin T gene (TNNT2) (Thierfelder 
et al., 1994), the α-tropomyosin gene (TPM1) (Thierfelder et al., 1994), the cardiac myosin binding 
protein C gene (MYBPC3) (Bonne et al., 1995; Watkins et al., 1995a), the myosin ventricular 
essential light chain 1 gene (MYL3) (Poetter et al., 1996), the myosin ventricular regulatory light 
chain 2 gene (MYL2) (Poetter et al., 1996), the cardiac troponin I gene (TNNI3) (Kimura et al., 
1997), the cardiac splicing isoform of the titin gene (TTN) (Satoh et al., 1999), the α-cardiac actin 
gene (ACTC) (Mogensen et al., 1999) the cardiac troponin C gene (TNNC1) (Hoffmann et al., 2001) 
and the α-myosin heavy chain gene (MYH6) (Niimura et al., 2002). The number and type of 
mutations, thus far identified in each of these genes, are summarised in table I.1. The identification 
of HCM-causing mutations in sarcomeric protein-encoding  genes led to the formation of a 
hypothesis that HCM is a disease of the cardiac sarcomere (Thierfelder et al., 1994; Watkins et al., 
1995c). Subsequently, however, HCM-causing mutations were also found in CSRP3, encoding 
muscle LIM protein (MLP) (Geier et al., 2003), and PRKAG2, encoding the γ2 subunit of 5’ 
adenosine monophosphate (AMP)-activated protein kinase (AMPK) (Blair et al., 2001; Gollob et al., 
2001; Arad et al., 2002).  
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TABLE I.1. Genes and mutations responsible for causing HCM, their loci and estimated frequency (adapted from Marian and Roberts, 2001) 
Protein Gene Locus Frequency # Mutations Mutation Type 
β-Myosin heavy chain MYH7 14q12 ~30% - ~40% 102 Mostly missense 
Cardiac myosin binding protein C MYBPC3 11p11.2 ~20% - ~42% 93 Mostly truncation, some missense 
Cardiac troponin T TNNT2 1q32 ~6% - ~20% 20 Mostly missense, some truncation 
α-Tropomyosin TPM1 15q22.1 ~5% 7 Missense mutations 
Cardiac troponin I TNNI3 19q13.2 ~5% - ~7% 14 Mostly missense 
Myosin ventricular essential light chain 1 MYL3 3p21.3-p21.2 <5% - ~7% 3 Missense mutations 
Myosin ventricular regulatory light chain 2 MYL2 12q23-q24.3 <5% 11 Mostly missense mutations 
Cardiac α-actin ACTC 11q <5% 4 Missense mutation 
Titin TTN 2q24.1 <5% 1 Missense mutation 
Cardiac troponin C TNNC1 3p21.3-3p14.3 <5% 1 Missense mutation 
α-Myosin heavy chain MYH6 14q12 <5% 1 Missense mutation 
5’ AMP-activated protein kinase PRKAG2 7q35-q36* <5% 4 Missense mutations 
Muscle LIM protein CSRP3 11p15.1* <5% 3 Missense mutations 
 
Frequency = percentage of cases of HCM caused by mutations in a particular gene (from Marian and Roberts, 2001 and Richard et al., 2003); * = 
human chromosomal location obtained from LocusLink available at: http://www.ncbi.nih.gov/LocusLink/list.cgi; # mutations = number of HCM-
causing mutations thus far identified. 
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I.1.1.1. Pathophysiology of HCM-causing mutations in sarcomeric protein-encoding genes 
 
With the exception of mutations in MYBPC3, the majority of HCM-causing mutations identified thus 
far are missense mutations or short in-frame deletions, resulting in the generation of mutant proteins 
that differ from the wild type protein by only one or a few amino acids (table I.1). Several studies 
have clearly shown that mutant proteins, generated by these mutations, are stably incorporated into 
the sarcomere, where they act as “poison peptides” resulting in a gain or loss of protein function 
(Seidman and Seidman, 2002) (table I.2 and references therein). Additionally, it was shown that 
truncated cardiac troponin T protein (cTNT), resulting from the TNNT2 splice donor site (SdS)+1 
g>a mutation (box 1) (Watkins et al., 1996), is also stably incorporated into the sarcomere and is, 
therefore, likely to act in a similar fashion (Watkins et al., 1996; Frey et al., 2000; Montgomery et 
al., 2001).  
 
The mechanisms involved in the disease pathogenesis of HCM-causing mutations resulting in the 
truncation of cardiac myosin binding protein C (cMyBPC), as a result of splice site, nonsense and 
frame-shift mutations in MYBPC3, is, however, controversial. As the majority of these cMyBPC 
truncation mutations result in the loss of the C-terminal region of the protein, essential for correct A-
band incorporation of cMyBPC into the sarcomere (sections I.7.3.1, I.7.3.2 and I.7.3.3), it was 
proposed that these mutations may result in haploinsufficiency, rather than act as “poison peptides” 
(Carrier et al., 1997; Rottbauer et al., 1997). This hypothesis is supported by findings that truncated 
cMyBPC was not detected by Western analyses in myocardial biopsies from HCM-affected 
individuals, carrying HCM-causing truncation mutations in MYBPC3 (Rottbauer et al., 1997; 
Moolman et al., 2000). Several studies have, however, shown that even though truncated cMyBPC is 
distributed more diffusely throughout the cardiomyocyte, truncated cMyBPC is incorporated into 
cardiac sarcomeres (Yang et al., 1998; Flavigny et al., 1999; Yang et al., 1999). Additionally, Harris 
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 9
et al., (2002) have shown that heterozygous MYBPC3 knockout mice do not display LVH, disarray, 
fibrosis or contractile dysfunction, while these features were all present in homozygous MYBPC3 
knockout mice. This finding suggests that the loss of a single MYBPC3 allele does not have any 
pathogenic effect and that other mechanisms may compensate for haploinsufficiency. In the light of 
these findings, it seems likely that mutations resulting in the truncation of cMyBPC also act as 
“poison peptides”, rather than acting through a mechanism of haploinsufficiency.  
 
In order to establish the pathological effect of “poison peptides”, resulting from HCM-causing 
mutations in sarcomeric protein-encoding genes, several in vitro, in situ and in vivo functional 
studies have been conducted. Phenotypicly the expression of these “poison peptides” in animal 
models generally caused disarray (at the sarcomeric, myocytic or myofibrillar levels), and fibrosis. 
However, LVH, arrhythmias and increased mortality were rare and often only induced following 
exercise (table I.2 and references therein). These findings indicate that disarray and fibrosis are in all 
likelihood the primary characteristics of HCM in humans, while LVH, the criterion that is generally 
used for clinical diagnosis, may be a secondary feature, caused by other cellular and physiological 
defects. 
 
Furthermore, these studies investigated the effect of mutant peptides on a wide array of physiological 
and contractile parameters, including intrinsic myosin adenosine triphosphosphatase (ATPase) 
activity, Ca2+-activated actomyosin ATPase activity, systolic function/contractility, diastolic 
function/relaxation, maximal Ca2+-activated force, sliding velocity and Ca2+-sensitivity of 
contraction. Surprisingly, it was shown that HCM-causing mutations, investigated in these studies, 
have a wide array of effects on the majority of these parameters, resulting in either hypo- or 
hypercontractility (table I.2 and references therein). The majority of these studies, however, found 
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that diastolic function was generally impaired, while Ca2+-sensitivity of contraction was enhanced 
(table I.2 and references therein). It can, therefore, be concluded that HCM-causing mutations in 
sarcomeric protein-encoding genes result in contraction at lower intracellular Ca2+ concentrations, 
which may in turn result in impaired relaxation and diastolic function.  
 
The mechanisms involved in this enhanced Ca2+-sensitivity of the contractile apparatus, resulting 
from the presence of HCM-causing mutations in nine different sarcomeric protein-encoding genes, 
remain elusive.  
 
I.1.1.2. Pathophysiology of HCM-causing mutations in non-sarcomeric protein encoding genes 
 
The discovery of HCM-causing mutations in CSRP3, encoding muscle LIM protein (MLP) (Geier et 
al., 2003), and PRKAG2, encoding the γ2 subunit of 5’ AMP-activated protein kinase (AMPK), 
(Blair et al., 2001; Gollob et al., 2001; Arad et al., 2002) has highlighted the fact that mutations in 
non-sarcomeric protein-encoding genes also cause HCM. Even though MLP is not classically 
regarded as a sarcomeric component, this protein plays an essential role in stabilising the interaction 
between the sarcomere and the cytoskeleton by binding to both α-actinin (sarcomeric), telethonin 
(sarcomeric) and βI-spectrin (cytoskeletal) (Arber et al., 1994; Arber et al., 1997; Flick and 
Konieczny, 2000; Knoll et al., 2002; Geier et al., 2003). It is, therefore, possible that mutations in 
this protein cause HCM by disrupting sarcomeric assembly and integrity, a mechanism proposed for 
the disease pathogenesis of HCM-causing mutations in titin and the light meromyosin (LMM) 
subfragment of myosin (Blair et al., 2002; Watkins, 2003). This view is supported by the finding that 
myofibrillar disarray and fibrosis, considered characteristic features of HCM-caused by sarcomeric 
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TABLE I.2. Functional analyses of HCM-causing mutations 
Mutation Type of study M ATPase AM ATPase Sys/C Dia/R Ca2+-sens Favg Vmax Phenotype Ref 
MHCR403Q In vivo  ― ― ↓ ↓ ↑ ― ↓ LVH, MH, ↑M, 
D, F, ECG, Arr 
1-6 
MHCR403Q In situ  ― ↓ ↓ ↓ ↑ ↓ ― D, F 7-9 
MHCR403Q In vitro  = ↑8,12/ ↓ ↓ ↓ ↑ ↓12/ ↓ ↑8/ ↓ ― 10-14 
MHCV606M In vitro  = = ― ― ― ― ↓ ― 13 
MHCR249Q In vitro  ↓ ↓ ― ― ― ― ↓ ― 13 
MHCR453C In vitro  ↓ ↓ ― ― ― ― ↓ ― 13 
MHCG716R In vitro  ― ↑ ― ― ― ― ↓ ― 14 
MHCR719Q In vitro  ― ↑ ― ― ― ― ↓ ― 14 
MHCR719W In vitro  ― ↑ ― ― ― ― ↓ ― 14 
MHCF513C In vitro  ― ↓ ― ― ― ― ↓ ― 14 
MHCG584R In vitro  ― ↑ ― ― ― ― ↓ ― 14 
cTNTR92Q In vivo  ― = ↑ / ↓17 ↓ ↑ ― ↓ F, D, ↓HW  15-17 
cTNTR92Q In situ  ― ― ― ― ― ― ↓ ― 18 
cTNTR92Q In vitro  ― = ― ― ↑ ― ― ― 19-20 
cTNTI79N In vitro  ― = ― ― ↑ / =18 ― ↑ ― 19-21 
cTNTF110I In vitro  ― ↑ ― ― = ― ― ― 19 
cTNTE244D In vitro  ― ↑ ― ― = ― ― ― 19 
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Mutation Type of study M ATPase AM ATPase Sys/C Dia/R Ca2+-sens Favg Vmax Phenotype Ref 
cTNTR278C In vitro ― = ― ― ↑ ― ― ― 19 
cTnTΔ In vivo  ― = ↓ ↓ ↑ ↓ ― F,D, ↑M, ↓HW, 
Arrei 
17, 
22-24 
αTMD175N In vivo  ― ― ↓ ↓ ↑ ― ― LVH, D, F 25 
cMyBPCΔC5-C10 In vivo/in vitro  ― ― = = ↑ ↓ ― D 26 
cMyBPCΔC8-C10 In vivo ― ― = = ― ― ― (MH, D, F) 
LVHLO 
5 
cMyBPCΔ10 In vivo  ― ― = = ― ↓ ↓ LVH 27 
cMyBPC (het ko) In vivo ― ― = = = ― ― ― 28 
cMyBPC (hom ko) In vivo ― ― ↓ ↓ ↓ ― ― LVH, D, F 28 
MLP (hom ko) In vivo ― ― ↓ ↓ ― ― ― DCM, CH, HF, 
D, F,  
29 
αTM = alpha tropomyosin; AM ATPase = actomyosin ATPase activity; Arr = arrhythmia; Arrei = exercise induced arrhythmia; Ca2+-sens = calcium 
sensitivity; CH = concentric hypertrophy; cMyBPC = cardiac myosin binding protein C; cTNT = cardiac troponin T; D = disarray; DCM = dilated 
cardiomyopathy; Dia/R = diastolic function / relaxation; ECG = electrocardiographic abnormalities; F = fibrosis; Favg = average force generated; 
het ko = heterozygous knockout; HF = heart failure; hom ko = homozygous knockout; HW = heart weight; LVH = left ventricular hypertrophy; 
LVHLO = late-onset left ventricular hypertrophy; M = mortality; M ATPase = myosin ATPase activity; MH = myocytic hypertrophy; MHC = myosin 
heavy chain; MLP = muscle LIM protein; Ref = reference; Sys/C = systolic function / contractility; Vmax = maximum sliding velocity; ↑ = increase; ↓ 
= decrease; = = unchanged; ― = not applicable/not reported; features in brackets refer to subtle variations. 1 = Marian et al., 1999; 2 = Geisterfer-
Lowrance et al., 1996; 3 = Berul et al., 1997; 4 = Spindler et al., 1998; 5 = Berul et al., 2001; 6 = Georgakopoulos et al., 1999; 7 = Kim et al., 1999; 
8 = Blanchard et al., 1999; 9 = Marian et al., 1995; 10 = Tyska et al., 2000; 11 = Gao et al., 1999; 12 = Sweeney et al., 1994; 13 = Sata and Ikebe, 
1996; 14 = Fujita et al., 1997; 15 = Tardiff et al., 1999; 16 = Oberst et al., 1998; 17 = Montgomery et al., 2001; 18 = Marian et al., 1997; 19 = 
Yanaga et al., 1999; 20 = Morimoto et al., 1998; 21 = Lin et al., 1996; 22 = Tardiff et al., 1998; 23 = Frey et al., 2000; 24 = Watkins et al., 1996; 25 
= Muthuchamy et al., 1999; 26 = Yang et al., 1998; 27 = Yang et al., 1999; 28 = Harris et al., 2002; 29 = Arber et al., 1997. 
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protein-encoding gene mutations (Maron and Ferrans, 1978; Watkins, 2003), were present in 
histological sections of hearts from homozygous MLP knockout mice (table I.2) (Arber et al., 1997). 
Homozygous MLP knockout mice also presented either with adulthood dilated cardiomyopathy 
(DCM), or an early phenotype characterised by concentric hypertrophy (table I.2) (Arber et al., 
1997). Watkins (2003) speculated that the DCM phenotype observed in a large proportion of these 
mice could be the result of a rapid progression of HCM to the dilated phase, rather than of DCM per 
se. The identification of a DCM-causing mutation in MLP, shown to disrupt the interaction between 
MLP and telethonin (Knoll et al., 2002), however, suggests that mutations in MLP are able to cause 
both HCM and DCM. 
 
The discovery of mutations in the γ2 subunit of AMPK, causing HCM with Wolff-Parkinson-White 
(WPW) syndrome (Blair et al., 2001; Gollob et al., 2001; Arad et al., 2002) has, however, broken the 
sarcomeric “golden thread” and led to the suggestion that mechanisms other that sarcomeric 
disruption may be involved in the development of HCM. AMPK has been described as the “fuel 
gauge”, or “low-fuel warning system” of the cell, that is switched on by depletion of adenosine 
triphosphate (ATP) (Hardie and Carling, 1997). AMPK is sensitive to AMP levels within the cell and 
is activated by a rising AMP/ATP ratio, indicative of energy depletion. In its activated state, AMPK 
inhibits enzymes in energy-consuming biosynthetic pathways, such as fatty-acid and sterol synthesis, 
increases glucose uptake and activates rate-limiting enzymes in glycolytic and fatty-acid oxidation 
pathways, thus reducing ATP consumption while also stimulating ATP production (figure I.1) 
(reviewed by Hardie and Carling, 1997; Blair et al., 2001; Tian et al., 2001; Gollob et al., 2001). 
 
The phenotypic expression of PRKAG2 mutations, however, differs from that classically associated 
with HCM caused by sarcomeric protein-encoding gene mutations. Specifically, in addition to 
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cardiac hypertrophy, PRKAG2 mutation carriers also present with pre-exitation (WPW), atrial 
fibrillation and progressive atrioventricular conduction block (Gollob et al., 2001; Arad et al., 2002). 
Furthermore, Arad et al., (2002) found no evidence of myocyte disarray and fibrosis, features 
generally associated with HCM, while large cytosolic vacuoles, proposed to contain amylopectin, a 
nonsoluble product of glycogen metabolism, were present in cardiomyocytes obtained from 
PRKAG2 mutation carriers. These findings prompted Arad et al., (2002) to propose that mutations in 
PRKAG2 produce a novel cardiac glycogen storage disease, characterised by cardiac hypertrophy 
and conduction abnormalities. The classification of mutations in PRKAG2 as causing either HCM 
with WPW, or a novel cardiac glycogen storage disease characterised by cardiac hypertrophy and 
conduction abnormalities, is largely dependent on whether or not myocytic disarray and fibrosis are 
regarded as pathogenic hallmarks of HCM (Maron and Ferrans, 1978; Watkins, 2003). Regardless of 
whether PRKAG2 mutation carriers are classified as having atypical HCM, or a separate disease 
entity, the notion that mutations in non-sarcomeric proteins, result in a disease phenotype similar to 
HCM, may provide invaluable insights into the mechanisms involved in the development of HCM 
(Blair et al., 2001; Crilley et al., 2003; Watkins, 2003). 
 
The identification of mutations in PRKAG2 supports a hypothesis that HCM-causing mutations in 
sarcomeric protein-encoding genes might result in ATP wastage through inefficient chemo-
mechanical force production/transduction in the sarcomere, rendering the cell vulnerable to ATP 
depletion during periods of increased cardiac demand (Redwood et al., 1999; Blair et al., 2001; 
Montgomery et al., 2001). This hypothesis is further supported by the findings that the ratio of 
phosphocreatine (PCr) to ATP was decreased in HCM-affected individuals, irrespective of 
symptomatic presentation, the presence of LVH, or the sarcomeric protein-encoding gene in which 
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Figure I.1. Regulation and function of 5’ AMP-activated protein kinase 
In response to an elevated AMP/ATP ratio, induced by increased ATP-consumption by the contractile 
apparatus and Ca2+-handling systems, resulting from β-adrenergic stimulation, AMP-activated protein kinase 
(AMPK) is activated through the actions of AMP-activated protein kinase kinase (AMPKK). Activation of 
AMPK, results in a decrease in non-essential ATP-usage, and increased ATP-production through fatty-acid 
oxidation, and glucose uptake. Additionally, AMPK-activation may also activate transcription factors 
(adapted from Gollob et al., 2001). 
 
the mutation occurred (Jung et al., 1998; Crilley et al., 2003). A similar decrease in the PCr/ATP 
ratio was also noted in a mouse model heterozygous for the αMHCR403Q mutation (homologue of the 
human βMHC R403Q HCM-causing mutation), in the absence of LVH (Spindler et al., 1998). 
Specifically, the finding that the PCr/ATP ratio was decreased in asymptomatic mutation carriers, 
not presenting with LVH, or ECG abnormalities, suggests that energetic abnormalities are likely to 
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be a primary, rather than a compensatory, feature of HCM (Crilley et al., 2003). Furthermore, Tian et 
al., (2001) have shown that a decrease in PCr/ATP ratio in a rat model of pressure-overload 
hypertrophy chronically elevated AMPK-activity, resulting in increased glucose uptake and 
metabolism. This finding suggests that the elevated PCr/ATP ratios observed in HCM mutation 
carriers (Crilley et al., 2003) may act in a similar way, and that chronic AMPK-activation may be a 
hallmark of LVH in general. 
 
Together, these findings strongly suggest that chronic energy depletion in the cardiomyocyte, 
whether resulting from inefficient chemo-mechanical force generation, caused by mutations in 
sarcomeric protein-encoding genes, or mutations in PRKAG2, could result in the development of 
cardiac hypertrophy. As β-adrenergic stimulation would result in an increase in ATP-consumption, 
by both the contractile apparatus and the Ca2+-reuptake system, the effects of HCM-causing 
mutations on cellular energetics may be exacerbated by β-adrenergic stimulation. Support for the 
view that β-adrenergic stimulation may be detrimental to HCM-affected individuals is drawn from 
two lines of evidence. Firstly, high-dose β-blocker therapy is used in the treatment of HCM and has 
been shown to significantly reduce the risk of SCD (Ostman-Smith et al., 1999). Secondly, strenuous 
physical exercise, which may result in β-adrenergic stimulation of the heart, has been implicated as a 
risk factor for the occurrence SCD in HCM patients and an HCM animal model (Frenneaux et al., 
1990; Maron et al., 1994; Geisterfer-Lowrance et al., 1996; Niimura et al., 1998; Konno et al., 2003). 
In the following sections, the effect of β-adrenergic stimulation in the heart will be discussed briefly. 
Specific reference will be made to the effect of β-adrenergic stimulation on phospholamban (PLB) 
and cardiac troponin I (cTNI), two proteins involved in Ca2+-homeostasis and Ca2+-activation of 
contraction respectively, functions which have previously been shown to be involved in the 
pathogenesis of HCM (section I.1.1.1). Particular attention will be given to the structure and 
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function of cMyBPC and cardiac titin. These proteins are of particular importance, as cMyBPC, the 
subject of the present study, and cardiac titin, a ligand of cMyBPC, are both phosphorylated as a 
result of β-adrenergic stimulation of the heart. 
 
I.2. EFFECT OF β-ADRENERGIC STIMULATION ON CARDIAC 
CONTRACTILITY 
 
Several studies, aimed at establishing the effect of β-adrenergic stimulation of the heart, have been 
carried out. The binding of noradrenalin or adrenergic agonists to the β-adrenergic receptor results in 
the activation of adenylate cyclase, which in turn, results in the elevation of intracellular cyclic AMP 
(cAMP) levels, activating cAMP-dependent protein kinase (PKA) (Lodish H, 1995). At the organ 
level, adrenergic stimulation of the heart results in a marked increase in contractile force of up to 
70% (England, 1975; Solaro et al., 1976).  
 
Although these studies have addressed the effect of β-adrenergic stimulation at the whole organ 
level, elucidating the effect thereof at the molecular level has been complicated by the presence of 
multiple PKA-dependent phospho-proteins within the cardiomyocyte. These include cTNI (Grand 
and Wilkinson, 1976; Solaro et al., 1976; Gao et al., 1994; Zhang et al., 1995), PLB (Movsesian et 
al., 1984; Kuschel et al., 1999; Chu et al., 2000), titin (Yamasaki et al., 2002) and cMyBPC (Hartzell 
and Titus, 1982; Hartzell and Sale, 1985; Gautel et al., 1995). As PKA-dependent phosphorylation of 
each of these four proteins plays an important role in the regulation of cardiac contractility, their 
structure, function and response to PKA-dependent phosphorylation will be discussed briefly in the 
following sections (I.4. I.5, I.6 and I.7). As both PLB and cTNI are essential components of the Ca2+-
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sensing/handling system, Ca2+-dependent regulation of cardiac contraction will also be discussed 
briefly in section I.3.  
 
I.3. CALCIUM-DEPENDENT REGULATION OF CARDIAC CONTRACTION 
 
Cardiac contraction is primarily stimulated by the release of Ca2+ from the sarcoplasmic reticulum 
(SR), stimulating actomyosin ATPase activity through thin filament activation, while relaxation is 
achieved through the sequestration of Ca2+ into the SR, resulting in deactivation of the thin filament 
and inhibition of actomyosin ATPase activity. The Ca2+-dependent events that lead to contraction 
during systole and relaxation during diastole are depicted in figure I.2. Briefly, depolarisation of the 
sarcolemma allows the opening of sarcolemmal L-type Ca2+-channels, allowing a minor Ca2+ influx 
through this channel, causing the stimulation of the ryanodine receptor (RyR) in the SR membrane. 
The binding of Ca2+ to the RyR, in turn, causes the rapid release of Ca2+ from the SR into the 
cytoplasm through the RyRs and Ca2+-release channels, resulting in a rapid increase in the 
cytoplasmic Ca2+ concentration (Fabiato, 1985; Frank et al., 2003). This sudden rise in cytoplasmic 
Ca2+ concentration results in the binding of Ca2+ to cardiac troponin C (cTNC), which leads to a 
cascade of conformational changes in the troponin-tropomyosin complex. These conformational 
changes result in thin filament activation (section I.5), which in turn, activates actomyosin ATPase 
activity, constituting cardiac contraction (systole) (Zot and Potter, 1987; Spyracopoulos et al., 1997). 
Relaxation (diastole) is achieved through the sequestration of cytoplasmic Ca2+. The main 
mechanism through which this is achieved, in mammalian cardiomyocytes, is through the action of 
SR Ca2+-ATPase (SERCA2a), which pumps Ca2+ back into the SR, while the sarcolemmal Na2+-Ca2+ 
exchanger and other slower systems also play a lesser role in the sequestration of cytoplasmic Ca2+ 
(Bers et al., 1996; Frank et al., 2003). The subsequent reduction in the cytoplasmic Ca2+-
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concentration causes the release of Ca2+ from cTNC, resulting in thin filament deactivation and 
inhibition of actomyosin ATPase activity (Chandra et al., 1997 and references therein).  
 
 
Extracellular 
    Cytoplasm 
 
 
 
 
 
 
 
Figure I.2. Ca2+-regulation of cardiac contraction 
     = Sarcolemal L-type Ca2+ channels,      = phospholamban;     = sarcomeric thick filaments;    = ryanodene 
receptors;     = Ca2+ release channels; green arrow = Ca2+ flow through the sarcolemal L-type Ca2+ channels 
following depolarisation of the sarcolemma;     = sarcomeric thin filaments;     = SERCA2a; SR = 
sarcoplasmic reticulum;     = sarcomeric M- and Z-lines;    = sarcolemmal and sarcoplasmic reticular 
membranes respectively. The black arrows indicate Ca2+ flux during systole and diastole respectively.  
 
I.4. PHOSPHOLAMBAN  
 
PLB, a 52 amino acid SR-membrane protein, is the primary regulator of SERCA2a activity. Under 
physiological conditions, about 40% of SERCA2a pumps are inhibited by the actions of PLB 
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(Brittsan et al., 2000). To date, three phosphorylation sites at residues 10, 16 and 17 of PLB have 
been identified. During β-adrenergic stimulation, residues 16 (serine) and 17 (threonine) are 
phosphorylated in a PKA-dependent fashion (Kuschel et al., 1999; Chu et al., 2000). The 
phosphorylation of residue 16 is the most important regulator of PLB activity, while the 
phosphorylation of residue 17 by either PKA or Ca2+/calmodulin-dependent protein kinase II (CaMK 
II), and residue 10 by Ca2+-activated phospholipid-dependent protein kinase (PKC), seems to also 
contribute, although, to a lesser extent, to PLB activity (Movsesian et al., 1984; Kuschel et al., 1999; 
Chu et al., 2000).  
 
In its unphosphorylated state, PLB is associated with SERCA2a and reduces the affinity of 
SERCA2a for Ca2+. Upon β-adrenergic stimulation, PLB is phosphorylated by PKA (at serine-16 
and threonine-17), causing it to dissociate from SERCA2a, thereby abolishing its inhibitory effect on 
SERCA2a function (Luo et al., 1994; Koss and Kranias, 1996). Thus PKA-dependent 
phosphorylation of PLB increases the rate at which Ca2+ is sequestered from the cytoplasm, aiding 
relaxation and diastolic function (Kranias et al., 1985; Frank et al., 2003). Furthermore, the increase 
in Ca2+ sequestration from the cytoplasm, induced by the PKA-dependent phosphorylation of PLB, 
increases the luminal SR Ca2+ load, which in turn increases the sensitivity of the RyR, leading to 
increased Ca2+-release from the SR following stimulation by Ca2+ influx via the L-type Ca2+ 
channels (Li et al., 2002). Dephosphorylation of PLB, associated with an increase in the affinity of 
PLB for SERCA2a is achieved through the action of calcineurin B (Munch et al., 2002).  
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I.5. CARDIAC TROPONIN I 
 
Troponin I (TNI), together with troponin C (TNC), troponin T (TNT) and α-tropomyosin (αTM), 
forms the troponin-tropomyosin complex (Stull and Buss, 1977; Wilkinson and Grand, 1978). 
Together these proteins are responsible for sensing intracellular Ca2+ flux and the Ca2+-dependent 
activation/deactivation of the thin filament, resulting in actomyosin ATPase activity being either 
activated or inhibited (Chandra et al., 1997 and references therein). In the following sections, the 
structure and function of the troponin-tropomyosin complex will be discussed briefly (section I.5.1), 
following which the effect of PKA-dependent phosphorylation of cTNI will be discussed (section 
I.5.2).  
 
I.5.1. STRUCTURE AND FUNCTION OF THE TROPONIN-TROPOMYOSIN COMPLEX 
 
Contraction of all vertebrate striated muscle is achieved through Ca2+-activation of the troponin-
tropomyosin complex. An increase in intracellular Ca2+ results in the binding of Ca2+ to the low-
affinity Ca2+-binding-site (regulatory binding-site), located in the N-terminal domain of cTNC 
(Robertson et al., 1982; Zot and Potter, 1987; Chandra et al., 1997; Spyracopoulos et al., 1997). 
Conformational changes in the N-terminal domain of cTNC brought about by the binding of Ca2+ 
increase its affinity for the inhibitory peptide of cTNI, resulting in an interaction between the N-
terminal domain of cTNC and the inhibitory peptide of cTNI (figure I.3) (Chandra et al., 1997 and 
references therein). This interaction weakens the binding between cTNI and actin resulting in the 
movement of α-TM on the thin filament, causing changes in actin structure that switch thin filaments 
to the “on state”, facilitating myosin ATPase activity (figure I.3) (Grand and Wilkinson, 1976; Syska 
et al., 1976; Wilkinson and Grand, 1978; Chandra et al., 1997). 
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I.5.2. cTNI AS SUBSTRATE FOR PKA 
 
Of the three TNI isoforms expressed in humans, namely, fast skeletal troponin I (fsTNI), slow 
skeletal troponin I (ssTNI) and cTNI, only the latter, which is expressed exclusively in cardiac tissue, 
is phosphorylated by PKA in vivo (Grand and Wilkinson, 1976; Saggin et al., 1989; Murphy, 2002; 
Westfall et al., 2002). Specifically, serine residues 23 and 24, located in the cardiac-specific 26 
residue N-terminal extension, are phosphorylated by PKA (figure I.4) (Perry and Cole, 1974; Grand 
and Wilkinson, 1976; Solaro et al., 1976; Wilkinson and Grand, 1978; Holroyde et al., 1984; 
Chandra et al., 1997).  
 
PKA-dependent phosphorylation of cTNI at these sites reduces the affinity of the N-terminal of cTNI 
for the C-terminal of cTNC, resulting in a conformational change in cTNC. This conformational 
change, in turn, results in a reduction in the affinity of the regulatory Ca2+-binding-site, located in the 
N-terminal of cTNC for Ca2+ (figure I.3), causing a rightward shift in the [Ca2+]/myosin ATPase-
force relationship without affecting the basal, or maximal, myofibrillar ATPase activities (figure 
I.5a) (England, 1976; Ray and England, 1976; Solaro et al., 1976; Wyborny and Reddy, 1978; 
Holroyde et al., 1984; Chandra et al., 1997). The reduction in the affinity of cTNC for Ca2+ causes a 
decrease in the peak saturation of the regulatory Ca2+ binding-site on cTNC and an increase in the 
rate of Ca2+ dissociation from this site (Robertson et al., 1982; Chandra et al., 1997). At first glance, 
a rightward shift in the [Ca2+]/myosin ATPase force relationship seems to be in conflict with the 
increase in contractility associated with β-adrenergic stimulation of the heart (England, 1975; Solaro 
et al., 1976). Holroyde et al., (1984), however, point out that the decrease in the affinity of cTNC for 
Ca2+ would aid relaxation, and thus cardiac diastolic function, during periods of β-adrenergic 
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stimulation, by reducing the amount of Ca2+ that has to be transported back to the SR to achieve 
relaxation. 
 
Cholenergic stimulation, leading to the activation of cyclic guanidine monophosphate (cGMP) 
mediated pathways results in the dephosphorylation of cTNI (figure I.5b) at residues 23 and 24 and 
the subsequent abolition of the rightward shift in [Ca2+]/myosin ATPase relationship, induced by β-
adrenergic stimulation (England, 1976; Horowits and Winegrad, 1983). Dephosphorylation of cTNI, 
however, occurs at a much slower rate than dephosphorylation of proteins responsible for the 
increase in Ca2+-activated force. This is evidenced by the finding that cTNI persists in its 
phosphorylated state long after the increase in Ca2+-activated force, induced by β-adrenergic 
stimulation of cardiac tissue, has returned to baseline levels (Horowits and Winegrad, 1983). This 
finding indicates that PKA-mediated phosphorylation of cTNI is not responsible for the increase in 
Ca2+-activated force observed in cardiac tissue following β-adrenergic stimulation. Secondly, this 
finding indicates that the systems responsible for the dephosphorylation of cTNI differ from those 
responsible for the dephosphorylation of the proteins phosphorylated by PKA, which is responsible 
for the increase in Ca2+-activated force.  
 
Furthermore, Zakhary et al., (1999) have shown that the baseline level of phosphorylated cTNI was 
significantly reduced in patients with DCM, compared to normal control individuals, while the 
baseline level of PLB phosphorylation remained unchanged (section I.4). This finding indicates that 
even though both proteins are phosphorylated by PKA upon β-adrenergic stimulation, different 
mechanisms are responsible for the phosphorylation of these two proteins. This led the authors to 
speculate that the phosphorylation of PLB and cTNI might be catalysed by different PKA 
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FIGURE I.3. Structure of troponin complex and α-tropomyosin during diastole and systole 
A. Structure of the troponin complex and α-tropomyosin relative to actin during diastole. B. Structure of the 
troponin complex and α-tropomyosin relative to actin during systole.     = cTNC;     = cTNC constitutive 
Ca2+/Mg2+ binding-sites;    = regulatory Ca2+ binding-site in the absence of bound Ca2+;     = regulatory 
Ca2+ binding-site with Ca2+ bound;     = cTNI; P* = cardiac-specific PKA phosphorylation site in cTNI; 
     = cTNT;       = α-tropomyosin;      = actin monomers forming part of the thin filament; C = indicates the 
carboxy-terminals of the components of the troponin complex; N = indicates the amino-terminals of the 
components of the troponin complex; the arrows in A and B indicate the relative positions of the troponin 
complex and α-tropomyosin during diastole and systole respectively (adapted from Solaro and Rarick, 1998). 
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Figure I.4. Schematic representation of cardiac troponin I 
      = Cardiac-specific N-terminal region;      = major troponin C binding-site;    = inhibitory peptide 
containing actin and troponin C binding-sites; P = phosphorylation sites. The numbers at the top of the figure 
indicate the residue numbers which designate the start and the end of functional regions; the numbers at the 
bottom of the figure indicate the residue numbers of the phosphorylation sites. 
 
isoenzymes (Zakhary et al., 1999). PKA type I, containing the RI regulatory subunit, is generally 
cytosolic and is, therefore, more likely to phosphorylate cTNI, while PKA type II, containing the RII 
subunit, tends to be compartmentalised by binding to A-kinase anchoring proteins (AKAPS), 
possibly in the SR-membrane, allowing it to preferentially phosphorylate PLB (Zakhary et al., 1999). 
This mechanism would allow for the spatial compartmentalisation of PKA within the cell, allowing 
the preferential phosphorylation of specific proteins under certain physiological conditions.  
 
 COOH       NH2 
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     1                       26          36                  52                                                      123                          145 
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Figure I.5. Proposed mechanisms involved in the cAMP-dependent phosphorylation and cGMP-dependent 
dephosphorylation of cTNI, as well as the effect thereof on Ca2+ sensitivity  
a) Effect of cAMP-dependant phosphorylation and cGMP-dependent dephosphorylation of cTNI on Ca2+ 
sensitivity of the contractile apparatus. b) Proposed mechanisms involved in the cAMP-dependent 
phosphorylation and cGMP-dependent dephosphorylation of cTNI (from Winegrad, 1984). 
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I.6. TITIN 
 
Titin is the largest protein known to be expressed in the human body and spans the length of the half 
sarcomere from Z-disk to M-line (Means, 1998). The functions of this protein include sarcomeric 
assembly during myofibrillogenesis and subsequent maintenance of sarcomeric integrity, as well as 
adding elasticity to the sarcomere, thereby aiding both contraction and relaxation. Based on these 
functions, titin has been described both as a molecular ruler (Furst et al., 1989a; Labeit et al., 1992; 
Gautel et al., 1993; Furst and Gautel, 1995) and a bi-directional spring (Furst et al., 1988; Linke et 
al., 1997; Cazorla et al., 2000; Freiburg et al., 2000). 
 
Alternative splicing of the TTN transcript gives rise to various tissue-specific titin isoforms, ranging 
in size from 2.97MDa to 3.7MDa (Labeit et al., 1990; Freiburg et al., 2000). The variation in these 
titin isoforms manifests only in the I-band region, giving rise to titins with varying elastic properties 
(Cazorla et al., 2000; Freiburg et al., 2000).  
 
As specifically the cardiac isoform of titin is phosphorylated by PKA, combined with the fact that 
this isoform interacts with cMyBPC, its structure and function will be discussed in detail in the 
following sections. In cases where functional or comparative studies relevant to cardiac titin were 
performed on skeletal isoforms, it will be indicated as such in the text. 
 
I.6.1. TITIN STRUCTURE 
 
Cardiac titin is a long filamentous protein of ~850-950nm in length and ~3-4nm in diameter, 
consisting predominantly of immunoglobulin type C2 (IgC2) and fibronectin type 3 (Fn3) domains 
and has thus been classified as a member of the intracellular immunoglobulin superfamily (Nave et 
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al., 1989; Labeit et al., 1992; Soteriou et al., 1993; Vinkemeier et al., 1993; Labeit and Kolmerer, 
1995). The N-terminal region is firmly anchored in the sarcomeric Z-disk and the protein extends all 
the way to the M-line, where the globular C-terminal region is firmly anchored (figure I.6) (Furst et 
al., 1988; Furst et al., 1989a; Nave et al., 1989; Labeit et al., 1992).  
 
The number of titin molecules per half-sarcomere has been estimated to be between six and seven 
(Liversage et al., 2001), leading Liversage et al., (2001) to propose a model with six titin molecules 
per half-sarcomere. According to this model, titin exists as variable oligomers. The number of titin 
molecules involved in this oligomerisation depends on its specific sarcomeric location, viz., A-band 
titin is found as dimers, the 22 IgC2-domain tandem repeat of I-band titin, located at the A-I 
junction, forms a hexamer constituting the end filament. The remainder of I-band titin is in the 
monomeric form, allowing individual molecules to associate with each of the thin filaments close to 
the Z-disk (Trinick, 1981; Linke et al., 1997; Liversage et al., 2001). The merit of this model will be 
discussed further in sections I.6.2-I.6.5, dealing with M-line, A-band, I-band and Z-disk titin, 
respectively. 
 
 
 
 
 
Figure I.6. Arrangement of titin in the sarcomere 
    = Titin filaments;     = thin filament;      = thick filaments;      = myosin binding proteins;      = Z-disk and 
M-line;     = positions of proposed titin phosphorylation sites;     = positions of titin kinase domains. The 
position of the Z-disk, I-band, A-band and M-line, as well as the molecular weight of titin in these regions, is 
shown at the top of the figure, while the various zones of the A-band are indicated at the bottom of the figure 
(from Labeit and Kolmerer, 1995). 
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I.6.2. M-LINE TITIN 
 
M-line titin consists of 10 IgC2 domains, designated M1 to M10, separated by seven interdomain 
insertions designated is1 to is7, ranging in size from 30 to 490 residues in length (figure I.7.) (Labeit 
et al., 1992; Gautel et al., 1993; Labeit and Kolmerer, 1995). M-line titin has been shown to interact 
with both M-protein and myomesin, thus anchoring the C-terminal of titin firmly in the M-line 
(Mayans et al., 1998; Nave et al., 1989; Vinkemeier et al., 1993). To date, however, the specific 
domains of M-line titin responsible for these interactions have not been identified, but are likely to 
involve specific IgC2 domains. Furthermore, the insertion between M5 and M6 (is4) contains four 
regions rich in lysine (K), serine (S) and proline (P) residues, designated KSP-motifs which is 
phosphorylated by KSP-kinase (Gautel et al., 1993). As KSP-kinase is active only in proliferating 
myoblasts and differentiating cells, it has been proposed that phosphorylation of the KSP-motifs may 
facilitate the binding of M-line titin to M-protein and myomesin during myofibrillogenesis, thus 
allowing incorporation of titin into the differentiating myofibril (Gautel et al., 1993; Furst and 
Gautel, 1995). In addition to M-line titin being bound to M-protein and myomesin, it has been 
proposed that M-line titin molecules from adjacent half-sarcomeres interact as antiparallel dimers 
(Gautel et al., 1993; Vinkemeier et al., 1993). This proposal is supported by findings that titin 
molecules are able to form end-on-end aggregates in vitro (Nave et al., 1989).  
 
 
 
 
Figure I.7. Domain organisation of C-terminal titin 
     = IgC2 domains M1 to M10,      = interdomain insertions is1 to is7,      = titin kinase domain (adapted from 
Gautel et al., 1993). 
   A-band                                                                           M-line
  is1                          is2                   is3          is4       is5         is6                      is7 
COOH 
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I.6.3. A-BAND TITIN 
 
The sarcomeric A-band can be subdivided into three zones. Firstly, the D-zone, representing the 
portion of the thick filament closest to the Z-disk, in which no myosin binding proteins (MyBP) are 
associated with the thick filament. Secondly, the C-zone, representing the central region of the thick 
filament, in which the MyBP molecules are found, and thirdly, the P-zone, representing the portion 
of the thick filament between the C-zone and the M-line (figure I.6.) (Labeit and Kolmerer, 1995). It 
should be noted that some authors use the term C-zone when referring to the region spanning only 
the outer seven 43nm periods (section I.7.2), representing the positions in which myosin binding 
protein C (MyBPC) is always present (Sjostrom and Squire, 1977). As the distribution of MyBPC 
varies between various muscle types, the term of C-zone as defined by Labeit and Kolmerer (1995), 
encompassing all eleven 43nm periods will be used in this review. 
 
A-band titin consists mainly of IgC2 and Fn3 domains and is found on the surface of the thick 
filament (Furst et al., 1988; Furst et al., 1989a; Labeit and Kolmerer, 1995), where it is constitutively 
bound to LMM (Furst et al., 1988; Labeit et al., 1992). It has been shown that specifically the Fn3 
domains of A-band titin interact with LMM, while the presence of IgC2 domains are essential for 
facilitating this interaction (Labeit et al., 1992; Jin, 1995). 
 
In addition to its interaction with LMM, A-band titin is also able to form side-by-side aggregates in 
vitro (Nave et al., 1989), lending support to the hypothesis of Liversage et al., (2001) that A-band 
titin molecules dimerise. This dimerisation is in all likelihood facilitated by homophilic interaction 
between Fn3 domains, found almost exclusively in A-band titin (Nave et al., 1989; Price and Gomer, 
1993; Labeit and Kolmerer, 1995). 
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I.6.3.1. D-zone titin 
 
D-zone titin consists entirely of IgC2 and Fn3 domains. The first 13 of these domains were originally 
described as part of the I-band by Labeit and Kolmerer (1995), who characterised them as a region 
with “complex domain architecture near the junction of the I- and A-bands”, hence their numbering 
as part of the I-band (I42-I54 by Labeit and Kolmerer (1995) and I106-I118 by Granzier and Labeit, 
2002). Trinick (1996), however, showed that these domains are in fact part of D-zone titin, rather 
than I-band titin, and, although this view is generally accepted, these domains are still numbered as if 
they were part of the I-band, rather than the A-band (Trinick, 1996). 
 
These 13 domains are followed by a highly ordered seven-domain super-repeat (IgC2-Fn3-Fn3-
IgC2-Fn3-Fn3-Fn3). This super-repeat is itself repeated six times with domains numbered A1-A42 
(figure I.8.) (Labeit and Kolmerer, 1995). 
 
 
 
Figure I.8. Organisation of D-zone titin 
     = IgC2 domains,     = Fn3 domains. The seven domains indicated in brackets are repeated six times 
(adapted from Labeit and Kolmerer, 1995). 
 
I.6.3.2. C-zone titin 
 
C-zone titin exhibits a regular architecture of an 11 domain super-repeat (IgC2-Fn3-Fn3-IgC2-Fn3-
Fn3-Fn3-IgC2-Fn3-Fn3-Fn3), itself repeated 11 times (see figure I.9) (Labeit et al., 1992; Politou et 
al., 1994; Labeit and Kolmerer, 1995). The length of each of these repeats is ~43nm, which is 
(                )6 
  I106                                                                                           I118             A1                                            A42
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consistent with the spacing between the positions occupied by the MyBPs in the sarcomeric C-zone, 
as well as the myosin helix repeat (Labeit et al., 1992).  
 
 
 
 
Figure I.9. Organisation of C-zone titin 
      = IgC2 domains,      = Fn3 domains. This series of 11 domains are repeated 11 times in the C-zone (from 
Labeit and Kolmerer, 1995). 
 
The 11-domain super-repeat determines the distribution of MyBPC and myosin binding protein H 
(MyBPH) within the C-zone, at a spacing of ~43nm, thus enabling C-zone titin to function as a 
molecular ruler (Furst et al., 1989a; Labeit et al., 1992). The first IgC2 domain of each of the 11-
domain super-repeats (A43, A54, A65, A76, A87, A98, A109, A120, A131, A142, A153) (section 
I.7.3.2) binds strongly to the C-terminal portion of MyBPC (Labeit et al., 1992; Labeit and 
Kolmerer, 1995; Freiburg and Gautel, 1996). It is interesting to note that the C-terminal region of 
MyBPC is also able to bind to domain A153 of titin, representing stripe 11, in which MyBPC has to 
date never been found in all muscle types investigated (table I.3) (for further discussion on this 
interaction see sections I.7.3.2 and IV.2) (Bennett et al., 1986; Labeit and Kolmerer, 1995; Freiburg 
and Gautel, 1996). 
 
I.6.3.3. P-zone titin 
 
The P-zone portion of titin has a less regular domain architecture than either D- or C-zone titin and 
consists of four IgC2 and three Fn3 domains, designated domains A164 to A170, a short unique 
(                          )11 
A43                                                                          A163
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sequence and a kinase domain (figure I.10.) (Labeit and Kolmerer, 1995). The kinase domain, 
designated titin kinase, shares significant homology with myosin-light chain kinase and has been 
shown to phosphorylate the Z-disk protein telethonin (Labeit and Kolmerer, 1995; Mayans et al., 
1998). 
 
Titin kinase is itself activated by phosphorylation by an as yet unidentified kinase and the binding of 
Ca2+/calmodulin, allowing it to bind to and phosphorylate the Z-disk protein telethonin (Mayans et 
al., 1998). The phosphorylation of telethonin has been postulated to be involved in 
myofibrillogenesis (Mayans et al., 1998). It is intriguing to note that titin kinase, located close to the 
M-line, about 1μm from the Z-disk in mature myofibrils, regulates Z-disk architecture. During 
myofibrillogenesis, however, titin is already anchored in the Z-disk at an early stage before 
associating with the thick filament. As the A-band and M-line portions of titin is at this stage not 
associated with the thick filament or M-line, it is possible for titin to fold back on itself, thereby 
allowing titin kinase to be transiently in close proximity to telethonin in the Z-disk (Furst et al., 
1989b; Mayans et al., 1998).  
 
 
 
Figure I.10. Organisation of P-zone titin 
     = IgC2 domains;      = Fn3 domains;      = titin-kinase domain; white box = unique sequence (from Labeit 
and Kolmerer, 1995). 
 
A164                                       A170          titin kinase
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I.6.4. I-BAND TITIN 
 
It is specifically in the I-band region of titin that isoform diversity, resulting from the alternative 
splicing of TTN, becomes apparent. I-band titin consists of three main components. Firstly, tandemly 
repeated IgC2 domains, secondly, the so-called PVEK domain, in which the amino acids P, E, K and 
V constitute ~70% of the domain, and, thirdly, other non-repetitive sequences of which the N2A and 
N2B elements are the most significant. The specific lengths of each of these segments is, however, 
isoform dependent (figure I.2.6.) (Labeit and Kolmerer, 1995; Freiburg et al., 2000; Granzier and 
Labeit, 2002). Together, these regions are responsible for the elastic properties of titin, allowing it to 
function as an adjustable bi-directional spring (Furst et al., 1988; Linke et al., 1997; Cazorla et al., 
2000; Freiburg et al., 2000). It has been established that there is a direct correlation between the 
length of differentially expressed titin isoforms and the compliance/passive tension of the muscle in 
which it is expressed (Furst et al., 1988; Linke et al., 1997; Cazorla et al., 2000; Freiburg et al., 
2000).  
 
I.6.4.1. I-band titin isoform diversity 
 
Numerous different skeletal and cardiac titin isoforms,varying specifically in their I-band regions, 
are generated by the alternative splicing of TTN (figure I.11) (Labeit and Kolmerer, 1995; Freiburg et 
al., 2000; Granzier and Labeit 2002). Generally, skeletal muscle titin isoforms contain more 
tandemly repeated IgC2 domains in the I-band region, and generally have a larger PVEK segment 
than cardiac titin isoforms. The main factor distinguishing the cardiac isoforms from their skeletal 
counterparts is, however, the presence of the N2B element (Labeit and Kolmerer, 1995; Freiburg et 
al., 2000; Granzier and Labeit, 2002). This element, consisting of three IgC2 domains and an unique 
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sequence of 572 amino acids in human titin, is constitutively found in all cardiac titin isoforms. In 
contrast, the N2A element, consisting of four IgC2 domains and an unique sequence of 106 amino 
acids in human titin, is present in all skeletal isoforms (figure I.11.) (Labeit and Kolmerer, 1995; 
Cazorla et al., 2000; Freiburg et al., 2000). Cardiac titin isoforms containing both the N2B and N2A 
elements are referred to as N2BA titin and contain a variable, but similar, number of IgC2 domains 
separating these elements (varying in number from 14 to 26) (figure I.11) (Labeit and Kolmerer, 
1995; Cazorla et al., 2000; Freiburg et al., 2000). As this difference in the number of IgC2 domains, 
and the subsequent difference in elastic properties (see section I.6.4.2), is quite small, all N2BA titin 
isoforms have been grouped together for the purpose of this discussion. 
 
The N2B cardiac titin isoform further differs from the larger N2BA cardiac titin isoform in that there 
are fewer tandemly repeated IgC2 domains separating the N2B element and the PVEK segment. 
Additionally, the PVEK segment found in the N2B isoform is significantly smaller than that of the 
N2BA isoform (figure I.11) (Labeit and Kolmerer, 1995; Cazorla et al., 2000; Freiburg et al., 2000; 
Granzier and Labeit, 2002). 
 
The N2B and N2BA cardiac titin isoforms are co-expressed in cardiac muscle and it has been shown 
that both isoforms may also be co-expressed within a single cardiomyocyte. The specific ratios at 
which these isoforms are expressed in cardiac tissue are both species and location, i.e. atrial and 
ventricular, specific (Cazorla et al., 2000; Freiburg et al., 2000; Neagoe et al., 2002). The N2BA 
isoform is predominantly expressed in atrial tissue, while the expression of cardiac titin isoforms 
within the ventricle varies according to species. There are conflicting reports regarding the 
expression of these two isoforms in the human ventricular myocardium. Freiburg et al., (2000) have 
shown that the N2BA isoform is predominant in the human ventricular myocardium, while Neagoe 
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et al., (2002) found that about 70% of ventricular titin is of the N2B isoform. Cardiomyocytes in 
which the larger N2BA titin is the predominant isoform, are more compliant than cardiomyocytes 
predominantly expressing the shorter N2B isoform (Cazorla et al., 2000; Freiburg et al., 2000). 
Conversely, cardiomyocytes predominantly expressing the N2B isoform generate more passive 
tension at a given sarcomeric length than do cardiomyocytes in which N2BA titin predominates 
(Cazorla et al., 2000; Freiburg et al., 2000).  
 
Additionally, a shorter titin isoform, known as novex 3 has also been described. This isoform, 
expressed in all striated muscle tissue (Granzier and Labeit, 2002) is made up mostly of the Z-disk 
portion of titin, but lacks the Z-repeats, as well as the proximal 15 IgC2 repeats of I-band titin and 
the so-called novex 3 element. It has been speculated that this titin isoform may be anchored in the 
Z-disk due to the presence of Z-disk titin IgC2 domains, while the novex 3 element may interact with 
either the thick filament or the end filament. This scenario is, however, highly unlikely as the Z-
repeats, essential for the anchoring of titin to α-actinin in the Z-disk, are absent in this isoform 
(Young et al., 1998). The physiological importance of this isoform, however, remains to be 
elucidated.  
 
I.6.4.2. I-Band titin as generator of passive tension  
 
In order to explain the stretch and subsequent generation of passive tension, it has been proposed that 
the elastic component of I-band titin, namely, the tandemly repeated IgC2 segments, the unique N2B 
segment and the PVEK segment, behave as a serially-linked wormlike chain (WLC) (Helmes et al., 
1999). A WLC is a deformable rod whose bending rigidity is expressed in terms of its persistence 
length. For instance, if a peptide in a rigid WLC has a long persistence length, a relatively small 
 37
 
 
Figure I.11. Splice isoform diversity of the I-band regions of titin 
Skeletal muscles express N2A-based titins that vary in size in different muscle types (two of many possible 
splice pathways are shown). Cardiac muscle express large N2BA and small N2B titins. All striated muscles 
express novex-3 titin (from Granzier and Labeit, 2002). 
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force would be required to straighten it, resulting in the generation of only a small amount of passive 
tension (Helmes et al., 1999). As the elastic segments of I-band titin are serially linked, and their 
extension is sequential, they will be discussed separately in the following sections. 
 
I.6.4.2.i. Tandem IgC2 domains acting as a rigid WLC 
The persistence length of the tandem IgC2-segments of I-band titin is marginally shorter than its 
chain length, as evidenced by its appearance as a “piled up” structure at the junction between the A- 
and I-bands, when the muscle is at rest (figure I.12) (Furst et al., 1988; Kellermayer et al., 1997; 
Tskhovrebova et al., 1997; Linke et al., 1998; Helmes et al., 1999). Helmes et al., (1999) proposed 
that this “piled up” conformation of the tandem IgC2-segments is energetically the most stable and is 
stabilised by weak non-covalent interdomain interactions (either intra-molecular or inter-molecular). 
Hence, force denaturation of these interactions, due to stretching of the muscle, would result in the 
generation of passive tension (figure I.12) (Helmes et al., 1999). Due to its relative high persistence 
length and rigidity, the straightening of the tandem IgC2 repeats will occur at low stretching force, 
with the subsequent generation of low levels of passive tension, which has been compared to the 
straightening of a leash (figure I.12) (Helmes et al., 1999).  
 
I.6.4.2.ii. PVEK as a WLC 
Although the PVEK segments of the various titin isoforms differ dramatically in size, they are all 
characterised by the abundance of the four amino acids P, V, E and K, which constitute about 70% of 
this domain (Labeit and Kolmerer, 1995; Granzier and Labeit, 2002). Additionally, the presence of 
clusters of negatively charged residues in the PVEK segment prevents the formation of stable tertiary 
structures, causing this segment of the protein to behave as an unfolded peptide, which is easily 
stretched (Labeit and Kolmerer, 1995; Trombitas et al., 1998; Helmes et al., 1999). 
 39
Like the tandemly repeated IgC2 domains of I-band titin, the PVEK segment also acts as a WLC, but 
is less rigid and has a shorter persistence length than the tandem IgC2 segments. Extension (force 
denaturation) of this segment requires a greater force than extension of the tandem IgC2 segments 
and will, therefore, only occur following complete extension of the tandem IgC2 segments. As the 
force that is required to cause the extension of the PVEK segment is slightly higher than predicted by 
the serially linked WLC model, it was proposed that weak non-covalent interactions might exist 
within this region when titin is “contracted” in the slack sarcomere (see figure I.12) (Helmes et al., 
1999). Entropic renaturation of the PVEK segment consequently leads to a logarithmic increase in 
passive tension that is significantly higher than that produced by the renaturation of tandem IgC2 
segments (Trombitas et al., 1998; Helmes et al., 1999). This finding prompted Helmes et al., (1999) 
to dub this segment the “force generator” (figure I.12). 
 
I.6.4.2.iii. N2B element as an adjustable generator of passive tension 
As the N2B element of cardiac titin has a shorter persistence length and lower rigidity than the 
tandem Ig-repeats and the PVEK segment, extension of this region only occurs following the 
complete extension of the tandem Ig-repeats and the PVEK segment (Helmes et al., 1999). 
Denaturation of the N2B element from its compact state results in a linear increase in passive tension 
(figure I.12) (Helmes et al., 1999). Due to the presence of more tandem Ig-domains and a longer 
PVEK segment in N2BA titin, denaturation of the N2B element in this isoform would occur at 
longer sarcomeric lengths than in the N2B isoform. 
 
I.6.4.2.iv. Domain denaturation as a mechanism for generating passive tension 
In vitro experiments have shown that titin displays step-like stress relaxation, when excessive 
stretching force is applied, due to the sequential denaturation of individual IgC2 domains in the 
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tandem Ig repeats of I-band titin (Rief et al., 1997; Tskhovrebova et al., 1997). Due to the variable 
stabilities of IgC2 domains in this region, the force-denaturation of these domains will occur 
sequentially, allowing for the elongation of I-band titin in a saw-tooth manner as increasing 
stretching force is applied to the sarcomere (~25nm per IgC2 domain denatured) (Rief et al., 1997; 
Tskhovrebova et al., 1997).  
 
Renaturation of these domains takes place on a slower timescale (~1 second) and only occurs when 
tensile force is completely released (Kellermayer et al., 1997; Rief et al., 1997). It is, therefore, 
unlikely that this mechanism would contribute to the generation of passive tension, and denaturation 
of IgC2 domains is unlikely to happen in vivo under normal physiological conditions (Trombitas et 
al., 1998), but may be a mechanism to protect the sarcomere from permanent damage by 
overstretching (Rief et al., 1997). 
 
I.6.4.3. I-band titin as a generator of restoring force 
 
In addition to the generation of passive tension, I-band titin has also been implicated in the 
generation of restoring force (Helmes et al., 1996). Restoring force allows the passive re-lengthening 
of cardiac myocytes back to their slack length following contraction, thereby aiding ventricular 
filling during the early stages of diastole (Helmes et al., 1996).  
 
The mechanism proposed for the generation of restoring force is similar to that proposed for the 
generation of passive tension (Labeit and Kolmerer, 1995; Helmes et al., 1999). Firstly, the tandem 
IgC2 repeats of I-band titin would straighten, followed by the denaturation of the PVEK region and 
the subsequent generation of restoring force (figure I.13) (Helmes et al., 1996; Helmes et al., 1999).
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                              Tandem Igs: “leash”  
 
 
 
                            PVEK: “force generator” 
 
 
 
                          Unique N2B sequence: “adjustable spring segment” 
 
 
 
Figure I.12. Model for passive tension development by N2B titin 
Left side: Titin’s I-band segment at sarcomeric lengths from near slack (top) to highly extended (bottom). 
Tandem Ig segments containing folded Ig domains depicted as thick red line; folded N2B-specific segment 
depicted as orange square; unfolded N2B-specific segment depicted as thin orange line; PVEK segment 
depicted as thin red line; noncovalent interactions between Ig domains and folded PVEK segment depicted as 
thin blue lines. The force-sarcomeric length relationship associated with the force-denaturation of each of 
these segments is shown in the graph in the top right-hand corner of the figure (from Helmes et al., 1999). 
}
            Force 
Sarcomere length 
} 
}
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In this instance, however, the force responsible for the straightening/denaturation of these segments 
of I-band titin would be a contractile, rather than a stretching force (Helmes et al., 1996; Helmes et 
al., 1999). This hypothesis, however, requires that a significant length of I-band titin has to be 
immobilised on the thin filament during late systole. Although I-band titin has been shown to 
associate with filamentous actin (F-actin), this is likely to be a relatively weak interaction that only 
occurs in the portion of I-band titin directly adjacent to the Z-disk (Nave et al., 1989; Jin, 1995; 
Linke et al., 1997). 
 
It was, however, recently shown that the PVEK region of N2B titin is able to bind to F-actin under 
physiological ionic strengths, a feature specific to the cardiac N2B titin isoform (Yamasaki et al., 
2001). This interaction is regulated in a Ca2+-dependent manner by S100A1, a member of the S100 
family of EF-hand calcium-binding proteins. At high Ca2+ concentrations, Ca2+-S100A1 binds to the 
PVEK segment of the N2B titin isoform, inhibiting its interaction with F-actin (Yamasaki et al., 
2001). The inhibition of this interaction by S100A1 at high Ca2+ concentrations suggests that the 
binding of the PVEK segment to F-actin would not play a major role during systole, but may be 
important during diastole when the cytoplasmic Ca2+ is low (Yamasaki et al., 2001).  
 
The possibility that the binding of the PVEK segment to F-actin may be of importance in the 
generation of restoring force was, however, not considered by Yamasaki et al., (2001). Although the 
critical Ca2+ concentration at which the PVEK-F-actin interaction is inhibited is not clear from the 
data presented by Yamasaki et al., (2001), it may be interesting to superimpose this data onto the 
Ca2+-activated actomyosin force curve. If this critical Ca2+ concentration is reached before all 
actomyosin activity is inhibited towards the end of systole, it could be postulated that a situation may 
occur where the PVEK segment of N2B titin may bind to the thin filament before all actomyosin 
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activity is inhibited. This would result in the straightening of I-band titin’s C-terminal tandem IgC2 
repeats, with the subsequent generation of restoring force (figure I.13). As the PVEK-segment of 
N2B titin is immobilised on the thin filament, this hypothesis would imply that the PVEK-segment 
and the proximal tandem Ig repeat (adjacent to the Z-line) would not participate in the generation of 
restoring force and that all restoring force is generated by the entropic renaturing of the distal Ig 
repeat (figure I.13).  
 
 
 
 
 
 
Figure I.13. Proposed mechanism for the generation of restoring force facilitated by an interaction 
between the PVEK segment of N2B titin and F-actin. 
Tandem Ig segments containing folded Ig domains depicted as thick red line; folded N2B-specific segment 
depicted as orange square; PVEK segment depicted as thin red line; non-covalent interactions between Ig 
domains and folded PVEK segment depicted as thin blue lines; Interaction between PVEK and F-actin 
depicted by thick blue line. The black arrow below the figure indicates the direction force generated by Ca2+-
activated actomyosin activity, while the red arrow indicates the direction of restoring force generated by the 
straightening of the tandem IgC2 segment. 
 
I.6.5. Z-DISK TITIN 
 
The N-terminal 209kDa of titin enters the Z-disk and contains ten IgC2 domains, numbered Z1 to 
Z10, which are associated with F-actin in the thin filament (figures I.14 and I.15) (Nave et al., 1989; 
Jin, 1995; Labeit and Kolmerer, 1995; Linke et al., 1997). In the region separating domain Z3 and 
Z4, a variable number of repeat sequences, unique to Z-disk titin, designated the Z-repeats, have 
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been identified (Gautel et al., 1996). In cardiac muscle there are five Z-repeats, designated zr1 to zr5 
(figure I.14), of which zr1, zr3 and zr5 have been shown to interact with the C-terminal region of α-
actinin (Gautel et al., 1996; Young et al., 1998). Additionally, the unique sequence separating the Z-
repeats and the Z4 IgC2 domain has also been shown to interact with the central spectrin-like repeat 
of α-actinin (figures I.14 and I.15) (Young et al., 1998). It has been proposed that these interactions 
are essential for Z-disk formation, and that the titin isoform-specific number of Z-repeats determines 
the number of Z-filaments in the Z-disk (Gautel et al., 1996; Young et al., 1998). The proposed 
arrangement of titin within the Z-disk is shown in figure I.15. 
 
 
 
 
Figure I.14. Domain organisation of Z-disk titin 
     = Z-repeats zr1 to zr5, numbered 1 to 5;     = Ig C2 like domains Z1 to Z10,       = unique sequences; * = 
α-actinin interaction sites. 
 
I.6.6. PKA-MEDIATED PHOSPHORYLATION OF TITIN 
 
It was recently shown that the cardiac-specific N2B element is mono-phosphorylated by PKA, upon 
β-adrenergic stimulation (Yamasaki et al., 2002). Previous studies have shown that β-adrenergic 
stimulation of intact cardiac myocytes led to a significant reduction in the generation of passive 
tension, specifically at relatively short sarcomeric lengths (Strang et al., 1994; Yamasaki et al., 
2002). These findings prompted Yamasaki et al., (2002) to speculate that PKA-dependent 
phosphorylation of the N2B element results in the denaturation of this element. This hypothesis 
implies that, during periods of β-adrenergic stimulation of the heart, the N2B element would be in a 
denatured state and would extend at short sarcomeric lengths during the initial stages of sarcomeric  
NH2 
   Z1    Z2            Z3    1  2  3  4  5                  Z4       Z5           Z6            Z7    Z8           Z9    Z10 
         *    *    *      * 
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Figure I.15. Proposed position of titin in the Z-disk 
      = non-repetitive sequences in Z-disk titin;      = Z-repeats of Z-disk titin;       = thin filament;       = point 
of interaction between Z-disk titin and α-actinin;      = IgC2 domains of Z-disk titin;     = spectrin-like 
domains of α-actinin (from Young et al., 1998). 
 
lengthening, with little passive tension being developed. Further stretching of the sarcomere would 
subsequently cause the sequential extension of the tandem IgC2 repeats and the PVEK domain, 
allowing the generation of passive tension comparable to that observed in the absence of adrenergic 
stimulation (Yamasaki et al., 2002). 
 
This reduction in the generation of passive tension is postulated to aid ventricular filling during 
periods of β-adrenergic stimulation, associated with an increase in heart rate (Yamasaki et al., 2002). 
As passive tension may significantly contribute to shortening velocity at longer sarcomeric lengths 
(Minajeva et al., 2002), the reduction in passive tension, brought about by β-adrenergic stimulation, 
may result in a decrease, rather than an increase, in force generation. This finding suggests that the 
PKA-dependent phosphorylation of titin is not responsible for the increase in force generation 
observed following β-adrenergic stimulation of the heart (England, 1975; Solaro et al., 1976).  
                   Z2     Z1 
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I.7. MYOSIN BINDING PROTEIN C 
 
Myosin binding protein C was first described three decades ago as a “contaminant of myosin 
preparations” (Offer et al., 1973). Since then, this protein has graduated from a mere contaminant to 
being an integral part of the thick filament with important structural and regulatory functions.  
 
The myosin binding protein family (MyBP) consists of MyBPC and MyBPH, both of which are 
members of the immunoglobulin superfamily (Vaughan et al., 1993). MyBPC and MyBPH share a 
significant amount of amino acid sequence homology, specifically in their C-terminal regions (figure 
I.16) (Vaughan et al., 1993).  
 
Three isoforms of MyBPC have been identified in striated muscle, namely, the fast skeletal 
(fsMyBPC), slow skeletal (ssMyBPC also previously known as MyBPX) and cardiac (cMyBPC) 
isoforms (Reinach et al., 1982; Yamamoto and Moos, 1983; Obinata et al., 1984). All three isoforms 
consist mainly of IgC2 and Fn3 domains (Einheber and Fischman, 1990; Furst et al., 1992; Vaughan 
et al., 1993; Weber et al., 1993). As the cardiac isoform is involved in the pathophysiology of HCM 
and plays an important role in the regulation of cardiac contractility, this isoform is specifically 
relevant to the present study. Its structure and function will, therefore, be described in detail in this 
section. 
 
I.7.1. STRUCTURE OF THE MyBP FAMILY 
 
The overall structure of cMyBPC is that of an elongated protein, about 40-44nm in length and 3nm 
in diameter (Hartzell and Sale, 1985). The skeletal MyBPC isoforms each consists of seven IgC2 
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(domains C1, C2, C3, C4, C5, C8 and C10) and three Fn3 domains (domains C6, C7 and C9) 
(Einheber and Fischman, 1990; Furst et al., 1992; Okagaki et al., 1993; Vaughan et al., 1993; Weber 
et al., 1993; Gautel et al., 1995; Carrier et al., 1997; Bennett et al., 1999), while the cardiac isoform 
has an additional N-terminal IgC2 domain (domain C0) (Carrier et al., 1997). In addition to IgC2 and 
Fn3 domains, the MyBPC family is characterised by the presence of a motif specific to MyBPC 
located between domains C1 and C2 (MyBPC motif) and a region rich in proline and alanine 
residues (PA-region). In the skeletal isoforms, the PA-region is located at the N-terminal of the 
protein, while it separates the C0 and C1 domains in the cardiac isoform (figure I.16.) (Einheber and 
Fischman, 1990; Furst et al., 1992; Okagaki et al., 1993; Vaughan et al., 1993; Weber et al., 1993; 
Gautel et al., 1995; Carrier et al., 1997; Bennett et al., 1999). Furthermore, short interdomain linker 
sequences are present between domains C4 and C5, C6 and C7, C7 and C8, as well as between 
domains C9 and C10 in all MyBPC isoforms (figure I.16) (Okagaki et al., 1993; http://smart.embl-
heidelberg.de/smart/). In addition to the presence of the C0 domain, the cardiac isoform further 
differs from the skeletal isoforms in that nine and twenty-eight amino acid residue loops are inserted 
into the MyBPC motif and the C5 domain, respectively (figure I.16) (Gautel et al., 1995; Yasuda et 
al., 1995; Freiburg and Gautel, 1996). 
 
The second member of the MyBP family, MyBPH, consists of only two IgC2 (domains 2 and 4), and 
two Fn3 domains (domains 1 and 3) (Vaughan et al., 1993). Interestingly the domain distribution of 
MyBPH corresponds precisely with that of the final four domains of MyBPC, namely Fn3-IgC2-
Fn3-IgC2. This conservation suggests a common function for MyBPH and the four C-terminal 
domains of MyBPC, namely binding of myosin and titin, with the major myosin binding-site located 
in the last IgC2 domain of both molecules (figure I.16) (Vaughan et al., 1993; Welikson and 
Fischman, 2002). 
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Figure I.16. Structure of the MyBPC and MyBPH 
Structure of a) MyBPH and b) cMyBPC. Circles = immunoglobulin C2 domains;     = fibronectin type 3 
domains;     = MyBPC motif;      = interdomain linkers;     = PA-region;     = unique N-terminal region of 
MyBPH; P  = PKA and MyBPC-associated kinase phosphorylation sites; red areas = cardiac-specific 
regions, absent in fsMyBPC and ss MyBPC. The arrows below the figure indicate the positions of the binding-
sites for light meromyosin (LMM), myosin S2 and titin. 
 
I.7.2. C-ZONE LOCALISATION OF MyBPC  
 
The myosin binding proteins (MyBPC and MyBPH) are found in 11 transverse stripes, spaced 43nm 
apart, in the C-zone of the sarcomere (numbered 1-11 from the Z-disk to the M-line) (figure I.17) 
(Offer, 1972). The distribution of MyBPC and MyBPH at these positions within the C-zone is, 
however, both species- and fibre-specific (table I.3) (Craig and Offer, 1976; Dennis et al., 1984; 
Bahler et al., 1985; Starr et al., 1985; Bennett et al., 1986; Bennett et al., 1999). The precise 
distribution of cMyBPC within the C-zone of the cardiac sarcomere has, however, not been reported. 
Incorporation of MyBPC into these specific positions in the C-zone is mediated by interactions 
between its C-terminal region and both LMM and C-zone titin (sections I.7.3.1 and I.7.3.2) (Okagaki 
et al., 1993; Labeit and Kolmerer, 1995; Freiburg and Gautel, 1996; Bennett et al., 1999; Miyamoto 
et al., 1999). 
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Figure I.17. Distribution of MyBPs within the sarcomere 
      = Sarcomeric M-line,      = thick filament;      = thin filaments;      = positions of the 43nm periods in 
which the MyBPs are found. The arrows at the top of the figure indicated the lengths of the P-, C- and D-
zones. 
 
I.7.3. INTERACTIONS OF MyBPC WITH OTHER SARCOMERIC COMPONENTS 
 
I.7.3.1. Interactions between MyBPC and LMM 
 
The major myosin binding-site of MyBPC is located in the C-terminal IgC2 domain (domain C10), 
which binds tightly to LMM (Okagaki et al., 1993). In studies in which MHC and various portions of 
MyBPC or MyBPH were co-transfected into COS cells, the presence of the C10 domain of MyBPC, 
or the co-equivalent H4 (C-terminal) domain of MyBPH, were required for MHC-MyBP co-polymer 
cable formation (Sebillon et al., 2001; Welikson and Fischman, 2002). Truncated MyBPC and 
MyBPH molecules, lacking the C10 or H4 domains respectively, co-localised with MHC within the 
COS cells but did not facilitate cable formation (Welikson and Fischman, 2002). These findings 
prompted Welikson and Fischman (2002) to speculate that the C10 domain of MyBPC and the H4 
domain of MyBPH are able to associate with more than one LMM molecule, thus serving as a 
multivalent crosslinker, facilitating cable formation. Previously, Miyamoto et al., (1999) showed that 
charged residues on the surface of the C10 domain facilitate its interaction with LMM. This finding 
P-zone 
0.2µm 
D-zone 
0.3µm 
C-zone 
0.3µm 
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Table I.3. Distribution of MyBP isoforms in various skeletal muscle types 
Pattern of immuno-labeling with fast skeletal MyBPC-, slow skeletal MyBPC- and MyBPH- antibodies, in the 
43nm period stripes in rabbit and chicken skeletal muscle. Data taken from Craig and Offer, 1976; Dennis et 
al., 1984; Bahler et al., 1985; Starr et al., 1985 and Bennett et al., 1986. Figures in brackets indicate where 
labeling was weak or where data suggests more than one protein occurs. 
 
Muscle  Fibre type fsMyBPC ssMyBPC MyBPH 
Rabbit     
psoas Unspecified 1-7*  
 Fast white 1-8 - 9 
 Fast intermediate 1-7 8 9 
 Fast red - 1-9 - 
 Slow red - 1-9 - 
plantaris Fast white 1-7 (9) 8-9 - 
 Fast intermediate (1-7) (1-7) 8-9 - 
 Fast red - 1-9 - 
 Slow red - 1-9 - 
solius Slow red - 1-9 - 
Chicken     
pectoralis fast (1-7) (9) - (1-7) 8-9 
PLD fast (1-6) (9) (10) (1-6) 7-8 (9) ? 
ALD slow - 1-9 - 
* = MyBPC isoform not specified Craig and Offer, 1976 
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led the authors to propose a model in which the C10 domain is partially imbedded in a surface 
groove of the thick filament backbone (section IV.3) (Squire, 1973; Chew and Squire, 1995; Squire 
et al., 1998), allowing it to interact with three or four LMM molecules through ionic interactions, 
thus facilitating crosslinking of LMM molecules (figure I.18) (Miyamoto et al., 1999). The specific 
implications and merit of this model will be further discussed in section IV.3.1.3. In the light of these 
findings, it seems likely that interaction between the C10 domain of MyBPC and LMM both 
facilitates the anchoring of MyBPC to the thick filament backbone and plays an essential role in the 
regulation of thick filament formation and maintenance (Okagaki et al., 1993; Welikson and 
Fischman, 2002). 
 
 
 
 
 
 
Figure I.18. Interaction-surface model between MyBPC domain C10 and LMM 
Relative space-packing models of domain C10 of MyBPC and LMM.      = Domain C10 of MyBPC;     = LMM 
molecules; R37, R73, R74, R56 and E52 = residues which affect binding affinity when mutated (numbering 
according to Miyamoto et al., 1999) (from Miyamoto et al., 1999). 
 
The finding that a truncated MyBPH construct, lacking the H4 domain, co-localised with MHC 
prompted Welikson and Fischman (2002) to propose that a secondary LMM binding-site is localised 
in the H1-H3 region of MyBPH. Based on the shared homology between the H1-H3 region of 
MyBPH and the C7-C9 region of MyBPC, the authors suggested that a secondary LMM binding-site 
might also be located in the C7-C9 region of MyBPC (Welikson and Fischman, 2002). This finding 
R37 
R73 R74 R56 
E52 
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is in step with the findings of Okagaki et al., (1993), who showed that, although the major myosin 
binding-site is located in the C10 domain, other regions of MyBPC were also able to interact with 
myosin. 
 
Although the interaction between domain C10 and LMM is likely to be essential for the stable 
anchoring of MyBPC to the thick filament backbone, this interaction alone cannot explain the 
specific C-zone localisation of MyBPC, as LMM is not restricted to only the C-zone (Okagaki et al., 
1993).  
 
I.7.3.2. Interaction between MyBPC and C-zone titin 
 
In addition to its interaction with LMM, the C-terminal region of MyBPC also interacts with C-zone 
titin, and it is likely to be this interaction that specifies the C-zone localisation of MyBPC (Labeit et 
al., 1992; Labeit and Kolmerer, 1995; Freiburg and Gautel, 1996). The major titin binding-site has 
been mapped to the three C-terminal domains of MyBPC (C8, C9 and/or C10) (figure I.16) (Labeit et 
al., 1992; Labeit and Kolmerer, 1995; Freiburg and Gautel, 1996). Although the specific location of 
this binding-site within the C8-C10 region remains unclear, the data presented by Freiburg and 
Gautel (1996) suggests that the titin binding-site is located in the C9-C10 region of MyBPC, rather 
than in the C8 domain, as a MyBPC C5-C8 peptide did not interact with titin. It can, therefore, be 
presumed that the major titin binding-site is housed in either the C9 or C10 domain of MyBPC, or 
may span the C9-C10 junction, thereby requiring the presence of both these domains. In the 
experiments conducted by Freiburg and Gautel (1996) the C8-C10 fragment bound tightly to each of 
the first IgC2 domains of the eleven 11-domain super-repeats that constitute C-zone titin (A43, A54, 
A65, A76, A87, A98, A109, A120, A131, A142, A153) (figure I.9 and section I.6.3.2). It is 
interesting to note that domain A153 of titin is also able to bind to the C-terminal region of MyBPC 
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in these in vitro binding assays, although MyBPC has to date never been found in stripe eleven of the 
43nm period, which corresponds to the position of this domain in the intact sarcomere (table I.3 and 
figure I.17) (Bennett et al., 1986; Labeit and Kolmerer, 1995; Freiburg and Gautel, 1996). 
Furthermore, the possibility of a secondary titin binding-site in the N-terminal or central region of 
MyBPC cannot be excluded by this study, as the methods employed were only able to detect 
relatively strong interactions in an in vitro environment (Freiburg and Gautel, 1996).  
 
I.7.3.3. Domain C7 of MyBPC essential for correct A-band incorporation 
 
Although the C9 and C10 domains of MyBPC house the major thick filament anchoring LMM and 
titin binding-sites (sections I.7.3.1 and I.7.3.2), Gilbert et al., (1996) have shown that the whole of 
the C7-C10 region of MyBPC is required for correct incorporation of MyBPC into the sarcomere. 
Although the presence of domain C7 is not absolutely essential for the C-zone incorporation of 
MyBPC, the presence of this domain dramatically increases the affinity and specificity of the binding 
of MyBPC to this region of the thick filament (Gilbert et al., 1996; Gilbert et al., 1999). The precise 
nature of the involvement of the C7 domain in facilitating this interaction, however, remains unclear. 
It can, therefore, be postulated that this domain may be involved in an, as yet, unidentified 
protein:protein interaction.  
 
I.7.3.4. Interaction between the MyBPC-motif and the S2 region of myosin 
 
In addition to interactions between the C-terminal region of MyBPC and components of the thick 
filament, the MyBPC-motif, located between domains C1 and C2 in the N-terminal region of 
MyBPC, interacts with the S2 region of myosin (figure I.16) (Moos et al., 1975; Starr and Offer, 
1978; Gruen and Gautel, 1999; Gruen et al., 1999; Kunst et al., 2000). The MyBPC-motif binds to 
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the proximal 126 amino acid residues of myosin S2, adjacent to the MRLC binding-site, independent 
of MyBPC or myosin isoforms (figures I.16 and I.19) (Gruen and Gautel, 1999; Gruen et al., 1999; 
Kunst et al., 2000). In the skeletal MyBPC isoforms, this interaction is thought to be constitutive, 
while this interaction is regulated by phosphorylation of the MyBPC-motif in the cardiac isoform 
(Gruen et al., 1999; Kunst et al., 2000) and may, therefore, play an essential role in the cMyBPC-
mediated regulation of cardiac contractility (section I.7.7).  
 
 
 
 
 
 
 
Figure I.19. Structure of myosin II protein 
       = Myosin subfragment 1 (myosin head region);       = α-helical portion of myosin II,     = myosin 
essential light chain;     = myosin regulatory light chain; blue arrow = MyBPC domain C10 binding-
site; red arrow = MyBPC-motif binding-site; HMM = heavy meromyosin; LMM = light 
meromyosin; S1 = heavy meromyosin subfragment 1; S2 = heavy meromyosin subfragment 2. 
 
I.7.3.5. Interaction between MyBPC and F-actin 
 
In vitro binding assays have shown that MyBPC is able to bind to F-actin at high ionic 
concentrations (>0.1M) (Moos et al., 1978; Moos, 1981). The precise region of MyBPC involved in 
this interaction has, however, remained unclear, until recently when Kulikovskaya et al., (2003) 
proposed that the C0 domain of cMyBPC interacts with F-actin, while Squire et al., (2003) proposed 
that the PA-region houses the F-actin binding-site.  
HMM 
S1 
S2 
LMM 
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Kulikovskaya et al., (2003) showed that the C0 domain of cMyBPC was able to interact with F-actin 
in vitro. In order to establish whether this interaction took place in vivo, skinned cardiac trabeculae 
were soaked in a relaxing solution containing various cMyBPC fragments (Kulikovskaya et al., 
2003). These experiments showed that the C0 domain of cMyBPC was able to bind to a myofibrillar 
protein, presumably F-actin, when endogenous cMyBPC was unphosphorylated (Kulikovskaya et al., 
2003).  
 
In contrast, the proposed presence of an F-actin binding-site in the PA-region of MyBPC (Squire et 
al., 2003) is based on multiple sequence alignments between this region of MyBPC and A1 MELC, 
which have been shown to be able to interact with F-actin (Timson et al., 1997; Timson et al., 1998; 
Squire et al., 2003). The presence of an interaction between the PA-region and F-actin, however, 
remains to be proven experimentally.  
 
I.7.4. PHOSPHORYLATION OF cMyBPC 
 
Phosphorylation of cMyBPC is mediated through two primary mechanisms. Firstly, an increase in 
intracellular Ca2+ concentration, below the threshold for thin filament activation (section I.2.1), 
results in the phosphorylation of cMyBPC to a maximum of one mol per mol cMyBPC (Schlender 
and Bean, 1991; Gautel et al., 1995; McClellan et al., 2001). This phosphorylation reaction is 
thought to be mediated by the actions of MyBPC-associated kinase, proposed to be a CaM kinase II 
that co-purifies with cMyBPC (Hartzell and Glass, 1984; Schlender and Bean, 1991; Gautel et al., 
1995). The second mechanism responsible for the phosphorylation of cMyBPC involves the cAMP-
mediated activation of PKA, upon β-adrenergic stimulation, resulting in cMyBPC being 
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phosphorylated to a maximum of three mol phosphate per mol cMyBPC (Hartzell and Titus, 1982; 
Hartzell and Sale, 1985; Gautel et al., 1995). 
 
In mammalian cMyBPC, the phosphorylation sites for both MyBPC-associated kinase and PKA are 
located in the MyBPC-motif (figure I.16) (Gautel et al., 1995; Mohamed et al., 1998). Amino acid 
sequence analysis of this region revealed the presence of four putative phosphorylation sites, 
designated sites A to D (figure I.20) (Gautel et al., 1995). Site-directed mutagenesis of these sites 
showed that, specifically, site B was the substrate for MyBPC-associated kinase, sites A, B and C the 
substrate for PKA and that site D was not phosphorylated by either kinase (Gautel et al., 1995). 
Additionally, mutagenesis of site B showed phosphorylation of this site, located in the cardiac-
specific LAGGGRRIS insertion, was essential for the subsequent phosphorylation of sites A and C 
by PKA (Gautel et al., 1995). Subsequently, McClellan et al., (2001) have shown that the in situ 
PKA-dependent phosphorylation of cMyBPC is dependent on an elevation of intracellular Ca2+ 
concentration. The incubation of skinned fibres in a solution containing a low concentration of Ca2+ 
(1.25mM) and PKA did not result in the phosphorylation of cMyBPC, while control fibres incubated 
in a solution containing 2.5mM Ca2+ and PKA resulted in cMyBPC being either di- or tri-
phosphorylated. Under neither of these conditions did the influx of Ca2+ from the bathing solution 
stimulate contraction, suggesting that the intracellular Ca2+ concentration necessary for PKA-
dependent phosphorylation of cMyBPC was lower than the threshold required for thin filament 
activation and subsequent contraction (McClellan et al., 2001). Based on these findings, McClellan 
et al., (2001) proposed that phosphorylation of cMyBPC by PKA can only take place once cMyBPC 
has been mono-phosphorylated by MyBPC-associated kinase.  
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From these findings, it can be concluded that cMyBPC would be phosphorylated, at the cardiac-
specific phosphorylation site in the MyBPC-motif (site B), by MyBPC-associated kinase in a Ca2+-
dependent fashion. In turn, mono-phosphorylation at site B would trigger a conformational change in 
the MyBPC-motif that would make the PKA-specific phosphorylation sites (sites A and C) 
accessible to PKA (Gautel et al., 1995; McClellan et al., 2001). It, however, remains unclear whether 
the phosphorylation/ dephosphorylation cycle of site B by MyBPC-associated kinase and MyBPC-
associated phosphatase (section I.7.5) is coupled to the normal myocytic Ca2+ flux, caused by 
depolarisation of the sarcolemma, or whether a time-averaged increase in the Ca2+-transient would be 
required for this site to be phosphorylated (McClellan et al., 2001).  
 
 
 
 
MGTGDLDLLS AFRRTSLAGG GRRISDSHED TGILDFSSLL KKRDSFRTRR DSKLEAPAEE 
DVWEILRQAP PSEYERIAFQ YGVTDLRGML KRLKGMRRDE KKSTA 
 
Figure I.20. Location of phosphorylation sites in cMyBPC 
The diagram at the top of the figure shows the C1-C2 region of cMyBPC, including the MyBPC motif in which 
the phosphorylation sites are found. Partial amino acid sequence of the MyBPC motif is shown below the 
diagram. Bold lettering = cardiac-specific LAGGGRRIS insertion; red, underlined lettering = putative 
phosphorylation sites, designated A, B, C and D (from Gautel et al., 1995). 
 
In addition to phosphorylation by MyBPC-associated kinase and PKA, it was shown that PKC is also 
able to phosphorylate sites A and C in the MyBPC-motif (Venema and Kuo, 1993; Mohamed et al., 
1998), while a PKC-specific phosphorylation site was also identified in the C9 domain of chicken 
cMyBPC (S1169 chicken cMyBPC sequence) (Mohamed et al., 1998). Multiple sequence 
…………..                                     ……………… C2C1 MyBPC motif 
A B C
D 
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alignments, however, revealed that phosphorylatable amino acids were absent at this position in 
domain C9 of both human and mouse cMyBPC (Mohamed et al., 1998). The functional importance 
of PKC phosphorylation of cMyBPC in vivo, however, remains unclear. 
 
The phosphorylation of cMyBPC at sites in the MyBPC-motif, by MyBPC-associated kinase and 
PKA, results in S2 being released from the MyBPC-motif (Gruen et al., 1999; Kunst et al., 2000; 
Levine et al., 2001), as well as an expansion in the thick filament backbone, thereby altering cardiac 
contractility (Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; Levine et al., 2001). 
The proposed mechanisms through which phosphorylation of cMyBPC cause these structural 
changes, resulting in alterations in the contractile properties of the sarcomere, will be discussed in 
detail in section I.7.6. 
 
I.7.5. DEPHOSPHORYLATION OF cMyBPC 
 
In vitro studies have shown that cMyBPC is dephosphorylated through the activation of cGMP 
dependent pathways, following cholinergic stimulation (Hartzell and Titus, 1982; Garvey et al., 
1988). Additionally, it was shown that a protein co-purifying with cMyBPC had some phosphatase 
activity and was able to reduce the phosphorylation level of cMyBPC by about 35%. As it has 
previously been shown that cMyBPC is dephosphorylated by phosphatases 1 and 2A in vitro 
(Schlender et al., 1987; Schlender et al., 1989), it was speculated that this MyBPC-associated 
phosphatase belongs to the same family (Schlender and Bean, 1991). cMyBPC is maximally tri-
phosphorylated by PKA and MyBPC-associated kinase (section I.4.3). It is, therefore, plausible that 
MyBPC-associated phosphatase is only able to dephosphorylate one of the three phosphorylation 
sites. As site B is phosphorylated specifically by MyBPC-associated kinase, while sites A and C are 
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both phosphorylated specifically by PKA, it can be speculated that MyBPC-associated phosphatase 
would specifically dephosphorylate site B, while sites A and C are probably dephosphorylated by 
cGMP dependent pathways, following cholinergic stimulation. The finding that the increase in 
actomyosin ATPase activity resulting from cMyBPC phosphorylation (section I.7.6) is lost even in 
the absence of cholinergic stimulation (England, 1976; Horowits and Winegrad, 1983), however, 
suggests that cMyBPC may also be dephosphorylated through other, as yet unidentified, mechanisms 
in vivo. 
 
I.7.6. FUNCTIONS OF cMyBPC 
 
Several studies have implicated cMyBPC as an important regulator of both thick filament structure 
(Koretz, 1979; Seiler et al., 1996; Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; 
Miyamoto et al., 1999; Kunst et al., 2000; Levine et al., 2001; Welikson and Fischman, 2002) and 
cardiac contractility (Hofmann et al., 1991; Weisberg and Winegrad, 1996; Weisberg and Winegrad, 
1998; Kunst et al., 2000; Levine et al., 2001; McClellan et al., 2001). In vitro and in situ studies have 
shown that MyBPC is essential for the formation of normal thick filaments, and that specifically the 
C-terminal domain (C10) was responsible for this function (Seiler et al., 1996; Miyamoto et al., 
1999; Welikson and Fischman, 2002). Harris et al., (2002), however, showed that sarcomeric 
assembly and maintenance was not dramatically affected by the absence of cMyBPC in homozygous 
cMyBPC knockout mice, even though these mice showed classical features of HCM and both 
systolic and diastolic function was impaired (table I.2). This finding strongly suggests that, even 
though MyBPC is able to modulate thick filament structure, it is not absolutely essential for thick 
filament assembly and that in the absence of cMyBPC other proteins, such as MyBPH, may fulfill 
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this function (Harris et al., 2002). The finding that contractile function, both systolic and diastolic, 
was impaired in these mice, however, underlines the regulatory role of cMyBPC.  
 
Recent studies have shown that phosphorylation of cMyBPC results in alterations in the structure of 
both the thick filament backbone (Weisberg and Winegrad, 1998; Levine et al., 2001) and 
crossbridges (Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; Kunst et al., 2000; 
Levine et al., 2001), and that these structural changes give rise to altered contractile properties. As 
these findings clearly show that the structural and regulatory functions of cMyBPC are intimately 
intertwined, they will be discussed together in the following sections. 
 
I.7.6.1. Effect of cMyBPC phosphorylation on thick filament structure 
 
In a study conducted by Levine et al., (2001), it was shown that cardiac sarcomeric thick filaments 
are found in one of three distinct structures, namely, a “disordered” structure, a “tight” structure and 
a “loose” structure. The prevalence of each of these structures was found to be directly correlated to 
the phosphorylation status of cMyBPC (figure I.21). 
 
I.7.6.1.i. “Disordered” thick filament structure 
When cMyBPC was unphosphorylated, the majority of thick filaments were found to be in the 
“disordered” structure (figure I.21). This structure is characterised by crossbridges extending from 
the thick filament backbone at varying angles (table I.4) (Levine et al., 2001). The total diameter of 
“disordered” thick filaments, including crossbridge extensions, varied from 24nm to 39nm (table I.4) 
(Levine et al., 2001). Previously, Weisberg and Winegrad (1996 and 1998) described a similar thick 
filament structure with a diameter of about 30 to 31nm, with crossbridges  
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Figure I.21. Effect of cMyBPC phosphorylation on thick filament structure 
Relation between the percentage of maximum phosphorylation of cMyBPC and the relative percentage of 
each of the structures of the thick filament. Black line = “loose” conformation; blue line = “disordered” 
conformation; red line =” tight” conformation. From Levine et al., 2001. 
 
extending about 2 to 7nm from the thick filament backbone, when cMyBPC was unphosphorylated 
(table I.4). In the light of the finding that the interaction between the MyBPC-motif of cMyBPC and  
myosin S2 is abolished by the phosphorylation of cMyBPC, it seems plausible that this interaction 
may alter crossbridge structure, thereby giving rise to thick filaments with a “disordered” structure 
(Gruen et al., 1999; Kunst et al., 2000; Levine et al., 2001), analogous to the findings of Knight 
(1996).  
 
Knight (1996) showed that an antibody directed against the 25 proximal amino acids of myosin S2, 
housing the MyBPC-motif binding-site (Gruen and Gautel, 1999; Gruen et al., 1999), binds 
specifically to MHC dimers in which myosin S2 is in a random coil, rather than a coiled-coil 
conformation (figure I.22) (Knight, 1996). It is unclear from this study whether the binding of this 
antibody was dependent on the presence of S2 fragments with a random coil conformation, or 
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whether the binding of the antibody induced the conformational change in S2 from coiled-coil to 
random coil (Knight, 1996). Although Knight (1996) favoured the former scenario, it is intriguing to 
speculate on  the possibility that the binding of a ligand, such as the MyBPC-motif, to this portion of 
S2 may dramatically affect the structure of S2.  
 
If the binding of the MyBPC-motif is indeed responsible for the transition of myosin S2 from a 
coiled-coil to a random coil conformation, it may explain the formation of thick filaments with a 
“disordered” structure. In this scenario, only a specific fraction of myosin S2 molecules would be 
associated with a MyBPC-motif when cMyBPC is unphosphorylated, and would, therefore, be in the 
random coil conformation. As myosin S2 in a random coil conformation is both longer, and more 
flexible, than S2 in a coiled-coil conformation (Knight, 1996), it may explain why crossbridges 
extend from the thick filament backbone at different angles when cMyBPC is unphosphorylated, 
resulting in thick filaments taking on a “disordered” conformation (Levine et al., 2001). 
 
I.7.6.1.ii. “Tight” thick filament structure 
When cMyBPC was mono-phosphorylated, the majority of thick filaments were found to be in the 
“tight” conformation (Levine et al., 2001) (figure I.21). This structure is characterised by the 
crossbridges being ordered along the thick filament backbone. The diameter of thick filaments with a 
“tight” structure, including crossbridge extensions, was generally 29.8nm (table I.4.2) (Levine et al., 
2001). Mono-phosphorylation of cMyBPC, at site B in the MyBPC-motif, is achieved through the 
actions of MyBPC-associated kinase in response to an increase in the intracellular Ca2+ concentration 
(section I.7.4) (Gautel et al., 1995; McClellan et al., 2001). Even though the precise extent of 
cMyBPC phosphorylation, required for the abolition of the interaction between the MyBPC-motif 
and myosin S2, has not been tested experimentally (Gruen et al., 1999; Kunst et al., 2000), Levine et 
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Figure I.22. Transition of myosin S2 from a coiled-coil conformation to a random coil conformation 
associated with the binding of an antibody to S2 
A = Conformation of myosin heavy chain dimers with S2 and LMM in the coiled-coil conformation; B = 
conformation of myosin heavy chain dimers with S2 in a random coil conformation, allowing the binding of a 
myosin S2 antibody.      = myosin heavy chain molecules;     = myosin S2 antibody (adapted from Knight, 
1996). 
 
al., (2001) proposed that it is the abolition of the MyBPC-myosin S2 interaction that results in the 
formation of the “tight” thick filament structure seen upon cMyBPC mono-phosphorylation.  
 
It could be proposed that the abolition of the interaction between the MyBPC-motif and myosin S2, 
by mono-phosphorylation of cMyBPC, would result in a conformational change in S2 from a random 
coil to a coiled-coil structure (Knight, 1996). This conformational change would result in a decrease 
in crossbridge flexibility and a subsequent increase in crossbridge order, with all crossbridges being 
arranged orderly along the thick filament backbone (Knight, 1996; Levine et al., 2001).  
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I.7.6.1.iii. “Loose” thick filament structure 
When cMyBPC was either di- or tri-phosphorylated, the majority of thick filaments were found to 
have a “loose” structure (figure I.21). As with thick filaments in the “tight” structure, crossbridges 
were highly ordered along the thick filament backbone. The diameter of thick filaments with a 
“loose” structure, including crossbridge extensions, was, however, significantly larger than thick 
filaments with a “tight” structure (34.2nm) (table I.2) (Levine et al., 2001). Previously, Weisberg and 
Winegrad, (1996 and 1998) described a similar thick filament structure with a diameter of about 
36nm, with crossbridges extending consistently only about 2nm from the thick filament backbone, 
following PKA-mediated phosphorylation of cMyBPC (table I.4). It was proposed that this increase 
in thick filament diameter was a result of an expansion in the thick filament backbone, rather than an 
increase in the distance that crossbridges extend into the interfilament space (Weisberg and 
Winegrad, 1998; Levine et al., 2001). Following phosphorylarion of site B by MyBPC-associated 
kinase, phosphorylation of sites A and C by PKA results in cMyBPC being di- and tri-
phosphorylated. It can, therefore, be speculated that expansion in the diameter of the thick filament 
backbone, resulting in the formation of thick filaments with a “loose” structure, would take place in 
response to β-adrenergic stimulation (Gautel et al., 1995; Weisberg and Winegrad, 1998; Levine et 
al., 2001; McClellan et al., 2001). The mechanisms through which PKA-dependent phosphorylation 
of cMyBPC results in the expansion of the thick filament backbone have, however, remained elusive. 
As results obtained in this study may shed new light onto this subject, these mechanisms will be 
discussed in section IV.3. 
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Table I.4. Effect of cMyBPC phosphorylation on thick filament structure 
Muscle 
type 
Species MYH type cMyBPC PO4 TF (bare zone) TF (A-band) TF backbone 
(A-band) 
Crossbridge 
extension 
Ref 
Skeletal Fish N.D. N 13-16nm 25-27nm* 13-15nm 6nm 1 
Cardiac Rat α-MHC N 20.1nm# 30nm/37nm# 16nm/23nm*# ND 2 
Cardiac Rat α-MHC Y 20.1nm# 36nm# 31.6nm*# ND 2 
Cardiac Rat α-MHC N 16nm# 31nm/37nm# 17nm/23nm*# 2-7nm 3 
Cardiac  Rat α-MHC Y 16nm# 36nm# 31.6nm*# 2.2nm 3 
Cardiac Rat β-MHC N N.D. 25nm/31nm# 21nm/27nm*# 2nm 3 
Cardiac Rat β-MHC Y N.D. 27nm# 25.4nm*# 0.8nm 3 
Cardiac Rat α-MHC N ND 24-39nm# ND “disordered” 4 
Cardiac Rat α-MHC Y (mono) ND 29.8nm# ND “close” 4 
Cardiac Rat α-MHC Y (di/tri) ND 34.2nm# ND “close” 4 
N = no; N.D. = not determined; Ref = reference; TF = thick filament diameter; Y = yes; * = deduced value; # = values not corrected for metal coat 
thickness; 1 = Squire et al., 1998; 2 = Weisberg and Winegrad, 1996; 3 = Weisberg and Winegrad, 1998; 4 = Levine et al., 2001. In cases where there 
was a bimodal distribution of thick filament diameters, the diameter of the most prevalent fraction is indicated in bold lettering. Deduced values were 
normalised for the contribution of crossbridge extensions to the total thick filament diameter. 
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I.7.7. EFFECT OF cMyBPC PHOSPHORYLATION ON CARDIAC CONTRACTILITY 
 
Several studies have shown that β-adrenergic stimulation of intact cardiac muscle results in a marked 
increase in contractile force, of up to 70% (England, 1975; Solaro et al., 1976). The findings that 
PKA-dependent phosphorylation of cTNI, PLB or titin does not result in an increase in force 
production (sections I.4; I.5; I.6) have resulted in a hypothesis that phosphorylation of cMyBPC is 
responsible for this increase in force production. This view is supported by the findings of McClellan 
et al., (1994) that cMyBPC is the only myofibrillar protein in which the degree of phosphorylation is 
consistently correlated with the level of  actomyosin ATPase activity in rat ventricular tissue upon 
adrenergic stimulation.  
 
At a structural level, phosphorylation of cMyBPC results, firstly, in the abolition of the interaction 
between the MyBPC-motif and myosin S2 (Gruen and Gautel, 1999; Gruen et al., 1999; Kunst et al., 
2000), resulting in the transition of thick filaments from the “disordered” to the “tight” structure 
(sections I.7.6.1.1 and I.7.6.1.2) (Levine et al., 2001). McClellan et al., (2001), however, showed that 
mono-phosphorylation of cMyBPC, responsible for this transition, is likely to be mediated by 
MyBPC-associated kinase in a Ca2+-dependent fashion, rather than by PKA (Gautel et al., 1995; 
Levine et al., 2001; McClellan et al., 2001). Secondly, PKA specifically phosphorylates sites A and 
C in the MyBPC-motif, resulting in cMyBPC being di- or tri-phosphorylated, leading to an 
expansion of the thick filament backbone and the formation of thick filaments with a “loose” 
structure (section I.7.6.1.3) (Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; Levine 
et al., 2001; McClellan et al., 2001). As these two mechanisms are likely to be activated by different 
stimuli and give rise to distinct thick filament structures, each likely to have specific contractile 
properties, they will be discussed separately in sections I.7.7.1 and I.7.7.2.  
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I.7.7.1. Transition of thick filaments from a “disordered” to a “tight” structure 
 
The transition of thick filaments from a “disordered” to a “tight” structure, caused by the Ca2+-
dependent mono-phosphorylation of cMyBPC by MyBPC-associated kinase, probably results in the 
abolition of the interaction between the MyBPC-motif and myosin S2 (Gautel et al., 1995; Gruen et 
al., 1999, Kunst et al., 2000; Levine et al., 2001; McClellan et al., 2001). Levine et al., (2001) have 
shown that this transition results in a small, non-significant increase in the likelihood that thick 
filaments will associate with thin filaments in vitro (table I.5). Even though this difference did not 
reach statistical significance, it may indicate that the degree of crossbridge order influences the 
ability of crossbridges to bind to thin filaments (Levine et al., 2001). It was also shown that the 
binding of antibodies to myosin S2 results in a decrease in Ca2+-activated force, maximal sliding 
velocity and fibre stiffness, without affecting myosin ATPase activity (Margossian et al., 1991; Sugi 
et al., 1992). If it is assumed that the phosphorylation-dependent interaction between the MyBPC-
motif and myosin S2 affects crossbridge structure and contractility in a similar fashion to antibodies 
binding to myosin S2 (section I.7.6.1.1), these findings may indicate that fewer crossbridges are 
formed between thick and thin filaments when cMyBPC is unphosphorylated, compared to when 
cMyBPC is in its phosphorylated state. 
 
Kunst et al., (2000) showed that the transformation of unphosphorylated cMyBPC C1-C2 fragments 
into skinned muscle fibres resulted in a decrease in Ca2+-activated force by about 50%, indicating 
that the interaction between the MyBPC-motif and myosin S2 may induce a similar effect to 
antibodies binding to S2 (Margossian et al., 1991; Sugi et al., 1992). Contrary to findings that the 
binding of antibodies to myosin S2 reduces muscle stiffness (Margossian et al., 1991; Sugi et al., 
1992), Kunst et al., (2000) found that the interaction between the exogenous MyBPC-motif and 
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myosin S2 induced a significant increase in both rigour force and stiffness, without altering dynamic 
muscle stiffness, while also causing a slight, but significant, leftward shift in the Ca2+/force 
relationship. These results were interpreted as suggesting that the binding of the exogenous MyBPC-
motif to myosin S2 promotes the binding of crossbridges to the thin filament, while impairing 
movement of the myosin head-tail junction, resulting in a reduction in force generation (Kunst et al., 
2000). Winegrad (2000), however, suggested that the decrease in Ca2+-activated force, induced by 
the interaction between the MyBPC-motif and myosin S2, might be indicative of a reduction in the 
number of crossbridges attached to the thin filament. The increase in rigour force and rigour 
stiffness, observed by Kunst et al., (2000), was interpreted by Winegrad (2000) as indicative of an 
increase in the rate of ATP-depletion, rather than an increase in the number of crossbridges attaching 
to the thin filament. The latter scenario is supported by the findings of Levine et al., (2001), namely, 
that thick filaments with a “disordered” structure are less likely to associate with thin filaments than 
with those with a “tight” structure. 
 
When interpreting the results of Kunst et al., (2000), caution should be taken that the effect of the 
interaction between the MyBPC-motif and myosin S2 is not overestimated, due to the fact that 
exogenous cMyBPC fragments were transformed into the skinned fibres. The addition of exogenous 
unphosphorylated cMyBPC fragments would increase the number of crossbridges affected by this 
interaction. The effects observed might, however, be analogous to HCM-causing truncation 
mutations, in which truncated cMyBPC fragments may reduce contractility through association with 
myosin S2.  
 
In summary, therefore, the binding of the MyBPC-motif to myosin S2, when cMyBPC is 
unphosphorylated (Gruen et al., 1999; Kunst et al., 2000), may cause the S2 fragments of a 
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subpopulation of myosin molecules to assume a random coil, rather than a coiled-coil conformation 
(Knight, 1996), giving rise to the “disordered” thick filament structure. It is possible to speculate that 
myosin molecules in which the S2 fragments are in the random coil conformation are either not able 
to bind to thin filaments, or do so with a lower affinity. This would reduce the number of 
crossbridges bound to thin filaments, thus resulting in a reduction in Ca2+-activated force and 
possibly actomyosin ATPase activity.  
 
The transition of thick filaments from the “disordered” structure to the “tight” structure is achieved 
through the Ca2+-sensitive phosphorylation of site B in the MyBPC-motif by MyBPC-associated 
kinase (Gautel et al., 1995; McClellan et al., 2001), abolishing the interaction between the MyBPC-
motif and S2 (Gruen et al., 1999; Kunst et al., 2000). The abolition of this interaction would result in 
all S2 fragments assuming a coiled-coil conformation, as evidenced by the increase in crossbridge 
order (Levine et al., 2001). This increase in crossbridge order promotes the formation of weak 
interactions between thick and thin filaments, thereby, potentiating the thick filament, resulting in 
increased force production during systole. The physiological advantage of the “disordered” thick 
filament structure, however, remains unclear. One possible advantage might be that a reduction in 
the number of crossbridges interacting with the thin filament may aid relaxation and diastolic 
function, while a reduction in actomyosin ATPase activity might also reduce energy consumption. 
 
I.7.7.2. Transition of thick filaments from a “tight” to a “loose” structure 
 
The transition of thick filaments from the “tight” to the “loose” structure is thought to be facilitated 
by the PKA-dependent phosphorylation of sites A and C in the MyBPC-motif (Gautel et al., 1995; 
Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; Levine et al., 2001; McClellan et al., 
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2001). As described in section I.7.6.1.3, this transition is in all likelihood the result of an expansion 
of the thick filament backbone (Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; 
Levine et al., 2001). It was postulated that the expansion of the thick filament backbone would 
increase the proximity of myosin S1 to the thin filaments, thus favouring the formation of weak 
interactions between myosin S1 and the thin filament (Weisberg and Winegrad, 1996; Weisberg and 
Winegrad, 1998). The formation of these weak interactions would potentiate the sarcomere for 
contraction when Ca2+ is released from the SR during early systole. As a whole, this would lead to 
the increase in force production, actomyosin ATPase activity and crossbridge cycling rate observed 
in cardiac muscle following β-adrenergic stimulation (Weisberg and Winegrad, 1996). This 
hypothesis is strongly supported by the findings of Levine et al., (2001), who showed that thick 
filaments in the “loose” conformation associated with thin filaments at a significantly higher 
frequency than those in either the “disordered” or “tight” conformation (table I.5).  
 
Table I.5. Frequency of interactions between thick and thin filaments 
 
Thick filaments % of the total thick filaments % of parallel pairs interacting 
Untreated “tight” 58 29 
Untreated 
“disordered” 
12 16 
Untreated “loose” 30 89* 
Average of total 
untreated  
 47# 
PKA treated “loose” 84 92* 
 
*Significant difference (p < 0.05) from “tight” or “disordered” filaments 
# Significant difference (p < 0.05) between averages of untreated and PKA-treated filaments 
(Adapted from Levine et al., 2001) 
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The increase in the number of crossbridges forming weak interactions with the thin filament may, 
however, impair relaxation, ventricular filling and diastolic function during periods of β-adrenergic 
stimulation. The finding that PKA-dependent phosphorylation of cTNI, PLB and titin all aid diastolic 
function (sections I.4; I.5 and I.6) may indicate that these mechanisms are compensatory to the 
impairment of diastolic function caused by the PKA-dependent phosphorylation of cMyBPC. 
 
I.7.7.3. Interaction between cMyBPC domain C0 and actin as a regulator of cardiac 
contractility 
 
In vitro functional studies in which MyBPC has been extracted from intact myocytes have shown 
that, although cMyBPC lacks intrinsic ATPase activity, it has the ability to modulate the actin-
activated ATPase activity of myosin (Offer et al., 1973). The finding that MyBPC is able to bind to 
F-actin in solution and to thin filaments in skeletal muscle at high ionic strength (Moos et al., 1978; 
Moos, 1981) has led to the hypothesis that MyBPC may inhibit actomyosin ATPase activity by 
competing with myosin S1 for binding-sites on actin. In order to test this hypothesis, skinned muscle 
fibres and cardiac myocytes were stretched to lengths at which the individual sarcomeres would 
measure more than 3.2μm. At these sarcomeric lengths, there would be no overlap between the C-
zone, in which MyBPC is found, and the thin filament, therefore, preventing these competitive 
interactions (Hofmann et al., 1991). Hofmann et al., (1991), however, found a similar tension-pCa 
relationship in both long and short sarcomeres, suggesting that the shift in the tension-pCa 
relationship observed after partial extraction of MyBPC was not due to competetive binding of 
MyBPC and myosin S1 with actin (Hofmann et al., 1991). This finding casts a doubt over whether 
the interaction between MyBPC and actin observed in vitro by Moos et al., (1978) and Moos (1981) 
occurs in vivo. Based on findings that diastolic function is impaired by the absence of cMyBPC in 
cMyBPC-knockout mice (Harris et al., 2002), Kulikovskaya et al., (2003) proposed that an 
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interaction between the C0 domain of cMyBPC and F-actin (section I.7.3.5) might act as a tether 
during contraction. According to this hypothesis, force generated during systole would lead to the 
extension of the PA-region (located between domains C0 and C1), which shares homology to the 
extendible PVEK region of titin (section I.6.4.2.ii). During diastole, refolding of the PA-region 
would, therefore, lead to the shortening of this region, resulting in the generation of passive tension, 
which in turn would aid relaxation and ventricular filling (Kulikovskaya et al., 2003). This scenario, 
however, seems highly unlikely, as the PA-region is only 50 amino acids in length. If the 
calculations for the maximal extended chain lengths of the PVEK region of titin used by Linke et al., 
(1994) and Trinick (1996) is extrapolated to calculate the maximal chain length of the PA-region of 
cMyBPC, the maximal chain length of the PA-region would only be about 17nm, thus, not allowing 
significant shortening of the sarcomere during contraction if C0 remains bound to actin.  
 
I.7.8. HCM-CAUSING MUTATIONS IN cMyBPC 
 
To date, 93 HCM-causing mutations have been identified in MYBPC3. Unlike mutations in the other 
12 genes in which HCM-causing mutations have thus far been identified (table I.1), in which most 
mutations are single amino acid substitutions, about two thirds of MYBPC3 HCM-causing mutations 
result in the truncation of cMyBPC (figure I.23 and table I.6). Various estimates of the frequency at 
which HCM-causing mutations in MYBPC3 contribute to the burden of disease have been made, e.g., 
about 20% (Marian and Roberts, 2001), about 42% (Richard et al., 2003) and 18.5% (Erdmann et al., 
2003). Caution should, however, be observed when interpreting these mutation frequency values, as 
various formulae have been used to calculate these frequencies. Some authors calculate mutation 
frequency values by dividing the number of mutations in MYBPC3 in their HCM-affected population 
by the total number of mutations found in their HCM-affected population (Richard et al., 2003), 
while other authors divide the number of mutations in MYBPC3 in their HCM-affected population by 
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the total number of HCM-affected individuals in their study group (Erdmann et al., 2003). 
Furthermore, the frequency of cMyBPC-associated HCM appears to vary quite dramatically between 
various populations. Richard et al., (2003) and Erdmann et al., (2003) have found that mutations in 
MYBPC3 are a more prevalent cause of HCM than mutations in MYH7 in the French and German 
HCM-affected populations. In stark contrast to these findings, Konno et al., (2003) found only one 
specific MYBPC3 HCM-causing mutation in eight probands in a panel consisting of 250 HCM-
affected individuals of Japanese descent, indicating that cMyBPC-associated HCM may be rare in 
the Japanese population. From these findings, it can be concluded that, while in some populations 
mutations in MYBPC3 may be a prevalent cause of HCM, it may be quite rare in other populations.  
 
I.7.8.1. Phenotypic expression of cMyBPC-associated HCM 
 
Mutations in MYBPC3 have been associated with reduced penetrance until the fifth decade of life 
(Charron et al., 1998; Niimura et al., 1998; Konno et al., 2003). Furthermore, it has been reported 
that HCM-related deaths are less prevalent in MYBPC3 mutation-carriers than TNNT2 mutation-
carriers, or patients in which “malignant” MYH7 mutations (e.g., the R403Q mutation in MYH7) 
have been identified (Charron et al., 1998; Niimura et al., 1998). These findings have led to the 
formulation of the hypothesis that MYBPC3 mutations cause a milder form of HCM than mutations 
in other sarcomeric protein-encoding genes (Niimura et al., 1998). Furthermore, mutations in 
MYBPC3 also often result in progression to the “burnt out” phase HCM in elderly individuals, which 
may result in such individuals being diagnosed with DCM, rather than HCM (Konno et al., 2003). In 
order to establish whether there are differences in the phenotypic expression of missense and 
truncation cMyBPC mutations, cMyBPC missense and truncation mutations have been investigated 
separately. The data thus obtained are, however, conflicting. Niimura et al., (1998) showed that 
missense mutations in MYBPC3 are associated with a higher incidence of SCD than HCM-causing 
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mutations resulting in the truncation of cMyBPC, while Erdmann et al., (2003) showed that 
MYBPC3 truncation mutations are associated with a more severe phenotype than MYBPC3 missense 
mutations. In contrast to the study by Niimura et al., (1998), SCD was a rare occurrence in the study 
by Erdmann et al., (2003). Furthermore, the phenotypic assessments made by Erdmann et al., (2003), 
were largely based on age of symptomatic presentation and the extent of LVH, which is not directly 
correlated to the risk of SCD (Watkins et al., 1995b; Moolman et al., 1997; Moolman-Smook et al., 
2000).  
 
Notwithstanding these studies that showed that HCM caused by mutations in MYBPC3 is associated 
with later disease onset and a relatively benign phenotype, some exceptions have been noted. In the 
Japanese population, for instance, Doi et al., (1999) found that the Δt mutation in exon 19 of 
MYBPC3, resulting in the loss of part of domain C4 through to domain C10 of cMyBPC (Kimura et 
al., 1997), was highly penetrant, even in younger individuals (Doi et al., 1999). Additionally, Konno 
et al., (2003) showed that typical features of HCM were present in a 16-year-old individual carrying 
the MYBPC3 R820Q mutation, generally associated with late-onset HCM, and that, even though this 
mutation was generally associated with a good prognosis, two incidents of SCD occurred in the same 
family. Taken together, these findings indicate that modulating factors, possibly more prevalent in 
some populations than in others, may play a role not only in the onset of HCM-associated symptoms 
and LVH, but also the underlying pathogenesis resulting in SCD (Charron et al., 1998; Konno et al., 
2003). In the light of these findings, where variable phenotypes have been assigned to specific 
mutations in MYBPC3, and where modifying factors seem to play an important role in disease 
presentation, caution should be exercised not to classify all cMyBPC-associated HCM as a mere 
mild form of the disease.  
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Figure I.23. HCM-causing mutations in cMyBPC 
Circles = immunoglobulin C2 domains;      = fibronectin type 3 domains;      = MyBPC motif;     = interdomain linkers; P = PKA and MyBPC-
associated kinase phosphorylation sites; red areas = cardiac-specific regions. The arrows below the figure indicate the positions of the binding-sites 
for light meromyosin (LMM), myosin S2 and titin respectively. The black lines above the figure indicate the respective lengths of the truncated 
cMyBPCs expressed as a result of HCM-causing mutations, while the positions of HCM-causing missense mutations are indicated above the diagram 
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of cMyBPC. 1 = Andersen et al., 2001; 2 = Niimura et al., 1998; 3 = Moolman-Smook et al., 1998; 4 = Yu et al., 1998; 5 = Carrier et al., 1997; 6 = 
Kimura et al., 1997; 8 = Bonne et al., 1995; 9 = Anan et al., 2002; 10 = Richard et al., 1999; 11 = Watkins et al., 1995a; 12 = Rottbauer et al., 1997; 
13 = Richard et al., 2003; 14 = Erdmann et al., 2001; 15 = Erdmann et al., 2003; 16 = Moolman et al., 2000; 17 = Konno et al., 2003; 18 = 
Jaaskelainen et al., 2002; 19 = Morner et al., 2003; 20 = Niimura et al., 2002; 21 = Barr et al., unpublished data available at 
http://genetics.med.harvard.edu/~seidman/cg3/muts/MYBPC3_mutations_TOC.html; 22 = Waldmuller et al., 2003. 
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Table I.6. HCM-causing mutations in MYBPC3 
Exon/Intron AA/Nt change Translational change Functional change Reference   
Ex 3 Δccaaggga Frame-shift Truncation, loss of partial C0-C10 Richard et al., 2003 
Ex 3 Q76X Nonsense Truncation, loss of partial C0-C10 Richard et al., 2003 
Ex 3  T59A Missense Single AA change in domain C1 Niimura et al., 2002 
Int 6 IVS6-2a>c Splicing Truncation, loss of partial C1-C10 Jaaskelainen et al., 2002 
Ex 7 D228N Missense Single AA change in domain C1 Andersen et al., 2001 
Ex 7 Y237S Missense Single AA change in domain C1 Morner et al., 2003 
Ex 7 H257P Missense Single AA change in domain C1 Richard et al., 2003 
Ex 7 E258K Missense/splicing Single AA change in domain C1/ 
truncation, loss of MyBPC-motif-C10 
Niimura et al., 1998; 
Richard et al., 2003; 
Erdmann et al., 2003 
Int 7 IVS7+1g>a Splicing Truncation, loss of MyBPC-motif-C10 Erdmann et al., 2001 
Int 7 IVS7-1g>a Splicing  Truncation, loss of MyBPC-motif-C10 Carrier et al., 1997 
Ex 8 G263R Missense Single AA change in MyBPC-motif Barr et al., * 
Int 8 IVS8+1g>a Splicing Truncation, loss of MyBPC-motif-C10 Niimura et al., 1998 
Ex 9 G278E Missense  Single AA change in LAGGGRRIS 
insertion in MyBPC-motif 
Richard et al., 2003 
Ex 9 G279A Missense  Single AA change in LAGGGRRIS 
insertion in MyBPC-motif 
Richard et al., 2003 
Ex 9 R282W Missense  Single AA change in LAGGGRRIS 
insertion in MyBPC-motif 
Erdmann et al., 2001 
Int 12 IVS12-2a>g Splicing  Truncation, loss of partial MyBPC-motif-
C10 
Niimura et al., 1998 
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Exon/Intron AA/Nt change Translational change Functional change Reference   
Ex 13 Δc Frame-shift Truncation, loss of partial MyBPC-
motif-C10 
Erdmann et al., 2003 
Ex 13 R326Q Missense/splicing Single AA change in MyBPC-motif/ 
Truncation, loss of partial MyBPC-
motif-C10 
Richard et al., 2003;  
Morner et al., 2003; 
Niimura et al., 2002 
Ex 13 L352P Missense  Single AA change in MyBPC-motif Richard et al., 2003 
Ex 14 Δc Frame-shift Truncation, loss of partial C2-C10 Erdmann et al., 2001 
Int 14 IVS14-2a>g Splicing  Truncation, loss of partial C2-C10 Richard et al., 2003 
Int 15 IVS15-13g>a Splicing Truncation, loss of partial C2-C10 Jaaskelainen et al., 2002 
Ex 16 Q425X Nonsense Truncation, loss of partial C2-C10 Niimura et al., 2002 
Ex 16 Δtt Frame-shift Truncation, loss of partial C2-C10 Richard et al., 2003 
Ex 16 Δt Frame-shift Truncation, loss of partial C2-C10 Richard et al., 2003 
Ex 16 Δc Frame-shift Truncation, loss of partial C2-C10 Richard et al., 2003 
Ex 16 E451Q Missense/splicing Single AA change in C2/ Truncation, 
loss of partial C2-C10 
Niimura et al., 1998 
Ex14 ∆cc Frame shift Truncation, loss of partial C3-C10 Waldmuller et al., 2003 
Ex 18 R495Q Missense Single AA change in C3 Niimura et al., 1998 
Ex 18 R502Q Missense  Single AA change in C3 Niimura et al., 1998 
Ex 18 R502W Missense  Single AA change in C3 Richard et al., 2003;  
Barr et al.,* 
Ex 18 ΔK504 1AA deletion Single AA deletion in C3 Richard et al., 2003 
Ex 18 G507R Missense Single AA change in C3 Erdmann et al., 2001 
Ex 18 G523W Missense Single AA change in C3 Erdmann et al., 2003 
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Exon/Intron AA/Nt change Translational change Functional change Reference   
Ex18 E542Q Missense/splicing Single AA change in C3/ Truncation, 
loss of partial C3-C10 
Carrier et al., 1997 
Ex 18 Δgc Frame-shift Truncation, loss of partial C3-C10 Richard et al., 2003 
Int 18 IVS17+2c>t Splicing  Truncation, loss of C4-C10 Richard et al., 2003 
Ex 19 K565X Nonsense Truncation, loss partial of C4-C10 Morner et al., 2003 
Ex 19 C566R Missense Single AA change in C4 Erdmann et al., 2001 
Ex 19 Δt Frame-shift Truncation, loss of partial C4-C10 Kimura et al., 1997 
Ex 20 Δa Frame-shift Truncation, loss of partial C4-C10 Richard et al., 2003 
Int 20 IVS20-2a>g Splicing  Truncation, loss of partial C4-C10 Erdmann et al., 2001 
Int 21 IVS21+2a>g Splicing  Truncation, loss of C5-C10 Bonne et al., 1995 
Ex 22 R654H Missense  Single AA change in C5 Moolman-Smook et al., 1998 
Ex 22 R668P Missense Single AA change in C5 Erdmann et al., 2003 
Ex 22 R668H Missense Single AA change in C5 Morner et al., 2003 
Ex 22 W683X Nonsense  Truncation, loss of partial C5-C10 Richard et al., 2003 
Ex 22 ∆cct ins gg Frame-shift Truncation, loss of partial C5-C10 Barr et al.,* 
Ex 23 Δc Frame-shift Truncation, loss of partial C5-C10 Niimura et al., 1998 
Ex 24 22bp duplication Frame-shift Truncation, loss of partial C5-C10 Richard et al., 2003 
Ex 24 Ins t Frame shift  Truncation, loss of partial C5-C10 Barr et al.,* 
Ex 24 N755K Missense  Single AA change in C5 Yu et al., 1998 
Int 24 IVS24+1g>a Splicing  Truncation, loss of C6-C10 Carrier et al., 1997; 
Barr et al.,* 
Int 24 IVS24+1g>t Splicing  Truncation, loss of C6-C10 Niimura et al., 1998 
Int 24 SBP tgat>tggt Splicing  Truncation, loss of C6-C10 Carrier et al., 1997 
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Exon/Intron AA/Nt change Translational change Functional change Reference   
Ex 25 Ins g Frame-shift Truncation, loss of partial C6-C10 Richard et al., 2003; 
Erdmann et al., 2001 
Ex 25 Ins g Splicing Truncation, loss of partial C6-C10 Moolman et al., 2000;  
Barr et al.,* 
Ex 26 K811R Missense Single AA change in C6 Richard et al., 2003 
Ex 26 ∆K812 1AA deletion Single AA deletion in C6 Jaaskelainen et al., 2002 
Ex 26 R820Q Missense Single AA change in C6 Konno et al., 2003 
Ex 26 A833V Missense Single AA change in C6 Richard et al., 2003; 
Erdmann et al., 2003 
Ex 26 ∆cg, ins tct Frame-shift Truncation, loss of partial C6-C10 Morner et al., 2003 
Ex 26 A833T Missense Single AA change in C6 Morner et al., 2003 
Ex 26 Δcgcgt Frame-shift Truncation, loss of partial C6-C10 Carrier et al., 1997; 
Richard et al., 2003 
Ex 26 Δgcgtc Frame-shift Truncation, loss of partial C6-C10 Richard et al., 2003 
Ex 26 Δc Frame-shift Truncation, loss of partial C6-C10 Richard et al., 2003 
Ex 27 Dup gcct Frame shift Truncation, loss of partial C7-C10 Barr et al.,* 
Int 27 IVS27+1g>a Splicing  Truncation, loss of partial C7-C10 Erdmann et al., 2001 
Int 27 IVS27-3c>g Splicing Truncation, loss of partial C7-C10 Niimura et al., 2002 
Ex 28 Δct Frame-shift Truncation, loss of partial C7-C10 Niimura et al., 1998 
Ex 28 Q969X Nonsense  Truncation, loss of partial C7-C10 Yu et al., 1998 
Int 28 IVS28+1g>a Splicing  Truncation, loss of partial C7-C10 Kimura et al., 1997 
Int 28 IVS28∆+1+2 Splicing Truncation, loss of partial C7-C10 Richard et al., 2003 
Ex 29 Δcg Frame-shift Truncation, loss of partial C8-C10 Anan et al., 2002 
Ex 30 R1002Q Missense Single AA change in C8 Niimura et al., 2002 
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Exon/Intron AA/Nt change Translational change Functional change Reference   
Ex 30 E1017K Missense  Single AA change in C8 Barr et al.,* 
Ex 30 Q1061X Nonsense Truncation, loss of partial C8-C10 Jaaskelainen et al., 2002 
Ex 30 Ins aa Frame-shift Truncation, loss of partial C8-C10 Niimura et al., 1998; 
Erdmann et al., 2001 
Ex 30 Δg Frame-shift Truncation, loss of partial C8-C10 Erdmann et al., 2001 
Ex 31 Ins c Frame-shift Truncation, loss of C9-C10 Barr et al.,* 
Ex31 E1096X Nonsense Truncation, loss of partial C9-C10 Richard et al., 2003 
Int 31 IVS31+1g>c Splicing  Truncation, loss of partial C9-C10 Watkins et al., 1995a 
Ex 32 V1115I  Missense Single AA change in C9 Erdmann et al., 2001 
Int 32 IVS32+1g>a Splicing Truncation, loss of partial C9-C10 Rottbauer et al., 1997 
Ex 33 A1194T Missense Single AA change in C10 Richard et al., 2003 
Ex 33 ∆c Frame shift Truncation, loss of partial C10 Barr et al.,* 
Ex 33 Δg Frame-shift Truncation, loss of partial C10 Richard et al., 2003 
Ex 33 A1255T Missense Single AA change in C10 Richard et al., 2003 
Int 33 ∆ 25bp Splicing  Truncation, loss of partial C10 Waldmuller et al., 2003 
Int 33 IVS33+1g>a Splicing  Truncation, loss of partial C10 Niimura et al., 1998 
Ex 34 Q1233X Nonsense Truncation, loss of partial C10 Erdmann et al., 2001 
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Exon/Intron AA/Nt change Translational change Functional change Reference   
Ex 34 11bp ins + Δ4bp Frame-shift Truncation, loss of partial C10 Carrier et al., 1997 
Ex 34 18bp ins  Duplication Duplication of 6AA in C10 Watkins et al., 1995a; 
Barr et al.,* 
Ex 34 Ins ttca Frame-shift Truncation, loss of partial C10 Erdmann et al., 2001 
 
AA = amino acid; bp = base pair; C0, C1, C2, C3, C4, C5, C6, C7, C8, C9, C10 = domains of cMyBPC; Ex = exon; ins = insertion; Int = intron; Nt 
= nucleotide; SBP = splice branch point; Δ = deletion; * = Barr et al., unpublished data, available at 
http://genetics.med.harvard.edu/~seidman/cg3/muts/MYBPC3_mutations_TOC.html. 
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I.7.8.2. Pathogenesis of HCM-causing mutations resulting in the truncation of cMyBPC 
 
Several studies have indicated that truncated cMyBPC peptides are incorporated into the cardiac 
sarcomere where they are likely to act as “poison peptides” (section I.1.1). The precise mechanisms 
through which these truncated peptides cause HCM is, however, still unclear and is likely to vary, 
depending on the length of the specific peptide. It can, for instance, be speculated that longer 
peptides in which only a portion of the C-terminal domains, responsible for the anchoring of 
cMyBPC to the thick filament (sections I.7.3.1, I.7.3.2, I.7.3.3), is truncated could compete with full-
length cMyBPC for LMM and titin binding-sites. Indeed, Yang et al., (1999) showed that truncated 
MyBPC, lacking only the C10 domain (housing the major LMM binding-site) was stably 
incorporated into the A-band of the sarcomeres of transgenic mice. From these findings, it seems 
likely that, even though the major LMM binding domain (C10) is absent, the presence of domains C8 
and C9, of which at least C9 may be involved in the binding of titin (Freiburg and Gautel, 1996), and 
domain C7, involved in the C-zone incorporation of cMyBPC (sections I.7.3.2, I.7.3.3), is sufficient 
for correct A-band incorporation of truncated cMyBPC (Yang et al., 1999). Due to their ability to 
compete for thick filament binding-sites with full-length cMyBPC, these truncated peptides may 
impair the ability of full-length cMyBPC to fulfill its structural and regulatory functions. 
 
Studies by Yang et al., (1998) and Flavigny et al., (1999) have shown that truncated cMyBPC 
peptides lacking the C-terminal domains, essential for association with the thick filament backbone 
(C7-C10) (sections I.7.3.1, I.7.3.2, I.7.3.3), are incorporated into the sarcomere, although their 
distribution is more diffuse. Flavigny et al., (1999) showed that truncated cMyBPC peptides lacking 
the C5-C10, or C3-C10 or MyBPC-motif-C10 were incorporated stably into the A-bands of about 
10% of myocytes in which they were expressed, while a more diffuse pattern of distribution of the 
 84
truncated peptides was observed in the remaining myocytes. Yang et al., (1999) also found A-band 
specific localisation of truncated cMyBPC peptides lacking the C5-C10 region, even though these 
peptides were also observed to be associated with the I-band and M-line, as well as being distributed 
diffusely throughout the cytoplasm. The A-band incorporation of truncated peptides containing the 
MyBPC-motif may be facilitated through interactions between this region and myosin S2 (section 
I.7.3.4). Interaction between truncated MyBPC peptides and S2 may result in alterations in 
crossbridge structure, thereby, affecting the ability of crossbridges to bind to thin filaments, resulting 
in alterations in the contractile properties of the sarcomere (section I.7.7.1). Additionally, this 
interaction between truncated cMyBPC peptides and S2 would not be restricted only to the specific 
positions in the A-band (C-zone) where cMyBPC is normally found, but would affect crossbridges 
throughout the A-band.  
 
The specific mechanisms through which truncated cMyBPC peptides lacking the C-terminal LMM 
and titin binding-sites, as well as the MyBPC-motif (e.g., truncated cMyBPC peptides lacking the 
MyBPC-motif-C10 region), are incorporated specifically into the sarcomeric A-band (Flavigny et al., 
1999), however, remain unclear. This finding, however, suggests that the C0-C1 region of cMyBPC 
(domains C0, PA-region and domain C1) houses an, as yet, unidentified A-band specific binding-
site. Based on hydrophobic cluster analysis of the C0 domain of cMyBPC and the My1 domain 
(myosin binding domain) of myomesin, which showed a 22% sequence identity and 42% sequence 
similarity between the myosin-binding region of My1 and a portion of cMyBPC domain C0, 
Flavigny et al., (1999) proposed that domain C0 may contain a myosin binding-site. As the 
association between the My1 domain myomesin and myosin occurs in the M-band, where only the 
LMM portion of myosin is present, it can be assumed that this homology suggests that domain C0 
would associate with LMM, rather than with HMM. Witt et al., (2001), however, proposed that the 
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C0 domain of cMyBPC could interact with myosin S2. Neither of these hypotheses is, however, 
supported by the findings of Gruen and Gautel (1999), who found no association between the C0-C1 
region of cMyBPC and myosin as a whole.  
 
Recently, however, Squire et al., (2003) and Kulikovskaya et al., (2003) proposed that the C0-C1 
region of cMyBPC might be able to interact with F-actin (section I.7.3.5). An interaction between the 
C0-C1 region of cMyBPC and F-actin would allow truncated cMyBPC peptides to be incorporated 
into the sarcomeric I-band, as well as the region of overlap between thick and thin filaments. These 
hypotheses are, therefore, consistent with the findings of Yang et al., (1998) who showed that 
truncated cMyBPC peptides lacking the C5-C10 region were found in the I-band, but they are not 
supported by the data of Flavigny et al., (1999), who showed that the truncated cMyBPC, consisting 
of only the C0C1 region, was incorporated specifically into the A-band and not the I-band. The 
possibility that the N-terminal region of cMyBPC contains an, as yet, unidentified A-band specific 
binding-site can, however, not be excluded.  
 
I.7.8.3. Pathogenesis of HCM-causing missense mutations in cMyBPC 
 
From the previous section it becomes apparent that HCM-causing mutations resulting in the 
truncation of cMyBPC are likely to act as poison peptides by being incorporated into the sarcomere, 
where they disrupt sarcomeric function. The mechanisms through which missense mutations in 
cMyBPC cause HCM are, however, largely unclear, as the functions of most of the domains in which 
they are found are unknown. It is plausible that the A1194T and A1255T mutations in the C10 
domain of cMyBPC (Richard et al., 2003) may affect the interaction between this domain and either 
LMM (Okagaki et al., 1993) or titin (Freiburg and Gautel, 1996). Similarly, as the C9 domain of 
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cMyBPC may be involved in the interaction between cMyBPC and titin, the V1115I mutation in 
domain C9 (Erdmann et al., 2001) may also affect this interaction. The G278E, G279A, R282W, 
R326Q and L352P mutations in the MyBPC-motif may either affect the phosphorylation of 
cMyBPC, or the binding of the MyBPC-motif to myosin S2. As no specific functions have been 
assigned to the C1, C2, C3, C4, C5, C6, or C7 domains, the mechanisms through which mutations in 
these domains (table I.6 and figure I.23) cause HCM remain unclear. It can be speculated that these 
mutations may adversely affect the stability of these domains, thus destabilising the protein as a 
whole. Alternatively, these mutations may affect the ability of these domains to bind to, as yet, 
unidentified ligands. 
 
I.8. PRESENT STUDY 
 
The present study forms part of an ongoing study in the laboratory of Prof Valerie Corfield, in which 
all genes in which HCM-causing mutations have been described are systematically screened for the 
presence of HCM-causing mutations in the South African HCM-affected population. In the present, 
study a panel of HCM-affected individuals was screened for the presence of HCM-causing mutations 
in MYBPC3 by the polymerase chain reaction (PCR) single strand conformation polymorphism 
(SSCP) technique, allowing the identification of both known and novel mutations and 
polymorphisms. Following the identification of altered mobility of single-stranded conformers, 
suggestive of nucleotide sequence variation, cycle sequencing was used to identify nucleotide 
sequence variations, which were confirmed by restriction enzyme digestion, where possible.  
 
In cases where nucleotide sequence changes were predicted to alter either the amino acid sequence of 
cMyBPC, or affect the reading frame or splicing of the MYBPC3 transcript, population-matched 
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control panels, consisting of at least 100 individuals, were screened for the presence of these 
sequence variants. Nucleotide sequence variants not found in control populations were regarded as 
putative HCM-causing mutations. Where putative HCM-causing mutations were predicted to alter 
the splicing of the MYBPC3 transcript, reverse transcription (RT) PCR was used to establish whether 
these putative mutations do indeed alter spicing. Additionally, family members of individuals in 
which putative HCM-causing missense-, splicing- and frame-shift mutations were identified were 
recruited if possible, and tested for the presence of the sequence variation. All individuals in which 
such sequence variations were identified, were subsequently assessed clinically in order to provide 
evidence of co-segregation of the putative mutation and the disease. Putative HCM-causing 
mutations were considered disease-causing if they were not identified in relevant control panels and, 
when possible to establish, if they co-segregated with HCM within a particular family.  
 
Additionally, based on previously published findings, as well as our own mutation-screening data, 
the C0-C1 region and C7 domain of MyBPC were identified as functionally important regions of 
cMyBPC (Gilbert et al., 1996; Flavigny et al., 1999; Gilbert et al., 1999; Kulikovskaya et al., 2003; 
Squire et al., 2003). It was, therefore, hypothesised that these regions of cMyBPC might interact 
with, as yet, unidentified ligands. This hypothesis was tested by screening cardiac cDNA libraries for 
the ligands of these regions, using the yeast two-hybrid (Y2H) method. This approach, as well as 
candidate-ligand Y2H-assays, led to the identification of two candidate ligands of the C7 domain, 
which were subsequently confirmed, using Y2H-based candidate-ligand assays (Moolman-Smook et 
al., 2002).  
 
This data, in conjunction with additional Y2H and biochemical data from our group and the group of 
Prof Hugh Watkins (Department of Cardiovascular Medicine, University of Oxford, UK), with 
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whom we collaborate, has led to the development of a novel proposed model of cMyBPC quaternary 
structure (Moolman-Smook et al., 2002). Based on specific domains of cMyBPC being 
juxtapositioned with other proteins/protein domains in this model of cMyBPC quaternary structure, 
putative ligands of several domains of cMyBPC were identified. Aditionally, based on the findings 
that PKA-mediated phosphorylation of cMyBPC results in an expansion of the thick filament 
backbone, a model of cMyBPC quaternary structure when cMyBPC was phosphorylated was 
proposed. This model led to the identification of domain C10 of cMyBPC as a putative ligand of the 
C3 domain of cMyBPC. The interaction between these two cMyBPC domains was subsequently 
confirmed by Y2H-based candidate-ligand assays, supporting the model of cMyBPC quaternary 
structure when cMyBPC is phosphorylated by PKA.  
 
The identification of ligands of specific regions of cMyBPC allows new insights into the 
mechanisms through which several HCM-causing missense mutations may have their pathogenic 
effect, by affecting protein:protein interactions. Additionally, the development of models of 
cMyBPC quaternary structure provide insights into mechanisms through which cMyBPC may 
regulate thick filament structure and cardiac contractility. 
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CHAPTER II: METHODS AND MATERIALS 
 
In this chapter, the methods employed and materials used will be described in detail. Basically, the 
present study can be subdivided into two main components. Firstly, the screening of MYBPC3 for the 
presence of HCM-causing mutations, and, secondly, the identification of ligands binding to specific 
domains of cMyBPC, using the Y2H method. The present chapter will, however, not be subdivided 
along these lines, as identical, or related, methods were used in both sections of this study. To avoid 
repetition, related methods will, therefore, be grouped together, irrespective of their use in either 
mutation screening, or as part of the Y2H method. For the sake of clarity, figures II.1; II.2 and II.3, 
show flow diagrams of how these methods were employed to achieve the goals of this study. 
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Figure II.1. Flow-diagram depicting the mutation screening protocol followed 
1 = section II.1; 2 = section II.2; 3 = section II.3; 4 = section II.4.1; 5 = section II.6.2; 6 = section II.8; 7 = 
sections II.10.1 and II.10.2; 8 = section II.10.3.1; 9 = section II.11.1. ASREA = allele-specific restriction 
enzyme analysis; ECG = electrocardiogram; HCM = hypertrophic cardiomyopathy; PCR-SSCP = 
polymerase chain reaction single strand conformation polymorphism; SNP = single nucleotide polymorphism. 
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Figure II.2. Flow-diagram depicting the procedures followed for the generation of Y2H constructs 
1 = section II.6.1.3; 2 = section II.6.3; 3 = section II.11.2; 4 = section II.12.3; 5 = section II.14.1; 6 = section 
II.12.1; 7 = section II.6.5; 8 = section II.4.7; 9 = section II.10.2; 10 = section II.14.2; 11 = section II.16.3.1; 
12 = section II.15.3; 13 = section II.16.1; 14 = section II.16.2. cDNA = copy DNA; E.coli = Escherichia coli; 
PCR = polymerase chain reaction; SD = selective dropout.. 
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Figure II.3. Flow-diagram depicting the procedures followed for the Y2H screening of cDNA libraries 
*= Only for Matchmaker system 3; 1 = sections II.15.1 and II.15.2; 2 =section II.15.4; 3 = section II.16.2; 4 
= section II.16.2.4; 5 = section II.16.2.5; 6 = appendix A; 7 = section II.16.3.3; 8 = section II.16.4.2.i; 9 = 
section II.16.4.1; 10 = section II.6.6; 11 = section II.11.3; 12 = section II.4.8; 13 = section II.14.1; 14 = 
section II.4.7; 15 = section II.14.2; 16 = section II.16.1; 17 = sections II.10.2 and II.10.3.3. β-Gal = β-
galactosidase; E.coli = Escherichia coli; LBAmp = Luria-Bertani media containing ampicillin; PCR = 
polymerase chain reaction; TDO = triple dropout medium; QDO = quadruple dropout medium; X-α-Gal = X-
α-galactosidase. 
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II.1. PATIENT SELECTION 
 
II.1.1. HCM-AFFECTED PANEL 
 
Genomic deoxyribonucleic acid (DNA), extracted from a panel of 84 probands with HCM had 
previously been established in the laboratory of Prof. V.A. Corfield. This panel formed the basis of 
investigations into the molecular causes of HCM in this study. During the course of this study, 
another 89 probands have been added to the test panel.  
 
This study was approved by the Ethics committee of the University of Stellenbosch, and informed 
verbal consent (parental in the case of minors) was obtained from all individuals included in the 
investigation. 
 
II.1.2. CONTROL PANELS 
 
In order to establish whether putative HCM-causing mutations identified during the course of this 
study were present in the general population, ethnically matched control panels consisting of at least 
100 individuals were screened for the presence of any particular putative mutation. The Caucasian 
and mixed ancestry control panels each consisted of DNA extracted from blood samples, collected 
from more than 100 apparently HCM-unaffected individuals. As a Xhosa control panel was not 
available, the panel used consisted of DNA samples obtained from non-insulin dependent diabetes 
mellitus (NIDDM) patients from this ethnic group. The Zulu control panel consisted of DNA 
samples obtained from 50 apparently HCM-unaffected individuals of Zulu descent, collected by Dr 
Karin Sliva at Baragwanath hospital in Gauteng South Africa.  
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II.2. CLINICAL EVALUATION 
 
Clinical evaluations included a physical examination, ECG and echocardiographic examination of 
patients, as well as an interview aimed at establishing whether a family history of HCM was present. 
These evaluations were performed either by the referring clinician, or Prof. P.A. Brink at Tygerberg 
Hospital. 
 
ECG evaluation involved standard 12-lead ECG. ECG abnormalities compatible with HCM were 
noted for each patient. These changes included abnormal repolarisation patterns, abnormal voltages 
and abnormal Q-waves. LVH on ECG was calculated using the point-system of Romhilt and Estes 
(Romhilt and Estes, 1968). 
 
Echocardiographic analysis was performed with an Ultramark 4 or 8 scanner using a 2.5-3.5 Mhz 
transducer. Cardiac dimensions were recorded with two-dimensional echocardiography according to 
established protocols (Maron et al., 1978). A maximal end-diastolic interventricular septal (IVS) 
thickness, left ventricular posterior wall (PW) thickness, as well as the location of the hypertrophy, 
were determined. Other echocardiographic changes compatible with HCM, such as the presence of 
asymmetric septal hypertrophy, systolic anterior motion of the mitral valve, and valvular 
abnormalities, were also recorded. 
 
Probands were classified as “distinct HCM” if typical features of HCM, in the absence of extrinsic 
inciting conditions such as hypertension, or valvular stenosis, and/or when a family history of the 
disease, were present. Probands presenting with HCM-like hypertrophy, but where other causes of 
hypertrophy could not be excluded, were classified as having “HCM-like disease”. Both these groups 
were entered into the molecular genetic mutation screening study. 
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II.3. SAMPLE COLLECTION 
 
Peripheral blood was collected from all participating individuals, by venous puncture. Two to four 
5ml ethylene-diamine-tetra-acetic acid (EDTA)-containing, and one to two heparin-containing, 
blood-collection tubes were drawn. These samples were subsequently used for DNA-extraction 
(EDTA tubes) (section II.4.1) and the establishment of Epstein-Barr virus (EBV) transformed cell 
lines (heparin tubes) (section II.5). 
 
II.4. NUCLEIC ACID EXTRACTION AND PURIFICATION 
 
II.4.1. GENOMIC DNA EXTRACTION 
 
II.4.1.1. Extracting nuclei from whole blood 
 
Blood was transferred from 5ml EDTA-containing collection tubes into a 50ml polypropylene tube 
(Greiner Labortechnik GmbH, Frickenhausen Germany) and 20ml ice-cold cell lysis buffer 
(appendix A) was added. After gently inverting the tube a few times, the sample was incubated on 
ice for 5-10min. The sample was then centrifuged at 3 000rpm for 10min at room temperature in a 
Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK). The supernatant was 
subsequently discarded and the pellet resuspended in 20ml ice-cold cell lysis buffer (appendix A), 
followed by another incubation- and centrifugation step as above. Following the second 
centrifugation step, the supernatant was discarded and the pellet resuspended in a mixture consisting 
of 900μl sodium-EDTA (appendix A) and 100μl 10% sodium dodecyl sulphate (SDS). The nuclei 
were immediately used for DNA extraction, or stored at -70°C. 
 100
II.4.1.2. Extraction of DNA from nuclei 
 
To the freshly prepared or thawed nuclei, 100μl of proteinase K (10 μg/ml) (Roche Biochemical, 
Basel, Switzerland) was added. Following overnight incubation at 37°C, 2ml ddH2O, 500μl 3M 
sodium-acetate (appendix A) and 25μl phenol/chloroform (appendix A) was added to the sample. 
The tubes were subsequently inverted and mixed gently for 10min on a Voss rotator (Voss, Maldon, 
England) at 4°C. The sample was then transferred to a glass Corex tube, and centrifuged in a Sorvall 
RC-5B refrigerated super-speed centrifuge (rotor SS34, Dupont Instruments) at 8 000rpm for 10min 
at 4°C.  
 
Following the transfer of the upper, DNA-containing, aqueous phase to a clean Corex tube, 25ml 
chloroform/octanol (appendix A) was added, after which the tube was closed with a polypropylene 
stopper and gently inverted for 10min on a Voss rotator (Voss, Maldon, England) at 4oC. This 
mixture was then centrifuged in a Sorvall RC-5B refrigerated super-speed centrifuge (rotor SS34, 
Dupont Instruments) at 8 000rpm for 10min at 4°C. After the transfer of the upper aqueous phase to 
a clean Corex tube, genomic DNA was ethanol precipitated, washed and resuspended as described an 
sections II.4.3 and II.4.4. 
 
Following resuspension, the optical density (OD) of the DNA was determined in a Milton Roy series 
120i spectrophotometer (Ivyland, PA, USA) at 260nm (OD260). The DNA concentration was 
determined by diluting 10μl DNA in 500μl 1x TE buffer (appendix A) and multiplying the OD260 
measurement by a factor of 2.5, estimating the DNA concentration in μg/μl. The OD260 to OD280 
ratio was used as an estimate of DNA purity (a ratio of approximately 1.8 was taken as an indication 
of pure DNA). 
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II.4.2. RNA EXTRACTION 
 
II.4.2.1. Lymphocyte isolation 
 
When fresh blood samples were available for ribonucleic acid (RNA) extraction, lymphocytes were 
isolated from whole blood. In short, 2ml of fresh blood was mixed with an equal volume of PBS 
buffer (appendix A). This mixture was carefully layered over 3ml of LSM® (Organon Teknika Corp, 
West Chester, NC, USA) in a 15ml polypropylene centrifuge tube (Greiner Labortechnik GmbH, 
Frickenhausen Germany). The mixture was then centrifuged at 6 000rpm for 30min at room 
temperature in a Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK). Following the 
removal of the clear supernatant layer, the mononuclear cell layer was transferred to a sterile 15ml 
centrifuge tube. The mononuclear cells were subsequently washed by adding an equal volume of 
PBS buffer (appendix A), followed by centrifugation at 3 700rpm for 10min at room temperature in a 
Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK). Following the removal of the 
supernatant, the cells were washed a second time in 5ml PBS buffer and precipitated by 
centrifugation at 3700rpm for 10min at room temperature in a Beckman model TJ-6 centrifuge 
(Beckman Coulter, Scotland, UK), before the supernatant was removed. These cells were then either 
used immediately for RNA extraction, or frozen at –70oC for future use. 
 
II.4.2.2. RNA extraction from lymphocytes 
 
RNA was extracted from lymphocyte cell-pellets, obtained either from freshly collected blood 
samples (section II.4.2.1) or from cells which had been EBV-transformed (section II.5). In short, 
750μl RNA-denaturing solution (appendix A) was added to lymphocyte cell-pellets and the cells 
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homogenised by repeated pipetting. Following homogenisation, 100μl of 2M NaAc (pH 4), 1ml of 
ddH2O saturated phenol (Sigma, St Louis, MO, USA) and 200μl of chloroform/isoamyl-alcohol 
(24:1) (Sigma, St Louis, MO, USA) were added. The addition of each of these reagents was followed 
by thoroughly mixing the mixture through vigorous pipetting. This mixture was then incubated on 
ice for 15min, after which it was centrifuged at 13 000rpm for 20min at 4oC in a Beckman Microfuge 
Lite (Beckman Instruments Inc., CA, USA). After centrifugation, the clear RNA-containing aqueous 
phase was transferred to a 2ml centrifuge tube. The RNA was then precipitated by the addition of 
two volumes of ice-cold 100% ethanol and the mixture incubated at -20oC for 1h before 
centrifugation at 13 000rpm for 20min at 4oC in a Beckman Microfuge Lite (Beckman Instruments 
Inc., CA, USA). Following centrifugation, the supernatant was removed from the RNA pellet. The 
RNA was then washed twice with 500μl 70% ethanol (made up with 0.2% diethylpyrocarbonate 
(DEPC) treated water (appendix A)) and re-pelleted by centrifugation at 13 000rpm for 10min at 4oC 
in a Beckman Microfuge Lite (Beckman Instruments Inc., CA, USA). The RNA pellet was air-dried 
for about 10min prior to re-suspension of the pellet in 50μl of nuclease-free water.  
 
In order to minimise ribonuclease (RNase) contamination of samples, all workbench surfaces, 
pipettes and apparatus used were treated with RNase Erase (ICD Biochemicals, Aurora, Ohio, USA). 
Furthermore, all pipette tips and centrifuge tubes used in the preparation of RNA samples were 
rinsed with a 0.2% DEPC (Sigma, St Louis, Missouri, USA) (appendix A) solution, prior to being 
autoclaved. 
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II.4.3. DNA PRECIPITATION 
 
Standard DNA precipitation was performed by adding two volumes of ice-cold 100% ethanol (and in 
some cases one tenth volume 3M NaAc) to the DNA sample. Following brief vortexing of this 
mixture, the DNA precipitate was either transferred to a clean 1.5ml centrifuge tube, using a sterile 
Pasteur pipette, or pelleted by centrifugation at 13 000rpm for 15min at room temperature in a 
Beckman Microfuge Lite (Beckman Instruments Inc., CA, USA) and the supernatant decanted. The 
DNA was subsequently washed twice with 70% ethanol (section I.4.4.). 
 
I.4.4. WASHING OF PRECIPITATED DNA PELLETS 
 
In order to remove all excess salts and solvents, precipitated DNA pellets were washed twice with 
70% ethanol. Each of these washes involved the addition of 1-2ml of 70% ethanol to the DNA pellet, 
followed by centrifugation at 13 000rmp for 2min at room temperature in a Beckman Microfuge Lite 
(Beckman Instruments Inc., CA, USA), or at 3 000rpm for 10min at 4oC in a Multex centrifuge 
(MSE Instruments, England). After the second wash, the supernatant was decanted and the pellet 
allowed to dry by inverting the tube on a section of Carlton paper towel at room temperature for 
approximately 30min, or until the pellet appeared dry. The pellet was then resuspended in an 
appropriate volume of sterile ddH2O, or 1x TE buffer (appendix A).  
 
II.4.5. PHENOL-CHLOROFORM DNA PURIFICATION 
 
Phenol:chloroform:isoamyl alcohol (PCI) treatment of DNA was conducted by adding an equal 
volume of PCI solution (25:24:1) (Sigma, St Louis, MO, USA) to the sample. The sample was then 
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vortexed for approximately 60s, and centrifuged at 13 000rpm for 15min at room temperature in a 
Beckman Microfuge Lite (Beckman Instruments Inc., CA, USA). The DNA-containing aqueous 
layer was carefully removed and transferred into a sterile tube prior to the DNA being ethanol 
precipitated as described in section II.4.3. 
 
II.4.6. GEL-PURIFICATION OF PCR PRODUCTS 
 
Gel-purification of PCR-amplified products was routinely performed in order to obtain pure PCR-
amplified products for DNA sequencing (section II.10) and cloning (section II.12). PCR products 
were electrophoresed in agarose gels and the appropriate band excised (II.7.1.2). This gel slice was 
subsequently transferred to a sterile, pre-weighed, 2ml Eppendorf microfuge tube. The gel slice was 
subsequently weighed and an appropriate volume of capture buffer (GFX® DNA purification kit, 
AmershamPharmacia Biotech, New Jersey, USA) (1μl/mg) added. The gel slice was then melted by 
incubation at 60°C for 10-15min, following which the mixture was applied to a DNA purification 
column (GFX® DNA purification kit, AmershamPharmacia Biotech, New Jersey, NJ, USA), that had 
been placed into a microfuge tube. The sample was then incubated for 1min at room temperature 
before being centrifuged at 13 000rpm for 30s at room temperature in a Beckman Microfuge Lite 
(Beckman Instruments Inc., CA, USA). Following centrifugation, the flow-through was discarded 
and the DNA washed by adding 500μl of wash buffer, supplied by the manufacturer 
(AmershamPharmacia Biotech, New Jersey, USA), to the column and centrifuging at 13 000rpm for 
30s at room temperature in a Beckman Microfuge Lite (Beckman Instruments Inc., California, USA). 
After this wash step, the DNA was eluted from the column by the addition of 30-50μl of ddH2O to 
the GFX column, incubation for 1min at room temperature and centrifugation for 1min at 13 000rpm 
in a Beckman Microfuge Lite (Beckman Instruments Inc., California, USA).  
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II.4.7. BACTERIAL PLASMID PURIFICATION 
 
One Escherichia coli (E.coli) colony, containing the plasmid of interest as determined by bacterial 
colony PCR (section II.6.5.), was picked from an appropriate selection agar plate (table II.10 and 
appendix A) and inoculated into 10ml of Luria-Bertani (LB)-medium (appendix A), containing the 
same selection antibiotic, in a 50ml polypropylene centrifuge tube. This culture was grown overnight 
at 37oC with shaking at 250rpm in a YIH DER model LM-530 shaking incubator (SCILAB 
Instrument Co Ltd., Taipei, Taiwan). The following morning, the cells were pelleted by 
centrifugation at 3 000rpm for 10min at room temperature in a Beckman model TJ-6 centrifuge 
(Beckman Coulter, Scotland, UK). The supernatant was then decanted and the pellet resuspended by 
gentle pipetting in 1ml of cell resuspention solution (appendix A). Two millilitres of cell lysis buffer 
(appendix A) was added and the contents mixed by gentle inversion, after which the mixture was 
incubated at room temperature for 5min. Following incubation, 2ml of neutralisation solution 
(appendix A) was added and the content mixed by gentle inversion, after which the mixture was 
incubated at room temperature for an additional 5min. Following this incubation step, 5ml of PCI 
(25:24:1) (Sigma, St Louis, MO, USA) was added and the content mixed by gentle inversion. In 
order to allow phase separation, this mixture was centrifuged at 3 000rpm for 15 min at 4oC in a 
Multex centrifuge (MSE Instruments, England, UK).  
 
The clear plasmid-containing aqueous phase was removed and transferred to a new sterile 50ml 
polypropylene tube. To this, 0.7x volume of 100% isopropanol (Merck, Darmstadt, Germany) was 
added and mixed well by gentle inversion. This mixture was centrifuged at 3 000rpm for 45min at 
4oC in a Multex centrifuge (MSE Instruments, England), in order to pellet the plasmid DNA. The 
supernatant was removed from the plasmid pellet, which was subsequently washed twice with 
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70% ethanol, air-dried (section II.4.4) and resuspended in 100-300μl H2O. An aliquot of plasmid 
preparation was resolved on a 1% agarose TAE gel (section II.7.1.3) to verify its integrity. 
 
II.4.8. YEAST PLASMID PURIFICATION 
 
Yeast cells containing the plasmid of interest were grown on appropriate agar selection plates 
(section II.16.3, table II.10 and appendix A) for two to five days. Following incubation, 
approximately 50μl of a yeast colony was picked and resuspended in 500μl of sterile ddH2O in a 
1.5ml centrifuge tube, and the cells pelletted by centrifugation at 13 000rpm for 30s in a Beckman 
Microfuge Lite (Beckman Instruments Inc., CA, USA). After the removal of the supernatant, the 
cells were resuspended in 200μl yeast lysis buffer (appendix A). A volume representing 
approximately 200μl of sterile 425-600μm glass beads (Sigma, St Louis, MO, USA), and 200μl PCI 
(25:24:1) (Sigma, St Louis, MO, USA), was then added. This mixture was subsequently vortexed 
vigorously three times for 30s, interspersed by a 30s incubation period at room temperature. In order 
to achieve phase separation, the mixture was centrifuged at 13 000rpm for 1min at room temperature 
in a Beckman Microfuge Lite (Beckman Instruments Inc., CA, USA), before the clear aqueous phase 
was removed and transferred to a fresh 1.5ml centrifuge tube.  
 
The DNA was then precipitated by adding 20μl of 3M NaAc (pH 6.0) (appendix A) and 500μl of 
95% ethanol, after which the mixture was incubated at –20oC for 30min. Following incubation, the 
mixture was centrifuged at 13 000rpm for 15min at room temperature in a Beckman Microfuge Lite 
(Beckman Instruments Inc., CA, USA), the supernatant decanted and the DNA pellet washed twice 
with 1ml of 70% ethanol, air-dried (section II.4.4) and resuspended in an appropriate volume of 
sterile ddH2O. 
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II.5. ESTABLISHMENT OF EBV TRANSFORMED CELL LINES 
 
EBV transformation of lymphocytes was performed in order to establish immortal cell lines from 
which RNA was extracted. In short, 4-5ml of heparin containing blood was layered over 3ml 
Histopaque (Sigma-Aldrich, St Louis, MO, USA), preheated to 22oC. This mixture was subsequently 
centrifuged at 1 800rpm for 20min at room temperature in a Beckman model TJ-6 centrifuge 
(Beckman Coulter, Scotland, UK). Following centrifugation, the white blood cell layer was 
transferred to a sterile 15ml polypropylene tube to which 3ml of 1x RPMI 1640-medium (Sigma, St 
Louis, MO, USA), preheated to 37oC, was added. This mixture was centrifuged at 1 000rpm for 30s 
at room temperature in a Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK), the 
supernatant decanted and the cells washed once more with 3ml of 1x RPMI 1640-medium (Sigma, St 
Louis, MO, USA).  
 
The cell-pellet was then resuspended in 1.5ml EBV-medium (appendix A) and transferred to a 25cm2 
cell culture flask. This culture was incubated upright for one week at 37oC with CO2 at 5% and 
humidity at 90%. During this incubation period, 0.5ml 1x RPMI 1640-medium (Sigma, St Louis, 
MO, USA) was added every third day. Following incubation, this culture was transferred to a 75cm2 
cell culture flask, which was additionally incubated at 37oC with CO2 at 5% and humidity at 90%. 
During this incubation period, 10ml 1x RPMI 1640-medium (Sigma, St Louis, MO, USA) was added 
every third day, until the volume of the culture reached 50ml, at which stage the culture was 
transferred to a sterile 50ml polypropylene tube. The cells were then pelleted by centrifugation at 1 
000rpm for 10min at room temperature in a Beckman model TJ-6 centrifuge (Beckman Coulter, 
Scotland, UK). Following centrifugation, the supernatant was decanted and the pellet resuspended in 
1ml 1x RPMI 1640-medium (Sigma, St Louis, MO, USA), containing 10% dimethylsulphoxide 
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(DMSO) (Sigma, St Louis, MO, USA), the cell-suspension transferred to a cryogenic tube, and 
subsequently stored in liquid N2. EBV-transformed lymphocytes were subsequently used for the 
extraction of RNA (section II.4.2). 
 
II.6. PCR METHODS 
 
II.6.1. PRIMER DESIGN AND SYNTHESIS 
 
Where possible, primer sequences were obtained from published data. In cases where such data were 
not available, primers were designed making use of nucleotide sequence data obtained from the 
GenBank Database (http://www.ncbi.nlm.nih.gov/Entrez). Primer sequences were analysed for 
compatibility of melting temperatures (Tm), self-complimentarity, as well as primer-primer 
complimentarity of primer sets, using DNAman version 4.0 sequence analysis software (Lynnion 
Biosoft Corp) prior to synthesis. All primers used in this study were either synthesised at the 
University of Cape Town DNA Synthesis Laboratory (University of Cape Town, CT, RSA) or at 
MWG-Biotech AG (Ebersberg, Germany). 
 
II.6.1.1. Mutation screening primers 
 
The sequences of all primers used for PCR-amplification of the 34 protein-encoding exons of 
MYBPC3 (section II.6.2) were obtained from published data (table II.1) (Carrier et al., 1997). These 
primer pairs were designed in such a way that both the exon and intronic regions directly flanking 
the exon were amplified, allowing the detection both of missense and splicing mutations (Carrier et 
al., 1997). With the exception of exons 3, 15, 16, 20 and 21, all exons were amplified individually in 
single PCR reactions. Due to its size, however, exon 3 was amplified in two overlapping fragments, 
designated exon 3a and 3b. The regions encompassing exons 15 and 16 (including intron 15), as well 
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as exons 20 and 21 (including intron 20), were amplified in single PCR reactions, due to the close 
proximity and small size of these neighbouring exons (Carrier et al., 1997).  
 
II.6.1.2. RT-PCR primers 
 
The sequences of primers used to amplify the MYBPC3 messenger RNA (mRNA) transcript, by 
reverse transcription PCR (RT-PCR) (section II.6.4), were obtained from published primer sequences 
(table II.2) (Carrier et al., 1997; Watkins et al., 1995a). Primers were selected on the basis that they 
flanked regions of the MYBPC3 transcript suspected of being affected by the putative HCM-causing 
splicing mutations.  
 
II.6.1.3. Y2H cloning primers 
 
All primers used to PCR-amplify specific domains/regions of MYBPC3 and TTN (section II.6.3), to 
be cloned into Y2H cloning vectors (section II.12), were designed as part of this study. In order to 
facilitate the subsequent cloning of these PCR-amplified fragments, a 5’ “tag” was added to all 
primers. The 5’ tags of forward primers always contained a restriction enzyme recognition site (NdeI, 
NcoI or SmaI) (table II.3). The 5’ tags of reverse primers always contained at least one transcription 
termination codon, and an EcoRI recognition site (table II.3). The sequences used to design the 
target-recognition portion of these primers were obtained from GenBank, and were chosen to 
amplify specific domains of the MYBPC3 and TTN transcripts (table II.3) 
(http://www.ncbi.nlm.nih.gov/Entrez, sequence accession numbers: NM_000256 and AJ277892, 
respectively). In cases where ambiguity regarding the location of domain boundaries existed, primers 
were designed to co-amplify inter-domain linkers, thus ensuring the amplification of complete target 
domains.  
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Table II.1. Primer sequences used in PCR amplification of protein-encoding exons of MYBPC3 
 
Exon Size (bp) Ta (oC) Forward primer sequence (5’>3’) Reverse primer sequence (5’>3’) 
2 292 54 CATGGTGAGTGCCTGGTGTGAC TTGGCTGTGTCCCCTCTCTGC 
3a 323 54 CCTGGCTCTCCCGACTGCTA ACTCCTGCCCGCTCTGTCTC 
3b 333 54 TTTAGCAAGAAGCCACGGTCA CTGGATGGATGGAGAGTCGCT 
4 287 54 CTTTCCTCATCCACAGCGGG GCTTTTGAGACCTGCCCTGG 
5 246 61 TGGGAGGCGGAGCTTGCAGTG CCCCTTCCCACCCCAATGCTG 
6 269 54 GCAGCAGGACACTCCCCAAG TGTCTCCACGACCCCGGT 
7 283 54 ATTACAGGCCTGAGCCACCG AGACCAGGACCCATGGGGAG 
8 271 60 TCTGAAGCCCCTTCCCCCAT GGCTCCTGTGGGGGTTAGACT 
9 252 54 CAGGGCTGGGGATGATTTGC AGGAGCAGGATGGGAGTGGA 
10 192 58 CCACTCCACTCCCATCCTGC ACAGTGCTGGGATTTGGAGCC 
11 254 58 GGTCTACCAGGTCGGCCCAA CAGGAGAAGCCCAAGGCACA 
12 267 58 GGGTGGGGTCCAGGTCTTTGA CCCTGTCCCTCTGCCCCTTC 
13 333 54 AAGGGGCAGAGGGACAGGG TCCTGTGTAGGGAAGGGCTAGC 
14 281 55 ACCTGGGCCCCAGCCACAG GAGGCAAGGCTATGGGGGTC 
15-16 384 55 CTCTCCTTTTGTCTCGGGGCT GGGTGAGCATGAGGGTTGGC 
17 263 54 CTGGGACCTGAGGATGTGGG GGTGGGTGGGTGGCAAGTG 
18 310 60 GTTCCAGAAGCACGGGGCA GTGGGGTGGGGGCTGAGG 
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Exon Size (bp) Ta (oC) Forward primer sequence (5’>3’) Reverse primer sequence (5’>3’) 
19 335 58 GGATTCACGCCACACCCACA TCTGCCTCTCTGTCCACCTGTC 
20-21 355 58 CTGGGGTATCTGGCAAGGCC GCGGGAAAGTGAGCAGAACC 
22 383 58 TGACCTGTGCTCCTCCTGGCTCT CTCTGCTGATTCTTCCACCC 
23 228 55 GGCAAGGTGGGCAGTGTGG TGAAAGACAAACGATCCTCCTCC
24 281 54 TCCTGGGGTCTGACTTGGA CTGAATGAGCGAACGGATG 
25 227 55 GCAACGTTACTCAAGGCCCTG CCACCTTCCCTCGGATCTGTT 
26 310 56 AACAGATCCGAGGGAAGGTGG TTTTTAACTGGGGAGGGGGC 
27 310 55 GATCTCCAGCTTCCCCAGGC GGTGTCCTCAACTTTCGGCAA 
28 300 56 ATCAGAGGAGTGGGCAGTGGG CAAGGGCCTGGGGTGTCAAT 
29 228 54 AGCTCTCTGGGCCTTGTCTCAA TATAGCCTCTCTCCCCTGGGG 
30 274 54 TGGAGTGATCCAGGTTCAGGGT GAAACAAGGGGGCTCAAGGAG 
31 274 68 TGGTTGGCAGGGGTGGGGTGG GCCTAGGCAGGGTGCACGTGGG 
32 325 56 GACCCCTCACCCTCCCTCTGCTG AGCCCCTGGTTGGAAGAATGAG 
33 267 59 TGGGAACAGGGAGAGGGGCC GCTCAACGTCGGGGCCTGTG 
34 345 55 GATGTGTCTCCCTGGGTCCCTG GAGGACAACGGAGCAAAGCCC 
35 237 58 TGGAGGTGCGAGGTGAGG TGGCCATCCCCAGGAGC 
 
The names of the primers refer to the exon(s) of MYBPC3 that they amplify, numbering according to Niimuta et al., 1998. All primer sequences 
obtained from Carrier et al., (1997). Size (bp) = size of the PCR-amplified fragment produced by primer pairs in base pairs; Ta = annealing 
temperature used for primer pairs in PCR reactions.  
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Table II.2. MYBPC3 RT-PCR primer sequences 
Name Sequence 5’>3’ Tm Reference 
275F ATT GCT GGC TCC TCC AAG GTC AAG T 65oC Watkins et al., 1995a 
301F TCG ACC TCA AGG TCA TAG AGG CAG 64oC Watkins et al., 1995a 
960R CCC TCG GGG TCC GGA AAC TGT CTC T 70oC Watkins et al., 1995a 
985R TCT GCT GGT GCC TCC AGC TTC GAG T 68oC Watkins et al., 1995a 
588F CCG CCT GTG GTC AAG TGG TT 56oC Carrier et al., 1997 
648F CAC CTG CAG CTG CAC GAC AG 57oC Carrier et al., 1997 
882R TGA TCC GCC GAC CAC CTC C 60oC Carrier et al., 1997 
1994R TGT CGG GCA CCA GCT CTT T 57oC Carrier et al., 1997 
Primers were named according to the number of the nucleotide at their 5’-end in GenBank 
(http://www.ncbi.nlm.nih.gov/Entrez, sequence accession number: NM_000256). Tm = melting temperature. 
 
II.6.1.4. Y2H insert screening primers 
 
In order to facilitate the amplification of inserts cloned into Y2H cloning vectors (sections II.6.5 and 
II.6.6), primers were designed to vector-specific sequences flanking the multiple cloning sites (MCS) 
of the pGBK-T7, pGAD-T7, pAS2.1 and pACT2 Y2H cloning vectors (section II.12.1). The specific 
target sequences to which these primers were designed were obtained from the ClontechTM 
MatchmakerTM vector handbook (available at: www.clontech.com) (table II.4). As these primer sets 
were periodically used in bacterial and yeast colony PCR-reactions (sections II.6.5 and II.6.6), which 
often generate non-specific, or weak PCR-amplified products, internal (nested) primer sets were also 
designed in some cases, thus facilitating nested PCR reactions (section II.6.7) (table II.4). 
 
 113
Table II.3. Primer sequences used in PCR amplification of target sequences encoding protein 
domains/regions used in Y2H assays 
 
Name  Sequence 5’>3’ 
MyBPC C0 FNdeI ATC GAA CAT ATG ATG CCT GAG CCG GGG AAG 
MyBPC C0 REcoRI ACT GCA GAA TTC CTA GGG CTC TGC CTT CTC TGC 
MyBPC C1 FNdeI ACT GCA GAA CAT ATG CCC ATT GGC CTC TTC GTG A 
MyBPC C1 REcoRI ACT GCA GAA TTC CTA CTC GTG GAC AGT GAG ATT GA 
MyBPC C2 FNdeI ACT GCA GAA CAT ATG GAT GAG AAG AAG AGC ACA GC 
MyBPC C2 REcoRI ACT GCA GAA TTC CTA GGG CTC TTT CAC AAA GAG CT 
MyBPC C3 FNdeI ACT GCA GAA CAT ATG CCT GTG CTC ATC ACG CGC 
MyBPC C3 REcoRI ACT GCA GAA TTC CTA CTT TTC CTG CAC AAT GAG CT 
MyBPC C5 FNcoI ACT GCA GAA CCA TGG AAC AGG AAC CTC CCA AGA TCC AC 
MyBPC C5 REcoRI ACT GCA GAA TTC CTA CAC GTC GAT GAC CTT GAC TGT 
MyBPC C6 FSmaI ACT GCA GAA CCC GGG ACC AGA CGC ACC TGC GGC CCC CAA 
MyBPC C6 REcoRI ACT GCA GAA TTC CTA GGG ACC GAT AGG CAT GAA GGG CTG GG 
MyBPC C7 FNdeI ACT GCA GAA CAT ATG CCC CCC AGC GAA CCC ACC CA 
MyBPC C7 REcoRI ACT GCA GAA TTC CTA GGG CAG CTG AAG CCG TGG CCG GTT 
MyBPC C8 FSmaI ACT GCA GAA CCC GGG ACC CAG GCA CCT GCG CCA GAC CAT TCA G 
MyBPC C8 REcoRI ACT GCA GAA TTC CTA CTT GTC AAC AAC CTG CAG CAC CAG CGT 
MyBPC C9 FSmaI ACT GCA GAA CCC GGG ACC AAG TCC TCC CCA GGA TCT CCG GG 
MyBPC C10 FSmaI ACT GCA GAA CCC GGG ACC AAG CTT CAC CCA GCC CCT GGT GAA C 
MyBPC C10 REcoRI ACT GCA GAA TTC CTA CTG AGG CAC TCG CAC CTC CAG GGG 
TTN A43 FNdeI ACT GCA GAA CAT ATG CCG GAG ATT GAT TTG GAT G 
TTN A43 REcoRI ACT GCA GAA TTC CTA AGT ATC TAA TAC TCT GAC ATT TAC G 
TTN A109 FNdeI ATC GCA GAA CAT ATG CCA GAA ATA GAA CTC GAT GC 
TTN A109 REcoRI ACT GCA GAA TTC TCA CTC ACT CAT GAG TCA AGA ACT CTG AGC 
TTN A112 FNdeI ACT GCA GAA CAT ATG AGA CAA CTT GGA GTG CCA G 
TTN A112 REcoRI ACT GCA GAA TTC TCA CTC ACT CAT CTG TCA AGG ACA ATT ATA GT 
TTN A116 FNdeI ACT GCA GAA CAT ATG GAC TCA GTT AGT GAG CCA TC 
TTN A116 REcoRI ACT GCA GAA TTC TCA CTC ACT CAT GCT GGT GGA CCA GGC TAA 
 
Blue lettering = template recognition sequences; green lettering = restriction enzyme recognition sequences; 
underlined lettering = stop codons. 
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Table II.4. Primer sequences used in the amplification of inserts present in Y2H cloning vectors 
 
Name Ta (oC) Forward primer sequence 5’>3’ Reverse primer sequence 5’>3’ 
pGBK-T7  50 TCA TCG GAA GAG AGT AG TCA CTT TAA AAT TTG TAT ACA 
pGBK-T7 N 51 CAG TTG ACT GTA TCG CCG AAT TAG CTT GGC TGC AAG C 
pGAD-T7  61 CTA TTC GAT GAT GAA GAT ACC CCA CCA AAC C GTG AAC TTG CGG GGT TTT TCA GTA TCT ACG AAT 
pAS2.1  55 TCA TCG GAA AGT AGT AAC CGT TTT AAA ACC TAA GAG TCA C 
pACT2  68 CTA TTC GAT GAT GAA GAT ACC CCA CCA AAC GTG AAC TTG CGG GGT TTT T CAG TAT CTA CGA 
pACT2 N 68 CTG TAT GGC TTA CCC ATA CGA TGT TCC GCG GGG TTT TTC AGT ATC TAC GAT TCA TAG 
 
Ta = annealing temperature 
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II.1.6.5. Site-directed mutagenesis primers 
 
In order to facilitate the introduction of the V896M putative HCM-causing mutation into the C7 
domain of cMyBPC by PCR-based site-directed mutagenesis (section II.6.8), two overlapping 
mutagenesis primers were designed from MYBPC3 mRNA sequences, obtained from GenBank 
(http://www.ncbi.nlm.nlm.nih.gov/Entrez, sequence accession number: NM_000256) (table II.5). 
These primers were designed to be complementary to each other and to span the mutant nucleotide 
(g15751a) responsible for the V896M putative HCM-causing mutation. In these primers, the wild 
type nucleotide (g15751) was replaced by the mutant nucleotide (a15751) (table II.5).  
 
Table II.5. Primer sequences of site-directed mutagenesis primers 
 
Name Sequence 5’>3’ Ta (oC)
CMyBPC C7V896M F CCA GAG CGC ATG GGA GCA GG 50 
CMyBPC C7V896M R CCT GCT CCC ATG CGC TCT GG 50 
 
Ta = annealing temperature 
 
II.6.2. ROUTINE PCR 
 
To facilitate the screening of MYBPC3 for the presence HCM-causing mutations by PCR-SSCP and 
allele-specific restriction enzyme analysis (ASREA), non-radioactive PCR was performed. All 34 
protein-encoding exons of MYBPC3 (exons 2-35) were PCR-amplified using published primer 
sequences (section II.6.1.1 and table II.1). 
 
In general, 200ng of human genomic DNA was aliquoted into a 0.5ml centrifuge tube (Eppendorf). 
To this, a cocktail consisting of the following reagents was added:- 160ng of each primer (table II.1), 
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1.5μl of an equimolar dNTP solution (consisting of 2.5mM each of dATP, dCTP, dTTP and dGTP), 
(Promega, Madison, WI, USA), 1.5μl of a 50mM MgCl2 solution (Bioline Ltd, London, UK), 5μl of 
a 10x NH4 PCR reaction buffer, supplied by the manufacturer (appendix A) (Bioline Ltd, London, 
UK), 0.5U BIOTAQTM DNA polymerase (Bioline Ltd, London, UK), 2.5μl formamide (Sigma 
Chemical Company, St Louis, Missouri, USA) and ddH2O to a final volume of 50μl.  
 
Thermal cycling was then performed in a GeneAmp® PCR system 9700 (PE Biosystems, Foster 
City, CA, USA) for 30 cycles. A typical cycling profile consisted of 30s at 94ºC, to allow 
denaturation of the double stranded DNA, 30s at the annealing temperature (Ta) of the primer pair 
(2-5ºC below the Tm of the primer with the lower Tm), to allow annealing of the primers, and 30-45s 
at 72ºC for extension. The specific annealing temperatures are listed in table II.1.  
 
Following amplification, 5μl aliquots of each amplified sample were electrophoresed on 1.5-2% 
agarose gels to verify the success of the PCR (section II.7.1.1). All PCR-amplified samples were 
stored at room temperature until further analysis. 
 
II.6.3. HIGH FIDELITY PCR 
 
High fidelity PCR was used to amplify portions of MYBPC3 and TTN coding sequences. These 
amplified products were subsequently cloned into Y2H cloning vectors, for use in Y2H assays. 
 
For the amplification of portions of MYBPC3, 50ng purified pRcCMV, containing full-length 
MYBPC3 copy DNA (cDNA) (a gift from Prof Hugh Watkins, constructed by Dr Zhili Li) was used 
as template. For the amplification of specific domains of TTN, 200ng of human genomic DNA was 
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used as template. The above-mentioned amount of selected template was aliquoted into a 0.5ml 
centrifuge tube (Eppendorf). To this, a cocktail mixture consisting of the following reagents was 
added:- 160ng of each primer (table II.3), 4μl of an equimolar dNTP solution, supplied by the 
manufacturer (TaKaRa Shuzo Co. Ltd, Shiga, Japan) (consisting of 2.5mM each of dATP, dCTP, 
dTTP and dGTP), 5μl of 10x Ex TaqTM Mg2+-containing reaction buffer supplied by the 
manufacturer (TaKaRa Shuzo Co. Ltd, Shiga, Japan), 1-2.5U of Ex TaqTM (TaKaRa Shuzo Co. Ltd, 
Shiga, Japan) and ddH2O to a final volume of 50μl.  
 
Thermal cycling was performed in a GeneAmp® PCR system 9700 (PE Biosystems, Foster City, CA, 
USA) for 30 cycles. A typical cycling profile consisted of 30s at 94ºC, to allow denaturation of the 
double stranded DNA, 30s at 2-5ºC below the Tm of the primer with the lower Tm (Ta), to allow 
annealing of the primers, and 1-4min at 72ºC for extension. Primer sequences and specific 
amplification conditions are listed in tables II.3 and II.6. Following amplification, 5μl aliquots of 
each amplified sample were electrophoresed on 1.0-1.5% agarose gels to verify the success of the 
PCR (section II.7.1.1). These PCR-amplified products were subsequently used for cloning into Y2H 
cloning vectors (section II.12). 
 
II.6.4. RT-PCR 
 
During the course of this study, several DNA sequence variations, which were postulated to alter 
RNA splicing, were identified (section III.1.3). In order to investigate whether these sequence 
variations alter splicing of the MYBPC3 transcript, RT-PCR was performed. In these RT-PCR 
reactions, RNA, extracted from either lymphocytes obtained from freshly collected blood samples 
(section II.4) or from EBV-transformed lymphocytes (section II.5), was used as template. In order to 
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Table II.6. Primer-pairs used for the amplification of bait and prey constructs used in Y2H assays 
 
Insert Type Plasmid 
used 
Forward primer  Reverse primer Ta 
(oC) 
cMyBPC C0 Bait pAS2.1 MyBPC C0 FNdeI MyBPC C0 REcoRI 65 
cMyBPC C0 Bait pGBKT7 MyBPC C0 FNdeI MyBPC C0 REcoRI 65 
cMyBPC C0C1 Bait pAS2.1 MyBPC C0 FNdeI MyBPC C1 REcoRI 65 
cMyBPC C0C1 Bait pGBKT7 MyBPC C0 FNdeI MyBPC C1 REcoRI 65 
cMyBPC C0C2 Bait pAS2.1 MyBPC C0 FNdeI MyBPC C2 REcoRI 55 
cMyBPC C3 Bait pGBKT7 MyBPC C3 FNdeI MyBPC C3 REcoRI 55 
cMyBPC C7 Bait pGBKT7 MyBPC C7 FNdeI MyBPC C7 REcoRI 65 
cMyBPC C7V896M Bait pGBKT7 pGBKT7 F pGBKT7 R 51 
TTN A43 Bait pGBKT7 TTN A43 FNdeI TTN A43 REcoRI 55 
cMyBPC C1 Prey pGADT7 MyBPC C1 FNdeI MyBPC C1 REcoRI 55 
cMyBPC C1C2 Prey pGADT7 MyBPC C1 FNdeI MyBPC C2 REcoRI 55 
cMyBPC C2 Prey pGADT7 MyBPC C2 FNdeI MyBPC C2 REcoRI 55 
cMyBPC C5 Prey pACT2 MyBPC C5 FNcoI MyBPC C5 REcoRI 60 
cMyBPC C6 Prey pACT2 MyBPC C6 FSmaI MyBPC C6 REcoRI 65 
cMyBPC C8 Prey pACT2 MyBPC C8 FSmaI MyBPC C8 REcoRI 65 
cMyBPC C8C10 Prey pACT2 MyBPC C8 FSmaI MyBPC C10 REcoRI 65 
cMyBPC C9 Prey pACT2 MyBPC C9 FSmaI MyBPC C9 REcoRI 65 
cMyBPC C9C10 Prey pACT2 MyBPC C9 FSmaI MyBPC C10 REcoRI 65 
cMyBPC C10 Prey pACT2 MyBPC C10 FSmaI MyBPC C10 REcoRI 65 
TTN A43 Prey pGADT7 TTN A43 FNdeI TTN A43 REcoRI 55 
TTN A109 Prey pGADT7 TTN A109 FNdeI TTN A109 REcoRI 55 
TTN A109A112 Prey pGADT7 TTN A109 FNdeI TTN A112 REcoRI 55 
TTN A112 Prey pGADT7 TTN A112 FNdeI TTN A112 REcoRI 55 
TTN A116 Prey pGADT7 TTN A116 FNdeI TTN A116 REcoRI 55 
 
Ta = annealing temperature; Type = type of Y2H construct (either bait or prey). 
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minimise RNase contamination of samples, all workbench surfaces, pipettes and apparatus used, 
were treated with RNase Erase (ICD Biochemicals, Aurora, Ohio, USA). Furthermore, all pipette 
tips and centrifuge tubes used in either the preparation of RNA samples, or first-strand cDNA 
synthesis, were rinsed with a 0.2% DEPC (Sigma, St Louis, Missouri, USA) (appendix A) solution, 
prior to being autoclaved. 
 
II.6.4.1. First-strand cDNA synthesis 
 
First-strand cDNA synthesis was performed using the Promega Reverse Transcription System 
(Promega, Madison, WI, USA), with minor adjustments to the manufacturer’s protocol. In short, 
0.5μg of random hexanucleotide primers (Promega, Madison, WI, USA) was added to 100–200ng of 
total RNA and the volume adjusted to 10μl by adding nuclease-free H2O. This mixture was then 
incubated for 5min at 70oC and snap cooled on ice for 5min. Following this incubation step, 10μl of 
a reaction mixture, consisting of 4μl 25mM MgCl2 (Promega, Madison, WI, USA), 2μl of 10x 
reverse transcription buffer (Promega, Madison, WI, USA), 2μl of a 10mM dNTP mixture (Promega, 
Madison, WI, USA), 0.5μl recombinant RNasin® ribonuclease inhibitor (Promega, Madison, WI, 
USA), 15U AMV reverse transcriptase (Promega, Madison, WI, USA) and nuclease-free H2O to a 
final volume of 20μl, was added to the sample. This mixture was subsequently incubated for 1h at 
42oC, 5min at 95oC and 5 min at 4oC. All incubations were performed in a Techne Genius PCR 
machine (Techne Ltd., Cambridge, UK). Aliquots of the first strand cDNA product were 
subsequently used for PCR amplification or frozen at -20oC for future use. 
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II.6.4.2. PCR Amplification of MYBPC3 cDNA 
 
In order to PCR amplify specific portions of the MYBPC3 transcript, nested PCR was performed 
(section II.6.7). The sequences of the primers used for these reactions, their annealing temperatures, 
and the combinations in which they were used, are summarised in tables II.2 and II.7. 
 
In short, 2μl of first strand cDNA (section II.6.4.1) was added to 48μl of a reaction mixture 
consisting of:- 5μl GeneAmp® 10x PCR buffer (Perkin Elmer, manufactured by Roche Molecular 
Systems Inc, Branchburg, NJ, USA), 1.1μl of a 10mM dNTP stock solution (Promega, Madison, WI, 
USA), 10pmol of each primer (tables II.2 and II.7), 0.5μl of AmpliTaq Gold™ (Perkin Elmer, 
manufactured by Roche Molecular Systems Inc, Branchburg, NJ, USA) and ddH2O to a final volume 
of 48μl.  
 
Thermal cycling was performed in a Techne Genius PCR machine (Techne Ltd., Cambridge, UK) 
for 30 cycles. A typical cycling profile consisted of 30s at 94ºC, to allow denaturation of the double 
stranded DNA, 30s at the Ta of the primer set, to allow annealing of the primers, and 1-4min at 72ºC 
for extension. Primer sequences and specific amplification conditions are listed in tables II.2 and II.7. 
Following amplification, 5μl aliquots of each RT-PCR product were electrophoresed and visualised 
on 1.5-2.5% agarose gels (section II.7.1.1).  
 
Table II.7. RT-PCR primer pairs used 
SNS investigated Type PCR F primer R primer  Ta (oC) 
Outer Rn 275F 985R 60 c2646t 
c4154t Nested Rn 301F 960R 62 
Outer Rn 588F 1994R 55 g4177a 
Nested Rn 648F 882R 55 
Rn = reaction; SNS = single nucleotide substitution; Ta = annealing temperature 
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II.6.5. BACTERIAL COLONY PCR 
 
For rapid identification of E.coli colonies harbouring the desired recombinant plasmid, to be used in 
Y2H assays, the presence of the insert was verified by performing bacterial colony PCR. 
 
In these PCR reactions, 160ng of Y2H vector-specific primers (table II.4), was added to PCR 
reaction-mixtures that were identical to those used for routine PCR (section II.6.2). The DNA 
template, used in routine PCR was, however, substituted by individual bacterial colonies, picked 
directly from the LB-agar plates containing the appropriate antibiotics (section II.12 and appendix 
A). In each set of bacterial colony PCR reactions, a positive control, consisting of an appropriate 
non-recombinant plasmid, and a negative control, consisting of a water blank, were concurrently set 
up to correctly ascertain which colonies harboured the insert, as well as to monitor contamination.  
 
Thermal cycling was performed in a GeneAmp® PCR system 9700 (PE Biosystems, Foster City, CA, 
USA). The cycling profile generally consisted of a single denaturing step of 7min at 94oC, followed 
by 30 cycles of a 30s denaturation step at 94oC, a 30s primer-annealing step at the Ta of the primer 
set (table II.4), and an extension step at 72oC. The length of the extension step was adjusted 
according to the expected insert size and varied between 30s and 4min (30s for fragments <1kb and 
up to 4min for fragments >3kb). PCR-amplified products were subsequently visualised on 1-2% 
agarose gels (section II.7.1.1). When colony PCR yielded weak or non-specific products, nested PCR 
reactions (section II.6.7) were performed, in which the nested vector-specific primers (table II.4) 
were used in a second round of PCR-amplification. 
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Following the identification of colonies harbouring the correct insert size by agarose gel-
electrophoresis, the identity of the insert was confirmed by a second colony PCR reaction. The same 
basic protocol was followed as described above, but in these reactions, vector-specific primer sets 
were substituted by appropriate insert-specific primer sets and the annealing temperature adjusted 
accordingly (table II.6). 
 
II.6.6. YEAST COLONY PCR 
 
In order to enable the restriction mapping of interactor prey-inserts, obtained from Y2H cDNA 
library-assays (section II.16.2), yeast colony PCR was performed. All reaction-mixtures, primer sets, 
cycling profiles and apparatus used were identical to those used for bacterial colony PCR (section 
II.6.5), with the only exception being that yeast, instead of bacterial colonies, picked from 
appropriate selective dropout (SD) plates (section II.12.1, table II.10 and appendix A), were used as 
template. 
 
II.6.7. NESTED PCR 
 
Nested PCR reactions were used to increase the specificity and sensitivity of cDNA synthesis 
(section II.6.4.2) and bacterial/yeast colony PCR (sections II.6.5 and II.6.6). With the exception of 
external (outer) primers being substituted by 160ng of each internal (nested) primer, reaction 
mixtures used for nested PCR were identical to those used for the first round of PCR amplification 
(sections II.6.4.2; II.6.5; II.6.6 and tables II.2; II.4). To these reaction mixtures, 0.5μl of first round 
PCR products were added as template. The apparatus used, and cycling profiles of nested PCR 
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reactions, were identical to those used in the first round of PCR amplification, with the exception of 
the Ta that was adjusted according to the specific nested primer set used (tables II.2 and II.4). 
 
II.6.8. SITE-DIRECTED MUTAGENESIS PCR 
 
In vitro site-directed mutagenesis PCR was used to introduce the V896M putative HCM-causing 
mutation into the C7 domain of cMyBPC. Two complimentary mutagenesis primers, into which the 
g15751a mutation responsible for V896M was introduced (cMyBPC C7V896M F and cMyBPC 
C7V896M R) (section II.6.1.5; table II.5), were used in conjunction with the pGBKT7 R and pGBKT7 
F primers (table II.4), respectively, in two separate high-fidelity PCR reactions (section II.6.3). In 
both these PCR-reactions, 50ng of pGBKT7-C7 bait construct was used as template (figure II.4). 
Thermal cycling was performed in a GeneAmp® PCR system 9700 (PE Biosystems, Foster City, CA, 
USA) for 30 cycles with cycling profiles consisting of 30s at 94ºC, to allow denaturation of the 
double stranded DNA, 30s at 50ºC, to allow annealing of the primers, and 1min at 72ºC for 
extension. The two PCR-amplified products thus generated were subsequently visualised on, and 
excised from, a 2% agarose gel (section II.7.1.1) (figure II.4).  
 
Following gel-purification of these PCR-amplified products (section II.4.6), a 10μl aliquot of each 
product was added to a reaction mixture consisting of:- 4μl of an equimolar dNTP solution (TaKaRa 
Shuzo Co. Ltd, Shiga, Japan) (consisting of 2.5mM each of dATP, dCTP, dTTP and dGTP), 5μl of 
10x Ex TaqTM Mg2+-containing reaction buffer (TaKaRa Shuzo Co. Ltd, Shiga, Japan), 2.5U of Ex 
TaqTM (TaKaRa Shuzo Co. Ltd, Shiga, Japan) and ddH2O to a final volume of 50μl. This mixture 
was subjected to 10 cycles of thermal cycling identical to that described above (figure II.4). 
Following thermal cycling, 160ng of each of the pGBKT7 F and pGBKT7 R primers was added to 
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the reaction mixture, which was subjected to a further 10 cycles of thermal cycling identical to that 
described above (figure II.4). The full-length mutagenesis PCR product thus obtained, was 
subsequently gel purified from a 2% agarose gel (sections II.7.1.2 and II.4.6), prior to it being cloned 
into the pGBKT7 Y2H bait-vector (section II.12). 
 
Rn A          Rn B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.4. Site-directed mutagenesis PCR 
1 = pGBKT7 F primer; 2 = cMyBPC C7V896M R primer; 3 = cMyBPC C7V896M F primer; 4; = pGBKT7 R 
primer; Rn = reaction 
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II.7. GEL-ELECTROPHORESIS 
 
II.7.1. AGAROSE GEL-ELECTROPHORESIS 
 
Agarose gel-electrophoresis was used to verify the success of PCR amplification (section II.6), the 
gel-purification of PCR amplification products (section II.4.6) and the visualisation of plasmids 
purified from E.coli (section II.4.7). 
 
II.7.1.1. Agarose gel-electrophoresis for the visualisation of PCR-amplified products 
 
The success of PCR and RT-PCR amplifications was verified by electrophoresis as follows: 5μl of 
each amplification product was mixed with 1μl of bromophenol blue loading dye (appendix A). This 
mixture was subsequently electrophoresed in a 1.4-2% (depending on the size of the amplified 
fragment) horizontal agarose gel, of either 15x9x1cm or 7x9x1cm dimensions, containing 1μg/ml 
ethidium bromide and 1x TBE buffer (appendix A). The molecular size marker, co-electrophoresed 
with all PCR-amplified products, was either bacteriophage λ DNA, digested with the PstI restriction 
enzyme (Promega, Madison, WI, USA) (λPst) (appendix A), Promega 100bp marker (Promega, 
Madison, WI, USA), or Roche molecular size marker VII (Roche Biochemical, Basel, Switzerland). 
Electrophoresis typically occurred at 10V/cm for 20min in 1x TBE running buffer (appendix A). 
 
The DNA fragments were subsequently visualised on a long wave 3UV transilluminator (UVP, Inc. 
Upland, CA, USA). Photographic records were obtained using an ITC polaroid camera and Sony 
video-graphic printer. 
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II.7.1.2. Agarose gel-electrophoresis for the gel-purification of PCR-amplified products 
 
In order to facilitate the gel-purification of PCR-amplified fragments, these fragments were 
electrophoresed and excised from agarose gels. Agarose gels were identical to those used for the 
visualisation of PCR-amplified fragments (section II.7.1.1). In this case, however, 5μl of 
bromophenol blue loading dye (appendix A) was mixed with 45μl of PCR-amplified product. 
Electrophoresis typically occurred at 10V/cm for 30-60min in 1x TBE running buffer (appendix A). 
Following electrophoresis, PCR-amplified fragments were visualised on a long wave 3UV 
transilluminator (UVP, Inc. Upland, CA, USA) and the relevant DNA bands excised from the gel, 
using a sterile surgical blade, for subsequent gel-purification (section II.4.6). 
 
II.7.1.3. Agarose gel-electrophoresis for the visualisation of plasmids purified from E.coli 
 
Plasmids purified from E.coli were visualised by electrophoresis on agarose gels as follows: 1-5μl of 
purified plasmid was mixed with 1μl of bromophenol blue loading dye (appendix A). This mixture 
was subsequently electrophoresed in a 1% horizontal agarose gel, of 7x9x1cm dimensions, 
containing 1μg/ml ethidium bromide and 1x TAE buffer (appendix A). λPst (appendix A) was co-
electrophoresed with purified plasmids as a molecular size marker. Electrophoresis typically 
occurred at 6V/cm for 45-60min in 1x TAE running buffer (appendix A). 
 
The purified plasmids were subsequently visualised on a long wave 3UV transilluminator (UVP, Inc. 
Upland, CA, USA). Photographic records were obtained using an ITC polaroid camera and Sony 
video-graphic printer. 
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II.7.2. NON-DENATURING POLYACRYLAMIDE GEL-ELECTROPHORESIS 
 
Polyacrylamide gel-electrophoresis was used to visualise restriction enzyme digested PCR-amplified 
products (sections II.11.1 and II.11.3). Typically, 5-10μl of digested PCR product was mixed with 
1μl of bromophenol blue loading dye (appendix A). This mixture was loaded into a polyacrylamide 
gel, of 100x80x1mm dimensions, containing 12% acrylamide and 1x TBE buffer (appendix A). In all 
cases either λPst marker (appendix A), or Promega 100bp marker (Promega, Madison, WI, USA), 
and an undigested sample were co-electrophoresed as controls. Electrophoresis was performed in 1x 
TBE running buffer (appendix A) at 15V/cm for 1-2 hours, following which fragments were 
visualised by silver staining (section II.9). 
 
II.8. SINGLE-STRAND CONFORMATIONAL POLYMORPHISM (SSCP) 
 
In order to investigate specific exons of MYBPC3 for the presence of nucleotide sequence variations, 
PCR-SSCP analysis was performed on PCR-amplified fragments of these exons (section II.6.2). A 
5μl aliquot of each PCR-amplified product was mixed with an equal volume of standard SSCP-
loading dye (appendix A). These mixtures were then heat-denatured at 95oC for 2min, before being 
loaded directly onto SSCP-gels (appendix A). Control samples that were co-electrophoresed included 
a non-denatured sample as control for the electrophoretic mobility of the double-stranded DNA, an 
amplified fragment from an unaffected individual as a negative control, and a 5μl aliquot of 
undenatured λPst (appendix A).  
 
SSCP gels were of 400x300x1mm dimensions and were covalently bound to GelBond® PAG film 
during polymerisation (BMA, Rockland, ME, USA), to facilitate subsequent silver staining (section 
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II.9). SSCP analysis involved electrophoresis of PCR-amplified products on two gel media, namely 
an 8% and a 10% mildly-denaturing gel (appendix A). Electrophoresis was performed at 25W 
constant power for 16-18 hours at 4oC, with 0.5x TBE (appendix A) as running buffer, in all cases.  
 
Following electrophoresis, gels were silver stained (section II.9) and air-dried for 4-6 hours, after 
which the gels were sealed in plastic bags and kept as permanent records. Samples in which mobility 
shifts were detected were re-amplified (section II.6.2), and re-analysed under similar SSCP 
conditions to distinguish false positives. Samples in which mobility shifts proved to be reproducible 
were directly sequenced (section II.10) to identify the nucleotide sequence variations. 
 
II.9. SILVER STAINING OF POLYACRYLAMIDE GELS 
I.9. SILVER STAINING OF POLYACRYLAMIDE GELS 
 
Silver staining was used to visualise DNA fragments on polyacrylamide gels (sections II.7.2 and 
II.8), and was performed in a manner modified from Bassan (1991). Following the removal of 
polyacrylamide-gels from the glass plates, these gels were immersed in a solution of 0.1% AgNO3 
(appendix A) and agitated for 10min on a Labcon orbital shaker (Labcon Pty Ltd, Maraisburg, RSA). 
Thereafter, gels were rinsed thoroughly with ddH2O before being agitated in a developing solution 
(appendix A) until stained DNA bands appeared. Gels were again rinsed thoroughly in ddH2O and 
either air-dried or photographed to obtain permanent records. 
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II.10. DNA SEQUENCING 
 
Direct cycle sequencing of gel-purified PCR-amplified products (section II.4.6) was used to detect 
nucleotide sequence variations, responsible for alterations in the electrophoretic mobility of single 
stranded conformers detected by PCR-SSCP analysis. For the sequencing of PCR-amplified 
products, both manual (section II.10.1) and automated (II.10.2) DNA sequencing were used. The 
direct sequencing of PCR-amplified products allowed the simultaneous detection of both alleles at a 
locus, so that homozygosity and heterozygosity could be verified in any sample.  
 
Automated cycle sequencing (section II.10.2) was also used to obtain the nucleotide sequence of all 
constructs used in Y2H assays (section II.12), as well as to obtain the nucleotide sequences of 
specific interactor prey-plasmids, identified in the various Y2H cDNA library-assays (section 
II.16.2). 
 
II.10.1. MANUAL DNA SEQUENCING  
 
Two to five microlitres of gel-purified PCR product (section II.4.6) was sequenced bi-directionally 
using the fmolTM Cycle Sequencing Kit (Promega, Madison, WI, USA), with some modifications to 
the manufacturer’s protocol. Specifically, the sequencing reaction mixture contained 2-5μl gel-
purified PCR product as template, 5μl of the supplied sequencing buffer, 6pmol of the appropriate 
PCR amplification primer (table II.1), 0.5μl of [α32P]-dCTP (Amersham International plc, Little 
Chalfont, Buckinghamshire, UK), 0.8μl of DMSO (Sigma, St Louis, MO, USA), ddH2O to a final 
volume of 16μl and 5U of sequencing grade Taq polymerase (Promega, Madison, WI, USA). Four 
microlitres of this mixture was added to four previously prepared, prechilled 500μl Eppendorf tubes, 
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each containing 2μl of a cocktail comprised of all four deoxynucleotides, as well as a specific 
dideoxynucleotide, ddATP, ddCTP, ddTTP or ddGTP, as supplied by the manufacturer (Promega, 
Madison, WI, USA). Samples were subsequently overlaid with 20μl of mineral oil to prevent 
evaporation during thermal cycling. 
 
Tubes were placed in a Techne GeneE (Techne Ltd., Cambridge, UK) thermal cycler, preheated to 
94oC, in which they were incubated, at 94oC, for 5min, prior to 30 cycles of thermal cycling, using 
the same temperature profile as in the original PCR amplification rection (table II.1). Following 
completion of thermal cycling, 4μl of the supplied stop solution (Promega, Madison, WI, USA) was 
added to each sample.  
 
These samples were subsequently heat-denatured at 95oC for 2min, and a 4μl aliquot of each sample 
loaded on a 5% denaturing polyacrylamide gel (of 300x400x0.4mm dimensions, containing 44% 
(w/v) urea and 1x TBE) (appendix A) that was mounted on an electrophoresis apparatus and 
subjected to 1800V for about 60min prior to loading of samples (appendix A). Electrophoresis 
typically took place in 0.5x TBE (appendix A) running buffer at 1800V. Shorter fragments (up to 
200bp in length) were electrophoresed until the bromophenol blue of the loading dye had migrated to 
the bottom of the gel. In order to obtain full-length nucleotide sequences of fragments larger than 
200bp, electrophoresis was interrupted once the bromophenol blue loading dye had migrated to the 
bottom of the gel. At this time, a second set of heat-denatured 4μl aliquots of each sample was 
loaded into separate wells. Electrophoresis was then continued at 1800V till the bromophenol blue 
loading dye co-migrating with these newly loaded samples had reached the bottom of the gel.  
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After completion of electrophoresis, gels were dismantled and transferred onto WhatmanTM 3MM 
Chromatography paper (Whatman International Ltd, Madstone, England, UK). The gels were then 
dried under vacuum (Slab gel drier, model SE 1160, Hoeffer Scientific Insr, San Francisco, CA, 
USA) for 1 hour and exposed to Cronex 4 X-ray film (Protea Medical Supplies, Cape Town, RSA) 
for 6 hours to overnight. 
 
II.10.2. AUTOMATED DNA SEQUENCING 
 
Automated DNA sequencing of cloned inserts (section II.12) and PCR-amplified fragments (section 
II.6) was performed at the Core Sequencing Facility of the Department of Genetics, University of 
Stellenbosch, RSA, using either an ABI Prism™ 377 or an ABI Prism™ 3100 automated sequencer 
(PE Applied Biosystems, Foster City, CA, USA). The primers used in these sequencing reactions 
were identical to those used in the initial PCR reactions, in cases where PCR-amplified products 
were sequenced (table II.1), or vector specific primers, in cases where Y2H constructs were 
sequenced (table II.4) 
 
II.10.3. DNA SEQUENCE ANALYSIS 
 
II.10.3.1. Sequence analysis of specific exons of MYBPC3 
 
Sequences were either read manually, when manual cycle sequencing was performed (section 
II.10.1), or with the help of the Chromas 1.6 computer program (Technelysium Pty Ltd, Helensvale, 
Queensland, Australia), when automated DNA sequencing was performed (section II.10.2). To 
facilitate the detection of mutations and polymorphisms occurring in exons of MYBPC3, nucleotide 
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sequences were manually compared to the wild type MYBPC3 sequence, obtained from the GenBank 
database (http://www.ncbi.nlm.nih.gov/Entrez, sequence accession number: Y10129). Where 
nucleotide sequence variations were identified, the DNAman version 4.0 sequence analysis program 
(Lynnion BioSoft Corp) was used to generate restriction enzyme maps of both the wild type and 
variant DNA sequences, in order to ascertain whether the sequence variants modified restriction 
enzyme recognition sites. If that were the case, ASREA (section II.11.1) was used to confirm 
sequencing results. Where nucleotide sequence variants did not alter any restriction enzyme 
recognition sites, these variants were to be considered confirmed only if the variant sequence was 
clearly visible in both sequencing directions, or was reproducible in a subsequent sequencing 
reaction from a fresh PCR product.  
 
Confirmed nucleotide variants were further analysed, in order to predict whether they would affect 
the amino acid sequence of cMyBPC, or whether they may affect splicing of the MYBPC3 transcript. 
Putative splicing mutations were identified by either comparing the nucleotide sequence surrounding 
the single nucleotide substitution (SNS) to splice acceptor site (SaS), splice donor site (SdS) and 
splice branch point (SbP) consensus sequences (Box 1), or by computational analysis performed by 
Dr Peter Rogan (University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA). 
Computational analysis involved the use of the Scan, MakeWalker, DNAPlot and Lister programs 
(personal communication, Dr Peter Rogan, 23 December 1999; Rogan et al., 1998). 
 
Nucleotide variations thus predicted to alter the cMyBPC protein, by either altering the amino acid 
sequence of cMyBPC, or predicted to result in the truncation of the protein, were classified as 
putative HCM-causing mutations. In these cases, ASREA- (when available) or SSCP-based tests 
(used in cases where nucleotide sequence variants did not alter restriction enzyme recognition sites) 
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were used to screen at least 100 unrelated control individuals of the same ethnicity as the proband, to 
ascertain whether the allele is present in the general population.  
 
Nucleotide variations postulated to cause aberrant splicing of the MYBPC3 transcript were further 
analysed by RT-PCR techniques (section II.6.4). Thus, DNA sequence variants were considered to 
be HCM-causing when they had an effect on the amino acid sequence of cMyBPC at conserved 
amino acid positions, or caused aberrant splicing of the MYBPC3 transcript, segregated with the 
disease in HCM-affected individuals and their family members, and were absent from 100 control 
individuals. Sequence variations found, that did not meet these criteria (when ascertainable), were 
not pursued. 
 
II.10.3.2. Sequence analysis of Y2H constructs 
 
Automated DNA-sequencing was used to test the integrity of all constructs used in Y2H assays 
(section II.12). These sequences were read, using the Chromas 1.6 computer program (Technelysium 
Pty Ltd, Helensvale, Queensland, Australia), and compared to wild-type sequences obtained from the 
GenBank database (http://www.ncbi.nlm.nih.gov/Entrez), in order to establish whether both the 
reading-frame and the nucleotide sequence of the specific bait- and prey-inserts were maintained 
during the cloning process.  
 
II.10.3.3. Sequence analysis of Y2H interactor prey constructs 
 
The nucleotide sequences of the inserts of prey constructs found to encode peptides that interacted 
with baits in Y2H library-assays (interactor preys) (section II.16.2) were also determined by 
automated DNA-sequencing. These sequences were read using the Chromas 1.6 computer program 
(Technelysium Pty Ltd, Helensvale, Queensland, Australia), and the protein products which they 
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encode identified using the BLASTX and BLASTP algorithms available from NCBI 
(http://www.ncbi.nlm.nih.gov/Blast).  
 
II.11. RESTRICTION ENZYME DIGESTION 
 
II.11.1. ALLELE-SPECIFIC RESTRICTION ENZYME ANALYSIS (ASREA) 
 
ASREA was used to confirm the presence of sequence variations identified by DNA sequencing 
(section II.10). Generally, 5μl of a PCR-amplified product was added to a cocktail containing 1-3U 
of the relevant enzyme (table II.8) in the appropriate buffer supplied by the manufacturer, in a total 
volume of 15μl. These samples were then incubated for 2h to overnight at the optimal temperature 
for the particular enzyme (table II.8).  
 
Half of this reaction mixture was subsequently mixed with 1μl of bromophenol blue loading dye 
(appendix A) prior to polyacrylamide gel electrophoresis (section II.7.2). In all cases either, λPst 
marker (appendix A), or Promega 100bp marker (Promega, Madison, WI, USA), and an aliquot of 
the undigested PCR-amplified sample were co-electrophoresed as controls. Following 
electrophoresis, fragments were visualised by silver staining (section II.9). 
 
II.11.2. RESTRICTION ENZYME DIGESTION FOR CLONING 
 
In order to facilitate the cloning of constructs to be used in Y2H assays, both Y2H cloning vectors 
and the PCR-products to be cloned were sequentially double-digested with appropriate restriction 
enzymes (table II.8). Generally, 30μl of either the PCR-amplified product to be cloned, or the 
specific Y2H cloning vector to be used (table II.9), were added to a cocktail containing 10-30U of 
the relevant restriction enzyme (table II.8), in the appropriate buffer supplied by the manufacturer, in 
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a total volume of 45μl. These samples were subsequently incubated for 3h at 37oC. Following this 
incubation period, the restriction enzyme was heat-inactivated by incubation at 60oC for 15min, after 
which the digested DNA was purified, by either DNA precipitation (section II.4.3) or gel-purification 
(section II.4.6), prior to digestion with the second restriction enzyme, which was performed as 
described above. The double-digested DNA samples were then once again purified by either DNA 
precipitation (section II.4.3), or gel-purification (section II.4.6). Double-digested Y2H cloning 
vectors were subsequently treated with calf intestinal alkaline phosphatase (CIP) (section II.12.2) and 
purified by DNA precipitation (section II.4.3), prior to being used in ligation reactions, while double-
digested PCR-amplified products were used directly in ligation reactions (section II.12.3). 
 
II.11.3. RESTRICTION MAPPING OF Y2H LIBRARY PREY-INSERTS 
 
In order to allow the grouping of identical prey-plasmids, identified by Y2H library-assays as 
interacting with a specific bait, prey-inserts of interactor colonies were PCR-amplified by yeast 
colony PCR (section II.6.6) and the PCR-products digested with HaeIII restriction enzyme 
(Promega, Madison, WI, USA). Generally, 5μl of the yeast colony PCR-amplified product was 
added to a cocktail containing 1-3U of HaeIII (Promega, Madison, WI, USA) in the appropriate 
buffer supplied by the manufacturer, in a total volume of 15μl. These samples were then incubated 
for 3h at 37oC. Following digestion, polyacrylamide gel-electrophoresis and silver staining were used 
to visualise restriction enzyme digested PCR-amplified products (sections II.7.2 and II.9). Prey-
inserts displaying identical HaeIII digestion patterns were additionally digested with RsaI (Promega, 
Madison, WI, USA) in a separate reaction, as described above. Prey-inserts displaying identical 
HaeIII and RsaI restriction patterns, were considered to be identical and only a representative prey 
clone used in subsequent Y2H assays (section II.16). 
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Table II.8. Restriction enzymes used 
RE Application Substrate Supplier 
AvaI ASREA of c8612t PCR-amplified product Roche Applied Science, Roche 
Biochemical, Basel, Switzerland 
AluI ASREA of a18443g 
and g19706a 
PCR-amplified product Promega, Madison, WI, USA 
BstEII  Verification of 
aberrant splicing 
RT-PCR-amplified product Promega, Madison, WI, USA 
EcoRI Cloning PCR-amplified product and Y2H 
bait- and prey-plasmids 
Promega, Madison, WI, USA 
HaeIII Restriction mapping of 
interactor prey-inserts 
Yeast colony PCR-amplified 
product 
Promega, Madison, WI, USA 
HhaI ASREA of g2785a PCR-amplified product Amersham, Little Chalfont, 
Buckinghamshire, UK 
HphI ASREA of t2510c and 
c2646t 
PCR-amplified product New England Biolabs, Beverly, 
MA, USA 
MnlI ASREA of g5047a PCR-amplified product New England Biolabs, Beverly, 
MA, USA 
NcoI Cloning PCR-amplified product and Y2H 
bait-plasmids 
Promega, Madison, WI, USA 
NdeI Cloning PCR-amplified product and Y2H 
bait-plasmids  
Promega, Madison, WI, USA 
NlaIII ASREA of g2626a, 
g15751a and c19731t 
PCR-amplified product New England Biolabs, Beverly, 
MA, USA 
NlaIV ASREA of c4825t and 
c13314g 
PCR-amplified product New England Biolabs, Beverly, 
MA, USA 
RsaI Restriction mapping of 
interactor prey-inserts 
Yeast colony PCR-amplified 
product 
Promega, Madison, WI, USA 
SmaI Cloning PCR-amplified product and Y2H 
bait-plasmids 
Promega, Madison, WI, USA 
 
ASREA = allele-specific restriction enzyme analysis; RE = restriction enzyme; RT-PCR = reverse 
transcription PCR; Y2H = yeast two-hybrid. 
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II.12. GENERATION OF Y2H CONSTRUCTS 
 
II.12.1. Y2H BAIT- AND PREY-VECTORS 
 
Y2H bait constructs were cloned into either the pAS2.1 (figure II.5) or pGBKT7 (figure II.6) Y2H 
bait-vectors, while Y2H prey constructs were cloned into either the pACT2 (figure II.7) or pGADT7 
(figure II.8) Y2H prey-vectors (BD Biosciences, Clontech, Palo Alto, CA, USA). 
 
II.12.2. ALKALINE PHOSPHATASE TREATMENT OF VECTORS 
 
Double digested Y2H cloning vectors were CIP-treated to remove the phosphate end groups, thereby 
reducing the chances of self-ligation of the vector. To achieve this, a 50μl aliquot of double-digested 
vector was incubated with 1μl of CIP (1U/μl) (Promega, Madison, WI, USA) at 37°C for 15min in 
the buffer supplied by the manufacturer, after which another 1μl of CIP (Promega, Madison, WI, 
USA) was added to the sample prior to incubation at 37ºC for a further 15min. Following incubation, 
0.02x volume of 0.5M EDTA was added and the sample incubated at 65°C for 20min, in order to 
inactivate the enzyme. The vector was subsequently purified by PCI treatment (section II.4.5). 
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Table II.9. Characteristics of Y2H cloning plasmids  
 
Plasmid Ampr Kanr TRP1 LEU2 CYN2 GAL4-
BD 
GAL4-
AD 
O2μ Of1 OpUC OpBR322 TADH1 TT7 TCYC1 PADH1 PT7 cMyc HA 
pAS2.1 + - + - + + - + + + - + - + + - - - 
pGBKT7 - + + - - + - + + + - + + - - + + - 
pACT2 + - - + - - + + - - + + - - + - - + 
pGADT7 + - - + - - + + - + - + - - + + - + 
 
Ampr = ampicillin resistance gene; Kanr = kanamycin resistance gene; TRP1 = TRP1 coding sequence; LEU2 = LEU2 coding sequence; CYN2 = 
CYN2 coding sequence; GAL4-BD = GAL4 DNA-binding domain coding sequence; GAL4-AD = GAL4 transcriptional activation domain coding 
sequence, O2μ = yeast 2μ origin of replication; Of1 = f1 bacteriophage origin of replication; OpUC = pUC origin of replication; OpBR322 = pBR322 
origin of replication; TADH1 = ADH1 transcription termination sequence; TT7 = T7 transcription termination sequence, TCYC1 = CYC1 transcription 
termination sequence; PADH1 = ADH1 promoter sequence; PT7  = T7 promoter sequence; cMyc = c-Myc epitope tag; HA = hemaglutinin epitope tag. 
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Figure II.5. Restriction map and multiple cloning site of pAS2.1 
a) Restriction map of the pAS2.1 Y2H bait-vector. The positions of unique restriction sites are 
indicated in bold. The positions of the ampicillin resistance- (Ampr), TRP1-, CYH2- and GAL4-BD 
coding sequences, the 2μ yeast-, f1 bacteriophage- and pUC plasmid origins of replication, the 
S.cerevisiae ADH1 promotor sequence, the CYC1 and S.cerevisiae ADH1 termination signal 
sequences and the position of the multiple cloning site (MCS) are indicated on the map. 
b) Nucleotide sequence of the pAS2.1 MCS. The positions of all unique restriction enzyme 
recognition sequences, stop codons and the final codon (147) of the GAL4-BD coding sequence are 
indicated on the map (from Clontech MATCHMAKER vectors handbook).  
 
a) 
b) 
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Figure II.6. Restriction map and multiple cloning site of pGBKT7 
a) Restriction map of the pGBKT7 Y2H bait-vector. The positions of the kanamycin resistance- (Kanr), TRP1- 
and GAL4-BD coding sequences, the 2μ yeast-, f1 bacteriophage- and pUC plasmid origins of replication, the 
truncated S.cerevisiae ADH1 promotor sequence (PADH1), the T7 RNA polymerase promoter, the T7 and 
S.cerevisiae ADH1 termination signal sequences, the position of the multiple cloning site (MCS) and the c-
Myc epitope tag, are indicated on the map. 
b) Nucleotide sequence of the pGBKT7 MCS. The positions of all unique restriction enzyme recognition 
sequences, stop codons in the T7 terminator sequence, the GAL4-BD coding sequence, the T7 promoter 
sequence, c-Myc epitope tag and the positions of various insert screening and sequencing primers are 
indicated on the map (from Clontech MATCHMAKER vectors handbook). 
a) 
b) 
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Figure II.7. Restriction map and multiple cloning site of pACT2 
a) Restriction map of the pACT2 Y2H prey-vector. The positions of unique restriction sites are indicated in 
bold. The positions of the ampicillin resistance- (Ampr), LEU2- and GAL4-AD coding sequences, the 2μ 
yeast-, and pBR322 plasmid origins of replication, the S.cerevisiae ADH1 promotor sequence, the 
S.cerevisiae ADH1 termination signal sequences, Lox sites (Lox1 and Lox2), the Hemagglutinin (HA) epitope 
tag and the multiple cloning site (MCS) are indicated on the map. 
b) Nucleotide sequence of the pACT2 MCS. The positions of all unique restriction enzyme recognition 
sequences, stop codons, the position of the final codon (881) of the GAL4-AD coding sequence, and the HA 
epitope tag are indicated on the map (from Clontech MATCHMAKER vectors handbook). 
a) 
b) 
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Figure II.8. Restriction map and multiple cloning site of pGADT7 
a) Restriction map of the pGADT7 Y2H prey-vector. The positions of the ampicillin resistance- (Ampr), LEU2- 
and GAL4-AD coding sequences, the 2μ yeast- and pUC plasmid origins of replication, the S.cerevisiae 
ADH1 promotor sequence (PADH1), the T7 RNA polymerase promoter, the S.cerevisiae ADH1 termination 
signal sequences (TADH1), the position of the multiple cloning site (MCS) and the HA epitope tag are indicated 
on the map. 
b) Nucleotide sequence of the pGADT7 MCS. The positions of all unique restriction enzyme recognition 
sequences, the T7 promoter sequence, the GAL4-AD coding sequence, the HA epitope tag, stop codons and 
the positions of various insert screening and sequencing primers are indicated on the map (from Clontech 
MATCHMAKER vectors handbook). 
a) 
b) 
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II.12.3. DNA LIGATION 
 
DNA ligations were performed to effect the generation of constructs used in Y2H-assays. Generally, 
2-7μl of purified double-digested PCR-product (sections II.6.3 and II.11.2) was added to 1μl of the 
appropriate double-digested, CIP-treated (section II.12.2), Y2H cloning vector. To this mixture, 1μl 
of 10x T4 DNA ligase buffer (Promega, Madison, WI, USA), 5U of T4 DNA ligase (Promega, 
Madison, WI, USA) and ddH2O to a final volume of 10μl were added. This mixture was 
subsequently incubated at 16°C for 14-16h. Following incubation, a 5μl aliquot of the ligation 
reaction mixture was transformed into E.coli strain DH5α (appendix B), and transformed bacterial 
colonies selected by growing them on LB-agar plates containing appropriate antibiotic (table II.10 
and appendix A). The presence of the correct insert was then confirmed by bacterial colony PCR 
(section II.6.5). 
 
II.13. BACTERIAL AND YEAST STRAINS 
 
II.13.1. BACTERIAL STRAINS 
 
In order to facilitate the selection and purification of Y2H constructs, ligation reaction mixtures 
(section II.12.3) were transformed (section II.14.1) into E.coli strain DH5α (appendix B). 
Transformed bacterial colonies were selected, based on their ability to grow on LB plates containing 
either ampicillin (when selecting pAS2.1-, pACT2- and pGADT7- based constructs), or kanamycin 
(when selecting pGBKT7- based constructs) (table II.10) (appendix A).  
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Table II.10. Generation of Y2H-constructs 
 
Restriction enzyme Selection media Construct name Insert Type Plasmid used 
5’ 3’ Bacterial Yeast 
pAS2.1-C0 cMyBPC C0 Bait pAS2.1 NdeI EcoRI LBAmp SD-W 
pGBKT7-C0 cMyBPC C0 Bait pGBKT7 NdeI EcoRI LBKan SD-W 
pAS2.1-C0C1 cMyBPC C0C1 Bait pAS2.1 NdeI EcoRI LBAmp SD-W 
pGBKT7-C0C1 cMyBPC C0C1 Bait pGBKT7 NdeI EcoRI LBKan SD-W 
pAS2.1-C0C2 cMyBPC C0C2 Bait pAS2.1 NdeI EcoRI LBAmp SD-W 
pGBKT7-C3 cMyBPC C3 Bait pGBKT7 NdeI EcoRI LBKan SD-W 
pGBKT7-C7 cMyBPC C7 Bait pGBKT7 NdeI EcoRI LBKan SD-W 
pGBKT7-C7V896M cMyBPC C7V896M Bait pGBKT7 NdeI EcoRI LBKan SD-W 
pGBKT7-A43 TTN A43 Bait pGBKT7 NdeI EcoRI LBKan SD-W 
pGADT7-C1 cMyBPC C1 Prey pGADT7 NdeI EcoRI LBAmp SD-L 
pGADT7-C1C2 cMyBPC C1C2 Prey pGADT7 NdeI EcoRI LBAmp SD-L 
pGADT7-C2 cMyBPC C2 Prey pGADT7 NdeI EcoRI LBAmp SD-L 
pACT2-C5 cMyBPC C5 Prey pACT2 NcoI EcoRI LBAmp SD-L 
pACT2-C6 cMyBPC C6 Prey pACT2 SmaI EcoRI LBAmp SD-L 
pACT2-C8 cMyBPC C8 Prey pACT2 SmaI EcoRI LBAmp SD-L 
pACT2-C8C10 cMyBPC C8C10 Prey pACT2 SmaI EcoRI LBAmp SD-L 
pACT2-C9 cMyBPC C9 Prey pACT2 SmaI EcoRI LBAmp SD-L 
pACT2-C9C10 cMyBPC C9C10 Prey pACT2 SmaI EcoRI LBAmp SD-L 
pACT2-C10 cMyBPC C10 Prey pACT2 SmaI EcoRI LBAmp SD-L 
pGADT7-A109 TTN A109 Prey pGADT7 NdeI EcoRI LBAmp SD-L 
pGADT7-
A109A112 
TTN A109A112 Prey pGADT7 NdeI EcoRI LBAmp SD-L 
pGADT7-A112 TTN A112 Prey pGADT7 NdeI EcoRI LBAmp SD-L 
pGADT7-A116 TTN A116 Prey pGADT7 NdeI EcoRI LBAmp SD-L 
 
LBAmp = Luria-Bertani media containing ampicillin;LBKan = Luria-Bertani media containing kanamycin; SD-L 
= selective dropout media lacking leucine; SD-W = selective dropout media lacking tryptophan. 
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Where pGBKT7-based bait constructs were used to screen cardiac cDNA libraries (pGBKT7-C0, 
pGBKT7-C0C1(2) and pGBKT7-C7), prey-plasmids were selected in a similar fashion, by 
transforming plasmids purified from diploid yeast cells (containing both bait- and prey constructs) 
into E.coli strain DH5α and selecting transformant colonies containing the prey-vector, by growing 
them on LB plates containing ampicillin (appendix A). In one cardiac cDNA library screen, 
however, pAS2.1-C0C1(1) was used as bait. In this case, selection of prey-plasmids was hampered 
by the fact that both the pAS2.1 bait-vector and the pACT2 prey-vector contained the ampicillin 
resistance gene. Plasmids purified from diploid yeast cells (containing both bait and prey constructs) 
were, therefore, transformed into E.coli strain KC8 (appendix B) and transformant colonies, each 
containing either a bait- or prey-plasmid, selected by growing them on LB plates containing 
ampicillin (appendix A). Transformant colonies were then replicated onto M9 agar plates lacking 
leucine (appendix A), therefore, allowing the selection of only transformant colonies in which the 
prey-plasmid was present. 
 
II.13.2. YEAST STRAINS 
 
All pAS2.1-based Y2H bait constructs (table II.10) were transformed into yeast strain PJ69-2A 
(appendix B), while pGBKT7-based Y2H bait constructs (table II.10) were transformed into yeast 
strain AH109 (appendix B). All prey constructs used during the course of this study, whether they be 
pACT2- or pGADT7- based (table II.10), were transformed into yeast strain Y187 (appendix B).  
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II.13.3. GENERATION OF BACTERIAL COMPETENT CELLS 
 
A scrape of either DH5α or KC8 (section II.13.1) strains of E.coli (appendix B) frozen glycerol 
stocks (stored at –70°C) were inoculated into 10ml LB-media. This culture was then incubated 
overnight at 37°C with shaking at 200rmp in a YIH DER model LM-530 shaking incubator 
(SCILAB Instrument Co Ltd., Taipei, Taiwan). Following incubation, a 1ml aliquot of this culture 
was inoculated into a 2l Erlenmeyer flask containing 200ml of freshly autoclaved LB-media 
(appendix A). This culture was then incubated at room temperature with shaking at 200rpm to mid 
log-phase on a Labcon orbital shaker (about 16 to 20 hours) (Labcon Pty Ltd, Maraisburg, RSA) (an 
OD600 of approximately 0.6), at which stage the culture was decanted into four 50ml polypropylene 
tubes and centrifuged at 3 000rpm for 15min at 4°C in a Multex centrifuge (MSE Instruments, 
England). The supernatant was subsequently discarded and the pellet resuspended in 8ml of ice–cold 
CAP buffer (appendix A). The cells were then re-pelleted by centrifugation at 3 000rpm for 15min at 
4°C in a Multex centrifuge (MSE Instruments, England, UK). The supernatant was discarded and the 
pellet once again resuspended in 4ml of ice-cold CAP buffer (appendix A). The suspended cells were 
subsequently aliquoted as 0.5ml aliquots into 2ml Eppendorf tubes, which were submersed in liquid 
nitrogen and stored at –70°C until further use. 
 
II.14. PLASMID TRANSFORMATION 
 
II.14.1. BACTERIAL PLASMID TRANSFORMATION 
 
For bacterial transformations, competent cells of bacterial strains KC8 and DH5α (appendix B) were 
generated as described in section II.13.3. Prior to transformation, an aliquot of the appropriate strain 
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was allowed to thaw on ice for 20-30min. Following this period, 1μl of yeast plasmid preparation, or 
5μl of a ligation reaction mixture (section II.12.3) was added to the competent cells and mixed gently 
by flicking the tube. This mixture was incubated on ice for an additional 20-30min, after which it 
was incubated at 42oC for 45s in a Lasec model 102 circulating waterbath (Lasec Laboratory and 
Scientific Company (Pty) Ltd., Cape Town, RSA). The transformation mixture was then incubated at 
room temperature for an additional 2min before adding 1ml of LB-media (appendix A) before being 
incubated at 37oC for 1h with shaking at 200rpm in a YIH DER model LM-530 shaking incubator 
(SCILAB Instrument Co Ltd., Taipei, Taiwan). Following this incubation period, 200μl of the 
transformation reaction mixture was plated out on LB-agar plates containing an appropriate selection 
antibiotic (table II.10). The remainder of the transformation mixture was centrifuged at 13 000rpm 
for 30s in a Beckman Microfuge Lite (Beckman Instruments Inc., CA, USA), the supernatant 
discarded and the cells resuspended in 200μl LB-media, which was also plated onto appropriate LB-
agar plates. These plates were then inverted and incubated for 16h at 37oC in a model 329 stationary 
CO2 incubator (Forma Scientific, Marietta, Ohio, USA). 
 
II.13.2. YEAST PLASMID TRANSFORMATION 
 
Yeast from the appropriate strain to be transformed was plated out onto YPDA agar plates (table 
II.10 and appendix A). These plates were subsequently incubated at 30oC for two to three days in a 
Sanyo MIR262 stationary ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan). 
Following incubation, a volume representing 20-50μl of yeast cells was picked and resuspended in 
1ml of sterile ddH2O in a sterile 2ml Eppendorf tube. The cells were then re-pelleted by 
centrifugation at 13 000rpm for 30s in a Beckman Microfuge Lite (Beckman Instruments Inc., CA, 
USA). Following the removal of the supernatant, the cell-pellet was resuspended in 1ml 100mM 
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lithium acetate (LiAc), and incubated for 5min at 30oC in a Sanyo MIR262 stationary ventilated 
incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan). After incubation, the cells were re-
pelleted by centrifugation at 13 000rpm for 20s in a Beckman Microfuge Lite (Beckman Instruments 
Inc., CA, USA). The LiAc was removed from the cell-pellet and the following reagents were added 
in this specific order:- 240μl 50% polyethylene glycol (PEG), 36μl 1M LiAc, 25μl 2mg/ml 
sonicated, heat-denatured, herring sperm DNA (Promega, Madison, WI, USA), 50ng plasmid 
preparation and finally sterile ddH2O to a final volume of 350μl. The cell-pellet was then 
resuspended by vigorous vortexing for at least 1min, after which the transformation mixture was 
incubated at 42oC for 25min in a Lasec model 102 circulating waterbath (Lasec Laboratory and 
Scientific Company (Pty) Ltd., Cape Town, RSA). Following this incubation period, the cells were 
pelleted by centrifugation at 13 000rpm for 30s in a Beckman Microfuge Lite (Beckman Instruments 
Inc., CA, USA), after which the supernatant was removed from the pellet. The cells were 
resuspended in 250μl sterile ddH2O, of which 150μl was plated out on appropriate selection plates 
(table II.10 and appendix A). These plates were incubated for two to five days at 30oC in a Sanyo 
MIR262 stationary ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan) 
 
II.15. QUALITY CONTROL OF Y2H CONSTRUCTS 
 
II.15.1. PHENOTYPIC ASSESSMENT OF YEAST STRAINS 
 
The phenotypes of all yeast host strains used in Y2H-assays were assessed prior to them being 
transformed with the various Y2H constructs. In all cases, non-transformed yeast host strains (Y187, 
PJ69-2A and AH109 (appendix B)) were plated onto SD-Ade, SD-His, SD-L, SD-W and SD-Ura agar 
plates (appendix A). Only non-transformed yeast that were unable to grow on SD-Ade, SD-His, SD-L 
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and SD-W media, but that were able to grow on SD-Ura medium, were selected for transformation and 
subsequent Y2H-assays.  
 
II.15.2. TOXICITY TESTS 
 
In order to establish whether any bait-peptides, used in Y2H library-assays, were toxic to the specific 
yeast host strain, growth-curves of yeast bait host strains transformed with the respective Y2H bait 
constructs (pGBKT7-C0, pGBKT7-C0C1, pGBKT7-C7 and pAS2.1-C0 transformed into yeast 
strains AH109 or PJ69-2A) were generated. These growth-curves were subsequently compared to 
growth-curves of identical yeast strains transformed with non-recombinant plasmids (AH109 
transformed with pGBKT7 or PJ69-2A transformed with pAS2.1) generated in concurrent 
experiments.  
 
Growth-curves were generated by growing transformed yeast strains to stationary phase in liquid  
SD-W-medium (appendix A) at 30oC with shaking at 200rpm (for 24-36h) in a YIH DER model LM-
510R shaking incubator (SCILAB Instrument Co Ltd., Taipei, Taiwan). Following this incubation 
period, a 1:10 dilution of this primary culture was made in liquid SD-W-medium. This culture was 
then incubated at 30oC for an additional 8-12h with shaking at 200rpm in a YIH DER model LM-
510R shaking incubator (SCILAB Instrument Co Ltd., Taipei, Taiwan). One millilitre aliquots of this 
culture were taken at hourly intervals, and the OD600 measurements of these aliquots plotted against 
time. These curves were also linearised by drawing a graph of the log of the OD600 measurements 
against time, and the slopes of these lines compared. Statistical analyses on the slopes of the 
linearised growth-curves were performed, using GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego CA, USA). 
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II.15.3. REPORTER GENE SELF-ACTIVATION TESTS 
 
In order to establish whether bait-GAL4BD or prey-GAL4AD fusion-proteins were able to 
autonomously activate transcription of reporter genes, yeast transformed with these constructs were 
grown on specific selection media (table II.10 and appendix A). Bait construct-containing yeast 
(strain AH109 or PJ69-2A) were plated out onto selective dropout media lacking tryptophan and 
histidine (SD-W-H), as well as selective dropout media lacking tryptophan, histidine and adenosine 
(SD-W-H-Ade) (Appendix A). Prey construct-containing yeast (strain Y187) were plated out onto 
selective dropout media lacking leucine and histidine (SD-L-H), as well as selective dropout media 
lacking leucine, histidine and adenosine (SD-L-H-Ade) (appendix A). Following incubation of these 
plates at 30oC for four days, the growth of yeast on these media was assessed. Clones that were 
unable to grow on these media were deemed suitable for Y2H assays. 
 
II.15.4. ESTABLISHMENT OF MATING EFFICIENCY 
 
In order to establish whether bait-peptides, to be used in Y2H library-assays, affected the mating 
efficiency of the yeast strain in which they were expressed, small-scale yeast matings were 
performed (section II.16.1). In these experiments, the appropriate transformed bait host strain (PJ69-
2A or AH109) was mated with prey host strain Y187 transformed with the non-recombinant pACT2 
Y2H prey-vector. Concurrent to these experiments, control matings were also performed. In control 
matings, the appropriate bait host strain, transformed with either the appropriate non-recombinant 
bait-vector (PJ69-2A transformed with pAS2.1, or AH109 transformed with pGBKT7), or a control 
bait-vector supplied by the manufacturer (PJ69-2A transformed with pVA3.1 or AH109 transformed 
with pGBKT7-53) (BD Biosciences, Clontech, Palo Alto, CA, USA), was mated with Y2H prey host 
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strain Y187, either transformed with the non-recombinant pACT2 Y2H prey-vector, or a control 
prey-vector supplied by the manufacturer (pTD1.1 or pGADT7-T) (BD Biosciences, Clontech, Palo 
Alto, CA, USA). Following overnight incubation, serial dilutions of the mating cultures were plated 
out onto SD-L, SD-W and SD-L-W plates, which were incubated for four days at 30oC in a Sanyo 
MIR262 stationary ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan). 
Following incubation, colony counts from these plates were used to calculate mating efficiency 
(appendix C). 
 
II.16. Y2H INTERACTION TESTS 
 
II.16.1. CANDIDATE LIGAND ASSAYS 
 
Small-scale yeast matings were used in order to directly test specific protein:protein interactions 
between bait and prey peptides. In short, one yeast colony (strain AH109 or PJ69-2A), into which a 
bait construct had been transformed, and one yeast colony (strain Y187), into which a prey construct 
had been transformed, were both inoculated into 1ml of YPDA media (appendix A) in a 2ml 
centrifuge tube (Eppendorf). These mating cultures were subsequently incubated overnight at 30oC 
with shaking at 200rpm in a YIH DER model LM-510R shaking incubator (SCILAB Instrument Co 
Ltd., Taipei, Taiwan). Following incubation, a 150ul aliquot of the mating culture was plated out 
onto SD-L-W plates (appendix A), and the plates incubated at 30oC for 2-5 days in a Sanyo MIR262 
stationary ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan), thereby selecting 
diploid yeast colonies in which bait and prey fusion-peptides were co-expressed.  
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II.16.2. LIBRARY-SCALE YEAST MATING 
 
Library-scale yeast matings were performed to identify unknown ligands of specific domains of 
cMyBPC (domains C0, C7 and the C0 to C1 region), from a cardiac cDNA library.  
 
II.16.2.1. Cardiac cDNA library 
 
A pre-transformed MATCHMAKER library (BD Biosciences, Clontech, Palo Alto, CA, USA), 
consisting of S.cerevisiae strain Y187 transformed with a cardiac cDNA library constructed in 
pACT2, was used in all Y2H library-assays. A limitation of the MATCHMAKER pre-transformed 
library used in this study was that cDNA was generated from mRNA by oligo(dT) priming. This 
implies that only the 3’ ends of large transcripts would be represented in these libraries, as the insert 
size in the libraries used was  estimated to be between 0.4 and 4kb (pretransformed human heart 
MATCHMAKER cDNA library product analysis certificate, BD Biosciences, Clontech, Palo Alto, 
CA, USA). Interactions between the baits and the N-terminal regions of large proteins would, 
therefore, remain undetectable in Y2H library-assays. 
 
II.16.2.2. Establishment of a bait culture 
 
Four yeast colonies (strain AH109 or PJ69-2A), transformed with the bait construct of interest, were 
inoculated into four separate 500ml Erlenmeyer flasks, each containing 50ml SD-W-media. The 
rationale for generating multiple bait cultures was to facilitate pooling of initial bait cultures, 
allowing the generation of a final bait culture with a titre of at least 1x1010. These cultures were 
incubated for 24h at 30oC with shaking at 200rpm in a YIH DER model LM-510R shaking incubator 
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(SCILAB Instrument Co Ltd., Taipei, Taiwan), after which the cultures were transferred to 50ml 
polypropylene tubes, and the cells pelleted by centrifugation at 3 000rpm for 10min at room 
temperature in a Beckman model TJ-6 centrifuge (Beckman Scotland, UK). Following 
centrifugation, the supernatants were discarded and the cells resuspended in 50ml SD-W (appendix 
A), after which the suspensions were transferred to sterile 500ml Erlenmeyer flasks, and the cultures 
incubated for a further 16-24h at 30oC with shaking at 200rpm in a YIH DER model LM-510R 
shaking incubator (SCILAB Instrument Co Ltd., Taipei, Taiwan). Following incubation, the titre of 
the bait culture was estimated by measuring the OD600 of a 1ml aliquot. The titre of the bait culture 
was then confirmed by means of a haemocytometer cell count. In cases where the titre of none of the 
individual bait cultures reached the threshold of at least 1x1010, an appropriate number of bait 
cultures (which when combined would represent >1x1010 cells) were transferred to 50ml 
polypropylene tubes (Greiner Labortechnik GmbH, Frickenhausen Germany) and the cells pelleted 
by centrifugation at 3 000rpm for 10min at room temperature in a Beckman model TJ-6 centrifuge 
(Beckman Coulter, Scotland, UK). After centrifugation, the supernatants were removed, the cell-
pellets resuspended in 10ml SD-W medium (appendix A), and the cultures combined in a single 50ml 
polypropylene tube.  
 
This entire bait culture was subsequently centrifuged at 3 000rpm for 10min at room temperature in a 
Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK). Following centrifugation, the 
supernatant was decanted and the cell-pellet resuspended in 5ml SD-W medium (appendix A). An 
appropriate number of 10μl aliquots of this culture was made, and subsequently used to perform 
control matings (section II.16.2.5). 
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II.16.2.3. Library mating 
 
A 1ml cardiac cDNA library yeast culture (BD Biosciences, Clontech, Palo Alto, CA, USA) was 
removed from storage at –70oC and thawed at 20oC for 20min. The library culture was then mixed by 
gentle vortexing and a 10ul aliquot set aside on ice for subsequent library titering (section II.16.2.4). 
The entire bait culture (section II.16.2.2) was subsequently added to 45ml of 2x YPDA media 
(appendix A), containing 10μg/ml kanamycin (Kan), in a 2l Erlenmeyer flask, to which the entire 
1ml library culture was added. This mating culture was incubated at 30oC for 24h with shaking at 
30rpm in a YIH DER model LM-510R shaking incubator (SCILAB Instrument Co Ltd., Taipei, 
Taiwan). 
 
Following incubation, the entire mating culture was transferred to a 50ml polypropylene tube and 
centrifuged at 3 000rpm for 10min at room temperature in a Beckman model TJ-6 centrifuge 
(Beckman Coulter, Scotland, UK). After removing the supernatant, the Erlenmeyer flask in which 
the library mating was performed, was rinsed twice with 40ml 2x YPDA medium containing 
10μg/ml Kan. Each time, the 2x YPDA medium used to rinse the flask was used to resuspend the 
cell-pellet, and the cells re-pelleted by centrifugation at 3 000rpm for 10min at room temperature in a 
Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK). Following the final 
centrifugation step, the supernatant was removed and the cell-pellet resuspended by gentle vortexing 
in 10ml of 0.5x YPDA, containing 10μg/ml Kan (appendix A). Serial dilutions of a 100μl aliquot of 
this cell-suspension were subsequently plated out onto 90mm SD-L, SD-W and SD-L-W plates 
(appendix A), while the remainder of the cell-suspension was plated out onto 50-60 150mm TDO 
plates (200μl per plate) (appendix A). TDO plates were incubated at 30oC for up to 14 days in a 
Sanyo MIR262 stationary ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan), 
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while colony counts were performed on the SD-L, SD-W and SD-L-W plates after four days, thereby 
allowing the calculation of the mating-efficiency of the library mating (appendix C), and the number 
of library plasmids screened (appendix C). 
 
II.16.2.4. Establishment of library titre 
 
Serial dilutions of the 10μl library culture aliquot (section II.16.2.3) were made with 0.5x YPDA 
containing 10μg/ml Kan (appendix A). These dilutions were subsequently plated onto SD-L plates 
(appendix A) and incubated at 30oC for four days in a Sanyo MIR262 stationary ventilated incubator 
(Sanyo, Electronic Company Ltd, Ora-Gun, Japan), after which colonies were counted in order to 
calculate the library titre (appendix C). 
 
II.16.2.5. Control matings 
 
Control matings were set up concurrently with all library-scale matings. In short, a 10μl aliquot of 
the bait culture (section II.16.2.2) and a single test prey colony (of at least 1mm in diameter) were 
co-inoculated in 1ml of 2x YPDA, containing 10μg/ml Kan (appendix A), in a 2ml centrifuge tube 
(Eppendorf). These cultures were subsequently incubated for 24h at 30oC with shaking at 30rmp in a 
YIH DER model LM-510R shaking incubator (SCILAB Instrument Co Ltd., Taipei, Taiwan). 
Following incubation, serial dilutions of these cultures were plated out onto SD-L, SD-W and SD-L-W 
plates (appendix A), which were incubated at 30oC for four days in a Sanyo MIR262 stationary 
ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan), after which colony counts 
were performed and mating efficiency calculated (appendix C). Control preys included non-
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recombinant prey-vector (pACT2), transformed into yeast strain Y187, and either the pTD1.1 or 
pGADT7-T control vectors (supplied by the manufacturer), transformed into yeast strain Y187. 
 
II.16.3. DETECTION OF ACTIVATION OF NUTRITIONAL REPORTER GENES 
 
II.16.3.1.Selection of transformant yeast colonies 
 
Yeast transformed with either bait- or prey-plasmids was plated out onto SD-W and SD-L plates, 
respectively (appendix A). Following incubation of these plates at 30oC for 4-6 days in a Sanyo 
MIR262 stationary ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan), 
transformant yeast colonies were picked and used in small-scale yeast matings (section II.16.1), or to 
grow large-scale bait cultures (section II.16.2.2) for library-scale yeast matings (section II.16.2). 
 
II.16.3.2. Selection of diploid yeast colonies 
 
Following small-scale yeast mating (section II.16.1), diploid yeast colonies, expressing both bait- 
and prey fusion-peptides, were selected by plating mating cultures onto SD-L-W plates (appendix A). 
These plates were subsequently incubated at 30oC for 4-6 days in a Sanyo MIR262 stationary 
ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan), following which activation 
of transcription of nutritional reporter genes were tested as described below. 
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II.16.3.3. Selection of yeast colonies containing putative interactor peptides 
 
In order to select diploid yeast colonies in which an interaction occured between the bait- and prey-
peptides, yeast were grown on TDO plates (appendix A), as well as solid phase SD media lacking 
leucine, tryptophan, histidine and adenine hemisulphate (Ade) (QDO plates) (appendix A). Growth 
of yeast colonies on TDO plates indicated transcriptional activation of the HIS3 nutritional reporter 
gene, while growth on QDO plates was indicative of transcriptional activation of both the HIS3 and 
ADE2 nutritional reporter genes, caused by an interaction between the bait- and prey-peptides. 
 
When the small-scale yeast mating protocol was used (section II.16.1), diploid yeast colonies were 
transferred directly from SD-L-W plates onto both TDO and QDO plates (appendix A). These plates 
were then incubated for 4-6 days at 30oC in a Sanyo MIR262 stationary ventilated incubator (Sanyo, 
Electronic Company Ltd, Ora-Gun, Japan), following which growth of yeast colonies on the 
respective media was assessed. In cases where growth were observed on TDO plates, but not on 
QDO plates, yeast were picked from the TDO plates and re-streaked onto QDO plates, following 
which these plates were incubated at 30oC for an additional 4-6 days in a Sanyo MIR262 stationary 
ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan), prior to growth being 
assessed. 
 
When library-scale matings were performed (section II.16.2.3), the mating culture was plated 
directly onto 50-60 150mm TDO plates. These were subsequently incubated for up to 14 days at 
30oC in a Sanyo MIR262 stationary ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, 
Japan). The growth of yeast colonies, in which transcription of the HIS3 reporter gene was activated, 
was assessed at two-day intervals, at which time colonies were picked and re-streaked onto TDO- 
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and QDO plates. These plates were then incubated for 4-6 days at 30oC in a Sanyo MIR262 
stationary ventilated incubator (Sanyo, Electronic Company Ltd, Ora-Gun, Japan), prior to 
phenotypic assessment of yeast colonies. 
 
Specific incubation periods were dependent on the bait-plasmid used. Where pGBKT7-based 
constructs, transformed into yeast strain AH109, were used, plates were assessed after four days, 
while yeast strain PJ69-2A, transformed with pAS2.1-based constructs, were incubated for six days 
prior to phenotypic assessment. Phenotypic assessment of yeast colonies on TDO and QDO plates 
took into account the size and robustness of yeast colonies on the selection medium, as well as the 
colour of the yeast colonies. 
 
II.16.4. DETECTION OF ACTIVATION OF COLOURIMETRIC REPORTER GENES 
 
II.16.4.1. X-α-Galactosidase assays 
 
X-α-Galactosidase assays were performed in order to establish whether transcription of the MEL1 
reporter gene had been activated by interaction between specific bait- and prey-peptides. These 
assays were only performed in Y2H experiments where the AH109 bait host strain was used. In 
short, yeast colonies, in which transcription of the HIS3 and ADE2 reporter genes was activated, 
were replicated from QDO plates onto a Hybond N+ nylon membrane. This membrane was 
subsequently placed colony-side up on a QDO-plate, onto which 200μl of a 20mg/ml X-α-Gal 
solution (BD Biosciences, Clontech, Palo Alto, CA, USA) had been spread just prior to use. These 
plates were then incubated for 16-48h at 30oC in a Sanyo MIR262 stationary ventilated incubator 
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(Sanyo, Electronic Company Ltd, Ora-Gun, Japan), following which blue colour development 
produced by the yeast colonies was assessed. 
 
II.16.4.2. β-Galactosidase assays 
 
II.16.4.2.i. Qualitative ß-galactosidase assays 
Filter-lift β-galactosidase assays were performed in order to establish whether transcription of the 
1acZ reporter gene had been activated by interaction between bait- and prey-peptides. In short, yeast 
colonies in which transcription of the HIS3 and ADE2 reporter genes was activated were lifted from 
QDO plates using a Hybond N+ nylon membrane (Amersham Pharmacia Biotech, Little Chalfont, 
Buckinghamshire, UK). This membrane was subsequently submersed, colony-side up, in liquid N2 
for 10s, after which the membrane was placed colony-side up on a Whatman #5 filter (Whatman 
International Ltd., Maidstone, England, UK) and incubated at room temperature for 20-30min, 
allowing the cells to thaw. This freeze-thaw cycle was subsequently repeated once more. The 
membrane was then placed colony-side up on a Whatman #5 filter (Whatman International Ltd., 
Maidstone, England) which had been presoaked in Z-buffer/X-gal solution (appendix A), and 
incubated at 30oC for 30min to 8h, following which the speed and intensity of blue colour 
development was assessed. 
 
II.16.4.2.ii. Quantitive β-galactosidase assays 
Quantitative β-galactosidase assays were performed, in order to quantify the relative strength of 
interactions between specific bait and prey fusion-peptides. In order to achieve this, diploid yeast 
colonies were picked from appropriate SD agar plates (table II.10 and appendix A) and inoculated 
into 5ml of appropriate liquid SD-medium (table II.10 and appendix A) in 50ml polypropylene tubes. 
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These cultures were subsequently incubated at 30oC with shaking at 250rpm in a YIH DER model 
LM-510R shaking incubator (SCILAB Instrument Co Ltd., Taipei, Taiwan), until stationary phase 
was reached (typically 24-30h). After incubation, the cultures were mixed well by vortexing, and the 
OD600 of a 1ml aliquot recorded. These primary cultures were subsequently diluted with YPDA-
medium, in order to obtain an OD600 of 0.2-0.3, in a total volume of 10ml. These cultures were then 
incubated for an additional 4-5h at 30oC with shaking at 250rpm in a YIH DER model LM-510R 
shaking incubator (SCILAB Instrument Co Ltd. Taipei, Taiwan). Following this incubation period, 
the cultures were mixed by vortexing and the OD600 of 1ml aliquots of each of the cultures recorded.  
 
Three 1.5ml aliquots of each culture were transferred to sterile 1.5ml centrifuge tubes (Eppendorf). 
These aliquots were then centrifuged at 13 000rpm for 30s at room temperature in a Beckman 
Microfuge Lite (Beckman Instruments Inc., CA, USA), the supernatant decanted, 1.5ml Z-buffer 
(appendix A) added to each tube and the cell-pellets resuspended by vortexing. The cells were 
subsequently pelleted once more by centrifugation at 13 000rmp for 30s at room temperature in a 
Beckman Microfuge Lite (Beckman Instruments Inc., CA, USA), the supernatants removed, and the 
cells resuspended in 300μl of Z-buffer (appendix A). One hundred microlitres of each of these cell 
resuspensions was subsequently transferred to fresh 1.5ml centrifuge tubes (Eppendorf), and the lids 
of these tubes punctured, using a sterile syringe needle. These tubes were then subjected to three 
freeze-thaw cycles, each consisting of immersing the tubes in liquid N2 for 60s, followed by 60s of 
incubation at 37oC. Following the freeze-thaw cycles, 700μl of freshly made Z-buffer/β-mercapto-
ethanol (appendix A) was added to each tube, as well as to an additional tube containing 100μl of Z-
buffer (appendix A), which was subsequently used as a negative control. To each of these tubes, 
including the negative control, 160μl of ONPG/Z-buffer (appendix A) was added, at which time a 
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timer was started. These tubes were subsequently incubated at 30oC until a yellow colour had 
developed, at which point the elapsed time was noted and 400μl of 1M Na2CO3 added to each 
yellowed tube to quench the reaction. The cellular debris was subsequently pelleted by centrifugation 
at 13 000rpm for 10min at room temperature in a Beckman Microfuge Lite (Beckman Instruments 
Inc., CA, USA) and the OD420 measurements of the supernatants taken. These OD420 measurements, 
the time to colour development and the cellular concentration of the YPDA cultures were used to 
calculate the β-gal unit measurement (appendix C). In order to establish whether differences in β-gal 
unit measurements were statistically significant, standard t-tests were performed using GraphPad 
Prism version 4.00 for Windows (GraphPad Software, San Diego CA, USA). 
 
II.16.5. INTERACTION SPECIFICITY TESTS 
 
Interaction specificity tests were used to establish whether interactions detected by Y2H assays, as 
evidenced by activation of reporter genes, were specific interactions between the particular bait- and 
prey-peptides. In short, yeast strain Y187 expressing specific prey-peptides was mated with the 
relevant bait host strain (strain PJ69-2A, or AH109), transformed with either non-recombinant bait-
plasmid (pAS2.1, or pGBKT7), or a control bait-plasmid supplied by the manufacturer (pVA3.1 or 
pGBKT7-53) (BD Biosciences, Clontech, Palo Alto, CA, USA). Following the selection of diploid 
clones (section II.16.3.2), these clones were streaked on TDO- and QDO-selection media (appendix 
A), thereby testing whether prey-peptides were able to interact with these heterologous bait-peptides. 
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CHAPTER III: RESULTS 
 
III.1. MUTATION SCREENING OF MYBPC3 
 
Screening of the HCM-affected panel of probands (section II.1) for known and novel HCM-causing 
mutations in all 34 protein-encoding exons of MYBPC3 (exons 2-35) by SSCP analysis (section II.8) 
resulted in the detection of several mobility shifts. DNA sequencing (section II.10) of samples, in 
which reproducible mobility shifts were detected, led to the identification of several SNS. 
Subsequent DNA sequence analysis (section II.10.3.1) facilitated the classification of these SNSs as 
silent polymorphisms, silent site sequence variations (ssSVs) (section III.1.1), putative HCM-causing 
missense mutations (section III.1.2), or putative splice site mutations (section III.1.3) (all of which 
are listed in table III.1).  
 
III.1.1. IDENTIFICATION OF SILENT POLYMORPHISMS AND ssSVs IN MYBPC3 
 
SNSs not predicted to alter the amino acid sequence of cMyBPC, or to alter the splicing of the 
MYBPC3 transcript, were classified as polymorphisms (SNSs with an allele a frequency of 1% or 
more in the HCM-affected panel), ssSVs (SNSs with an allele a frequency lower than 1% in the 
HCM-affected panel). During the course of this study, several such non-deleterious polymorphisms 
and ssSVs were identified (table III.1 and figures III.1-III.15). 
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Table III.1. Sequence variations identified in MYBPC3  
 
Ex/Int Sequence Position Codon AA Type RE site #Heterozygotes Status Figure 
Int 4 t2510c Ex5 SaS -51bp N.A. N.A. Polym HphI Het. = 8% Novel III.1 
Ex 5 g2626a Ex5 CS gtg>atg V158M pMSM NlaIII 1 Novel III.16 
Ex 5 c2646t Ex5 CS ggc>ggt G164G pSSM HphI Het = 8% Novel III.28 & III.29 
Int 5 ins/del c2735 Ex6 SaS –13bp N.A. N.A. Polym - Het = 34% Novel III.2 
Ex 6 g2774a Ex6 CS cgc>cac R177H pMSM - 5 Novel III.20 
Ex 6 g2785a Ex6 CS gcc>acc A181T pMSM HhaI 2 Novel III.18  
Int 6 c4154t Int6 SbP +1bp N.A. N.A. pSSM - 2 Novel III.32 & III.33 
Int 6 g4177a Ex7 SaS +1bp N.A. N.A. pSSM - 1 Novel III.30 & III.31 
Ex 8 c4825t Ex8 CS acc>act T262T Polym NlaIV Het = 18% Novel III.11 
Int 8 a4962g Ex9 SaS –74bp N.A. N.A. ssSV - 1 Novel III.3 
Ex 9 g5047a Ex9 CS gga>gaa G278E pMSM MnlI 1 Known III.22 
Int 12 c6114a Ex12 SdS +25bp N.A. N.A. Polym - 2 Novel III.4 
Int 13 g8168a Ex14 SaS –31bp N.A. N.A. Polym - Het. = 17% Novel III.5 
Int 15 c8612t Ex16 SaS –66bp N.A. N.A. Polym AvaI 2 Novel III.6 
Ex 18 g9140a Ex18 CS ggg>agg G507R pMSM - 1 Known III.24 
Ex 18 g9187a Ex18 CS gcg>gca A522A ssSV - 1 Novel III.12 
Ex 23 c12474t Ex 23 CS agc>agt S708S Polym - Het = 5% Novel III.13 
Ex 24 Δc 13255 Ex 24 CS F.S. 756> F.S. 756> pFSM - 1 Novel III.34 
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Ex/Int ΔSequence Position Codon ΔAA Type RE site #Probands Status Figure 
Ex 24 g13199a Ex 24 CS acg>aca T737T ssSV - 1 Novel III.14 
Int 24 c13314g Ex24 SdS +18bp N.A. N.A. Polym NlaIV Het = 6% Novel III.7 
Ex 27 g15751a Ex27 CS ctg>atg V896M pMSM NlaIII 1 Novel III.26 
Ex 31 a18443g Ex 31 CS gaa>gag E1096E Polym AluI Het = 41% Novel III.15 
Int 33 g19143a Ex33 SdS +30bp N.A. N.A. Polym - 2 Novel III.8 
Int 34 c19731t Ex35 SaS –66bp N.A. N.A. Polym NlaIII Het = 59% Novel III.9 
Int 34 g19706a Ex35 SaS –91bp N.A. N.A. ssSV AluI 1 Novel III.10 
Δ = deletion; AA = amino acid; CS = coding sequence; Ex = exon; F.S. = frame shift; Het = observed heterozygosity; Int = intron; N.A. = not 
applicable; pFSM = putative frame shift mutation; pMSM = putative HCM-causing missense mutation; pSSM = putative HCM-causing splicing 
mutation; Polym = polymorphism; RE = restriction enzyme used in ASREA to confirm the presence of the sequence variant; SaS = splice acceptor 
site; SdS = splice donor site. Positions of intronic SNPs relative to SaS and SdS are indicated as the number of nucleotides that the SNP is removed 
from the nearest intron/exon boundary (box 1). Nucleotide sequence numbers according to GenBank database (http://www.ncbi.nlm.nih.gov/Entrez) 
accession #: Y10129. Substituted nucleotides are underlined; status refers to whether a sequence variant is novel, or has been described elsewhere 
(Known). #Probands refers to the number of probands in the HCM-affected control panel, or the observed heterozygosity of the sequence variant in 
the HCM-affected panel. 
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Figure III.1. Identification of the novel t2510c polymorphism in intron 4 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 5 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the t allele (t/t); lane 2 = heterozygous individual (t/c). The arrows indicate the 
mobility shift caused by the t/c polymorphism at nucleotide 2510 in a heterozygous individual.  
b) Partial sequence of the minus-strand of intron 4 of MYBPC3 in an individual heterozygous for the t2510c 
polymorphism, showing the a/g substitution on the minus-strand. 
c) Genotyping of the MYBPC3 t2510c polymorphism by ASREA. Products of the HphI restriction enzyme 
digestion of the 246bp PCR-amplified product of exon 5 were electrophoresed on a 12% polyacrylamide gel. 
The internal HphI sites generate 10bp, 30bp, 65bp and 141bp fragments in t/t homozygotes, while the t2510c 
polymorphism abolishes an HphI restriction site, resulting in  an additional 206bp fragment in t/c 
heterozygotes. The 10bp and 30bp restriction fragments could not be resolved under these electrophoretic 
conditions, while the 65bp fragment is not shown. Lane 1 = λPst marker; lane 2 = individual homozygous for 
the t allele (t/t); lane 3 = heterozygous individual (t/c). 
d) Schematic representation of the exon 5 PCR-amplified product, indicating the position of the HphI sites. * 
= variable restriction enzyme site. 
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a)    1              2              3           b)  
 
 
 
 
 
 
              c) 
 
 
 
 
 
 
Figure III.2. Identification of the novel ins/del c2735 polymorphism in intron 5 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 6 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
heterozygous individual; lane 2 = individual homozygous for the c deletion allele; lane 3 = individual 
homozygous for the c insertion allele.  
b) Partial sequence of the plus-strand of intron 5 of MYBPC3 in an individual homozygous for the c 2735 
deletion allele. 
c) Partial sequence of the plus-strand of intron 5 of MYBPC3 in an individual homozygous for the c 2735 
insertion allele.  
This polymorphism did not alter a restriction enzyme recognition site and could, therefore, not be confirmed 
by ASREA. 
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a)       1               2     b) 
 
 
 
 
 
 
 
 
 
 
 
Figure III.3. Identification of the novel a4962g ssSV in intron 8 of MYBPC3  
a) PCR-SSCP analysis of the MYBPC3 exon 9 PCR-amplified product on an 8% MD-SSCP gel. Lane 1 = 
individual homozygous for the a allele (a/a); lane 2 = heterozygous individual (a/g). The arrow indicates the 
mobility shift caused by the a/g ssSV at nucleotide 4962 in a heterozygous individual.  
b) Partial sequence of the plus-strand of intron 8 of MYBPC3 in an individual heterozygous for the a4962g 
ssSV, showing the a/g substitution. 
This ssSV did not alter a restriction enzyme recognition site and could, therefore, not be confirmed by ASREA. 
 A
A/G 
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a)    1              2       b) 
 
 
 
 
 
 
 
 
 
 
Figure III.4. Identification of the novel c6114a polymorphism in intron 12 of MYBPC3  
a) PCR-SSCP analysis of the MYBPC3 exon 12 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the c allele (c/c); lane 2 = heterozygous individual (c/a). The arrows indicate the 
mobility shift caused by the c/a polymorphism at nucleotide 6114 in a heterozygous individual.  
b) Partial sequence of the plus-strand of intron 12 of MYBPC3 in an individual heterozygous for the c6114a 
polymorphism, showing the c/a substitution. 
This polymorphism did not alter a restriction enzyme recognition site and could, therefore, not be confirmed 
by ASREA. 
C/A 
 172
 
a)            1           2    b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.5. Identification of the novel g8168a polymorphism in intron13 of MYBPC3  
a) PCR-SSCP analysis of the MYBPC3 exon 14 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g/a polymorphism at nucleotide 8168 in a heterozygous individual.  
b) Partial sequence of the plus-strand of intron 13 of MYBPC3 in an individual heterozygous for the g8168a 
polymorphism, showing the g/a substitution. 
This polymorphism did not alter a restriction enzyme recognition site and could, therefore, not be confirmed 
by ASREA. 
G/A G/A 
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a)     1               2            b.) 
 
 
 
 
 
 
 
 
 
 
Figure III.6. Identification of the novel c8612t polymorphism in intron 15 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 15 and 16 PCR-amplified product on an 8% MD-SSCP gel. 
Lane 1 = individual homozygous for the c allele (c/c); lane 2 = heterozygous individual (c/t). The arrow 
indicates the mobility shift caused by the c8612t polymorphism in a heterozygous individual.  
b) Partial sequence of the plus-strand of intron 15 of MYBPC3 in an individual heterozygous for the c8612t 
polymorphism, showing the c/t substitution. 
This polymorphism did not alter a restriction enzyme recognition site and could, therefore, not be confirmed 
by ASREA. 
C/T 
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a)     1               2         b) 
 
 
 
 
 
 
 
c)    1        2         3        4       d) 
 
 
 
 
 
 
Figure III.7. Identification of the novel c13314g polymorphism in intron 24 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 24 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the c allele (c/c); lane 2 = heterozygous individual (c/g). The arrows indicate the 
mobility shift caused by the c/g polymorphism at nucleotide 13314 in a heterozygous individual.  
b) Partial sequence of the plus-strand of intron 24 of MYBPC3 in an individual heterozygous for the c13314g 
polymorphism, showing the c/g substitution. 
c) Genotyping of the MYBPC3 c13314g polymorphism by ASREA. Products of the NlaIV restriction enzyme 
digestion of the 281bp PCR-amplified product of exon 24 were electrophoresed on a 12% polyacrylamide gel. 
The internal NlaIV sites generate 21bp, 39bp, 70bp and 151bp fragments in c/c homozygotes, while the 
presence of the g allele abolishes an NlaIV site, resulting in an additional 190bp fragment in c/g 
heterozygotes. The 21bp and 39bp restriction fragments could, however, not be resolved under these 
electrophoretic conditions. Lane 1 = λPst marker; lane2 = individual homozygous for the c allele (c/c); lane 3 
= heterozygous individual (c/g); lane 4 = undigested exon 24 PCR-amplified product. 
d) Schematic representation of the PCR-amplified product, indicating the position of the NlaIV sites. * = 
variable restriction enzyme site. 
C/G 
        NlaIV                          NlaIV*  NlaIV 
  70bp                   151bp                 39bp   21bp 281bp 
190bp 
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70bp 
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a)      1                2   b) 
 
 
 
 
 
 
 
Figure III.8. Identification of the novel g19143a polymorphism in intron 33 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 33 PCR-amplified product  on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g/a polymorphism at nucleotide 19143 in a heterozygous individual.  
b) Partial sequence of the plus-strand of intron 33 of MYBPC3 in an individual heterozygous for the g19143a 
polymorphism, showing the g/a substitution. 
This polymorphism did not alter a restriction enzyme recognition site and could, therefore, not be confirmed 
by ASREA. 
G/A 
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a)      1        2        3       b) 
 
 
 
 
 
 
c)      1         2       3       4   d) 
 
 
 
 
 
Figure III.9. Identification of the novel c19731t polymorphism in intron 34 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 35 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the c allele (c/c); lane 2 = heterozygous individual (c/t); lane 3 = individual 
homozygous for the t allele (t/t).  
b) Partial sequence of the plus-strand of intron 35 of MYBPC3 in an individual heterozygous for the c19731t 
polymorphism, showing the c/t substitution. 
c) Genotyping of the MYBPC3 c19731t polymorphism by ASREA. Products of the NlaIII restriction enzyme 
digestion of the 237bp PCR-amplified product of exon 35 were electrophoresed on a 12% polyacrylamide gel. 
The internal NlaIII site generates 185bp and 52bp fragments in c/c homozygotes, while the presence of the t 
allele generates an additional NlaIII site, resulting in additional 137bp and 48bp fragments in c/t 
heterozygotes. Lane 1 =λPst marker; lane 2 = heterozygous individual (c/t), ; lane 3 = individual homozygous 
for the t allele (t/t); lane 4 = undigested 237bp exon 35 PCR-amplified fragment.. 
d) Schematic representation of the PCR-amplified product, indicating the position of the NlaIII sites. * = 
variable restriction enzyme site. 
                          NlaIII*     NlaIII 
            137bp                 48bp             52bp  
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a)      1            2   b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)      1           2           3       d) 
 
 
 
 
 
 
 
 
  
 
Figure III.10. Identification of the novel g19706a ssSV in intron 34 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 35 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 =heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g/a polymorphism at nucleotide 19706 in a heterozygous individual.  
b) Partial sequence of the minus-strand of exon 35 of MYBPC3 in an individual heterozygous for the 
g19706a polymorphism, showing the c/t substitution on the minus-strand. 
c) Genotyping of the MYBPC3 g19706a polymorphism by ASREA. Products of the AluI restriction enzyme 
digestion of the 237bp PCR-amplified product of exon 35 were electrophoresed on a 12% polyacrylamide gel. 
The internal AluI site generates 153bp and 84bp fragments in g/g homozygotes, while the presence of the a 
allele generates an additional AluI site, resulting in additional 112bp and 41bp fragments in g/a 
heterozygotes. The 41bp fragment could not be resolved under these electrophoretic conditions. Lane 1 = λPst 
marker; lane 2 = individual homozygous for the g allele (g/g); lane 3 = heterozygous individual (g/a). 
d) Schematic representation of the amplified product, indicating the position of the AluI sites. * = variable 
restriction enzyme site. 
                          AluI*    AluI 
            112bp             41bp            84bp  
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a)     1                 2      b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)     1        2        3       4          d) 
 
 
 
 
 
 
 
 
 
 
 
Figure III.11. Identification of the novel T262T polymorphism in exon 8 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 8 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the c allele (c/c); lane 2 = heterozygous individual (c/t). The arrow indicates the 
mobility shift caused by the c/t polymorphism at nucleotide 4825 in a heterozygous individual.  
b) Partial sequence of the coding strand of exon 8 of MYBPC3 in an individual heterozygous for the c4825t 
polymorphism, showing the c/t substitution. 
c) Genotyping of the MYBPC3 c4825t polymorphism by ASREA. Products of the NlaIV restriction enzyme 
digestion of the 270bp PCR-amplified product of exon 8 were electrophoresed on a 12% polyacrylamide gel. 
The presence of the t allele generates an NlaIV site, resulting in the generation of 218bp and 52bp fragments 
in c/t heterozygotes. Lane 1 = λPst marker; lane 2 = individual homozygous for the c allele (c/c); lane 3 = 
heterozygous individual (c/t); lane 4 = undigested 270bp exon 8 PCR-amplified fragment. 
d) Schematic representation of the PCR-amplified product, indicating the position of the NlaIV sites. * = 
variable restriction enzyme site. 
C/T 
      NlaIV*         
 52bp                           218bp 
270bp 
218bp 
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a)      1            2   b) 
 
 
 
 
 
 
 
 
 
Figure III.12. Identification of the novel A522A ssSV in MYBPC3 exon 18 
a) PCR-SSCP analysis of the MYBPC3 exon 18 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g/a polymorphism at nucleotide 9187 in a heterozygous individual. 
b) Partial sequence of the coding strand of exon 18 of MYBPC3 in an individual heterozygous for the g9187a 
sSSV, showing the g/a substitution at nucleotide 9187. 
This ssSV did not alter a restriction enzyme recognition site and could, therefore, not be confirmed by ASREA. 
 
 
 
G/A 
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a)      1              2   b) 
 
 
 
 
 
 
 
 
 
Figure III.13. Identification of the novel S708S polymorphism in MYBPC3 exon 23 
a) PCR-SSCP analysis of the MYBPC3 exon 23 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the c allele (c/c); lane 2 = heterozygous individual (c/t). The arrows indicate the 
mobility shift caused by the c/t polymorphism at nucleotide 12474 in a heterozygous individual. 
b) Partial sequence of the coding strand of exon 23 of MYBPC3 in an individual heterozygous for the c12474t 
polymorphism, showing the c/t substitution. 
This polymorphism did not alter a restriction enzyme recognition site and could, therefore, not be confirmed 
by ASREA. 
 
C/T 
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a)        1             2           b) 
 
 
 
 
 
 
 
Figure III.14. Identification of the novel T737T ssSV in exon 24 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 24 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g/a polymorphism at nucleotide 13199 in a heterozygous individual.  
b) Partial sequence of the coding strand of exon 24 of MYBPC3 in an individual heterozygous for the 
g13199a SsSV, showing the g/a substitution. 
This ssSV did not alter a restriction enzyme recognition site and could, therefore, not be confirmed by ASREA. 
 
 
 
G/A 
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a)    1        2         3   b) 
 
 
 
 
 
 
 
 
 
 
c)    1             2            3         d) 
 
 
 
 
 
 
 
Figure III.15. Identification of the novel E1096E polymorphism in exon 31 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 31 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the a allele (a/a); lane 2 = heterozygous individual (a/g); lane 3 = individual 
homozygous for the g allele (g/g). 
b) Partial sequence of the coding strand of exon 31 of MYBPC3 in an individual heterozygous for the 
a18443g polymorphism, showing the a/g substitution. 
c) Genotyping of the a18443g polymorphism by ASREA. Products of the AluI restriction enzyme digestion of 
the 273bp PCR-amplified product of exon 31 were electrophoresed on a 12% polyacrylamide gel. The g allele 
creates an AluI site, resulting in the generation of additional 189bp and 84bp fragments. Lane 1 = λPst 
marker; lane2 = heterozygous individual (a/g); lane 3 = individual homozygous for the a allele (a/a). 
d) Schematic representation of the amplified product, indicating the position of the induced AluI site. * = 
variable restriction enzyme site. 
A/G
                                                 AluI*   
             189bp                                     84bp 
273bp 
189bp 
84bp 
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III.1.2. PUTATIVE MISSENSE MUTATIONS IN MYBPC3 
 
During the course of this study, several non-synonymous SNSs were identified within the coding 
sequence of MYBPC3 (exons), and classified as putative HCM-causing missense mutations (table 
III.1). In order to establish whether these SNSs are indeed disease-causing, ethnically-matched 
control panels were screened for the presence of these SNSs (section II.1.2). Additionally, multiple 
sequence alignments were performed in order to establish whether amino acid substitutions occurred 
at conserved residues. 
 
III.1.2.1. Identification of the MYBPC3 V158M putative HCM-causing missense mutation 
 
The V158M putative HCM-causing missense mutation was detected in one individual, of Caucasian 
descent, in the HCM-affected panel. This putative disease-causing mutation, caused by the g2626a 
SNS in exon 5 of MYBPC3 (figure III.16), occurs at a conserved residue in the C1 domain of 
cMyBPC (figure III.17). Following the screening of a control panel, consisting of 110 individuals of 
Caucasian descent, this SNS was detected in three individuals. 
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a)     1         2             b) 
 
 
 
 
 
 
 
c)     1        2        3                     d) 
 
    
 
 
 
 
 
Figure III.16. Identification of the novel V158M putative HCM-causing missense mutation in exon 5 of 
MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 5 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g2626a SNS in a heterozygous individual.  
b) Partial sequence of the coding strand of exon 5 of MYBPC3 in a heterozygous individual, showing the g/a 
substitution. 
c) Genotyping of the MYBPC3 V158M putative HCM-causing mutation by ASREA. Products of the NlaIII 
restriction enzyme digestion of the 246bp PCR-amplified product of exon 5 were electrophoresed on a 12% 
polyacrylamide gel. The NlaIII site is absent in the g/g homozygote, indicated by the presence of only the 
246bp product, while the presence of the a allele creates an NlaIII site, resulting in the generation of 173bp 
and 73bp fragments. Lane 1 = λPst marker; lane2 = individual homozygous for the g allele (g/g); lane 2 = 
heterozygous individual (g/a). 
d) Schematic representation of the PCR-amplified product, indicating the position of the induced NlaIII site. * 
= variable restriction enzyme site.
NlaIII* 
                173bp                             73bp 
246bp 
173bp 
73bp 
 
G/A 
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Figure III.17. Cross-species/isoform multiple sequence alignment of a portion of the C1 domain of MyBPC 
Chicken cMyBPC = chicken cardiac myosin binding protein C; frog cMyBPC = frog cardiac myosin binding 
protein C; human cMyBPC = human cardiac myosin binding protein C; human fsMyBPC = human fast 
skeletal myosin binding protein C; human ssMyBPC = human slow skeletal myosin binding protein C; mouse 
cMyBPC = mouse cardiac myosin binding protein C; mouse fsMyBPC = mouse fast skeletal myosin binding 
protein C; * = absolute conservation of amino acid residue; : = charge of amino acid residue conserved; . = 
conserved as a hydrophobic or hydrophilic amino acid residue. The arrow at the top of the figure indicates 
the position of cardiac myosin binding protein C residue 158 which is affected by the V158M putative HCM-
causing mutation (multiple sequence alignment performed using ClustalW, available at 
http://www.ebi.ac.uk/servicestmp/clustalw). 
 
III.1.2.2. Identification of the MYBPC3 A181T putative HCM-causing missense mutation 
 
The A181T putative HCM-causing missense mutation was detected in two individuals, both of 
mixed ancestry, in the HCM-affected panel. This putative disease-causing mutation, caused by the 
g2785a SNS in exon 6 of MYBPC3 (figure III.18), occurs at an non-conserved residue in the C1 
domain of cMyBPC (figure III.19). Following the screening of a control panel, consisting of 105 
individuals of mixed ancestry, this SNS was detected in two individuals.  
Human cMyBPC 
Mouse cMyBPC 
Chicken cMyBPC 
Frog cMyBPC 
Human fsMyBPC 
Mouse fsMyBPC 
Human ssMyBPC 
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 a)       1           2   b) 
 
 
 
 
 
 
 
 
 
c)     1       2       3       4  d) 
 
 
 
 
 
 
 
Figure III.18. Identification of the novel A181T putative HCM-causing mutation in exon 6 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 6 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g2785a SNS in a heterozygous individual.  
b) Partial sequence of the coding strand of exon 6 of MYBPC3 in a heterozygous individual, showing the g/a 
substitution. 
c) Genotyping of the MYBPC3 A181T putative HCM-causing mutation by ASREA. Products of the HhaI 
restriction enzyme digestion of the 269bp PCR-amplified product of exon 5 were electrophoresed on a 12% 
polyacrylamide gel. The internal HhaI sites generate 34bp, 48bp, 82bp and 105bp fragments in g/g 
homozygotes, while the presence of the a allele abolishes an HhaI site, resulting in an additional 187bp 
fragment in g/a heterozygotes. The 34bp and 48bp fragments could, however, not be resolved under these 
electrophoretic conditions. Lane 1 = λPst marker; lane 2 = individual homozygous for the g allele (g/g); lane 
3 = heterozygous individual (g/a); lane 4 = undigested exon 6 PCR-amplified fragment. 
d) Schematic representation of the PCR-amplified product, indicating the position of the HhaI sites. * = 
variable restriction enzyme site.
G/A 
                HhaI*                     HhaI       HhaI 
    82bp                  105bp              48bp     34bp 
105bp 
269bp 
187bp 
82bp 
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Figure III.19. Cross-species/isoform multiple sequence alignment of a portion of the C1 domain of MyBPC 
Chicken cMyBPC = chicken cardiac myosin binding protein C; frog cMyBPC = frog cardiac myosin binding 
protein C; human cMyBPC = human cardiac myosin binding protein C; human fsMyBPC = human fast 
skeletal myosin binding protein C; human ssMyBPC = human slow skeletal myosin binding protein C; mouse 
cMyBPC = mouse cardiac myosin binding protein C; mouse fsMyBPC = mouse fast skeletal myosin binding 
protein C; * = absolute conservation of amino acid residue; : = charge of amino acid residue conserved; . = 
conserved as a hydrophobic or hydrophilic amino acid residue. The arrow at the top of the figure indicates 
the position of cardiac myosin binding protein C residue 181 which is affected by the A181T putative HCM-
causing mutation (multiple sequence alignment performed using ClustalW, available at 
http://www.ebi.ac.uk/servicestmp/clustalw). 
 
 
III.1.2.3. Identification of the MYBPC3 R177H putative HCM-causing missense mutation 
 
The R177H putative HCM-causing missense mutation was detected in five individuals in the HCM-
affected panel. Two of these individuals were of mixed ancestry, two were of Caucasian descent and 
one individual was of Xhosa descent. This putative disease-causing mutation, caused by the g2774a 
SNS in exon 6 of MYBPC3 (figure III.20), occurs at a conserved residue in the C1 domain of 
cMyBPC (figure III.21). Following the screening of a control panel, consisting of 235 individuals of 
Xhosa descent (n = 137) and mixed ancestry (n = 105), this SNS was detected in six individuals, all 
of Xhosa descent. 
Human cMyBPC 
Mouse cMyBPC 
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a)        1            2     b) 
 
 
 
 
 
 
 
 
 
 
 
Figure III.20. Identification of the novel R177H putative HCM-causing mutation in exon 6 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 6 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g2774a SNS in a heterozygous individual.  
b) Partial sequence of the coding strand of exon 6 of MYBPC3 in a heterozygous individual, showing the g/a 
substitution. 
This putative mutation did not alter a restriction enzyme recognition site and could, therefore, not be 
confirmed by ASREA. 
G/AA 
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Figure III.21. Cross-species/isoform multiple sequence alignment of a portion of the C1 domain of MyBPC 
Chicken cMyBPC = chicken cardiac myosin binding protein C; frog cMyBPC = frog cardiac myosin binding 
protein C; human cMyBPC = human cardiac myosin binding protein C; human fsMyBPC = human fast 
skeletal myosin binding protein C; human ssMyBPC = human slow skeletal myosin binding protein C; mouse 
cMyBPC = mouse cardiac myosin binding protein C; mouse fsMyBPC = mouse fast skeletal myosin binding 
protein C; * = absolute conservation of amino acid residue; : = charge of amino acid residue conserved; . = 
conserved as a hydrophobic or hydrophilic amino acid residue. The arrow at the top of the figure indicates 
the position of cardiac myosin binding protein C residue 177 which is affected by the R177H putative HCM-
causing mutation (multiple sequence alignment performed using ClustalW, available at 
http://www.ebi.ac.uk/servicestmp/clustalw). 
 
III.1.2.4. Identification of the MYBPC3 G278E putative HCM-causing missense mutation 
 
The G278E putative HCM-causing missense mutation was detected in one individual, of mixed 
ancestry, in the HCM-affected panel. This putative disease-causing mutation, caused by the g5047a 
SNS in exon 9 of MYBPC3 (figure III.22), occurs at a conserved residue in the cardiac-specific 
LAGGGRIS insertion in the MyBPC-motif (figure III.23). Following the screening of a control 
panel, consisting of 104 HCM-unaffected individuals of mixed ancestry, this SNS was detected in 
five individuals.  
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a)      1              2      b) 
 
 
 
 
 
 
 
 
 
c)     1       2       3       4          d) 
 
 
 
 
 
 
 
 
 
Figure III.22. Identification of the G278E polymorphism in exon 9 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 9 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g5047a SNS in a heterozygous individual.  
b) Partial sequence of the coding strand of exon 9 of MYBPC3 in a heterozygous individual, showing the g/a 
substitution. 
c) Genotyping of the MYBPC3 G278E putative HCM-causing missense mutation by ASREA. Products of the 
MnlI restriction enzyme digestion of the 252bp PCR-amplified product of exon 9 were electrophoresed on a 
12% polyacrylamide gel. The internal MnlI sites generate 18bp, 37bp, 70bp and 127bp fragments in g/g 
homozygotes, while the presence of the a allele abolishes an MnlI site, resulting in an additional 164bp 
fragment in g/a heterozygotes. The 18bp and 37bp fragments could, however, not be resolved under these 
electrophoretic conditions. Lane 1 = λPst marker; lane 2 = individual homozygous for the g allele (g/g); lane 
3 = heterozygous individual (g/a); lane 4 = undigested exon 9 PCR-amplified fragment. 
d) Schematic representation of the PCR-amplified product, indicating the position of the MnlI sites. * = 
variable restriction enzyme site. 
                 MnlI  MnlI*                            MnlI 
    70bp         37bp               127bp             18bp    127bp 
252bp 
164bp 
70bp 
G/A 
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Figure III.23. Cross-species/isoform multiple sequence alignment of a portion of the MyBPC-motif of 
MyBPC 
Chicken cMyBPC = chicken cardiac myosin binding protein C; frog cMyBPC = frog cardiac myosin binding 
protein C; human cMyBPC = human cardiac myosin binding protein C; human fsMyBPC = human fast 
skeletal myosin binding protein C; human ssMyBPC = human slow skeletal myosin binding protein C; mouse 
cMyBPC = mouse cardiac myosin binding protein C; mouse fsMyBPC = mouse fast skeletal myosin binding 
protein C; * = absolute conservation of amino acid residue; : = charge of amino acid residue conserved; . = 
conserved as a hydrophobic or hydrophilic amino acid residue. The arrow at the top of the figure indicates 
the position of cardiac myosin binding protein C residue 278 which is affected by the G278E putative HCM-
causing mutation (multiple sequence alignment performed using ClustalW, available at 
http://www.ebi.ac.uk/servicestmp/clustalw). 
 
III.1.2.5. Identification of the MYBPC3 G507R putative HCM-causing missense mutation 
 
The G507R putative HCM-causing missense mutation was detected in one individual, of Zulu 
descent, in the HCM-affected panel. This putative disease-causing mutation, caused by the g9140a 
SNS in exon 18 of MYBPC3 (figure III.24), occurs at a highly conserved residue in the C3 domain of 
cMyBPC (figure III.25). This SNS was not present in a control panel consisting of 50 individuals of 
Zulu descent and 50 individuals of Xhosa descent.  
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 a)      1            2        b) 
 
 
 
 
 
 
 
 
 
Figure III.24. Identification of the G507R putative HCM-causing mutation in exon 18 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 18 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrows indicate the 
mobility shift caused by the g9140a SNS in a heterozygous individual. 
b) Partial sequence of the coding strand of exon 18 of MYBPC3 in an individual heterozygous for the g9140a 
SNS, showing the g/a substitution at nucleotide 9140. 
This mutation did not alter a restriction enzyme recognition site and could, therefore, not be confirmed by 
ASREA. 
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Figure III.25. Cross-species/isoform multiple sequence alignment of a portion of the C3 domain of MyBPC 
Chicken cMyBPC = chicken cardiac myosin binding protein C; frog cMyBPC = frog cardiac myosin binding 
protein C; human cMyBPC = human cardiac myosin binding protein C; human fsMyBPC = human fast 
skeletal myosin binding protein C; human ssMyBPC = human slow skeletal myosin binding protein C; mouse 
cMyBPC = mouse cardiac myosin binding protein C; mouse fsMyBPC = mouse fast skeletal myosin binding 
protein C; * = absolute conservation of amino acid residue; : = charge of amino acid residue conserved; . = 
conserved as a hydrophobic or hydrophilic amino acid residue. The arrow at the top of the figure indicates 
the position of cardiac myosin binding protein C residue 507 which is affected by the G507R putative HCM-
causing mutation (multiple sequence alignment performed using ClustalW, available at 
http://www.ebi.ac.uk/servicestmp/clustalw). 
 
III.1.2.6. Identification of the MYBPC3 V896M putative HCM-causing missense mutation 
 
The V896M putative HCM-causing missense mutation was detected in one individual, of Caucasian 
descent, in the HCM-affected panel. This putative disease-causing mutation, caused by the g15751a 
SNS in exon 27 of MYBPC3 (figure III.26), occurs at a conserved residue in the C7 domain of 
cMyBPC (figure III.27). The g15751a SNS was not detected in a control panel consisting of 102 
individuals of Caucasian descent. 
 
Human cMyBPC 
Mouse cMyBPC 
Chicken cMyBPC 
Frog cMyBPC 
Human fsMyBPC 
Mouse fsMyBPC 
Human ssMyBPC 
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     d) 
 
 
 
 
 
 
 
 
 
 
Figure III.26. Identification of the novel V896M putative HCM-causing mutation in exon 27 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 27 PCR-amplified product on an 8% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele; lane 2 = heterozygous individual (g/a). The arrow indicates the 
mobility shift caused by the g15751a SNS in a heterozygous individual.  
b) Partial sequence of the non-coding strand of exon 27 of MYBPC3 in an individual heterozygous for the 
g15751a SNS, showing the c/t substitution on the non-coding strand. 
c) Genotyping of the MYBPC3 V896M putative HCM-causing missense mutation by ASREA. Products of the 
NlaIII restriction enzyme digestion of the 310bp PCR-amplified product of exon 27 were electrophoresed on a 
12% polyacrylamide gel. The internal NlaIII site generates 236bp and 74bp fragments in g/g homozygotes, 
while the presence of the a allele creates an additional NlaIII site, resulting in additional 142bp and 94bp 
fragments in g/a heterozygotes. Lane 1 = λPst marker; lane 2 = individual homozygous for the g allele (g/g); 
lane 3 = heterozygous individual (g/a). 
d) Schematic representation of the PCR- amplified product, indicating the position of the NlaIII sites. * = 
variable restriction enzyme site. 
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Figure III.27. Cross-species/isoform multiple sequence alignment of a portion of the C7 domain of MyBPC 
Chicken cMyBPC = chicken cardiac myosin binding protein C; frog cMyBPC = frog cardiac myosin binding 
protein C; human cMyBPC = human cardiac myosin binding protein C; human fsMyBPC = human fast 
skeletal myosin binding protein C; human ssMyBPC = human slow skeletal myosin binding protein C; mouse 
cMyBPC = mouse cardiac myosin binding protein C; mouse fsMyBPC = mouse fast skeletal myosin binding 
protein C; * = absolute conservation of amino acid residue; : = charge of amino acid residue conserved; . = 
conserved as a hydrophobic or hydrophilic amino acid residue. The arrow at the top of the figure indicates 
the position of cardiac myosin binding protein C residue 896 which is affected by the V896M putative HCM-
causing mutation (multiple sequence alignment performed using ClustalW, available at 
http://www.ebi.ac.uk/servicestmp/clustalw). 
 
 
III.1.3. IDENTIFICATION OF PUTATIVE SPLICING MUTATIONS IN MYBPC3 
 
Several SNSs identified during the course of this study (table III.1) were predicted to alter the 
splicing of the MYBPC3 transcript. These SNSs, occurring in both the exonic and intronic regions of 
MYBPC3, were, therefore, deemed to be putative splicing HCM-causing mutations.  
 
Human cMyBPC 
Mouse cMyBPC 
Chicken cMyBPC 
Frog cMyBPC 
Human fsMyBPC 
Mouse fsMyBPC 
Human ssMyBPC 
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III.1.3.1. Identification of the exon 5 SdS -13 c>t putative splicing mutation  
 
The c2646t SNS, occurring in the coding sequence of exon 5 (table III.1 and figure III.28), was 
detected in eight probands in the HCM-affected panel. This SNS causes codon 164 to change from 
ggc to ggt, both encoding glycine (G) (G164G). Computational analysis, however, revealed that this 
SNS creates a cryptic SdS 15bp upstream of, and approximately of the same strength as, the natural 
exon 5 SdS, as described by Carrier et al., (1997) (figure III.29). It was, therefore, hypothesised that 
this cryptic SdS may be utilised preferentially, due to the processivity of splicing (personal 
communication, Dr Peter Rogan, 23 December 1999), and that this SNS may act as an HCM-causing 
splicing mutation (figure III.29). 
 
RT-PCR analysis (section II.6.4 and table II.7) was, however, hampered by the fact that the RT-PCR 
product resulting in the normal splicing of the MYBPC3 transcript, and that produced by the putative 
aberrantly spliced transcript, were similar in size (659bp and 644bp, respectively) (figure III.29). The 
possibility that this small size difference would not be detectable by agarose gel electrophoresis was 
resolved by digestion of RT-PCR products with BstEII, as this site would be absent from the 
aberrantly spliced transcript. Following digestion of the RT-PCR product with BstEII, only the 
digested 435bp and 224bp fragments were detected (figure III.29), indicating that the c2646t SNS 
does not affect splicing of the MYBPC3. 
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a)       1           2    b) 
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     d) 
 
 
 
 
Figure III.28. Identification of the exon 5 SdS -13 c>t putative HCM-causing splicing mutation 
a) PCR-SSCP analysis of the MYBPC3 exon 5 PCR-amplified product  on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the c allele (c/c); lane 2 = heterozygous individual (c/t). The arrows indicate the 
mobility shift caused by the c2646t SNS in a heterozygous individual.  
b) Partial sequence of the coding strand of exon 5 of MYBPC3 in an individual heterozygous for the c2646t 
SNS, showing the c/t substitution. 
c) Genotyping of the MYBPC3 c2646t putative HCM-causing splicing mutation by ASREA. Products of the 
HphI restriction enzyme digestion of the 246bp PCR-amplified product of exon 5 were electrophoresed on a 
12% polyacrylamide gel. The internal HphI sites generate 10bp, 30bp, 65bp and 141bp fragments in c/c 
homozygotes, while the presence of the t allele creates an additional HphI site, resulting in additional 136bp 
and 5bp fragments in c/t heterozygotes. The 5bp, 10bp and 30bp fragments could, however, not be resolved 
under these gel conditions. Lane 1 = λPst marker; lane 2 = heterozygous individual (c/t); lane 3 = individual 
homozygous for the c allele (c/c). 
d) Schematic representation of the PCR-amplified product, indicating the position of the HphI sites. * = 
variable restriction enzyme site.  
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Figure III.29. RT-PCR analysis of the exon 5 SdS -13 c>t putative HCM-causing splicing mutation 
a) Diagrammatic representation of the MyBPC3 splice pathway in the exon 4-6 region. The sequence of the 
cryptic splice donor site generated by the c2646t SNS, is indicated in the oval at the bottom of the figure.  
      = Intronic sequence;     = exons; Ex = exon;       = normal splicing pattern;      = postulated aberrant 
splicing pattern caused by the c2646t SNS; SaS = splice acceptor site; SbP = splice branch point; SdS = 
splice donor site. 
b) RT-PCR products electrophoresed on a 2% agarose gel. The normal splicing pattern would result in the 
generation of a 659bp fragment, while the RT-PCR product resulting from an aberrantly spliced transcript 
would result in the generation of a 644bp fragment. Lane 1 = Roche molecular size marker VII; lane 2 = 
individual homozygous for the c allele (c/c); lane 3 = heterozygous individual (c/t). 
c) Products of the BstEII restriction enzyme digestion of the ~659bp RT-PCR product, electrophoresed on a 
2% agarose gel. The internal BstEII site generates 435bp and 224bp fragments in the RT-PCR product 
generated from the normally spliced transcript, while this BstEII site would be abolished in RT-PCR products 
generated from the aberrantly spliced transcript, resulting in the generation of an additional 644bp 
fragments. Lane 1 = Roche molecular size marker VII, lane 2 = undigested sample from an individual 
homozygous for the c allele (cc), lane 3 = sample from an individual homozygous for the c allele (cc) digested 
with BstEII, lanes 4, 5 and 6 = samples from a heterozygous individual (c/t) digested with BstEII, lane 7 = 
undigested sample from a heterozygous individual (c/t).  
           SdS                 SbP  SaS                               SdS                              SbP   SaS 
GATGGCGAGGT
T 
Ex 4     Ex 5     Ex 6 
~659bp 
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III.1.3.2. Identification of the exon 7 SaS +1 g>a putative splicing mutation  
 
The g4177a SNS, occurring at position +1 of the exon 7 SaS (box 1, table III.1, figures III.30 and 
III.31), was detected in one proband, of mixed ancestry, in the HCM-affected panel. The g4177a 
SNS was not detected in a control panel consisting of 107 individuals of mixed ancestry. 
Computational analysis revealed that this SNS may inactivate the natural exon 7 SaS, as described by 
Carrier et al., (1997). It was hypothesised that the g4177a SNS would cause the skipping of MYBPC3 
exon 7 (personal communication, Dr Peter Rogan, 23 December 1999) (figure III.31). 
 
RT-PCR analysis revealed the presence of a ~225bp fragment, resulting from the amplification of the 
normally spliced transcript, as well as an additional ~107bp fragment (figure III.31). The size of the 
additional fragment was consistent with the expected fragment size resulting from amplification of a 
transcript in which exon 7 was skipped. Manual sequencing of the 107bp RT-PCR product 
confirmed that this fragment resulted from the skipping of exon 7 in the MYBPC3 transcript (figure 
III.31).  
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a)     1         2   b) 
 
 
 
 
 
 
 
 
 
 
Figure III.30. Identification of the exon 7 SaS +1 g>a putative HCM-causing splicing mutation  
a) PCR-SSCP analysis of the MYBPC3 exon 7 PCR-amplified region on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the g allele (g/g); lane 2 = heterozygous individual (g/a). The arrow indicates the 
mobility shift caused by the g4177a SNS in a heterozygous individual.  
b) Partial sequence of the minus-strand at the MYBPC3 intron 6 - exon 7 boundary in an individual 
heterozygous for the g4177a SNS, showing the c/t substitution on the minus-strand. 
The g4177a SNS did not affect any restriction enzyme recognition sites and could, therefore, not be confirmed 
by ASREA.  
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Figure III.31. RT-PCR analysis of the exon 7 SaS +1 g>a putative HCM-causing splicing mutation 
a) Diagrammatic representation of the MyBPC3 splice pathway in the exon 6-8 region. The sequence of the 
exon 7 SaS affected by the g4177a SNS is indicated in the oval at the bottom of the figure.      = Intronic 
sequence;     = exons; Ex = exon;     = normal splicing pattern;      = postulated aberrant splicing pattern 
caused by the g4177a SNS; SaS = splice acceptor site; SbP = splice branch point; SdS = splice donor site. 
b) RT-PCR products electrophoresed on a 12% polyacrylamide gel. The normal splicing pattern would result 
in the generation of a 225bp fragment, while the RT-PCR product resulting from an aberrantly spliced 
transcript would result in the generation of a 107bp fragment. Lane 1 = individual homozygous for the g 
allele (g/g); lane 2 = heterozygous individual (g/a). 
c) Partial sequence of the non-coding strand of the ~107bp fragment. Exon 6 sequence indicated in green 
lettering, exon 8 sequence indicated in red lettering. 
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III.1.3.3. Identification of the intron 6 SbP +1 c>t putative splicing mutation  
 
The c4154t SNS, occurring in intron 6 (table III.1 and figure III.32), was detected in two probands, 
both of mixed ancestry, in the HCM-affected panel. This SNS occurs 24bp upstream of the exon 7 
SaS and at position +1 of the intron 6 SbP (figure III.33). Computational analysis revealed that this 
SNS slightly weakens the exon 7 SaS, and would probably not affect the splicing of the MYBPC3 
transcript. The possibility that this SNS might inactivate the exon 7 SaS, resulting in the skipping of 
MYBPC3 exon 7, could, however, not be excluded (personal communication, Dr Peter Rogan, 23 
December 1999). RT-PCR analysis revealed the presence of only a ~659bp fragment (figure III.33), 
resulting from the amplification of the normally spliced transcript, suggesting that this SNS does not 
affect the splicing of the MYBPC3 transcript.  
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a)      1             2      b) 
 
 
 
 
 
 
 
 
 
 
Figure III.32.Identification of the novel intron 6 SbP +1 c>t  putative HCM-causing mutation  
a) PCR-SSCP analysis of the MYBPC3 exon 7 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the c allele (c/c); lane 2 = heterozygous individual (c/t). The arrows indicate the 
mobility shift caused by the c4154a in a heterozygous individual.  
b) Partial sequence of the plus-strand of intron 6 of MYBPC3 in an individual heterozygous for the c4154t 
putative HCM-causing splicing mutation, showing the c/t substitution. 
The c4154t SNS did not affect any restriction enzyme recognition sites and could, therefore, not be confirmed 
by ASREA. 
 
C/T
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Figure III.33. RT-PCR analysis of the intron 6 SbP +1 c>t putative HCM-causing splicing mutation  
a) Diagrammatic representation of the MyBPC3 splice pathway in the exon 6-8 region. The sequence 
surrounding the intron 6 SbP affected by the c4154t SNS, is indicated in the oval at the bottom of the figure.  
      = intronic sequence;       = exons; Ex = exon;     = normal splicing pattern;      = postulated aberrant 
splicing pattern caused by the c4154t SNS; SaS = splice acceptor site; SbP = splice branch point; SdS = 
splice donor site. 
b) RT-PCR products electrophoresed on a 2% agarose gel. The normal splicing pattern would result in the 
generation of a 659bp fragment, while the RT-PCR product, resulting from an aberrantly spliced transcript, 
would result in the generation of a 541bp fragment. Lane 1 = Roche molecular size marker 7; lane 2 = 
individual homozygous for the c allele (c/c); lane 2 = heterozygous individual (c/t). 
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III.1.4. IDENTIFICATION OF THE NOVEL Δc13255 FRAME-SHIFT HCM-CAUSING 
MUTATION IN EXON 24 OF MYBPC3 
 
The deletion of a cytosine residue in exon 24 of MYBPC3 at position 13255 (Δc13255) (table III.1 
and figure III.34) was detected in one individual, of mixed ancestry, in the HCM-affected panel. This 
mutation is predicted to cause a frame-shift, resulting in the addition of 65 novel amino acids, prior 
to the generation of a stop codon and the truncation of the protein. The truncated protein thus 
generated, would consist of domains C0-C5. This mutation was not found in 100 control individuals 
of mixed ancestry. 
 
III.2. GENOTYPE:PHENOTYPE ASSOCIATION STUDIES 
 
In order to establish the phenotypic expression of putative HCM-causing mutations identified during 
the course of this study, clinical data obtained from mutation carriers were used to conduct 
genotype:phenotype association studies (sections III.2.1 and III.2.2). As families of probands 
identified as carrying the G507R and Δc13255 putative HCM-causing mutations could not be traced, 
comprehensive genotype:phenotype association studies could not be performed. The phenotypic 
presentation of the proband carrying the G507R mutation is, therefore, given in section III.2.3. 
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Figure III.34.Identification of the novel Δc 13255 HCM-causing mutation in exon 24 of MYBPC3 
a) PCR-SSCP analysis of the MYBPC3 exon 24 PCR-amplified product on a 10% MD-SSCP gel. Lane 1 = 
individual homozygous for the wild type allele; lane 2 = individual heterozygous for the Δc allele. The arrow 
indicates the mobility shift caused by the Δc13255 putative HCM-causing mutation, in a heterozygous 
individual.  
b) Partial sequence of the coding strand of exon 24 of MYBPC3 in an individual heterozygous for the 
Δc13255 HCM-causing mutation, showing the deletion of nucleotide 13255 (Δc). 
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III.2.1. GENOTYPE:PHENOTYPE ASSOCIATION OF THE MYBPC3 V896M PUTATIVE 
HCM-CAUSING MUTATION 
 
Six individuals of pedigree 120 (figure III.35) were genotyped for the presence of the V896M 
putative HCM-causing mutation. Of the individuals genotyped, four tested positive for the V896M 
mutation. Clinical assessment of mutation carriers revealed that only the proband (individual II.2) 
fulfilled the echocardiographic criteria for the diagnosis of HCM (table III.3). Both individuals II.1 
and II.2 presented with angina, while individual I.2 had dyspnoea and palpitations, and was 
diagnosed with congestive heart failure due to DCM at the age of 75 years (table III.2). Although no 
symptoms of HCM, or ECG-abnormalities associated with HCM were present in individual III.1, 
echocardiographic measurement of the interventricular septum (IVS) was at the upper limits of the 
normal range at age 19 years (tables III.2 and III.3).  
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  Not investigated                      Mutation present, clinically affected 
 
 
  Mutation absent              Deceased 
 
 
  Mutation present, clinically unaffected            Proband 
 
 
Figure III.35. Pedigree 120 in which the MYBPC3 V896M putative HCM-causing mutation segregates 
Clinically affected individuals were diagnosed with HCM on at least the strictest echocardiographic criterion 
of a maximal left ventricular wall thickness of 13mm or more, or the electrocardiographic criterion of left 
ventricular hypertrophy, based on the points system of Romhilt and Estes. 
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Table III.2. Symptoms present in individuals carrying the V896M putative HCM-causing mutation 
 
Ind 
no 
Sex/Age at 
diagnosis (yrs) 
Syncope/ 
Presyncope 
Dyspnoea Palpitations Angina Cardiac 
failure 
I.2 F/75 - y y - y 
II.1 M/54 - - - y - 
II.2 M/50 - - - y - 
III.1 M/27 - - - - - 
 
F = female; Ind no = individual identity number (figure III.35), M = male; y = feature present; yrs = years; - 
feature absent. 
 
Table III.3. Echocardiographic and electrocardiographic features present in individuals with the V896M 
putative HCM-causing mutation 
 
Echocardiographic features ECG features Ind 
no 
Sex/ 
Age 
(yrs) 
IVS 
(mm) 
PW 
(mm) 
Area of 
Hypert 
ASH SAM Valve Ab 
Rep
Inc 
V 
Ab 
Qs 
↑A R&E 
LVH 
I.2 F/75 8 10 N.A. - - - - - - - - 
II.1 M/54 11 11 N.A. - - - - - y - - 
II.2 M/50 17 14 IVS y y - - - y - - 
III.1 M/27 11 11 N.A. - - - - - - - - 
 
Ab Qs = abnormal Q-waves; Ab Rep = abnormal repolarisation; ASH = asymmetrical hypertrophy; F = 
female; Hypert = hypertrophy; Inc V = increased voltages; Ind no = individual identity number (figure 
III.35); IVS = inter-ventricular septum; M = male; N.A. = not assessed; PW= posterior left ventricular free 
wall; R&E LVH = left ventricular hypertrophy by Romhilt and Estes criteria; SAM= systolic anterior motion 
of the mitral valve; y = feature present; yrs = years; ↑A = atrial hypertrophy; - = feature absent. 
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III.2.2. PHENOTYPIC EFFECT OF THE MYBPC3 EXON 7 SaS +1 g>a PUTATIVE HCM-
CAUSING SPLICING MUTATION, IN A COMPOUND HETEROZYGOTE 
 
The exon 7 SaS +1 g>a putative HCM-causing splicing mutation was identified in only one proband 
in the HCM-affected panel, in which the TNNT2 R92W HCM-causing mutation had previously been 
described (Moolman et al., 1997; Moolman-Smook et al., 1999) (figure III.36). Three individuals of 
pedigree 137 (figure III.36) were genotyped for the presence of the TNNT2 R92W HCM-causing and 
MYBPC3 exon 7 SaS +1 g>a putative HCM-causing splicing mutations. Of the individuals 
genotyped, two carried the previously identified TNNT2 R92W HCM-causing mutation, while the 
MYBPC3 exon 7 SaS +1 g>a putative HCM-causing splicing mutation was found only in the 
proband, who was a compound heterozygote, carrying both these mutations (figure III.31). Clinical 
assessment of mutation carriers (individuals II.2 and III.2; figure III.36 and tables III.4 and III.5) 
revealed that only the proband (individual II.2) fulfilled the Romhilt and Estes criteria for the 
diagnosis of LVH on ECG, while neither of these individuals fulfilled the echocardiographic criteria 
for the diagnosis of HCM (table III.3).  
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Figure III.36. Pedigree 137 in which both the TNNT2 R92W HCM-causing mutation and MYBPC3 exon 
7 SaS +1 g>a putative HCM-causing splicing mutation were identified 
Clinically affected individuals were diagnosed with HCM on at least the strictest echocardiographic criterion 
of a maximal left ventricular wall thickness of 13mm or more, or the electrocardiographic criterion of left 
ventricular hypertrophy, based on the points system of Romhilt and Estes. 
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Table III.4. Symptoms present in individuals from pedigree 137 carrying the TNNT2 R92W HCM-causing 
mutation 
 
Ind 
no 
Sex/Age at 
diagnosis (yrs) 
Syncope/ 
Presyncope 
Dyspnoea Palpitations Angina Cardiac 
failure 
II.2* M/49 - - - - - 
III.2 F/21 - - - - - 
 
F = female; Ind no = individual identity number (figure III.36), M = male; y = feature present; yrs = years; - 
feature absent; * = compound heterozygote for the TNNT2 R92W HCM-causing mutation and the MYBPC3 
exon 7 splice acceptor site putative HCM-causing mutation. 
 
Table III.5. Echocardiographic and electrocardiographic features present in individuals from pedigree 137 
with the TNNT2 R92W HCM-causing mutation 
 
Echocardiographic features ECG features Ind 
no 
Sex/ 
Age 
(yrs) 
IVS 
(mm) 
PW 
(mm) 
Area of 
Hypert 
ASH SAM Valve Ab 
Rep 
Inc 
V 
Ab 
Qs 
↑A R&E 
LVH 
II.2* M/49 9.0 9.0 n.a. - - - y y - y y 
III.2 F/21 8.0 7.0 n.a. - - - - - - - n 
 
Ab Qs = abnormal Q-waves; Ab Rep = abnormal repolarisation; ASH = asymmetrical hypertrophy; F = 
female; Hypert = hypertrophy; Inc V = increased voltages; Ind no = individual identity number (figure 
III.36); IVS = inter-ventricular septum; M = male; n = no; n.a. = not applicable; PW= posterior left 
ventricular free wall; R&E LVH = left ventricular hypertrophy by Romhilt and Estes criteria; SAM= systolic 
anterior motion of the mitral valve; y = feature present; yrs = years; ↑A = atrial hypertrophy; - = feature 
absent; * = compound heterozygote for the TNNT2 R92W HCM-causing mutation and the MYBPC3 exon 7 
SaS +1 g>a putative HCM-causing mutation. 
 213
III.2.3. PHENOTYPIC EXPRESSION OF THE MYBPC3 G507R PUTATIVE HCM-
CAUSING MUTATION 
 
As the family of the proband carrying the G507R putative HCM-causing mutation could not be 
traced, a detailed genotype:phenotype correlation study could not be done, nor could it be shown that 
this putative HCM-causing mutation segregates with HCM in this family. The proband, a 50 year old 
woman of Zulu descent, presented with dyspnoea, palpitations and angina. ECG-analysis revealed 
increased voltages, abnormal repolarisation and fulfilled the Romhilt and Estes criteria for the 
diagnosis of HCM, while echocardiographic evaluation revealed severe LVH with a maximal wall 
thickness of 25mm (IVS) as well as systolic anterior motion of the mitral valve. Additionally, the 
mother of the proband died suddenly at the age of 40 years of unknown, but non-violent, causes. 
 
III.3. YEAST TWO-HYBRID ASSAYS 
 
III.3.1. QUALITY CONTROL OF Y2H CONSTRUCTS 
 
III.3.1.1. Sequence analysis of Y2H constructs 
 
Sequence analysis of constructs used in Y2H-assays (section II.10 and table II.9) revealed that the 
reading-frame of all inserts was maintained. Furthermore, BLASTX analysis 
(http://www.ncbi.nlm.nih.gov/Blast) of insert sequences revealed that the deduced amino acid 
sequences of all bait- and prey-peptides, used in Y2H-assays, were identical to relevant amino acid 
sequences in the GenBank database (http://www.ncbi.nlm.nih.gov/Entrez). 
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III.3.1.2. Toxicity tests of Y2H constructs 
 
All yeast transformed with bait- or prey- constructs were able to grow on appropriate selection media 
(table II.10 and appendix A), indicating that none of the bait- or prey-peptides used in Y2H-assays 
were toxic to the yeast and that the phenotypes of the yeast strains were retained. Additionally, 
growth-curves were constructed for yeast strains transformed with all bait constructs used in Y2H 
library-assays (section II.16.1; figures III.37 and III.38). There was never any significant difference 
between the slopes of the Linearised growth-curves of yeast transformed with bait constructs, and 
yeast transformed with the relevant non-recombinant bait-vector (figures III.37 and III.38). It was, 
therefore, concluded that none of the peptides encoded by bait constructs used in Y2H library-assays 
were toxic to, or significantly affected growth of, the yeast strains in which they were expressed. 
 
III.3.1.3. Reporter gene self-activation tests 
 
None of the yeast strains transformed with any bait- or prey-constructs, used in Y2H-assays, were 
able to grow on relevant selection media (section II.15.3, tables II.10, III.6 and appendix A). It was, 
therefore, concluded that none of the peptides encoded by these constructs were able to 
independently activate transcription of either the HIS3 or ADE2 reporter genes.  
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Figure III.37. Linearised growth-curve of yeast strain PJ69-2A transformed with pAS2.1-based Y2H bait-
vectors 
Linearised growth-curves (log OD600 plotted against time) of yeast strain PJ69-2A transformed with pAS2.1-
C0C1 bait-plasmid or pAS2.1 non-recombinant plasmid. 
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Figure III.38. Linearised growth-curves of yeast strain AH109 transformed with pGBKT7-based Y2H bait-
vectors 
Linearised growth-curves (log OD600 plotted against time) of yeast strain AH109 transformed with pGBKT7-
C0 bait-plasmid, pGBKT7-C0C1 bait-plasmid, pGBKT7-C7 bait-plasmid or pGBKT7 non-recombinant 
plasmid. 
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Table III.6. Reporter gene self-activation tests of Y2H constructs 
Yeast selection medium  
Construct name 
 
Type SD
-W-H SD-W-H-Ade SD-L-H SD-L-H-Ade 
pAS2.1-C0 Bait X X N.A. N.A. 
pGBKT7-C0 Bait X X N.A. N.A. 
pAS2.1-C0C1 Bait X X N.A. N.A. 
pGBKT7-C0C1 Bait X X N.A. N.A. 
pAS2.1-C0C2 Bait X X N.A. N.A. 
pGBKT7-C7 Bait X X N.A. N.A. 
pGBKT7-C7V896M Bait X X N.A. N.A. 
pGBKT7-A43 Bait X X N.A. N.A. 
pGADT7-C1 Prey N.A. N.A. X X 
pGADT7-C1C2 Prey N.A. N.A. X X 
pGADT7-C2 Prey N.A. N.A. X X 
pACT2-C5 Prey N.A. N.A. X X 
pACT2-C6 Prey N.A. N.A. X X 
pACT2-C8 Prey N.A. N.A. X X 
pACT2-C8C10 Prey N.A. N.A. X X 
pACT2-C9 Prey N.A. N.A. X X 
pACT2-C9C10 Prey N.A. N.A. X X 
pACT2-C10 Prey N.A. N.A. X X 
pGADT7-A109 Prey N.A. N.A. X X 
pGADT7-A109A112 Prey N.A. N.A. X X 
pGADT7-A112 Prey N.A. N.A. X X 
pGADT7-A116 Prey N.A. N.A. X X 
 
SD-L-H = selective dropout yeast media lacking leucine and histidine; SD-L-H-Ade = selective dropout yeast 
media lacking leucine, histidine and adenosine; SD-W-H = selective dropout yeast media lacking tryptophan 
and histidine; SD-W-H-Ade = selective dropout yeast media lacking tryptophan, histidine and adenosine; N.A. = 
not applicable; X = no growth observed. 
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Table III.7. Effect of bait-peptides on yeast mating efficiency 
 
Mating  Mating efficiency (%) 
pAS2.1 (PJ69-2A) x pACT2 (Y187) 1.1% 
pVA3.1 (PJ69-2A) x pTD1.1 (Y187) 1.0% 
pAS2.1-C0C1 (PJ69-2A) x pACT2 (Y187) 0.4% 
pGBKT7 (AH109) x pACT2 (Y187) 4.2% 
pGBKT7-53 (AH109) x pGADT7-T (Y187) 38.1% 
pGBKT7-C0C1 (AH109) x pACT2 (Y187) 0.8% 
pGBKT7-C0 (AH109) x pACT2 (Y187) 3.7% 
pGBKT7-C7 (AH109) x pACT2 (Y187) 1.1% 
 
Bait- and prey- host strains in brackets; control matings in italics; test matings of bait constructs in bold. 
 
III.3.1.4. Effect of bait-peptides on mating efficiency  
 
In order to establish whether any of the bait-peptides used in Y2H library-assays affected the mating 
ability of the bait host strain, small-scale yeast matings were performed and mating efficiencies 
calculated (section II.16.3). Although results of such experiments showed a great deal of inter-
experimental variation, bait constructs generally inferred a slight mating disadvantage (table III.7). In 
order to reduce the possibility that this reduction in mating efficiency might adversely affect the 
number of library clones screened during subsequent Y2H library-assays, bait cultures used in these 
assays (section II.17.2.2) were grown to a titre of >1x 1010/ml, one order higher than that suggested 
by the manufacturer of the MATCHMAKER Y2H systems (BD Biosciences, Clontech, Palo Alto, 
CA, USA), and two orders of magnitude greater than the titre of the yeast library to be screened. 
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III.3.2. YEAST TWO-HYBRID LIBRARY-ASSAYS 
 
During the course of this study, four Y2H cardiac cDNA library-screening assays were performed. In 
two of these assays, the C0C1 region of cMyBPC was used as bait, while the C0 and C7 domains of 
cMyBPC were used as bait in each of the two remaining Y2H library-assays. One of the library-
assays, in which the C0C1 region of cMyBPC was used as bait, was performed in the 
MATCHMAKER GAL4 Two-Hybrid System 2 (cMyBPC C0C1 (1)), while the other, as well as 
library-assays in which the C0 and C7 domains of cMyBPC were used as bait, were all performed in 
the MATCHMAKER GAL4 Two-Hybrid System 3 (cMyBPC C0C1 (2), cMyBPC C0 and cMyBPC 
C7). The rationale for preferentially using the MATCHMAKER GAL4 Two-Hybrid System 3, 
which only became available during the course of this study, as well as for repeating the cMyBPC 
C0C1 (1) library-assay, is discussed in detail in section IV.4.1.  
 
III.3.2.1. cMyBPC C0C1 Y2H library-assay (1) 
 
The pAS2.1-C0C1 bait construct (table II.10), transformed into S. cerevisiae strain PJ69-2A, was 
used to screen a pACT2-based cardiac cDNA library, pre-transformed into S. cerevisiae strain Y187 
(BD Biosciences, Clontech, Palo Alto, CA, USA) (section II.17.2.2). The screening of an estimated 
1.04 x106 library clones yielded 77 clones in which transcription of the HIS3 reporter gene was 
activated, as evidenced by their ability to grow on TDO-selection medium. Of these 77 clones, only 
six were able to grow on QDO-selection medium, indicating additional activation of transcription of 
the ADE2 reporter gene. Filter β-galactosidase assays showed that transcription of the LacZ reporter 
gene was activated in all six clones (table III.8). Interaction-specificity tests (section II.17.7) showed 
that three of these clones contained prey-peptides which activated transcription of the HIS3 and 
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ADE2 reporter genes in the presence of heterologous baits, and were, therefore, discarded as non-
specific interactor clones (table III.8). The remaining three clones were classified as putative true 
interactor clones. Following DNA sequencing of the cDNA inserts contained in these clones, 
BLAST-analysis was used to identify interactor peptides (table III.9). Two of these peptides were 
identified as human Jun coactivator (COP9) subunit 5, while the other peptide was identified as the 
human homeobox protein MOX-1. As both these proteins have a nuclear localisation, they were not 
deemed plausible ligands of cMyBPC (section IV.4.1). 
 
Table III.8 cMyBPC C0C1 (1) putative interactor clones  
 
Colony phenotype 
(after 6 days) 
 
β-galactosidase assay 
Specificity tests 
(after 6 days) 
QDO 
 
 
 
Clone # R&S Colour 
 
Time 
 
Colour 
x pAS2.1
QDO 
x pTD1.1 
QDO 
 
1 
 
aa 
 
LP 
 
2 hours 
 
+ + + 
 
aa 
 
X 
3 aaa LP 2 hours + + + aa aaa 
7 aa P 2 hours + + aa X 
9 a P 2 hours + + aaa aaa 
34 aa LP 2 hours + + + aa aaa 
77 a P 3 hours + a X 
 
LP = light pink; P = pink; QDO = solid medium lacking lacking Leu, Trp, His and Ade; R&S = robustness 
and size of colony; Time = time to blue colour development; a = weak; aa = intermediate; aaa = 
strong; + = light blue; + + = blue; + + + = dark blue; X = no growth observed. 
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Table III.9. Identification of cMyBPC C0C1 (1) primary putative interactor clones 
 
Genomic hit In-frame ORF protein hit  
Clone # Identity Accession # Identity Accession #
Length 
(AA) 
 
E-value
Cellular 
localisation 
 
1 
 
H.s. Jun activation 
domain 
 
U65928 
 
H.s. Jun coactivator; 
COP9 (constitutive 
photomorphogenic), 
subunit 5 
 
AAP36860 
 
152 
 
9x10-62 
 
Nuclear 
7 H.s. Jun activation 
domain 
U65928 H.s. Jun coactivator; 
COP9 (constitutive 
photomorphogenic), 
subunit 5 
AAP36860 160 4x10-77 Nuclear 
77 H.s mesenchyme 
homeo box 1 
(MEOX1) 
XM_008351 H.s. Homeobox protein 
MOX-1 
NP_004518 168 3x10-70 Nuclear 
 
AA = amino acids; Hs = Homo sapiens; ORF = open reading frame 
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III.3.2.2. cMyBPC C0C1 Y2H library-assay (2) 
 
The pGBKT7-C0C1 bait construct (table II.10), transformed into S. cerevisiae strain AH109, was 
used to screen a pACT2-based cardiac cDNA library, pre-transformed into S. cerevisiae strain Y187 
(BD Biosciences, Clontech, Palo Alto, CA, USA) (section II.17.2.2). The screening of an estimated 
1.4 x106 library clones yielded 324 clones in which transcription of the HIS3 reporter gene was 
activated. Of these clones, 265 were able to grow on QDO-selection medium, indicating additional 
activation of transcription of the ADE2 reporter gene. Filter β-galactosidase assays and X-α-
galactosidase assays allowed elimination of an additional 60 of the 265 clones, due to their inability 
to activate transcription of the LacZ and MEL1 reporter genes (table III.10). The remaining 205 
clones were classified as either primary or secondary interactor clones, based on the size, robustness 
and colour of the colony, as well as their respective β-galactosidase and X-α-galactosidase 
phenotypes (time to, and intensity of, colour development). In total, 111 primary and 94 secondary 
interactor clones were identified. 
 
Restriction mapping of the prey-inserts (section II.11.3) of all primary and secondary interactor 
clones revealed the presence of eight groups of identical clones, as well as 70 unique clones (table 
III.10). Each of these groups was subsequently represented by a single clone in interaction-
specificity tests, reducing the number of primary interactor clones to 78. Interaction-specificity tests 
(section II.17.7) were performed on 76 primary interactor clones and four secondary interactor 
clones, each representing a group of identical secondary interactor clones. These tests showed that 
only ten clones (all primary interactor clones) contained prey peptides that did either not activate 
transcription of the HIS3 and ADE2 reporter genes in the presence of heterologous  
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baits, or activated transcription of these genes very weakly, and were, therefore, considered to be 
specific interactor clones (table III.10). These specific interactor clones, as well as two additional 
primary interactor clones, from which the prey-plasmid could not be purified, and could thus not be 
used in interaction-specificity tests, were subsequently sequenced.  
 
Six of the total number of putative interactor clones were identified by BLAST analysis as encoding 
a portion of M-line titin and two as encoding human multiple PDZ-domain protein (table III.11). The 
remaining preys identified were deemed to be implausible binding partners of the C0C1 domain of 
cMyBPC, due to their cellular location, or because they encoded very short peptides with no 
significant protein database matches (table III.11 and section IV.4.1). 
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Table III.10. Putative interactor clones from the Y2H library screen with the C0C1 (2) region of cMyBPC  
 
Colony phenotype 
(QDO) 
(after 4 days) 
 
X-α-galactosidase 
assay 
 
Specificity tests 
(after 4 days) 
 
 
 
 
Clone # 
 
 
 
# Clones 
represented 
 
R&S 
 
Colour 
 
Time 
 
Colour 
 
 
 
 
Classification 
x pGBKT7 
(QDO) 
x pGBKT7-53
(QDO) 
 
 
 
Sel seq 
(Y/N) 
1 1 aaa W 16 hours + + + 1’ aaa aaa N 
4 1 aaa W 16 hours + + + 1’ aaa aaa N 
6 1 aaa LP 16 hours + + 1’ a aaa N 
12 1 aaa W 16 hours + + 1’ aa a N 
13 1 aaa LP 16 hours + + 1’ aaa aaa N 
14 1 aaa LP 16 hours + + + 1’ aa a Y 
16 1 aaa LP 16 hours + + 1’ aaa aaa N 
17 1 aaa LP 16 hours + + 1’ aa aaa N 
18 1 aaa LP 16 hours + + 1’ aa aaa N 
19 1 aa P 16 hours + + + 1’ X aa Y 
20 1 aaa LP 16 hours + + + 1’ aaa aaa N 
26 1 aaa W 16 hours + + 1’ aaa aaa N 
31 1 aaa LP 16 hours + + + 1’ aaa aaa N 
32 1 aaa W 16 hours + + + 1’ X X Y 
35 1 aaa W 16 hours + + 1’ aa a N 
38 1 aaa W 16 hours + + + 1’ aaa aaa N 
43 21 aaa W 16 hours + + 1’ X a Y 
46 1 aaa W 16 hours + + + 1’ aa aa N 
48 2 aa LP 16 hours + 2’ aa aaa N 
51 1 aaa W 16 hours + + + 1’ aa aaa N 
54 1 aaa LP 16 hours + + + 1’ aaa aaa N 
66 2 aa P 16 hours + + 2’ aa aa N 
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Colony phenotype 
(QDO) 
(after 4 days) 
 
X-α-galactosidase 
assay 
 
Specificity tests 
(after 4 days) 
 
 
 
 
Clone # 
 
 
 
# Clones 
represented 
 
R&S 
 
Colour 
 
Time 
 
Colour 
 
 
 
 
Classification 
x pGBKT7 
(QDO) 
x pGBKT7-53
(QDO) 
 
 
 
Sel seq 
(Y/N) 
68 1 aaa W 16 hours + + + 1’ aaa aaa N 
83 2 a P 16 hours + + + 2’ aaa aaa N 
85 1 aa W 16 hours + + + 1’ aaa aaa N 
88 1 aaa W 16 hours + + + 1’ aaa aaa N 
89 1 aaa LP 16 hours + + 1’ a aaa N 
96 1 aaa LP 16 hours + + 1’ aa aaa N 
100 2 aa W 16 hours + 2’ aa aa N 
105 1 aa LP 16 hours + + 1’ aa aaa N 
124 1 aaa W 16 hours + + 1’ aaa aaa N 
126 1 aaa W 16 hours + + 1’ aaa aaa N 
127 1 aaa LP 16 hours + + 1’ aaa aaa N 
128 1 aaa W 16 hours + + + 1’ aaa aaa N 
129 1 aaa W 16 hours + + + 1’ aaa aaa N 
140 1 aa W 16 hours + + 1’ aa aa N 
141 1 aaa W 16 hours + + 1’ aaa aaa N 
142 1 aaa W 16 hours + + 1’ aaa aaa N 
143 1 aaa LP 16 hours + + + 1’ aaa aa N 
144 1 aa LP 16 hours + + + 1’ a aa N 
145 1 aaa LP 16 hours + + + 1’ aaa aaa N 
147 1 aa W 16 hours + + 1’ aaa aaa N 
160 1 aa LP 16 hours + + 1’ aa aaa N 
164 1 aaa W 16 hours + + 1’ aaa aaa N 
170 1 aa W 16 hours + + + 1’ aaa aaa N 
171 1 aaa W 16 hours + + + 1’ NT NT Y 
184 1 aaa LP 16 hours + + + 1’ aaa aaa N 
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Colony phenotype 
(QDO) 
(after 4 days) 
 
X-α-galactosidase 
assay 
 
Specificity tests 
(after 4 days) 
 
 
 
 
Clone # 
 
 
 
# Clones 
represented 
 
R&S 
 
Colour 
 
Time 
 
Colour 
 
 
 
 
Classification 
x pGBKT7 
(QDO) 
x pGBKT7-53
(QDO) 
 
 
 
Sel seq 
(Y/N) 
186 1 aaa W 16 hours + + 1’ aa aaa N 
189 1 aaa LP 16 hours + + 1’ a aa N 
196 1 aa LP 16 hours + + + 1’ X aaa N 
198 1 aa LP 16 hours + + + 1’ a aa N 
213 1 aa LP 16 hours + + + 1’ X aa N 
214 1 aa W 16 hours + + + 1’ a a Y 
215 1 aaa W 16 hours + + + 1’ aa aa N 
216 1 aaa W 16 hours + + + 1’ aaa aaa N 
222 2 aaa W 16 hours + + 1’ aaa aaa N 
226 1 aaa W 16 hours + + + 1’ aaa aa N 
227 2 aa LP 16 hours + + + 1’ a aaa N 
228 1 aa W 16 hours + + + 1’ a aa N 
230 1 aaa LP 16 hours + + + 1’ NT NT Y 
231 1 aaa LP 16 hours + + 1’ aa aaa N 
235 1 aaa LP 16 hours + + + 1’ aaa aaa N 
239 1 aaa W 16 hours + + + 1’ aa aaa N 
242 1 aaa W 16 hours + + + 1’ aaa aa N 
245 1 aaa LP 16 hours + + 1’ aaa aaa N 
247 1 aa LP 16 hours + + 1’ X aa Y 
251 1 aa LP 16 hours + + + 1’ aaa aaa N 
252 1 aa LP 16 hours + + + 1’ a aaa N 
255 1 aaa LP 16 hours + + + 1’ aaa aaa N 
256 1 aa LP 16 hours + + 1’ aa aa N 
258 1 aa LP 16 hours + + 1’ aa aaa N 
259 1 aaa LP 16 hours + + 1’ a a Y 
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Colony phenotype 
(QDO) 
(after 4 days) 
 
X-α-galactosidase 
assay 
 
Specificity tests 
(after 4 days) 
 
 
 
 
Clone # 
 
 
 
# Clones 
represented 
 
R&S 
 
Colour 
 
Time 
 
Colour 
 
 
 
 
Classification 
x pGBKT7 
(QDO) 
x pGBKT7-53
(QDO) 
 
 
 
Sel seq 
(Y/N) 
262 1 aa LP 16 hours + + + 1’ X aa Y 
263 3 aaa W 16 hours + + 1’ aa aaa N 
264 1 aaa LP 16 hours + + 1’ aa aa N 
266 1 aa LP 16 hours + + + 1’ aaa aa N 
267 1 aa LP 16 hours + + + 1’ aaa aaa N 
268 1 aaa LP 16 hours + + + 1’ a a Y 
275 1 aaa LP 16 hours + + 1’ aaa aaa N 
277 1 aaa W 16 hours + + + 1’ aaa aaa N 
278 1 aa LP 16 hours + + 1’ aaa aaa N 
280 1 aa LP 16 hours + + + 1’ aa aa N 
281 1 aaa LP 16 hours + + + 1’ aaa aa N 
282 1 aaa LP 16 hours + + 1’ aa aa N 
286 1 aaa LP 16 hours + + + 1’ aa a N 
294 1 aaa W 16 hours + + 1’ X aa Y 
297 1 aaa LP 16 hours + + + 1’ aaa a N 
298 1 aaa LP 16 hours + + + 1’ aaa aaa N 
306 1 aaa W 16 hours + + 1’ a a Y 
316 1 aaa LP 16 hours + + + 1’ aa aaa N 
324 1 aaa LP 16 hours + + + 1’ aaa aaa N 
 
LP = light pink; N = no; NT = not tested; P = pink; R&S = robustness and size of colony; Sel seq = selected for sequencing; Time = time to blue 
colour development; W = white; X = no growth; a = weak; aa = intermediate; aaa = strong; + = light blue; + + = blue; + + + = dark blue; 
1’ = primary colony; 2’ = secondary colony. 
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Table III.11. Identification of primary putative interactor clones from the Y2H library screen (2) with the C0C1 region of cMyBPC 
 
Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession #
Length 
(AA) 
 
E-value 
 
Cellular 
localisation 
 
14 
 
H.s. titin (TTN) 
 
XM_038279 
 
H.s. titin 
 
NP_003310 
 
69 
 
2x10-33 
 
Sarcomeric 
19 H.s. multiple PDZ domain 
protein (MPDZ) 
NM_003829 H.s. Multiple PDZ 
domain protein  
NP_003820 667 4x10-13 Cytoplamic/ 
cytoskeletal 
43 H.s. Isolate F192 (PL56) 
mitochondrion, complete 
genome 
AY339593 H.s. Cytochrome c 
oxidase subunit I 
AAK17768 165 7x10-83 Mitochondrial 
inner 
membrane 
171 H.s. BAC clone RP11-
809N18 (E = 0.0) 
AC058822 - N.A. N.A. N.A. N.A. 
214 H.s. Isolate F192 (PL56) 
mitochondrion, complete 
genome 
AY339593 H.s. Cytochrome c 
oxidase subunit I 
AAK17768 165 7x10-83 Mitochondrial 
inner 
membrane 
230 H.s. titin (TTN) XM_038279 H.s. titin NP_003310 58 1x10-11 Sarcomeric 
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Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession #
Length 
(AA) 
 
E-value 
 
Cellular 
localisation 
247 H.s. Isolate F192 (PL56) 
mitochondrion, complete 
genome 
AY339593 H.s. Cytochrome c 
oxidase subunit I 
AAK17768 190 2x10-82 Mitochondrial 
inner 
membrane 
259 H.s. titin (TTN) XM_038279 H.s. titin NP_003310 56 2x10-22 Sarcomeric 
262 H.s. titin (TTN) XM_038279 H.s. titin NP_003310 56 5x10-22 Sarcomeric 
268 H.s. titin (TTN) XM_038279 H.s. titin NP_003310 56 5x10-22 Sarcomeric 
294 H.s. Multiple PDZ domain 
protein (MPDZ) 
NM_003829 H.s. Multiple PDZ 
domain protein 
NP_003820 37 4x10-13 Cytoplamic/ 
cytoskeletal 
306 H.s. titin (TTN) XM_038279 H.s. titin NP_003310 34 2x10-4 Sarcomeric 
 
AA = amino acids; H.s. = Homo sapiens; N.A. = not applicable; - = no protein match found 
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III.3.2.3. cMyBPC C0 Y2H library-assay  
 
The pGBKT7-C0 bait construct (table II.10), transformed into S. cerevisiae strain AH109, was used 
to screen a pACT2-based cardiac cDNA library, pre-transformed into S. cerevisiae strain Y187 (BD 
Biosciences, Clontech, Palo Alto, CA, USA) (section II.17.2.2). The screening of an estimated 
1.1x106 library clones yielded 69 clones in which transcription of the HIS3 reporter gene was 
activated. Of these clones, 40 were able to grow on QDO-selection medium, indicating activation of 
transcription of the ADE2 reporter gene. Filter β-galactosidase assays and X-α-galactosidase assays 
allowed the elimination of an additional 14 of the 40 clones, based on their inability to activate 
transcription of the LacZ and MEL1 reporter genes (table III.12). The remaining 26 clones were 
classified as either primary interactor clones, or secondary interactor clones, based on the size, 
robustness and colour of the colony on QDO selection medium, as well as their β-galactosidase and 
X-α-galactosidase phenotypes (time to, and intensity of, colour development). In total 16 primary 
and 10 secondary clones were identified. 
 
Restriction mapping of the library inserts (section II.11.3) of all primary and secondary clones 
revealed the presence of five groups of identical clones (table III.12), as well as eight unique primary 
clones, that were each represented by a single clone in subsequent Y2H assays. The 13 primary 
interactor clones thus identified (table III.12) were subsequently sequenced and the prey inserts 
identified by BLAST-analysis. Two of the prey inserts encoded RAN binding protein 9, one encoded 
sarcoglycan delta subunit, one encoded tousled-like kinase 1 and one encoded an ATPase Na+/K+ 
exchanger, while the remaining preys were identified as portions of a human genomic DNA clone 
RP4-614C10 (table III.13 and section IV.4.1). BLASTX and BLASTP analysis of clones containing 
portions of human genomic DNA clone DJ0614C10, as well as the portion of clone DJ0614C10 with 
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which they shared homology, revealed the absence of any known genes, or open reading frames 
(ORFs) of any significant length, as determained by BLASTX analysis. The peptides encoded by 
these clones were, therefore, deemed to be implausible binding partners of the C0 domain of 
cMyBPC.  
 
Interaction-specificity tests (section II.11) performed on clones 1, 3, 6 and 16, encoding sarcoglycan 
delta subunit, tousled-like kinase 1, ATPase Na+/K+ exchanger and RAN binding protein 9, 
respectively, showed that these prey peptides activated transcription of the HIS3 and ADE2 reporter 
genes in the presence of heterologous baits (table III.13) and were, therefore, not considered to be 
specific ligands of the C0 domain of cMyBPC (section IV.4.1).  
 
Table III.12. Putative interactor clones from the Y2H library screen with the C0 domain of cMyBPC  
 
Colony phenotype 
(QDO) 
X-α-galactosidase 
assay 
 
 
 
Clone # 
 
 
# Clones 
represented 
 
R&S 
 
Colour 
 
Time 
 
Colour 
 
 
 
Clasn 
 
 
Sel seq 
(Y/N) 
1 1 aaa W 16 hours + + + 1’ Y 
3 1 aaa LP 24 hours + + 1’ Y 
6 1 aaa W 16 hours + + + 1’ Y 
9 1 aaa W 16 hours + + + 1’ Y 
16 1 aaa W 16 hours + + + 1’ Y 
22 1 aaa LP 16 hours + + 1’ Y 
31 1 aaa W 16 hours + + 1’ Y 
38 1 aaa W 16 hours + + + 1’ Y 
43 2 aaa W 16 hours + + + 1’ Y 
44 1 aa LP 16 hours + + 1’ Y 
47 1 aaa LP 16 hours + + + 1’ Y 
48 2 aaa W 16 hours + 1’ Y 
57 2 aaa LP 16 hours + 1’ Y 
 
Clasn = classification; LP = light pink; N = no; NT = not tested; R&S = robustness and size of 
colony; Sel seq = selected for sequencing; Time = time to blue colour development; W = white; X = 
no growth; Y = yes;  a = weak; aa = intermediate; aaa = strong; + = light blue; + + = blue; 
+ + + = dark blue; 1’ = primary colony; - = discarded. 
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Table III.13. Identification of primary putative interactor clones from the Y2H library screen with the C0 domain of cMyBPC 
 
Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession #
 
E-value
Length 
(AA) 
 
Cellular 
location 
Specific 
interaction 
(Y/N) 
 
1 
 
H.s. 
Sarcoglycan, 
delta subunit 
 
XM_003929 
 
H.s. Delta-
sarcoglycan (35 kDa 
dystrophin-associated 
glycoprotein) 
 
Q92629  
 
1x10-37 
 
90 
 
Cytoskeletal 
(dystrophin-
associated) 
 
N 
3 H.s. Tousled-like 
kinase 1 (TLK1) 
AF162666 H.s. Tousled–like 
kinase 1 (aca PKU) 
NP_036422 1x10-48 150 Nuclear N 
6 H.s. ATPase, 
Na+/K+ 
transporter 
XM_001571 H.s. Na+/K+-
transporting ATPase 
beta-1 chain 
P06583 5x10-22 61 Sarcolemmal N 
9 H.s. clone RP4-
614C10 (chr 2) 
(E = 0.0) 
AC006453 - N.A. N.A. N.A. N.A. NT 
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Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession #
 
E-value
Length 
(AA) 
 
Cellular 
location 
Specific 
interaction 
(Y/N) 
 
16 
 
H.s. Ran binding 
protein 9 
 
NM_005493 
 
H.s. Ran binding 
protein 9 
 
XP_344581 
 
2x10-92 
 
702 
 
Centrosomal 
 
N 
22 H.s. clone RP4-
614C10 (chr 2) 
(E = 0.0) 
AC006453 - N.A. N.A. N.A. N.A. NT 
31 H.s. clone RP4-
614C10 (chr 2) 
(E = 0.0) 
AC006453 - N.A. N.A. N.A. N.A. NT 
38 H.s. clone RP4-
614C10 (chr 2) 
(E = 0.0) 
AC006453 - N.A. N.A. N.A. N.A. NT 
43 H.s. clone RP4-
614C10 (chr 2) 
(E = 0.0) 
AC006453 - N.A. N.A. N.A. N.A. NT 
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Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession #
 
E-value
Length 
(AA) 
 
Cellular 
location 
Specific 
interaction 
(Y/N) 
 
44 
 
H.s. clone RP4-
614C10 (chr 2) 
(E = 0.0) 
 
AC006453 
 
- 
 
N.A. 
 
N.A. 
 
N.A. 
 
N.A. 
 
NT 
47 H.s. Ran binding 
protein 9 
NM_005493 H.s. Ran binding 
protein 9 
AAH52781 1x10-84 702 Centrosomal NT 
48 H.s. clone RP4-
614C10 (chr 2) 
(E = 0.0) 
AC006453 - N.A. N.A. N.A. N.A. NT 
57 H.s. clone RP4-
614C10 (chr 2) 
(E = 0.0) 
AC006453 - N.A. N.A. N.A. N.A. NT 
 
AA = amino acid; chr = chromosome; H.s. = Homo sapiens, N = no; N.A. = not applicable; NT = Not tested; Y = yes; - = no protein match found 
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III.3.2.4. cMyBPC C7 Y2H library-assay 
 
The pGBKT7-C7 bait construct (table II.10), transformed into S. cerevisiae strain AH109, was used 
to screen a pACT2-based cardiac cDNA library, pre-transformed into S. cerevisiae strain Y187 (BD 
Biosciences, Clontech, Palo Alto, CA, USA) (section II.17.2.2). The screening of an estimated 
1.2x106 clones yielded 124 clones in which transcription of the HIS3 reporter gene was activated. Of 
these clones, 101 were able to grow on QDO-selection medium, indicating activation of transcription 
of the ADE2 reporter gene. Filter β-galactosidase assays and X-α-galactosidase assays led to the 
elimination of an additional 19 of the 101 clones, based on their inability to activate transcription of 
the LacZ and MEL1 reporter genes (table III.14). The remaining 82 clones were classified as either 
primary, or secondary interactor clones, based on the size, robustness and colour of the colony, as 
well as their β-galactosidase and X-α-galactosidase phenotypes (time to, and intensity of, colour 
development). In total, 28 primary and 54 secondary clones were identified. 
 
Restriction mapping of the library inserts (section II.11.3) of all primary- and secondary- interactor 
clones revealed the presence of two groups of identical clones, as well as some unique clones (table 
III.14). Each group was subsequently represented by a single clone, used for DNA sequencing. The 
nucleotide sequences of the cDNA inserts contained in all 24 representative primary clones, as well 
as one secondary clone, that represented a group of eight clones, were subsequently used for 
BLAST-analyses, allowing the identification of interactor peptides (table III.15). Nineteen of the 
prey-peptides identified were deemed to be implausible binding partners of the C7 domain of 
cMyBPC, due to either their cellular localisation, or the fact that they encoded very short peptides 
with no significant protein database matches (table III.15). One of the prey inserts was identified as 
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encoding a partial cMyBPC domain C10, one as encoding myomesin 2 (M-protein), and three as 
encoding M-line titin. The identification of a clone encoding a partial C10 peptide confirmed the 
presence of an interaction between the C7 and C10 domains of cMyBPC, previously identified in 
candidate-ligand Y2H assays. Additionally, the titin and M-protein peptides were regarded as 
informative ligands, based on the fact that they are members of the intracellular immunoglobulin 
superfamily, notwithstanding their M-line localisation (section IV.2). 
 
Interaction specificity tests (section II.17.7) were performed on clones expressing partial cMyBPC, 
M-line titin and M-protein peptides. These tests showed that the M-line titin and cMyBPC peptides 
interacted specifically with domain C7 of cMyBPC, while the M-protein interaction was found to be 
non-specific, as evidenced by its ability to activate transcription of the HIS3 and ADE2 reporter 
genes in the presence of heterologous baits (table III.15 and section IV.2).  
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Table III.14. Putative interactor clones identified in the cMyBPC domain C7 Y2H library-assay 
 
Colony phenotype 
(QDO) 
X-α-galactosidase 
assay 
 
 
 
Clone # 
 
 
# Clones 
represented 
 
R&S 
 
Colour 
 
Time 
 
Colour 
 
 
 
Clasn 
 
 
Sel seq 
(Y/N) 
2 1 aa LP 16 hours + + + 1’ Y 
3 1 aa W 16 hours + + + 1’ Y 
4 1 aaa LP 16 hours + + + 1’ Y 
5 1 aaa W 16 hours + + + 1’ Y 
7 1 aa LP 16 hours + + + 1’ Y 
9 1 aa LP 16 hours + + 1’ Y 
10 8 a P 16 hours + + 2’ Y 
12 1 aa P 16 hours + +* 1’ Y 
16 1 aa W 16 hours + + + 1’ Y 
20 1 aa LP 16 hours + + + 1’ Y 
24 1 aa LP 16 hours + + 1’ Y 
27 1 aaa W 16 hours + + 1’ Y 
30 1 aa LP 16 hours + + + 1’ Y 
31 1 aa LP 16 hours + + + 1’ Y 
33 1 aa LP 16 hours + + 1’ Y 
35 1 aa LP 16 hours + + 1’ Y 
40 1 aaa W 16 hours + + 1’ Y 
46 1 aa W 16 hours + + 1’ Y 
48 1 aa LP 16 hours + + + 1’ Y 
53 1 aaa W 16 hours + + + 1’ Y 
67 1 aaa LP 16 hours + + + 1’ Y 
72 1 aa P 16 hours + +* 1’ Y 
84 1 aaa LP 16 hours + + 1’ Y 
99 5 aa LP 16 hours + + + 1’ Y 
119 1 aa LP 16 hours + + 1’ Y 
 
Clasn = classification; LP = light pink; N = no; NT = not tested; P = pink; R&S = robustness and size of 
colony; Sel seq = selected for sequencing; Time = time to blue colour development; W = white; X = no 
growth; Y = yes; a = weak; aa = intermediate; aaa = strong; + = light blue; + + = blue; + + + = 
dark blue; 1’ = primary colony; 2’ = secondary colony; * selected as primary colony based on strong β-
galactosidase phenotype. 
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Table III.15. Identification of primary interactor clones selected in the cMyBPC domain C7 Y2H library-assay 
 
Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession # 
Length 
(AA) 
 
E-value 
 
Cellular 
location 
Specific 
interaction
(Y/N) 
 
2 
 
H.s. Mitochondrial 
genome 
 
AF347015 
 
H.s. cytochrome c 
oxidase subunit II 
 
AAP90859 
 
89 
 
1x10-24 
 
Mitochondrial 
inner 
membrane 
 
NT 
3 H.s. ATP synthase, H+ 
transporting, 
mitochondrial F1 
complex, alpha subunit, 
isoform 1 
BT007209 H.s. ATP synthase, H+ 
transporting, 
mitochondrial F1 
complex, alpha subunit, 
isoform 1 
AAP36942 471 1x10-81 Mitochondrial NT 
4 H.s. ATPase, H+ 
transporting, lysosomal 
13kDa, V1 subunit G 
isoform 1 (ATP6V1G1) 
(E = 1x10-101) 
NM_004888 - N.A. N.A. N.A. N.A. NT 
5 H.s. Titin (TTN) XM_038279 H.s. titin NP_003310 595 1x10-73 Sarcomeric Y 
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Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession # 
Length 
(AA) 
 
E-value 
 
Cellular 
location 
Specific 
interaction
(Y/N) 
 
7 
 
H.s. PAC clone RP5-
997N5 (E = 0.0) 
 
AC004945 
 
- 
 
N.A. 
 
N.A. 
 
N.A. 
 
N.A. 
 
NT 
9 H.s. Platelet-activating 
factor 
acetylhydrogenase α-
subunit (PAFAH1B1)  
(E = 1x10-48) 
NM_000430 - N.A. N.A. N.A. N.A. NT 
10 H.s. Mitochondrial 
genome 
AF347015 M.a. cytochrome 
oxidase chain I 
AAB82423 36 6x10-12 Mitochondrial 
inner 
membrane 
NT 
12 H.s. Collagen type I, α2 
subunit (COL1A2) 
XM_029246 H.s. Alpha2(I) collagen AAB69977 76 6x10-32 Extacellular 
matrix 
NT 
16 H.s. Cardiac myosin 
binding protein C 
(MYBPC3) 
X84075 H.s. Cardiac myosin 
binding protein C 
NP_000247 39 8x10-16 Sarcomeric Y 
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Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession # 
Length 
(AA) 
 
E-value 
 
Cellular 
location 
Specific 
interaction
(Y/N) 
 
20 
 
H.s. Titin (TTN) 
 
XM_038279 
 
H.s. titin 
 
NP_003310 
 
35 
 
2x10-13 
 
Sarcomeric 
 
Y 
24 H.s. Titin (TTN) XM_038279 H.s. titin NP_003310 35 2x10-13 Sarcomeric Y 
27 H.s. 
phosphoglucomutase 1 
BT006961 H.s. 
phosphoglucomutase 1 
XP_001442 54 5x10-6 Cytoplasmic NT 
30 H.s. Mitochondrial 
genome 
AF347015 H.s. NADH 
dehydrogenase subunit 
2 
AA088476 89 3x10-10 Mitochondrial NT 
31 H.s. Mitochondrial 
genome 
AF347015 H.s. NADH 
dehydrogenase subunit 
1 
AAK17324 62 4x10-43 Mitochondrial NT 
33 H.s. Genomic clone 
RP5-1137017 (E = 0.0) 
AL133295 - N.A. N.A. N.A. N.A. NT 
35 H.s. Mitochondrial 
genome 
AF347015 H.s. Quinolinare 
phosphorybosyltransfer
ase 
AAP36539 63 2x10-28 Mitochondrial NT 
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Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession # 
Length 
(AA) 
 
E-value 
 
Cellular 
location 
Specific 
interaction
(Y/N) 
 
40 
 
H.s. Mitochondrial 
genome 
 
AF347015 
 
H.s. Cytochrome 
oxidase subunit III 
 
AA066832 
 
152 
 
1x10-47 
 
Mitochondrial 
inner 
membrane 
 
NT 
46 H.s. Mitochondrial 
genome 
AF347015 H.s. Cytochrome c 
oxidase subunit 1 
AAK17768 150 3x10-57 Mitochondrial 
inner 
membrane 
NT 
48 H.s. Mitochondrial 
genome 
AF347015 H.s. NADH 
dehydrogenase subunit 
1 
AAK17324 87 9x10-26 Mitochondrial NT 
53 H.s. Myomesin 2 (M-
protein) (MYOM2) 
XM_005198 H.s. Myomesin 2 (M-
protein) 
NP_003961 62 2x10-40 Sarcomeric N 
67 H.s. Mitochondrial 
genome 
AF347015 H.s. NADH 
dehydrogenase 
AAP90895 103 5x10-10 Mitochondrial 
inner 
membrane 
NT 
72 H.s. Mitochondrial 
genome 
AF347015 M.a. cytochrome 
oxidase chain I 
AAB82423 40 9x10-28 Mitochondrial 
inner 
membrane 
NT 
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Genomic hit In-frame ORF protein hit  
 
Clone# 
 
Identity 
 
Accession # 
 
Identity 
 
Accession # 
Length 
(AA) 
 
E-value 
 
Cellular 
location 
Specific 
interaction
(Y/N) 
 
84 
 
H.s. chemokine-like 
factor super family 6 
(CKLFSF6) (321bp E = 
1x10-178) 
 
AF479261 
 
- 
 
N.A. 
 
N.A. 
 
N.A. 
 
N.A. 
 
NT 
46 H.s. Mitochondrial 
genome 
AF347015 H.s. Cytochrome c 
oxidase subunit 1 
AAK17768 150 3x10-57 Mitochondrial 
inner 
membrane 
NT 
99 H.s. Mitochondrial 
genome 
AF347015 H.s. NADH 
dehydrogenase subunit 
1 
AAK17324 62 3x10-7 Mitochondrial NT 
119 H.s. Mitochondrial 
genome 
AF347015 H.s. ATP synthase F0 
subunit 6 
AAP89457 120 1x10-62 Mitochondrial NT 
 
AA = amino acid; H.s. = Homo sapiens; M.a. = Mesocricetus auratus; N = no; NT = not tested; Y = yes; - = no protein match found 
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III.3.3. MULTIPLE SEQUENCE ALIGNMENT ANALYSIS OF TITIN INTERACTOR 
PREY CLONES AND TITIN 
 
The titin interactor clones identified as putative ligands of the C7 domain of cMyBPC and the C0C1 
region of cMyBPC encoded portions of M-line titin, varying in length between 34 and 595 amino 
acids. As these clones all encoded portions of titin embedded in the M-line and, as cMyBPC is found 
in the C-zone, interactions between this region of titin and cMyBPC were deemed implausible.  
 
BLASTP (http://www.ncbi.nlm.nih.gov/Blast) analysis of these clones, however, revealed that the 
shorter titin interactor peptides shared a high degree of homology with several other domains of titin. 
In order to identify which domains of titin shared the highest homology with these short M-line titin 
peptides, sequential ClustalW (http://www.ebi.ac.uk/servicestmp/) two-sequence alignments were 
performed, using the 35 amino acid titin interactor peptide (clones 20 and 24, table III.15) and the 
full-length titin amino acid sequence (http://www.ncbi.nlm.nih.gov/Entrez accession number 
NP_003310). These alignments revealed that the 35 amino acid M-line titin peptide shared highest 
homology with each of the eleven domains of C-zone titin, previously reported to interact with the 
C9C10 region of MyBPC (Labeit and Kolmerer, 1995) (section I.7.3.2; table III.15 and figures III.39 
and III.40).  
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     A43                     A54                  A65                    A76                  A87                   A98                  A109                A120                   A131               A142                  A153 
 
 
Figure III.39. Organisation of C-zone titin 
The position of titin within the half sarcomere is shown at the top of the figure (see figure I.6). The domain organisation of C-zone titin is shown at the 
bottom of the figure, with the domain numbers of the first IgC2 of each eleven domain super-repeat indicated. The position of the clone 24 M-line titin 
peptide is indicated by the purple box at the right of the figure and the numbers of the eleven stripes in which the MyBPs are found are shown above 
each stripe.      = IgC2 domains;      = Fn3 domains. 
 
 
COOH 
COOH 
NH2 
NH2 
Z disk                                                  I band                                                                                           A band                                                           M line 
   D zone                       C zone                               P zone 
Clone 24 peptide 
   1   2   3    4   5    6   7   8    9  10  11 
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Table III.16. Amino acid homology shared between the 35 amino acid M-line titin peptide and specific C-
zone titin domains  
C-zone titin domain Identity (%) Similarity (%) 
A43 29% 71% 
A54 34% 77% 
A65 26% 69% 
A76 37% 74% 
A87 40% 86% 
A98 34% 74% 
A109 49% 80% 
A120 26% 80% 
A131 31% 71% 
A142 29% 74% 
A153 37% 77% 
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     0Clone_24
    38A43
    40A54
    39A65
    29A76
    33A87
    36A98
    38A109
    38A120
    39A131
    38A142
    38A153
Consensus
........................................
..VIVRAGCPIRLFAIVRGRPAPKVTWRKVGIDNVVRKGQ
KTLILRAGVTMRLYVPVKGRPPPKITWSKPNVNLRDRIGL
RTLVVRAGLSIRIFVPIKGRPAPEVTWTKDNINLKNRAN.
.........TLRLFVPIKGRPAPEVKWARDHGESL..DKA
.....RAGGSLRLFVPIKGRPTPEVKWGKVDGEIR..DAA
..IVVRAGGSARIHIPFKGRPTPEITWSREEG.EFT.DKV
KVVVLRASATLRLFVTIKGRPEPEVKWEKAEG.ILT.DRA
KTLIVKAGASFTMTVPFRGRPVPNVLWSKPDTDLRTRA..
.SVIAKAGEDVQVLIPFKGRPPPTVTWRKDEKNLGSDARY
QTHVVRAGASIRLFIAYQGRPTPTAVWSKPDSNLSLRA..
KTVTIRAGASLRLMVSVSGRPPPVITWSKQGIDLASRA..
rag s rlfvp kgrp p vtw k l r
    28Clone_24
    76A43
    79A54
    77A65
    68A76
    72A87
    75A98
    77A109
    77A120
    79A131
    77A142
    77A153
Consensus
...........IIMDVQKQDGGLYTLSLGNEFGS.DSATV
.VDLVDTMAFLVIPNSTRDDSGKYSLTLVNPAGE.KAVFV
DIKSTDFDTFLRCENVNKYDAGKYILTLENSCGK.KEYTI
.IENTESFTLLIIPECNRYDTGKFVMTIENPAGK.KSGFV
SIESTSSYTLLIVGNVNRFDSGKYILTVENSSGS.KSAFV
IIDVTSSFTSLVLDNVNRYDSGKYTLTLENSSGT.KSAFV
QIEKGVNYTQLSIDNCDRNDAGKYILKLENSSGS.KSAFV
QIEVTSSFTMLVIDNVTRFDSGRYNLTLENNSGS.KTAFV
YVDTTDSRTSLTIENANRNDSGKYTLTIQNVLSA.ASLTL
SIENTDSSSLLTIPQVTRNDTGKYILTIENGVGEPKSSTV
DIHTTDSFSTLTVENCNRNDAGKYTLTVENNSGS.KSITF
IIDTTESYSLLIVDKVNRYDAGKYTIEAENQSGK.KSATV
i t s t l i nvnr d gky ltlen sg ksafv
    34Clone_24
    81A43
    84A54
    82A65
    73A76
    77A87
    80A98
    82A109
    82A120
    84A131
    82A142
    82A153
Consensus
NIHIRS
NVRVL
VVKVL
NVRVL
NVRVL
TVRVL
TVKVL
NVRVL
VVKVL
SVKVL
TVKVL
LVKVY
vkvl
 
Figure III.40. Multiple sequence alignment of cMyBPC domain C7 ligand 24 and C-zone domains of titin 
Multiple sequence alignment of the 35 amino acid titin clone identified from the cMyBPC domain C7 library 
screen (clones 20 and 24, table III.12.) and the first Ig-domain of each of the 11, C-zone titin eleven-domain 
super-repeats. Titin domains, numbered according to Labeit and Kolmerer (1995). Conserved residues 
highlighted by gray shading with degrees of shading indicating the degree of conservation. 
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III.3.4. CANDIDATE LIGAND Y2H-ASSAYS 
 
Small-scale yeast matings (section II.17.1) were used to facilitate the detection of interactions 
between specific domains of cMyBPC and specific candidate ligands. Candidate ligands were chosen 
based either on their position within the sarcomere, rendering them capable of interacting with 
cMyBPC, or them previously having been reported to interact with cMyBPC, or plausible ligands of 
cMyBPC that share significant homology with implausible sarcomeric ligands, found to spuriously 
interact with specific domains of cMyBPC in Y2H library-assays. 
 
III.3.4.1. Identification of cMyBPC domain C10 as a ligand of the cMyBPC domain C7 
 
Based on the identification of an interaction between the C5 and C8 domains of cMyBPC 
(Moolman-smook et al., 2002), the C6 and C10 domains of cMyBPC were identified as candidate 
ligands of the C7 domain (section IV.2). In order to test whether either of these domains interacted 
with domain C7, small-scale yeast matings were used to co-express domain C7 bait fusion-peptides 
with cMyBPC domains C6- and C10- prey fusion-peptides, in diploid yeast cells. As additional 
controls, C5- and C8- prey fusion-peptides were also co-expressed with C7 bait fusion peptides. 
These experiments showed that only yeast cells co-expressing the C7 bait and C10 prey fusion-
peptides activated transcription of the HIS3 and ADE2 nutritional reporter genes, thus allowing them 
to grow on QDO selection plates, indicating that only domain C10 of cMyBPC specifically interacts 
with domain C7 (figure III.41 and section IV.2.1).  
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Figure III.41. Identification of cMyBPC domain C10 as the ligand of the cMyBPC domain C7 
Growth of diploid yeast on QDO medium indicates interaction between respective bait and prey fusion-
peptides, leading to activation of transcription of the HIS3 and ADE2 nutritional reporter genes. C7 = yeast 
strain AH109 transformed with pGBKT7-C7 bait construct; C5 = yeast strain Y187 transformed with pACT2-
C5 prey construct; C6 = yeast strain Y187 transformed with pACT2-C6 prey construct; C8 = yeast strain 
Y187 transformed with pACT2-C8 prey construct; C10 = yeast strain Y187 transformed with pACT2-C10 
prey construct; x = mated to in small-scale yeast mating. 
 
III.3.4.2. Identification of specific IgC2 domains of C-zone titin as ligands of the cMyBPC 
domain C7 
 
Based on the amino acid sequence conservation shared by specific C-zone titin domains with the M-
line titin peptide identified as a ligand of cMyBPC domain C7 in the Y2H library-assay (section 
III.3.2.4, tables III.15, III.16, figures III.39; III.40), these domains were considered plausible ligands 
of cMyBPC domain C7. In order to test this hypothesis, cMyBPC domain C7 bait fusion-peptides 
were co-expressed with titin domain A43, A109, A112, A116 and A109-A112 prey fusion-peptides  
C7xC10 C7xC5 
C7xC6 C7xC8 
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(figure III.39). These experiments showed that only yeast cells co-expressing the C7 bait fusion 
peptide and either the titin domain A43, A109, or A109-A112 prey fusion-peptide, activated 
transcription of the HIS3 and ADE2 nutritional reporter genes, thus allowing them to grow on QDO 
selection plates (figure III.42 and table III.17). In order to establish whether these interactions were 
specific, a cMyBPC domain C2 bait fusion-peptide was co-expressed with titin domains A43- and 
A109- prey-peptides, but no growth was observed on QDO selection plates, indicating that domain 
C2 of cMyBPC does not interact with either of these titin domains (figure III.42). 
 
Phenotypic differences between diploid yeast cells co-expressing domain C7 of cMyBPC and 
domain A43 of titin, and those co-expressing domain C7 of cMyBPC and either domain A109 or the 
A109-A112 region of titin, suggesed that domain C7 of cMyBPC interacted more strongly with 
domain A43 of titin than with domain A109 of titin. These phenotypic differences included: the 
ability of yeast co-expressing domain C7 of cMyBPC and domain A43 of titin to grow on highly 
stringent QDO media directly from rich mating media, while yeast co-expressing domain C7 of 
cMyBPC, and either domain A109 or the A109-A112 region of titin, required passage via TDO 
media. Secondly, yeast colonies in which the C7 and A43 domains were co-expressed, were larger 
and lighter coloured than yeast colonies co-expressing C7 and either domain A109 or the A109-
A112 region of titin (figure III.42, table III.17 and section IV.2.2).  
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Figure III.42. Detection of an interaction between domain C7 of cMyBPC and C-zone titin 
Growth of diploid yeast on QDO medium indicates interaction between respective bait and prey fusion-
peptides, leading to activation of transcription of the HIS3 and ADE2 nutritional reporter genes. C7 = yeast 
strain AH109 transformed with pGBKT7-C7 bait construct, C2b = yeast strain AH109 transformed with 
pGBKT7-C2 bait construct; C2p = yeast strain Y187 transformed with pGADT7-C2 prey construct; C9 = 
yeast strain Y187 transformed with pACT2-C9 prey construct; C10 = yeast strain Y187 transformed with 
pACT2-C10 prey construct; C9-C10 = = yeast strain Y187 transformed with pACT2-C9C10 prey construct; 
A43 = yeast strain Y187 transformed with pGADT7-A43 prey construct; A109 = yeast strain Y187 
transformed with pGADT7-A109 prey construct; A112 = yeast strain Y187 transformed with pGADT7-A112 
prey construct; A109-A112 = yeast strain Y187 transformed with pGADT7-A109A112 prey construct; A116 = 
yeast strain Y187 transformed with pGADT7-A116 prey construct; x = mated to in small-scale yeast mating. 
 
C7xC2p      C7xC9         C7xC10     C7x 
                C9-10 
C7xA43      C7xA109    C7xA112    C7x 
                   A109-112 
C7xA116    C2bxA43     C2bxA109 C2bxC10   
 250
Table III.17. Assessment of interactions between domain C7 of cMyBPC and C-zone titin 
 
Mating TDO (LW) QDO (LW) QDO (TDO) 
 
C7 x A43 
 
aa 
 
aa 
 
aaa 
C7 x A109 aaa X aa 
C7 x A109-A112 aa X aaa 
C7 x A112 a X X 
C7 x A116 X X NT 
C2 x A43 X X NT 
C2 x A109 X X NT 
C2 x C10 X X NT 
 
C7 = yeast strain AH109 transformed with pGBKT7-C7 bait construct, C2 = yeast strain AH109 transformed 
with pGBKT7-C2 bait construct; A43 = yeast strain Y187 transformed with pGADT7-A43 prey construct; 
A109 = yeast strain Y187 transformed with pGADT7-A109 prey construct; A112 = yeast strain Y187 
transformed with pGADT7-A112 prey construct; A109-A112 = yeast strain Y187 transformed with pGADT7-
A109A112 prey construct; A116 = yeast strain Y187 transformed with pGADT7-A116 prey construct; x = 
mated to in small-scale yeast mating; TDO = TDO selection medium; QDO = QDO selection medium, (LW) 
= yeast transferred from SD-L-W medium; (TDO) = yeast transferred from TDO selection medium; NT = not 
tested; X = no growth observed; a = weak growth; aa = intermediate growth; aaa = robust growth. 
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III.3.4.3. Establishment of the effect of the V896M putative HCM-causing mutation in 
cMyBPC domain C7 on its interaction with cMyBPC domain C10 and titin domain A43 
 
In order to establish whether the V896M mutation in domain C7 of cMyBPC abolishes its interaction 
with either cMyBPC domain C10 or titin domain A43, these domains were co-expressed as prey 
fusion-peptides with a domain C7 bait fusion-peptide into which V896M was engineered (section 
II.6.8). Yeast co-expressing either the wild-type, or C7V896M bait fusion-peptides and either the 
cMyBPC domain C10, or titin domain A43 prey fusion-peptides, were able to grow on QDO 
selection media, indicating that the V896M mutation did not abolish either of these interactions.  
 
Quantitative ONPG β-galactosidase assays (section II.17.6) were subsequently performed, in order to 
establish whether the presence of the V896M putative HCM-causing mutation in cMyBPC domain 
C7 affected the strength of its interaction with either cMyBPC domain C10 or titin domain A43. 
These assays, performed in triplicate, showed that the presence of V896M in domain C7 of cMyBPC 
significantly strengthened its interaction with the C10 domain of cMyBPC (p = 0.0047) (figure 
III.43). However, V896M did not affect the interaction between cMyBPC domain C7 and titin 
domain A43 (figure III.43). These assays were subsequently repeated twice, and although absolute β-
galactosidase unit values differed, the relative strength of interactions, as well as the significance of 
the strengthening of the C7:C10 interaction by the presence of the V896M in cMyBPC domain C7, 
remained constant (data not shown) (section IV.5).  
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Figure III.43. Quantitative ONPG β-galactosidase assays performed to establish the effect of the V896M 
mutation in domain C7 of cMyBPC 
B-gal units = β-galactosidase units; pVAxpTD = yeast strain AH109 transformed with pVA.3.1, mated with 
yeast strain Y187 transformed with pTD1.1; C7xC10 = yeast strain AH109 transformed with pGBKT7-C7, 
mated with yeast strain Y187 transformed with pACT2-C10; VMxC10 = yeast strain AH109 transformed with 
pGBKT7-C7V896M, mated with yeast strain Y187 transformed with pACT2-C10; C7xA43 = yeast strain AH109 
transformed with pGBKT7-C7, mated with yeast strain Y187 transformed with pGADT7-A43. VMxA43 = 
yeast strain AH109 transformed with pGBKT7-C7V896M, mated with yeast strain Y187 transformed with 
pGADT7-A43; C7xpGAD = yeast strain AH109 transformed with pGBKT7-C7, mated with yeast strain Y187 
transformed with non-recombinant pGADT7; VMxpGAD = yeast strain AH109 transformed with pGBKT7-
C7V896M, mated with yeast strain Y187 transformed with non-recombinant pGADT7, * = statistically 
significant variation in strength of interaction (p = 0.0047) 
 
* 
 253
III.3.4.4. Identification of specific IgC2 domains of C-zone titin as putative ligands of the C0C1 
region of cMyBPC 
 
Based on the amino acid sequence conservation shared by specific C-zone titin domains and the M-
line titin peptide identified as a ligand of the C0C1 region of cMyBPC in Y2H library-assays 
(sections III.3.2.2.; III.3.2.4.; tables III.10.; III.16 and figures III.39; III.40), these domains were 
considered plausible ligands of the C0C1 region of cMyBPC. In order to test this hypothesis, 
cMyBPC C0C1 bait fusion-peptides were co-expressed with titin domain A43, A109, A112, A116 
and A109-A112 prey fusion-peptides (figure III.39). Transcription of the HIS3 and ADE2 nutritional 
reporter genes were not activated in any of these yeast cells, as evidenced by their inability to grow 
on QDO selection plates (table III.18 and section IV.4.3.2).  
 
Table III.18. Assessment of interactions between the C0C1 region of cMyBPC and C-zone titin 
Mating TDO (LW) QDO (LW) QDO (TDO) 
C0C1 x A43 a X X 
C0C1 x A109 aa X X 
C0C1 x A112  aaa X X 
C0C1 x A109A112  aa X X 
C0C1 x A116 X X NT 
 
Assessment of growth of diploid yeast on TDO and QDO selection media to allow detection of interaction 
between respective bait and prey fusion-peptides, leading to activation of transcription of the HIS3 and ADE2 
nutritional reporter genes. C0C1 = yeast strain AH109 transformed with pGBKT7-C0C1 bait construct; A109 
= yeast strain Y187 transformed with pGADT7-A109 prey construct, A112 = yeast strain Y187 transformed 
with pGADT7-A112 prey construct; A109A112 = yeast strain Y187 transformed with pGADT7-A109A112 
prey construct; A116 = yeast strain Y187 transformed with pGADT7-A116 prey construct; x = co-expression 
of bait and prey fusion-peptides encoded by the respective constructs in diploid yeast cells, subsequent to 
small-scale yeast mating; TDO = TDO selection medium; QDO = QDO selection medium, (LW) = yeast 
transferred from SD-L-W medium; (TDO) = yeast transferred from TDO selection medium; NT = not tested; X 
= no growth observed; a = weak growth; aa = intermediate growth; aaa = robust growth. 
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III.3.4.5. Identification of an interaction between the C3 and C10 domains of cMyBPC  
 
Based on our model of cMyBPC quaternary structure (Moolman-Smook et al., 2002 and section 
IV.3), combined with findings that phosphorylation of cMyBPC results in an expansion of the thick 
filament backbone, as well as the dimensions of the “expanded” thick filament backbone (sections 
I.4.6.1.3 and IV.3.2), the C-terminal domains of cMyBPC and specific IgC2 domains of C-zone titin 
were considered as plausible ligands of the C3 domain of cMyBPC. In order to test this hypothesis, 
cMyBPC domain C3 bait fusion-peptides were co-expressed with cMyBPC domain C2, C5; C9, C10 
and C9-C10, as well as titin domain A43, A109, A112 and A109-A112, prey fusion-peptides. These 
experiments showed that only yeast cells co-expressing the C3 bait fusion-peptide, and either the 
C10, C9-C10 or A109 prey fusion-peptides, activated transcription of the HIS3 and ADE2 nutritional 
reporter genes, thus allowing them to grow on QDO selection plates (figure III.44).  
 
III.3.4.6. N-terminal cMyBPC domains as candidate ligands of the cMyBPC C0C1 region 
 
In order to establish whether the C0C1 region of cMyBPC interacts with specific N-terminal 
domains of cMyBPC, candidate-ligand Y2H-assays were performed. In these experiments, yeast 
strain PJ69-2A transformed with either pAS2.1-C0, pAS2.1-C0C1 or pAS2.1-C0C2 (table II.10) was 
mated with yeast strain Y187 transformed with pACT2-C1, pACT2-C1C2, pACT2-C2, or non-
recombinant pACT2 prey-vector. Although weak growth on QDO selection media was observed in 
some cases, these results could not be reproduced consistently (table III.19).  
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Figure III.44. Detection of an interaction between domains C3 and C10 of cMyBPC  
Growth of diploid yeast on QDO medium indicates interaction between respective bait and prey fusion-
peptides, leading to activation of transcription of the HIS3 and ADE2 nutritional reporter genes. C3 = yeast 
strain AH109 transformed with pGBKT7-C3 bait construct, C2b = yeast strain AH109 transformed with 
pGBKT7-C2 bait construct; C2p = yeast strain Y187 transformed with pGADT7-C2 prey construct; C5 = 
yeast strain Y187 transformed with pACT2-C5 prey construct; C9 = yeast strain Y187 transformed with 
pACT2-C9 prey construct; C10 = yeast strain Y187 transformed with pACT2-C10 prey construct; C9-C10 = 
= yeast strain Y187 transformed with pACT2-C9C10 prey construct; A43 = yeast strain Y187 transformed 
with pGADT7-A43 prey construct; A109 = yeast strain Y187 transformed with pGADT7-A109 prey construct; 
A112 = yeast strain Y187 transformed with pGADT7-A112 prey construct; A109-A112 = yeast strain Y187 
transformed with pGADT7-A109A112 prey construct; x = mated to in small-scale yeast mating.  
 
C3xC2         C3xC9         C3xC10      C3xC9-10 
C3xA43      C3xA109     C3xA112     C3x 
                     A109-112 
C3xC5        C2bxA43      C2bxA109  C2bxC10 
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Table III.19. N-terminal domains of cMyBPC as candidate ligands of the C0C1 region of cMyBPC 
 
Mating TDO (LW) QDO (LW) QDO (TDO) 
 
C0 X C1 
 
aa 
 
X 
 
X 
C0 X C1C2 aa X X 
C0 X C2 aa X a 
C0 X pACT2 X X NT 
C0C1 x C1 aa a a 
C0C1 x C1C2 aa X X 
C0C1 x C2 a X a 
C0C1 x pACT2 a a X 
C0C2 x C1 a X a 
C0C2 x C1C2 a X X 
C0C2 x C2 X X NT 
C0C2 x pACT2 X X NT 
 
Assessment of growth of diploid yeast on TDO and QDO media, enabling the detection of interaction between 
respective bait and prey fusion-peptides. C0 = yeast strain PJ69-2A transformed with pAS2.1-C0 bait 
construct, C0C1 = yeast strain PJ69-2A transformed with pAS2.1-C0C1 bait construct; C0C2 = yeast strain 
PJ69-2A transformed with pAS2.1-C0C2 bait construct; C1 = yeast strain Y187 transformed with pACT2-C1 
prey construct C1C2 = yeast strain Y187 transformed with pACT2-C1C2 prey construct; C2 = yeast strain 
Y187 transformed with pACT2-C2 prey construct; pACT2 = yeast strain Y187 transformed with non-
recombinant pACT2 prey-plasmid; x = prey construct co-expression of bait and prey fusion-peptides encoded 
by the respective constructs in diploid yeast cells, subsequent to small-scale yeast mating; TDO = TDO 
selection medium; QDO = QDO selection medium, (LW) = yeast transferred from SD-L-W medium; (TDO) = 
yeast transferred from TDO selection medium; NT = not tested; X = no growth observed; a = weak growth; 
aa = intermediate growth; aaa = robust growth. 
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III.3.4.7. Cardiac actin as a candidate ligand of the C0C1 region of cMyBPC  
 
Recently, Kulikovskaya et al., (2003) showed that the C0 domain of cMyBPC was able to interact 
with cardiac actin monomers in in vitro binding-assays, while Squire et al., (2003) proposed that the 
PA-region of cMyBPC may interact with F-actin. In the light of these findings, cardiac actin was 
considered a candidate ligand of the C0C1 region of cMyBPC. 
 
In order to test this hypothesis, candidate-ligand Y2H-assays were performed. In these experiments, 
yeast strain AH109 transformed with either pGBKT7-C0, or pGBKT7-C0C1 (table II.10), was mated 
with yeast strain Y187 transformed with pACT2-Cl182, pACT2-Cl268, pACT2-Cl286, or non-
recombinant pACT2 prey-vector. The pACT2-Cl182, pACT2-Cl268 and pACT2-Cl286 are preys 
that were previously identified as candidate ligands of the C1C2 region of cMyBPC in a Y2H 
library-assay by Dr Hanlie Moolman-Smook, and encoded the C-terminal 211, 288 and 176 amino 
acid residues of cardiac actin (377 amino acid residues), respectively. No growth was, however, 
observed on either TDO or QDO selection media when these preys were co-expressed with either the 
C0 or C0C1 bait fusion-peptides (table III.20), indicating the absence of an interaction between 
cardiac actin and the N-C0C1 region of cMyBPC. 
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Table III.20. Cardiac actin as a candidate ligand of the C0C1 region of cMyBPC 
 
Mating TDO (LW) QDO (LW) 
 
C0 x Cl182 
 
X 
 
X 
C0 x Cl268 X X 
C0 x Cl286 X X 
C0 x pACT2 X X 
C0C1 x Cl182 X X 
C0C1 x Cl267 X X 
C0C1 x Cl286 X X 
C0C1 x pACT2 X X 
 
Assessment of growth of diploid yeast on TDO and QDO media, enabling the detection of interaction between 
respective bait and prey fusion-peptides. C0 = yeast strain AH109 transformed with pGBKT7-C0 bait 
construct, C0C1 = yeast strain AH109 transformed with pGBKT7-C0C1 bait construct; Cl182 = yeast strain 
Y187 transformed with pACT2-Cl182 prey construct; Cl268 = yeast strain Y187 transformed with pACT2-
Cl286 prey construct;Cl268 = yeast strain Y187 transformed with pACT2-Cl286 prey construct; pACT2 = 
yeast strain Y187 transformed with non-recombinant pACT2 prey-plasmid; x = prey construct co-expression 
of bait and prey fusion-peptides encoded by the respective constructs in diploid yeast cells, subsequent to 
small-scale yeast mating; TDO = TDO selection medium; QDO = QDO selection medium, (LW) = yeast 
transferred from SD-L-W medium; X = no growth observed. 
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CHAPTER IV: DISCUSSION 
 
During the couse of this study, the screening of MYBPC3 for HCM-causing mutations has led to the 
identification of several novel putative HCM-causing mutations. The identification of these putative 
disease-causing mutations in specific domains of cMyBPC indicates that these domains/regions are 
of functional importance, as these “experiments of nature” are likely to have a deleterious effect. As 
cMyBPC has no enzymatic activity, it was postulated that these domains/regions are involved in, as 
yet, unidentified protein:protein interactions. In order to test this hypothesis, specific 
domains/regions of cMyBPC, affected by putative HCM-causing mutations identified in this and 
other studies, were used in Y2H-assays, allowing the identification of ligands binding to these 
domains. The subsequent identification of the ligands of specific domains of cMyBPC has 
significantly contributed towards the generation of a novel model of cMyBPC quaternary structure, 
shedding new light on the function of this protein, as well as providing insights into the pathogenesis 
of MyBPC-associated HCM. 
 
IV.1. PUTATIVE HCM-CAUSING MUTATIONS IN cMyBPC 
 
IV.1.1. PUTATIVE HCM-CAUSING MISSENSE MUTATIONS IN cMyBPC 
 
IV.1.1.1. V158M putative HCM-causing missense mutation in cMyBPC 
 
The V158M putative HCM-causing missense mutation, caused by the g2626a (GenBank sequence 
accession number: Y10129, available at: http://www.ncbi.nlm.nih.gov/Entrez) SNS in exon 5 of 
MYBPC3 (figure III.16), was detected in one individual, of Caucasian descent, in the HCM-affected 
panel (section III.1.2.1). The V158M putative HCM-causing mutation occurs at a residue in the C1 
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domain of cMyBPC that is conserved as an aliphatic residue (V, L or I), as assessed by cross-species 
and cross-isoform multiple sequence comparisons (figure III.17), and results in this residue being 
replaced by a sulphur-containing M residue. As the V158M putative HCM-causing mutation was 
also detected in three individuals in a control panel consisting of 110 individuals of Caucasian 
descent, this variant was considered to be a polymorphism, rather than an HCM-causing mutation, 
and was, therefore, not pursued further.  
 
IV.1.1.2. A181T putative HCM-causing missense mutation in cMyBPC 
 
The A181T putative HCM-causing missense mutation, caused by the g2785a SNS in exon 6 of 
MYBPC3 (figure III.18), was detected in two individuals, both of mixed ancestry, in the HCM-
affected panel (section III.1.2.2). The A181T putative HCM-causing mutation occurs at a residue in 
the C1 domain of cMyBPC that is not conserved in cross-species and cross-isoform multiple 
sequence comparisons (figure III.19). The A181T putative HCM-causing mutation results in this 
hydrophobic aliphatic residue being replaced by a hydrophilic hydroxyl-containing residue. As the 
A181T putative HCM-causing mutation was also detected in two individuals in a control panel 
consisting of 105 individuals of mixed ancestry, this variant was considered to be a polymorphism, 
rather than an HCM-causing mutation, and was, therefore, not pursued further. 
 
IV.1.1.3. R177H putative HCM-causing missense mutation in cMyBPC 
 
The R177H putative HCM-causing missense mutation, caused by the g2774a SNS in exon 6 of 
MYBPC3 (figure III.20), was detected in two individuals in the HCM-affected panel (section 
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III.1.2.3). One of the individuals carrying this putative HCM-causing mutation was of Caucasian 
descent, while the other was of Xhosa descent.  
 
The R177H putative HCM-causing mutation occurs at a residue in the C1 domain of cMyBPC that is 
conserved as a basic, hydrophilic residue in cross-species and cross-isoform multiple sequence 
comparisons (either R or K) (figure III.21). The R177H putative HCM-causing mutation results in a 
conservative substitution of an R residue at position 177 by a hydrophilic basic H residue. As the 
R177H putative HCM-causing mutation was also detected in six individuals in a control panel 
consisting of 137 individuals of Xhosa descent, this variant was considered to be a polymorphism, 
rather than an HCM-causing mutation, and was, therefore, not pursued further. 
 
IV.1.1.4. G278E putative HCM-causing missense mutation in cMyBPC 
 
The G278E putative HCM-causing missense mutation, caused by the g5047a SNS in exon 9 of 
MYBPC3 (figure III.22), was detected in one individual of mixed ancestry in the HCM-affected 
panel (section III.1.2.4). The G278E putative HCM-causing mutation occurs at a residue that is 
conserved as an aliphatic residue (either a G or an A) in the cardiac-specific LAGGGRRIS insertion 
in the MyBPC-motif (figure III.23). The G278E putative HCM-causing mutation results in the 
substitution of a hydrophobic aliphatic G residue with a hydrophilic E residue. As this substitution 
results in the introduction of a negative charge in the LAGGGRRIS insertion, G278E was considered 
to be a strong candidate for being a disease-causing mutation. The G278E putative HCM-causing 
mutation was, however, detected in five individuals in a control panel consisting of 104 individuals 
of mixed ancestry, and was considered a polymorphism, rather than an HCM-causing mutation.  
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Recently, however, Richard et al., (2003) described G278E in an HCM-affected individual and 
assigned disease-causing status to this “mutation”, based on the sequence conservation of this residue 
and its absence in 100 control individuals. Based on the finding that this “mutation” is reasonably 
prevalent in the control population screened in the present study, combined with the fact that Richard 
et al., (2003) did not show segregation of G278E with HCM in a family, it is proposed that G278E is 
not a main-locus HCM-causing mutation. The possibility that G278E may have a more subtle 
functional effect and may, in combination with an HCM-causing main-locus mutation or even with 
other non-pathogenic polymorphisms with subtle functional effects, play a role in the pathogenesis of 
HCM, cannot be excluded. 
 
IV.1.1.5. G507R putative HCM-causing missense mutation in cMyBPC 
 
The G507R putative HCM-causing missense mutation, caused by the g9140a SNS in exon 18 of 
MYBPC3 (figure III.24) was detected in one individual of Zulu descent in the HCM-affected panel 
(section III.1.2.5). As the Zulu control panel at our disposal only consisted of 50 individuals, this 
panel, as well as a Xhosa control panel, consisting of an additional 50 individuals, were screened for 
the presence of the G507R putative HCM-causing mutation (section II.2). As the Xhosa and Zulu 
ethnic groups both belong to the Nguni family of tribes, that split about 600 years ago to give rise to 
the Xhosa, Zulu, Swazi and Ndebele tribes, it can be presumed that these two ethnic groups are 
genetically closely related (information obtained from: 1Up Info - Country Study & Country Guide - 
South Africa, available at http://www.1upinfo.com/country-guide-study/south-africa/south-
africa51.html). The G507R putative HCM-causing mutation was not present in either of these control 
panels, suggesting that it might be an HCM-causing mutation. 
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This putative HCM-causing mutation occurs at a residue in the C3 domain of cMyBPC that is highly 
conserved as a G residue in cross-species and cross-isoform multiple sequence comparisons (figure 
III.25). The G507R putative HCM-causing mutation results in this uncharged, hydrophilic, aliphatic 
G residue being replaced by a basic hydrophilic R residue. Based on the conservation of this residue 
and its absence in a control population, it was considered to be a possible disease-causing mutation. 
As DNA samples and clinical records of family members of the proband carrying the G507R 
putative HCM-causing mutation were not available, it was impossible to establish whether G507R 
segregated with HCM in the family of the proband.  
 
Recently, Erdmann et al., (2001) also described G507R in an HCM-affected individual and described 
it as an HCM-causing mutation, on the basis that it caused a charge change at a conserved residue 
and was not present in 50 control individuals. As Erdmann et al., (2001) were unable to establish 
whether this mutation segregated with HCM in a family setting, and they only screened 50 control 
individuals, the possibility that G507R is a rare non-disease-causing polymorphism could not be 
ruled out by this study. Although, segregation of G507R with HCM could not be shown in either the 
present study, or that by Erdmann et al., (2001), this mutation was present in two distinct HCM-
affected populations and absent in matched control populations (totalling 150 individuals). This 
finding, combined with the fact that this mutation results in a charge change at a highly conserved 
residue, provides strong evidence that G507R is an HCM-causing mutation rather than a naturally 
occurring polymorphism. 
 
Furthermore, there are striking similarities between the phenotypic presentation of the probands 
identified as carrying the G507R mutation in the present study and in that of Erdmann et al., (2001). 
The proband in the present study, a female of Zulu descent, was diagnosed with HCM at the age of 
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50 years and presented with dyspnoea, palpitations and angina (section III.2.3), while the proband in 
the study by Erdmann et al., (2001), a male of Caucasian descent, presented with dyspnoea and 
palpitations at age 30 years. Furthermore, echocardiography revealed that both these probands had 
severe LVH of, primarily, the interventricular septum (IVS). The proband in this study had a 
maximal left ventricular wall thickness of 25mm (IVS) (section III.2.3), while the proband in the 
study of Erdmann et al., (2001) had a maximal left ventricular wall thickness of 30mm (IVS) and 
required sinoatrial ablation. The proband in the present study, however, also had systolic anterior 
motion of the mitral valve (section III.2.3), while this feature was absent in the proband carrying the 
G507R mutation in the study by Erdmann et al., (2001). ECG-analysis of the proband in the present 
study revealed increased voltages, abnormal repolarisation and fulfilled the Romhilt and Estes 
criteria for the diagnosis of HCM (section III.2.3), while the proband in the study by Erdmann et al., 
(2001) presented with supraventrivular arrythmias and repeated monomorphic ventricular 
tachycardia.  
 
Additionally, the proband in the study by Erdmann et al., (2001) presented with recurrent syncope 
and required implantation of an implantable cardiac defibrillator, suggesting that this proband was at 
risk of SCD. As the mother of the proband in the present study died suddenly at the age of 40 years 
of unknown, non-violent, causes (section III.2.3), it seems possible that a high risk of SCD may also 
be associated with the G507R mutation in this family. 
 
These phenotypic similarities between carriers of this mutation suggest that G507R is indeed an 
HCM-causing mutation. From the findings of the present study, and that of Erdmann et al., (2001), it 
can be suggested that the G507R HCM-causing mutation in the C3 domain of cMyBPC results in 
HCM characterised by pronounced LVH, ECG abnormalities and an increased risk of SCD. The 
putative functional effect of the G507R is discussed in section IV.5.1. 
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IV.1.1.6. V896M putative HCM-causing missense mutation in cMyBPC 
 
The V896M putative HCM-causing missense mutation, caused by the g15751a SNS in exon 27 of 
MYBPC3 (figure III.26) was detected in one individual of Caucasian descent in the HCM-affected 
panel (section III.1.2.6). The V896M putative HCM-causing mutation occurs at a residue in the C7 
Fn3 domain of cMyBPC that is conserved as an aliphatic uncharged hydrophobic residue in cross-
species and cross-isoform multiple sequence comparisons (V or I) (figure III.27). The V896M 
putative HCM-causing mutation results in this residue being replaced by a sulphur-containing 
hydrophobic M residue. As the V896M putative HCM-causing mutation was not detected in a 
control panel consisting of 102 individuals of Caucasian descent, it was considered likely to be an 
HCM-causing mutation. Family members of the proband were, therefore, investigated for the 
presence of V896M, in order to establish whether this putative disease-causing mutation segregated 
with HCM in this family. 
 
Following the genotyping of the six available individuals in pedigree 120 for the presence of 
V896M, four individuals were found to carry this putative HCM-causing mutation (individuals I.2, 
II.1, II.2 and III.1; figure III.35 and tables III.2 and III.3) (section III.2.1). Clinical assessment of 
these four individuals revealed that only the proband (individual II.2; figure III.35 and tables III.2 
and III.3) fulfilled the echocardiographic criteria for the diagnosis of HCM (table II.3) of a maximal 
left ventricular wall thickness of more than 13mm. Both the proband (individual II.2; figure III.35) 
and his eldest brother (individual II.1; figure III.35) presented with angina (table III.2), while the 
only ECG abnormality in either of these individuals were abnormal Q-waves (table III.3). These 
findings, combined with the echocardiographic finding that individual II.1 (figure III.35) has a 
maximal left ventricular wall thickness of 11mm (table III.3), which is at the upper limit of 
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normality, suggest that, even though this individual does not fulfill the echocadiographic, or the 
Romhilt and Estes criteria for diagnosis of HCM, he may be affected by HCM.  
 
Additionally, the mother of the proband (individual I.2; figure III.35) presented with dyspnoea and 
palpitations and was diagnosed with congestive heart failure (table III.2) due to DCM at the age of 
75 years. Although there is no ECG evidence of HCM in this patient, ECG-features generally 
associated with HCM, may have been lost due to congestive heart failure. It is plausible that the 
diagnosis of DCM may be indicative of dilatation due to end-stage HCM (“burnt out HCM”), which 
was previously shown to be common in elderly individuals with MyBPC-associated HCM (Konno et 
al., 2003). Although no symptoms of HCM, or ECG-abnormalities associated with HCM, were 
present in individual III.1 (figure III.35 and table III.2), echocardiographic measurement of the IVS 
was at the upper limits of the normal range at age 19 years. This may be indicative of MyBPC-
associated HCM, which is generally associated with disease presentation later in life (Charron et al., 
1998; Niimura et al., 1998; Konno et al., 2003).  
 
The younger brother of the proband (individual II.4; figure III.35) died suddenly at the age of 28 
years while running, and, although no clinical, molecular, or postmortem data were available for this 
individual, it seems plausible that his death might have been due to HCM-associated SCD. These 
data suggest that the V896M putative HCM-causing mutation may segregate with HCM in pedigree 
120, and that V896M is indeed an HCM-causing mutation. From this data, it was concluded that 
V896M is associated with reduced penetrance, with late-onset mild LVH, progressing to congestive 
heart failure at an advanced age, while an increased risk of SCD cannot be excluded. 
 270
Subsequent to this mutation being published as an HCM-causing mutation (Moolman-Smook et al., 
1999), however, Jaaskelainen et al., (2002), Richard et al., (2003) and Morner et al., (2003) identified 
V896M in both HCM-affected individuals and HCM-unaffected control populations. These findings 
prompted Jaaskelainen et al., (2002) and Morner et al., (2003) to describe V896M as a naturally 
occurring polymorphism, while Richard et al., (2003) proposed that V896M may act as a modifying 
factor. The functional effect of V896M was further investigated and is discussed in sections IV.5 and 
IV.5.4. 
 
IV.1.2. PUTATIVE HCM-CAUSING SPLICING MUTATIONS IN MYBPC3 
 
IV.1.2.1. Exon 5 SdS -13 c>t putative HCM-causing splicing mutation in MYBPC3 
 
The c2646t putative HCM-causing splicing mutation, identified in the exon 5 coding sequence, 13bp 
upstream of the exon 5 SdS, was detected in eight probands in the HCM-affected panel (section 
III.1.3.1 and figure III.28). This SNS causes codon 164 to change from ggc to ggt, both encoding G 
(G164G). Computational analysis, performed by Dr Peter Rogan (University of Missouri-Kansas 
City School of Medicine, Kansas City, Missouri, USA), showed that this SNS creates a cryptic SdS 
15bp upstream of the natural exon 5 SdS, as described by Carrier et al., (1997). As the cryptic SdS 
created by the c2646t SNS was predicted to be approximately the same strength as the natural exon 5 
SdS, it was hypothesised that this cryptic SdS may be utilised preferentially, due to the processivity 
of splicing (personal communication, Dr Peter Rogan, 23 December 1999). If indeed the cryptic SdS 
generated by the c2646t SNS was utilised preferentially to the natural exon 5 SdS, it was predicted 
that this would lead to the deletion of five amino acid residues in the C1 domain of cMyBPC, and 
could, therefore, act as an HCM-causing mutation. RT-PCR analysis, however, revealed that this 
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SNS does not affect the splicing of the MYBPC3 transcript (section III.1.3.1 and figure III.29) and is, 
therefore, likely to be a naturally occurring polymorphism, rather than an HCM-causing mutation.  
 
IV.1.2.2. Exon 7 SaS +1 g>a putative HCM-causing splicing mutation in MYBPC3 
 
The g4177a SNS, occurring at position +1 of the exon 7 SaS (ex7 SaS+1 g>a) (table III.1, section 
III.1.3.2 and figure III.30), was detected in one proband, of mixed ancestry, in the HCM-affected 
panel. Computational analysis, performed by Dr Peter Rogan (University of Missouri-Kansas City 
School of Medicine, Kansas City, Missouri, USA), revealed that this SNS may inactivate the natural 
exon 7 SaS, as described by Carrier et al., (1997). It was hypothesised that the g4177a SNS would 
cause the skipping of MYBPC3 exon 7 (personal communication, Dr Peter Rogan, 23 December 
1999).  
 
RT-PCR analysis revealed that this SNS did affect the splicing of the MYBPC3 transcript, resulting 
in the skipping of exon 7 (section III.1.3.2 and figure III.31). It is predicted that the skipping of exon 
7 would result in a frame-shift in the C1 domain of cMyBPC following amino acid residue 168, the 
addition of 90 novel amino acids, and the subsequent truncation of the protein, resulting in the loss of 
the C-terminal portion of the C1 domain through the C10 region of the protein (figure IV.1).  
 
 
 
Figure IV.1. Structure of the truncated cMyBPC protein predicted to be created by the exon 7 
SaS+1 g>a putative HCM-causing splicing mutation 
Circles = immunoglobulin C2 domains;       = PA-region;      = novel amino acids; red area = cardiac-
specific C0 domain.  
C1 C0 
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Following the genotyping of the two available family members of the proband (pedigree 137), it was 
found that only the proband in this pedigree (individual II.2; figure III.36) carries the MYBPC3 
g4177a putative HCM-causing splicing mutation. Additionally, the TNNT2 R92W HCM-causing 
founder mutation was previously shown to segregate with the disease in pedigree 137 (Moolman et 
al., 1997; Moolman-Smook et al., 1999), with the proband being a compound heterozygote for the 
TNNT2 R92W HCM-causing and the MYBPC3 g4177a putative HCM-causing splicing mutations. In 
the light of these findings, it was impossible to show segregation between the MYBPC3 g4177a 
putative HCM-causing splicing mutation and HCM in this pedigree. The finding that the g4177a 
SNS was not detected in a control panel consisting of 107 individuals of mixed ancestry is, however, 
suggestive that g4177a may be a disease-causing mutation in its own right. Additional support that 
g4177a may be an HCM-causing mutation comes from the studies by Erdmann et al., (2001) and 
Carrier et al., (1997) who have shown that two distinct splicing mutations occurring in intron 7 of 
MYBPC3, both resulting in the skipping of exon 8, cause HCM. Both these mutations would result in 
the generation of truncated cMyBPC that would be only marginally longer than that caused by the 
g4177a putative HCM-causing splicing mutation (218 amino acid residues, compared to 168 amino 
acid residues). In the light of these findings, it seems likely that g4177a is an HCM-causing 
mutation, rather than a naturally occurring polymorphism. 
 
Due to the fact that only the proband in pedigree 137, a compound heterozygote, carries g4177a, it is 
impossible to assign a phenotype to this putative HCM-causing mutation. It is, however, intriguing to 
note that, notwithstanding the high incidence of SCD in individuals in this family (figure III.36), 
which is generally a feature of the TNNT2 R92W HCM-causing mutation (Moolman et al., 1997; 
Moolman-Smook et al., 1999), the proband who carries both this mutation and the MYBPC3 g4177a 
putative splicing mutation, has escaped SCD till the age of 49 years. It can, therefore, be speculated 
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that in a TNNT2 R92W background, the MYBPC3 g4177a splicing mutation does not convey an 
increased risk of SCD, and may in fact reduce the risk of SCD. 
 
IV.1.2.3. Intron 6 SbP +1 g>a putative HCM-causing splicing mutation in MYBPC3 
 
The c4154t SNS, occurring 1bp downstream of the intron 6 SbP, was identified in two probands in 
the HCM-affected panel, who were both of mixed ancestry (section III.1.3.3 and figure III.32). 
Computational analysis, performed by Dr Peter Rogan (University of Missouri-Kansas City School 
of Medicine, Kansas City, Missouri, USA), revealed that this SNS slightly weakens the exon 7 SaS, 
and even though it was predicted to be unlikely, the possibility that it might inactivate the exon 7 
SaS, resulting in the skipping of exon 7, could not be excluded (personal communication, Dr Peter 
Rogan, 23 December 1999). RT-PCR analysis, however, revealed that this SNS did not affect the 
splicing of the MYBPC3 transcript (section III.1.3.3 and figure III.33) and was, therefore, likely to be 
a polymorphism, rather than an HCM-causing mutation, and was, therefore, not pursued further. 
 
IV.1.3. PUTATIVE HCM-CAUSING FRAME-SHIFT MUTATION IN MYBPC3 
 
IV.1.3.1. Δc 13255 Frame-shift putative HCM-causing mutation 
 
The ∆c13255 frame-shift putative HCM-causing mutation was identified in one individual of mixed 
ancestry in the HCM-affected panel. As this putative HCM-causing mutation was not identified in 
100 control individuals of mixed ancestry, it was postulated that ∆c13255 was likely to be an HCM-
causing mutation. This mutation results in a frame-shift after amino acid residue 754 in the C5 
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domain of cMyBPC and is predicted to result in the addition of 65 novel amino acids, prior to the 
generation of a stop codon and the truncation of the protein (figure IV.2).  
 
 
 
Figure IV.2. Structure of the truncated cMyBPC protein predicted to be created by the ∆c13255 frame-shift 
putative HCM-causing mutation 
Circles = immunoglobulin C2 domains;      = MyBPC motif;       = interdomain linker;      = PA-region;  
     = novel amino acids;  P  = PKA and MyBPC-associated kinase phosphorylation sites; red areas = 
cardiac-specific regions.  
 
As this mutation was only detected in only one individual, whose family could not be traced, it was 
impossible to establish whether this mutation segregated with HCM within a family setting, nor was 
it possible to accurately establish the phenotype associated with this mutation. On the basis that 
several other previously described mutations also result in the generation of truncated cMyBPC in 
which a similar portion of cMyBPC is truncated (partial C5 through to C10) (table I.6; Niimura et al., 
1998; Richard et al., 2003), combined with the fact that ∆c13255 was not found in a matched control 
panel, ∆c13255 was described as an HCM-causing mutation (Moolman-Smook et al., 1999). 
 
IV.2. PROPOSED MODEL OF cMyBPC QUATERNARY STRUCTURE 
 
The discovery of an interaction between the C5 and C8 domains of cMyBPC, by Dr Hanlie 
Moolman-Smook from our laboratory, indicated that cMyBPC was able to dimerise. This finding 
was in agreement with findings that MyBPC molecules are able to dimerise and possibly to form 
higher aggregates (Offer et al., 1973; Hartzell and Sale, 1985; Welikson and Fischman, 2002). 
Additionally, the finding that cMyBPC molecules purify as v-shaped particles with arm lengths of 
C4 C3 C2 C1 C0 C5  
MyBPC  
motif 
P   P  P  
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about 22.1nm (±4.5nm) (Hartzell and Sale, 1985), suggests that the hinge in the v-shape is likely to 
be located in the interdomain linker region separating the C4 and C5 domains of cMyBPC (Okagaki 
et al., 1993; http://smart.embl-heidelberg.de/smart/). As both domains C5 and C8 are located on the 
same (C-terminal) arm of the v-shape, it was considered likely that the interaction between the C5 
and C8 domains of cMyBPC would be inter-, rather than intra-molecular (Moolman-Smook et al., 
2002). If indeed the C5:C8 interaction is inter-molecular, it was considered that cMyBPC molecules 
would be able to interact in either a parallel, or antiparallel orientation. In an antiparallel 
arrangement, it would be possible that domains C5 and C8 of one cMyBPC molecule would interact 
with domains C8 and C5 of another cMyBPC molecule. In this orientation, domain C7 of one 
cMyBPC molecule would be juxtapositioned with domain C6 of another (figure IV.3a). In a parallel 
orientation, however, an interaction between domain C5 of one cMyBPC molecule with domain C8 
of another would result in domains C7 and C10 of two cMyBPC molecules being juxstapositioned 
(figure IV.3b) (Moolman-Smook et al., 2002).  
 
In order to establish in which of these orientations cMyBPC molecules dimerise, domains C6 and 
C10 were considered candidate ligands of the C7 domain of cMyBPC. Candidate-ligand Y2H-assays 
revealed the presence of a specific interaction between the C7 and C10 domains of cMyBPC, while 
domain C7 was unable to interact with domain C6 (section III.3.4.1 and figure III.41) (Moolman-
Smook et al., 2002). The existence of an interaction between these domains of cMyBPC is supported 
by the findings of Welikson and Fischman (2002), who have shown that C7-C10 MyBPC fragments, 
transfected into COS cells, were able to aggregate, while C8-C10 fragments did not. Additionally, 
this interaction may also explain why the C7 domain of cMyBPC is essential for correct C-zone 
incorporation of cMyBPC into the sarcomere (Gilbert et al., 1996; Gilbert et al., 1999). The presence 
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a) 
 
 
 
 
b) 
 
 
Figure IV.3. C5:C8 mediated dimerisation of cMyBPC molecules in an antiparallel and parallel fashion 
a) cMyBPC molecules dimerising in an antiparallel orientation, stabilised by interactions between domains 
C5 and C8; b) cMyBPC molecules dimerising in a parallel orientation, stabilised by interactions between 
domains C5 and C8;   = positions of interactions between C5 and C8 domains;     = interdomain linkers; 
boxes = fibronectin type 3 domains; ovals = immunoglobulin C2 domains;   = positions of C7 domains, 
indicating the juxtapositioning of these domains with the C6 and C10 domains when cMyBPC molecules 
dimerise in the antiparallel and parallel orientations, respectively; red area = cardiac-specific insertion in 
the C5 domain. In the interest of clarity, only the six C-terminal domains of cMyBPC, constituting the one 
“arm of the v-shape” of cMyBPC, are shown. 
 
of an interaction between the C7 and C10 domains of cMyBPC was subsequently confirmed in co-
immunoprecipitation (CoIP) analyses (personal communication Dr Hanlie Moolman-Smook, 12 
September 2003).  
 
The identification of this interaction indicates that cMyBPC molecules are likely to dimerise in a 
parallel, rather than an antiparallel, orientation, with interactions between domains C5 and C7 of one 
cMyBPC molecule interacting with domains C8 and C10 of another (Moolman-Smook et al., 2002). 
Together, this data was used to develop a novel model of cMyBPC quaternary structure (Moolman-
Smook et al., 2002). In this model, cMyBPC homo-trimerises to form a “tight collar” around the 
thick filament backbone, with domains C5-C7 of one cMyBPC molecule overlapping with domains 
C9 C7 C6 C10 C8 C 5 
C9 C7 C6 C10 C8 C  
5
C9 C7 C6 C10 C8 C 5 
C9 C7C6 C10 C8 C 5 
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C8-C10 of the following cMyBPC molecule (figure IV.4) (Moolman-Smook et al., 2002). It was 
postulated that this trimeric “tight collar” structure would be stabilised by the interaction  
between domains C5 and C8, as well as between domains C7 and C10 (figure IV.4) (Moolman-
Smook et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV.4 Proposed model of cMyBPC quaternary structure 
Blue arrows = positions of interactions between C7 and C10 domains of two consecutive cMyBPC molecules; 
blue, green and red molecules = three consecutive cMyBPC molecules trimerised to form a “tight collar” 
around the thick filament backbone; red arrows = positions of interactions between C5 and C8 domains of 
two consecutive cMyBPC molecules; yellow cylinder = thick filament backbone (consisting of light 
merromyosin and titin molecules) (from Moolman-Smook et al., 2002).  
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In addition to this model being in agreement with the position of the bend in cMyBPC molecules and 
the finding that MyBPC molecules are able to dimerise or form higher aggregates, as stated 
previously, this model is also supported by the findings of several other studies. Firstly, MyBPC is 
located on the surface of the thick filament backbone, as was shown by immunochemical studies 
(Offer et al., 1973). Secondly, the trimeric structure of MyBPC is in agreement with findings that 
two to four (most likely three) MyBPC molecules are found at each 43nm period in the sarcomeric 
C-zone (Offer et al., 1973; Morimoto and Harrington, 1974; Bennett et al., 1986). Thirdly, previous 
studies have shown the axial extent of MyBPC on the thick filament backbone to be about 7nm 
(Craig and Offer, 1976), which is roughly the width of two IgC2 or Fn3 domains lying side-by side 
(Nave et al., 1989; Labeit et al., 1992; Soteriou et al., 1993; Vinkemeier et al., 1993), which is in 
agreement with the double layered cMyBPC collar proposed by Moolman-Smook et al., (2002). 
 
Additionally, in the model proposed by Moolman-Smook et al., (2002), domains C5-C10 of 
cMyBPC are associated with the thick filament backbone, while domains C0-C4 extend into the 
interfilament space, with a bend in the molecule occurring between domains C4 and C5. This 
arrangement is supported by the findings that the C-terminal domains of MyBPC bind to LMM and 
titin in the thick filament backbone (Okagaki et al., 1993; Freiburg and Gautel, 1996; Welikson and 
Fischman, 2002), while the N-terminal portion of MyBPC extends away from the thick filament 
backbone, allowing it to interact with myosin S2 and possibly actin (Hartzell and Sale, 1985; Gruen 
and Gautel, 1999; Gruen et al., 1999; Kunst et al., 2000; Kulikovskaya et al., 2003; Squire et al., 
2003).  
 
This model also for the first time, assigns a function to the C7 domain of cMyBPC. Previous studies 
have shown that the C7-C10 region of cMyBPC was necessary for correct A-band incorporation of 
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cMyBPC into the sarcomere, indicating that the C7 domain is of specific functional significance 
(section I.7.3.3) (Gilbert et al., 1996; Gilbert et al., 1999). In the model of cMyBPC quaternary 
structure proposed by Moolman-Smook et al., (2002), the C7 to C10 region of cMyBPC would be 
the minimal C-terminal portion of the protein required to form a collar around the thick filament 
backbone (figure IV.4). 
 
One shortcoming of the model proposed by Moolman-Smook et al., (2002) is, however, that it did 
not take into account the quaternary structure of the thick filament backbone, that is in all likelihood 
not a simple cylindrical structure as portrayed in figure IV.4. In section IV.3, the currently accepted 
model of thick filament backbone structure will be discussed and the cMyBPC “tight collar” 
arrangement integrated into this model. Additionally, this integrated model of thick filament and 
cMyBPC quaternary structure will be used to generate a hypothesis of the mechanisms through 
which phosphorylation of cMyBPC may alter thick filament structure and regulate cardiac 
contractility (section IV.3). 
 
IV.2.1. cMyBPC DOMAIN C7 LIBRARY-ASSAY 
 
In order to cofirm the presence of an interaction between the C7 and C10 domains of cMyBPC, as 
well as to establish whether the C7 domain interact with any other ligands, domain C7 of cMyBPC 
was used as bait in a Y2H library assay. In this assay, the MATCHMAKER GAL4 Two-Hybrid 
System 3 (BD Biosciences, Clontech, Palo Alto, CA, USA) was used to screen a pre-transformed 
cardiac cDNA library. This assay allowed the identification of human cytochrome c oxidase 
(subunits I [four independent clones], II [one clone] and III [one clone]), human ATP synthase (H+ 
transporting, mitochondrial F1 complex, alpha subunit, isoform 1 [one clone] and the F0 subunit 
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[one clone]), NADH dehydrogenase (subunits 1 [four independent clones] and 2 [one clone]), human 
quinolinare phosphorybosyltransferase (one clone), human α2(I) collagen (one clone), human 
phosphoglucomutase 1 (one clone), human myomesin 2 (M-protein) (one clone), human titin (three 
independent clones) and human cMyBPC (one clone) as putative ligands of the C7 domain of 
cMyBPC (section III.3.2.4 and table III.15).  
 
Cytochrome c oxidase (subunits I, II and III), ATP synthase (H+ transporting, mitochondrial F1 
complex, alpha subunit, isoform 1 and the F0 subunit), NADH dehydrogenase (subunits 1 and 2) and 
quinolinare phosphorybosyltransferase were not considered plausible ligands of cMyBPC, based on 
their localisation in the mitochondrion. Similarly, based on its extracellular localisation, α2(I) 
collagen was not considered a plausible ligand of the C7 domain of cMyBPC. Additionally, as 
phosphoglucomutase 1 has not been localised specifically to the sarcomeric A-band, interaction 
between this protein and the C7 domain of cMyBPC was not considered to be of specific 
significance to this study, but may require further investigation in future studies (table III.15). 
Notwithstanding its sarcomeric localisation, M-protein was also not considered to be a plausible 
ligand of the C7 domain of cMyBPC for several reasons. Firstly, the interaction between domain C7 
and M-protein was found to be non-specific in interaction-specificity tests (table III.13). Secondly, 
similar spurious interactions between M-protein peptides and other regions of cMyBPC (the C5 
domain and C1C2 region of cMyBPC) were previously detected in Y2H library-assays (personal 
communication Dr Hanlie Moolman-Smook). Finally, as M-protein is localised in the sarcomeric M-
line, while cMyBPC is found in the C-zone, an interaction between these proteins was deemed 
highly unlikely. 
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The cMyBPC clone identified as a putative ligand of the C7 domain of cMyBPC encoded only the 
C-terminal 39 amino acids of cMyBPC (sections III.3.2.4 and table III.15), constituting a partial C10 
domain. Interaction specificity tests showed that the interaction between domain C7 and this partial 
C10 peptide was indeed specific (table III.15). In order to gain insight into the specific region of the 
C10 domain of cMyBPC involved in the interaction with the C7 domain, the relative positions of the 
C-terminal 39 amino acids of this domain, shown to interact with domain C7 (sections III.3.2.4, IV.2 
and table III.13), were mapped to the three-dimensional structure of telokin (chain A) (three-
dimensional model of an IgC2 domain) (figure IV.21). This analysis revealed that the C-terminal 39 
amino acids of cMyBPC constituted β-strands E, F and G of the C10 domain of cMyBPC. In 
complete IgC2 domains, β-strands A, B, D and E form a four-stranded β-sheet (ABDE), while β-
strands C, F and G form a three-stranded β-sheet (CFG), with each of these two β-sheets forming a 
distinct ligand-binding surface. These two β-sheets associate to form a β-sandwich (Idowu et al., 
2003; http://pfam.wustl.edu/). It is postulated that in the 39 amino acid C10 peptide, β-strands F and 
G may form a partial β-sheet, the tertiary structure of which is stabilised by the presence of β-strand 
E (figure IV.3). In the light of this finding, it is likely that the C7 binding-site is located on the three-
stranded (CFG), rather than the four-stranded (ABDE), β-sheet of the C10 domain of cMyBPC.  
 
Additionally, the interaction between domain C7 of cMyBPC and putative interactor clones encoding 
titin was also found to be specific in interaction specificity tests (section III.3.2.4 and table III.15). In 
the light of this finding, combined with the sarcomeric localisation of titin, Y2H candidate-ligand 
assays were used to further investigate the possibility of an interaction between domain C7 of 
cMyBPC and titin (section IV.2.2). 
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IV.2.2. IDENTIFICATION OF A SPECIFIC INTERACTION BETWEEN THE C7 DOMAIN 
OF cMyBPC AND C-ZONE TITIN 
 
Three of the interactor clones identified in the C7 Y2H library-assay encoded portions of the C-
terminal region of titin, which varied in size from 35 to 595 amino acids in length (sections III.3.2.4, 
IV.2 and table III.15). As the region of titin encoded by these clones would be embedded in the M-
line in the intact sarcomere, while cMyBPC is found in the C-zone, the region encoded by these 
clones was not considered to be a plausible ligand of cMyBPC (section III.3.2.4 and table III.15). 
BLAST-P and multiple sequence alignment analyses, however, revealed that the minimal titin clone 
identified as interacting with domain C7 (a 35 amino acid peptide encoding the partial M10 IgC2 
domain of titin) (sections III.3.2.4, IV.2 and table III.15), shared highest homology with the first 
IgC2 domain of each of the eleven-domain super-repeats constituting C-zone titin (sections I.6.3.2, 
III.3.3; figures I.9, III.39, III.40 and table III.16). These domains shared between 26% and 49% 
amino acid sequence identity with the 35 amino acid C-terminal titin peptide, while the sequence 
similarity varied between 69% and 86% (table III.16 and figure III.40). This is considerably higher 
than the average sequence identity and sequence similarity shared by IgC2 domains of the 
intracellular immunoglobulin superfamily, which was estimated to be about 20-30% and 40-45%, 
respectively (Politou et al., 1994; Vinkemeier et al., 1993). Based on this finding, the first IgC2 
domain of each of the eleven-domain super-repeats, previously shown to interact with the C-terminal 
region of cMyBPC (Freiburg and Gautel, 1996), were considered plausible ligands of the C7 domain 
of cMyBPC.  
 
As C-zone titin was not expected to be represented in the cardiac cDNA library that was screened, 
due to the gigantic size of the titin transcript (>27kb) (section II.16.2.1), Y2H candidate-ligand 
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assays were performed to test whether the C7 domain of cMyBPC did indeed interact with these 
IgC2 domains of C-zone titin. In these assays, the first IgC2 domain of the first and the seventh 
eleven-domain super-repeat of A-band titin (domains A43 and A109 of titin) were used as candidate 
preys in Y2H candidate-ligand assays (figure III.39). These assays clearly showed that domain C7 of 
cMyBPC interacts specifically with these two domains, while it did not interact with either the 
second or the third IgC2 domain of the seventh eleven-domain super-repeat (domains A112 and 
A116, respectively) (section III.3.4.2; figures III.39 and III.42). The interaction between domain C7 
of cMyBPC and the A43 and A109 IgC2 domains of C-zone titin was subsequently confirmed by 
CoIP analysis (personal communication Dr Hanlie Moolman-Smook, 12 September 2003).  
 
At first glance, the identification of this interaction is in stark contrast to the findings of Freiburg and 
Gautel (1996), who showed that only the C8-C10 region of cMyBPC interacted with titin. From the 
study of Freiburg and Gautel (1996), however, the possibility of a secondary titin binding-site cannot 
be excluded, as the methods employed were only able to detect relatively strong interactions in an in 
vitro environment (Freiburg and Gautel, 1996).  
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IV.3. QUATERNARY STRUCTURE OF THE A-BAND THICK FILAMENT 
BACKBONE 
 
One shortcoming of the model of cMyBPC quaternary structure proposed by Moolman-Smook et al., 
(2002) is that it did not address the quaternary structure of the A-band thick filament backbone, of 
which it forms part. Furthermore, as it has been shown that PKA-mediated phosphorylation of 
cMyBPC results in an expansion of the thick filament backbone in αMHC-containing thick filaments 
(Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; Levine et al., 2001), the dimensions 
of the model of cMyBPC quaternary structure proposed by Moolman-Smook et al., (2002) would 
only be applicable when cMyBPC is either un- or mono-phosphorylated (“disordered” and “tight” 
thick filament structures) (section I.7.6). As an adjunct to the present study it was undertook to 
incorporate the model of cMyBPC quaternary structure proposed by Moolman-Smook et al., (2002) 
into the quaternary structure of the thick filament backbone. Additionally, data generated in the 
present study was used to devise a novel model of thick filament quaternary structure following 
PKA-mediated phosphorylation of cMyBPC (“loose” thick filament structure). In order to allow the 
generation of these models, data regarding the quaternary structure of the A-band thick filament 
backbone, consisting of LMM, titin and cMyBPC, had to be considered. 
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IV.3.1. QUATERNARY STRUCTURE OF THE “DISORDERED”/”TIGHT” A-BAND 
THICK FILAMENT BACKBONE  
 
IV.3.1.1. LMM thick filament backbone structure 
 
The thick filament is composed mainly of three elements, namely, myosin molecules (each 
consisting of two myosin heavy chain monomers, two MELCs and two MRLCs (Widnell, 1990) 
(figure I.22), titin and the MyBPs. Each myosin heavy chain monomer can be further subdivided into 
the LMM portion, also referred to as the myosin rod section, and the HMM portion, which can be 
further subdivided into an S1 (also referred to as the myosin head) and S2 subfragments (figure I.19) 
(Widnell and Pfenninger, 1990). The thick filament backbone consists mainly of LMM, while HMM 
extends away from the thick filament backbone, where it is arranged in a three-stranded 9/1 helix of 
pitch 9 x 14.3nm and a repeat of 3 x 14.3nm, with the two heads of one myosin molecule on each 
lattice site on the helix (figure IV.5) (reviewed by Chew and Squire, 1995). As LMM is the major 
component of the thick filament backbone, as opposed to HMM which forms the crossbridges that 
extend from the backbone towards the thin filament (figure I.22) (Widnell and Pfenninger, 1990), 
only the structure of LMM will be discussed in detail in this section. 
 
Each LMM monomer consists entirely of an α-helix, and dimerises with another LMM monomer 
through the formation of a coiled-coil (figures I.22 and IV.5) (Knight, 1996). The way in which these 
LMM dimers associate to form the thick filament backbone has, however, remained a contentious 
issue and several models for the arrangement of LMM within the thick filament backbone have been 
proposed (Squire, 1973; Squire, 1979; Stewart et al., 1981; reviewed by Chew and Squire, 1995). 
Subsequent measurements of the fish skeletal muscle A-band thick filament backbone (outer radius,  
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including MyBPs and titin, = 6.5-7.5nm; hollow inner core radius = 1.5-2nm; radial packing 
thickness = 4-5nm) made by Squire et al., (1998) have, however, excluded most of these models and 
favour the curved crystalline layer model proposed by Squire (1973). This model predicted that the 
thick filament backbone (composed of only LMM) has an outer radius of ~7nm, a hollow inner core 
of ~1.5-2nm, with the LMM dimers separated by ~0.2nm, and aligned nearly parallel to the long axis 
of the thick filament (figure IV.5) (Squire, 1973; Chew and Squire, 1995; Squire et al., 1998).  
 
The curved crystalline layer model (Squire, 1973) is compatible with the empiric measurements of 
the thick filament backbone and also allows for the arrangement of crossbridges in a three-stranded 
9/1 helix conformation (Chew and Squire, 1995, Squire et al., 1998). A shortcoming of this model is, 
however, that it only accounts for the positioning of LMM within the thick filament backbone, and 
does not take accessory proteins into account. Furthermore, the dimensions predicted by this model 
for a thick filament backbone composed entirely of LMM is greater than that of the measured values 
of the A-band fish skeletal muscle thick filament backbone that include the accessory proteins 
(Squire et al., 1998). It should, therefore, be considered that the dimensions predicted by the curved 
crystalline layer model may not be absolutely accurate.  
 
The following sections describe how previously reported data, as well as data generated in the 
present study regarding the structure, position and interaction of titin and cMyBPC, were used to 
obtain an integrated model of the A-band thick filament backbone quaternary structure that takes into 
account the three main components of the thick filament backbone: LMM, titin and MyBPC. 
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Figure IV.5. Colour representation of a 42.9nm segment of the curved crystalline layer model of a 
vertebrate striated myosin muscle filament 
The top and bottom panels show stereo pairs of the structure viewed from the axial and transverse directions, 
respectively. The colour codes indicate the relative positions of the amino acids along the sequence with 
increasing distance from the C-terminus indicated by red, yellow, green, blue, and finally white where the 
myosin heads originate (Chew and Squire, 1995). 
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IV.3.1.2. Incorporation of A-band titin into the curved crystalline layer model of the thick 
filament backbone  
 
Liversage et al., (2001) proposed a model in which six titin molecules are found in each half-
sarcomere, with A-band titin being in a dimeric form (section I.6.3). These titin dimers are located on 
the surface of the thick filament (Furst et al., 1988; Labeit et al., 1992; Jin, 1995; Labeit and 
Kolmerer, 1995) where they are constitutively bound to LMM (section I.6.3) (Furst et al., 1988; 
Labeit et al., 1992), and are arranged parallel to the long axis of the thick filament (Squire et al., 
1998; Liversage et al., 2001). 
 
As the arrangement of LMM within the thick filament backbone, according to the curved crystalline 
layer model, results in the formation of nine major surface grooves (Squire, 1973; Chew and Squire, 
1995, Squire et al., 1998), it was considered likely that the titin dimers would be partially imbedded 
in three of these surface grooves (figures IV.5 and IV.6). Even though these surface grooves do not 
run absolutely parallel to the axis of the thick filament, they are arranged in an open-angled zigzag 
pattern on the surface of the thick filament (figure IV.5) (Chew and Squire, 1995, Squire et al., 
1998). It is possible that titin may be found in these surface grooves, thus allowing the overall 
orientation of titin to be parallel to the long axis of the thick filament, as proposed by Liversage et 
al., (2001) (figure IV.6a).  
 
In order to establish the contribution made by these titin dimers to the total diameter of the thick 
filament backbone, as well as to establish an accurate diameter for this structure 
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in the absence of titin dimers, the curved crystalline model of the myosin backbone was used as a 
basis for producing detailed scale drawings of the A-band thick filament backbone in the presence of 
titin dimers (figure IV.6). In the construction of these scale drawings, several assumptions were 
made. Aside from assuming that LMM dimers are arranged in the thick filament backbone according 
to the curved crystalline layer model proposed by Squire (1973), it was assumed that A-band titin is 
found in the dimeric form and is aligned parallel to the long axis of the thick filament (Liversage et 
al., 2001), and, finally, that the IgC2 and Fn3 domains, constituting A-band titin, have a diameter of 
about 2.5nm (Nave et al., 1989; Labeit et al., 1992; Soteriou et al., 1993; Vinkemeier et al., 1993).  
 
Thus, three titin dimers were positioned in three of the surface grooves in the LMM thick filament 
backbone, with the diameter of the titin representations determined relative to the scale of an LMM 
dimer in the curved crystalline layer model. Thereafter, the scale of these drawings was reset with the 
outer diameter of the thick filament backbone, containing titin dimers, fixed at 13.0nm and this scale 
used for subsequent calculations in the present study (figure IV.6a). This value of 13nm was derived 
from the measurements of the native fish skeletal muscle A-band thick filament backbone, made by 
Squire et al., (1998) as being between 13 and 15nm. These empirically derived measurements were 
specifically chosen because they were corrected for the thickness of the metal coat used in electron 
microscopy studies, and also included the contribution made by the accessory thick filament 
proteins, titin and MyBPC. Specifically, the minimal value of 13nm was 
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chosen as titin would be expected to be present, and contribute to the diameter of the thick filament 
backbone, throughout the A-band, while MyBPC would only contribute to the diamerer of the thick 
filament backbone at seven to nine specific locations, where it is present.  
 
 
 
 
 
 
 
 
 
 
 
Figure IV.6. Incorporation of A-band titin into the thick filament backbone 
Diagramatic representaton of transverse sections of the thick filament backbone, showing the arrangement of 
LMM and titin dimers within the thick filament backbone that was drawn to scale. a) Arrangement of LMM in 
the thick filament backbone according to the curved crystalline layer model, also showing the proposed 
position of titin dimers within the surface grooves; b) arrangement of only LMM in the thick filament 
backbone according to the curved crystalline layer model.       ;   ; ;      = LMM dimers from different layers; 
     = titin molecules (modified from Chew and Squire, 1995). 
 
a)            b) 
13,0nm (8.67 grid units) ~11.7nm (7.78 grid units) 
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From the grid of these scale drawings, it was then possible to deduce the specific diameter of the 
thick filament in the absence of “accessory proteins,” which was estimated at being ~11.7nm (figure 
IV.6b). This value is slightly less than, but reconcilable with, the diameter of LMM thick filaments, 
according to the curved crystalline layer model proposed by Squire (1973). 
 
IV.3.1.3. Incorporation of cMyBPC into the curved crystalline model of the thick filament 
backbone  
 
Following the incorporation of titin dimers into the curved crystalline model of A-band thick 
filament quaternary structure, the quaternary structure, position and interactions of cMyBPC at its 
seven to nine specific positions within the A-band was considered. Several features of cMyBPC had 
to be taken into account, to achieve this. Firstly, the C10 domain of cMyBPC interacts with more 
than one LMM molecule (Okagaki et al., 1993; Miyamoto et al., 1999; Welikson and Fischman, 
2002), and it has been proposed that this domain of cMyBPC is partially imbedded in a surface 
groove of the thick filament backbone (Chew and Squire, 1995; Miyamoto et al., 1999). The specific 
orientation of the C10 domain in a surface groove as proposed by Miyamoto et al., (1999) (figure 
I.18) was, however, not considered essential, as this arrangement requires a deep groove on the 
surface of the thick filament formed by four LMM dimers (figure I.18), a feature absent from the 
curved crystalline layer model of Squire (1973) (figure IV.5), on which it was reportedly based. The 
data presented by Miyamoto et al., (1999) and Welikson and Fischman (2002), however, provide 
compelling evidence that the C10 domain interacts with more than one LMM dimer, thereby 
crosslinking LMM dimers. It was, therefore, considered essential that the C10 domain should be able 
to interact with at least two LMM dimers, preferably from two different layers of the curved 
crystalline layer model.  
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Secondly, the C9 and/or C10 domain(s) of cMyBPC is/are known to interact with C-zone titin 
(Labeit et al., 1992; Labeit and Kolmerer, 1995; Freiburg and Gautel, 1996). Additionally, the 
dimensions of the thick filament backbone, including the “accessory proteins” titin and MyBPC, as 
measured by Squire et al., (1998), as well as the dimensions of cMyBPC (Hartzell and Sale, 1985) 
and individual IgC2, Fn3 domains, and the positions of interdomain linkers in cMyBPC (Nave et al., 
1989; Labeit et al., 1992; Okagaki et al., 1993; Soteriou et al., 1993; Vinkemeier et al., 1993), had to 
be taken into account.  
 
Based on the interactions between the C5 and C8 and between the C7 and C10 domains of cMyBPC 
(Moolman-Smook et al., 2002), and the rationale supporting the collar model of cMyBPC quaternary 
structure (section IV.2) (Moolman-Smook et al., 2002), this model was assumed to be essentially 
correct. The basis of this model, viz., three cMyBPC molecules trimerising and forming a “tight 
collar” around the thick filament backbone, with overlap between the C5-C7 domains of one 
cMyBPC molecule with domains C8-C10 of another, was, therefore, kept. Moreover, based on the 
interaction between the C7 domain of cMyBPC and C-zone titin identified in this study (sections 
III.3.2.4, III.3.4.2 and IV.2.2), the C7 domain also had to be juxtapositioned with C-zone titin. 
 
Thus, the trimeric tight cMyBPC collar (Moolman-Smook et al., 2002) was incorporated into the 
curved crystalline layer model (Squire, 1973; Chew and Squire, 1995; Squire et al., 1998) into which 
the postulated positions of titin dimers had been integrated (section IV.6.1.2 and figure IV.6). From 
these detailed scale drawings, it appeared that two arrangements of the cMyBPC trimeric “tight 
collar” were possible, both of which fulfill all the requirements stated above (figures IV.7a and 
IV.7b).  
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The major differences between these two arrangements are, firstly, that, in the arrangement proposed 
in figure IV.7a, both domains C9 and C10 of cMyBPC would be able to interact with titin, while in 
the arrangement proposed in figure IV.7b, the C9 domain of cMyBPC would not be able to interact 
with titin. Previously, Freiburg and Gautel (1996) have implicated the C9 and C10 domains of 
cMyBPC in the binding of titin. From the data presented by Freiburg and Gautel (1996) it is, 
however, unclear whether both of these domains are involved in this interaction, or whether the 
major titin binding-site may, in fact, be located entirely on the C10 domain. Secondly, in figure 
IV.7a, the interdomain linker between the C9 and C10 domains, as well as the interdomain linker 
between the C6 and C7 domains of cMyBPC (Okagaki et al., 1993; http://smart.embl-
heidelberg.de/smart/), bridges the titin dimers in the major surface grooves. In the arrangement 
proposed in figure IV.7b, titin is bridged only by the interdomain linker between domains C7 and 
C8.  
 
In order to establish which of these two cMyBPC arrangements is more likely, the respective lengths 
of these interdomain linkers were obtained from Genbank (http://www.ncbi.nlm.nih.gov/entrez/; 
sequence accession NP_000247) and analysed using SMART and Pfam protein sequence analysis 
software (available at: http://smart.embl-heidelberg.de/smart/ and 
http://www.sanger.ac.uk/Software/Pfam/, respectively). The lengths of these interdomain linkers 
were found to be 15, 34 and 40 amino acid residues for the C6-C7, C7-C8 and C9-C10 linkers, 
respectively. The formula for calculating maximum chain length of peptides, used by Rief et al., 
(1997) and Tskhovrebova et al., (1997) to calculate the maximum chain length of extended IgC2 
domains in I-band titin (section I.6.4.2.iv), was used to calculate the respective maximal chain 
lengths of these interdomain linker peptides in this study. The maximum chain lengths of the C6-C7, 
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C7-C8 and C9-C10 interdomain linkers are calculated to be 3.75, 8.5 and 10nm, respectively (a value 
of ~0.25nm per amino acid residue).  
 
From the scale drawings of the curved crystalline layer model in which titin dimers were included 
(figure IV.6), it was estimated that the minimal linker length necessary to bridge titin dimers was 
about 2.8nm. It is, therefore, possible that any of these three interdomain linkers would be able to 
bridge titin dimers. The C6-C7 interdomain linker (15 amino acid residues) would, however, need to 
be extended to a length of close to its maximum chain length in order to do so, thus allowing for very 
little secondary structure of this linker, while the C7-C8 and C9-C10 linkers are of sufficient length 
to bridge titin, even if they took on a more compact secondary structure. Additionally, the 
interdomain linker separating the C7 and C8 domains, which spans the titin dimers in the 
arrangement depicted in figure 7b, was predicted to contain “regions of low compositional 
complexity”, while the other two linkers did not contain such regions. “Regions of low 
compositional complexity are regions of biased composition that are often mosaics of a small 
number of amino acids and have been shown to be functionally important in some proteins, but they 
are generally not very well understood” (data obtained from: 
http://www.sanger.ac.uk/Software/Pfam/).  
 
Recently Idowu et al., (2003) showed that about ten amino acid residues, previously predicted to be 
part of the interdomain linker separating the C4 and C5 domains of cMyBPC, by SMART and Pfam 
protein sequence analysis software, actually formed part of the C5 domain of cMyBPC. The 
possibility that predicted interdomain linkers separating domains C6 and C7, as well as between C9 
and C10, may also form part of the IgC2 and Fn3 domains by which they are flanked can, therefore, 
not be excluded. The finding that the interdomain linker between the C7 and C8 domains of 
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cMyBPC contains “regions of low compositional complexity,” however, suggests that this region 
would indeed be an interdomain linker, rather than forming part of either the C7 or C8 domain of 
cMyBPC.  
 
Furthermore, the dimensions of the thick filament backbone, including both titin and cMyBPC, were 
deduced from these scale drawings (figure IV.7a and b) and compared to the maximal diameter of 
the A-band native fish skeletal muscle thick filament backbone of 15nm (Squire et al., 1998). This 
value of 15nm was specifically chosen based on the fact that cMyBPC would only be present at, and 
contribute to the diameter of thick filaments in, seven to nine specific positions in the C-zone. The 
deduced diameters of thick filaments, in which the cMyBPC “tight collar” was arranged in the two 
possible fashions, were 15.60 and 15.35nm for the arrangements depicted in figures IV.7a and IV.7b, 
respectively. As both these values are in good agreement with the maximal measured diameter of A-
band native fish skeletal muscle thick filament of 15nm (Squire et al., 1998), neither of these 
arrangements could be excluded on this basis. The finding that the linker between the C6 and C7 
domains of cMyBPC may be too short to bridge titin, combined with the finding that the dimensions 
obtained from the scale drawing of the conformation depicted in figure IV.7b is closer to the 
measured values of Squire et al., (1998), has led to the arrangement depicted in figure IV.7b being 
favoured by this author. Future candidate-ligand assays may help distinguish between the two 
models.  
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Figure IV.7 Incorporation of cMyBPC into the thick filament backbone 
Diagrammatic representation of transverse sections of the thick filament backbone, showing the proposed 
arrangement of LMM and titin dimers, as well as cMyBPC molecules within the thick filament backbone, that 
was drawn to scale. Two possible arrangements of the cMyBPC trimeric “tight collar” are depicted in a) and 
b), respectively.      ;    ;       molecules = three consecutive partial cMyBPC molecules trimerising  
to form a “tight collar” around the thick filament backbone;      ;     ;     = LMM dimers from different layers; 
     = titin molecules. The N-terminal regions of cMyBPC molecules (domains C0 to C3) are not indicated in 
the figure and are expected to extend into the interfilament space (modified from Chew and Squire, 1995). 
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IV.3.2. EFFECT OF cMyBPC PHOSPHORYLATION ON THICK FILAMENT BACKBONE 
STRUCTURE 
 
Several studies have shown that phosphorylation of cMyBPC results in an expansion in the thick 
filament diameter in αMHC-containing thick filaments, which encompasses changes both in thick 
filament backbone and crossbridge structure (Weisberg and Winegrad, 1996; Weisberg and 
Winegrad, 1998; Levine et al., 2001). As discussed in sections I.7.6 and I.7.7, it is likely that this 
expansion in the thick filament backbone would be the result of cMyBPC being either di- or tri-
phosphorylated by PKA, following β-adrenergic stimulation, thus giving rise to the “loose” thick 
filament structure (Gautel et al., 1995; Weisberg and Winegrad, 1996; Weisberg and Winegrad, 
1998; Levine et al., 2001). The effect of this phosphorylation event on the quaternary structure of the 
A-band thick filament backbone has, however, not been studied in detail to date. 
 
In particular, the studies of Weisberg and Winegrad (1996 and 1998) and Levine et al., (2001) 
merely measured the increase in total thick filament dimensions upon cMyBPC phosphorylation and 
did not consider how much of this increase in diameter was due to expansion of the thick filament 
backbone itself (figure IV.8 and box 2). Moreover, as the measurements made by Weisberg and 
Winegrad (1996 and 1998) and Levine et al., (2001) were not corrected for the thickness of the metal 
coat used in electron microscopy, absolute values of thick filament diameter could not be used 
directly in conjunction with Squire’s values.  
 
The data from the Winegrad laboratory were, therefore, used in the present study to calculate the 
relative magnitude of thick filament backbone expansion, and this value added to the measurements 
of the A-band fish skeletal muscle thick filament backbone made by Squire et al., (1998). These 
calculations were done by, firstly, calculating the diameter of the A-band thick filament backbone by  
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subtracting the distance that the crossbridges extend into the interfilament space from the total 
diameter of the thick filaments in which cMyBPC was either unphosphorylated, or fully 
phosphorylated, by PKA. The magnitude of the expansion of the thick filament backbone was then 
calculated by deducting the backbone diameter when cMyBPC was phosphorylated from its diameter 
when cMyBPC was unphosphorylated (box 2). From these calculations, the diameter of the thick 
filament backbone was calculated to increase by between 14.6nm (deduced from data presented by 
Weisberg and Winegrad, 1998) and 15.6nm (deduced from data presented by Weisberg and 
Winegrad, 1996) following phosphorylation of cMyBPC by PKA (calculations shown in box 2). 
Consequently, when these values were added to the diameter of the A-band fish skeletal muscle thick 
filament backbone previously reported by Squire et al., (1998), it was estimated that the diameter of 
the thick filament backbone itself would increase to about 29.6 to 30.6nm, following cMyBPC 
phosphorylation. 
 
a)      b) 
 
Figure IV.8. Dimensions of α-myosin “tight” and “loose” heavy chain containing cardiac thick filaments  
Measurements of the cardiac muscle A-band thick filament when a) cMyBPC is unphosphorylated (thick 
filaments with a “tight” structure) and b) cMyBPC is triphosphorylated by PKA (thick filaments with a 
“loose” structure).     = thick filament backbone;      = crossbridge extensions. The total dimensions of the 
thick filament, as well as the extent of crossbridge extension, as measured Weisberg and Winegrad (1998) is 
shown in a) and b) when cMyBPC was unphosphorylated and triphosphorylated, respectively. 
 
 
~7nm 
~2nm 
Thick 
filament 
diameter 
~31nm 
~2.2nm 
Thick 
filament 
diameter 
~36nm 
 299
 
 
 
 
 
 
 
 
 
 
 
 
 
TF = thick filament 
 
 
BOX 2 
FORMULAE 
 
       TF backbone diameter = Total maximal TF diameter – 2(Maximal crossbridge extension) 
 
       TF backbone diameter expansion = Maximal TF backbone diameter cMyBPC-PO4 – MaximalTF backbone diameter cMyBPC 
 
 
 
TF backbone diameter cMyBPC*  = 30nm* – 2(7nm#)  *Values obtained from Weisberg and Winegrad, 1996 
     = 16nm    #Values obtained from Weisberg and Winegrad, 1998 
          
TF backbone diameter cMyBPC-PO4* = 36nm* – 2(2.2nm#) 
     = 31.6nm   As the distances that crossbridges extend into the interfilament 
         space was not given in the study by Weisberg and Winegrad   
TF backbone diameter expansion*  = 31.6nm – 16nm  (1996), values of 7nm when cMyBPC was unphosphorylated 
     = 15.6nm   and 2.2nm when cMyBPC was phosphorylated, measured by 
         Weisberg and Winegrad (1998) were used when calculating  
TF backbone diameter cMyBPC#  = 31nm# – 2(7nm#)  thick filament backbone diameters. 
     = 17nm 
         None of the measurements obtained from these studies were  
TF backbone diameter cMyBPC-PO4# = 36nm# – 2(2.2nm#)  corrected for the thickness of the metal coat applied to thick  
     = 31.6nm   filaments prior to X-ray diffraction. 
 
TF backbone diameter expansion#  = 31.6nm – 17nm  Specific values given in table I.4 
     = 14.6nm 
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It is plausible that this expansion of the thick filament is facilitated by, or at least necessitates, the 
abolition of interactions between the C5 and C8 domains, the C7 and C10 domains, as well as the 
interaction between the C7 domain of cMyBPC and titin, following PKA-dependent phosphorylation 
of cMyBPC. The mechanisms through which the PKA-dependent phosphorylation of sites in the 
MyBPC-motif, located in the N-terminal region of the protein, results in the abolition of these 
interactions between domains located in the central to C-terminal region of cMyBPC are, however, 
still unclear. The long distance effects of PKA-dependent phosphorylation of sarcomeric components 
are, however, not unprecedented. It was, for instance, shown that PKA-dependent phosphorylation of 
residues in the N-terminal region of cTNI causes conformational changes in cTNC, resulting in a 
significant reduction in the affinity of cTNC for Ca2+ (Chandra et al., 1997).  
 
IV.3.2.1. Proposed structure of LMM dimers in the “expanded” thick filament backbone 
 
In order to gain an understanding of how LMM dimers, arranged in the curved crystalline layer 
model, may be rearranged to give rise to an “expanded” thick filament structure, another series of 
scale drawings was made in the present study (figure IV.9). In these scale drawings, it was assumed 
that the different layers of LMM dimers in the curved crystalline layer model would slide across each 
other, thus allowing all 36 LMM dimers to be arranged in a circular structure (figure IV.9). 
Furthermore, it was assumed that the inter-molecular spacing between LMM dimers of about 0.2nm, 
predicted in the curved crystalline layer model (Squire, 1973), would be retained following 
expansion of the thick filament backbone.  
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Figure IV.9. Proposed mechanism of LMM thick filament expansion 
Scale drawings of the arrangement LMM dimers in the thick filament backbone. a) Arrangement of LMM 
molecules in the thick filament backbone according to the curved crystalline layer model of Squire, (1973) 
(“compact” arrangement); d) proposed arrangement of LMM dimers in the “expanded” thick filament 
following phosphorylation of cMyBPC; b) and c) show possible intermediate arrangements of LMM dimers, 
showing how the various layers of LMM dimers might shift across each other to form the circular 
“expanded” arrangement depicted in d). The estimated diameters of the “compact” and “expanded” 
arrangements are indicated in a) and d), respectively.                  = LMM dimers from different layers in the 
curved crystalline layer model.  
~11.7nm (7.78 grid units) 
21.6nm (14.40 grid units) 
a)     b)
c)     d)
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From these scale drawings, the maximal diameter of thick filaments consisting of only LMM dimers 
was estimated as being about 21.6nm (figure IV.9). The possibility that expansion of the thick 
filament backbone may also result in an increase in the inter-molecular spacing of LMM dimers, thus 
resulting in the generation of a thick filament with a larger diameter, cannot be dismissed.  
 
IV.3.2.2. Position of titin dimers on the “expanded” thick filament backbone 
 
Following the construction of these scale drawings of “expanded” thick filaments consisting entirely 
of LMM dimers, the positions of titin dimers in the thick filament backbone were considered. Firstly, 
it was assumed that titin dimers would remain on the surface of the thick filament, where they would 
retain interaction with LMM dimers. When positioning titin dimers on the “expanded” LMM 
backbone, it was considered that titin dimers would, in all likelihood, remain in contact with the 
same LMM dimers as in the “compact” thick filament conformation (figures IV.6 and IV.7). In the 
“compact” thick filament conformation, however, titin dimers interacted with LMM dimers from 
different layers, thus indicating that at least one of the titin:LMM interactions would have to be 
abolished during the expansion of the thick filament backbone. Depending on the specific interaction 
abolished, it is possible that titin dimers could be positioned at two different positions on the LMM 
backbone (figures IV.9b and IV.9c). From scale drawings to which titin dimers were added in the 
two possible positions depicted in figures IV.9b and IV.9c, the diameter of the “expanded” thick 
filament, including titin, was deduced to be about 23.1nm, irrespective of whether titin dimers were 
positioned as depicted in either figure IV.10b or IV.10c. 
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Figure IV.10. Proposed positions of titin dimers on the “expanded” LMM thick filament backbone 
a) Position of LMM dimers on the “compact” thick filament backbone, b) and c) two possible positions of titin 
dimers on the thick filament backbone following expansion thereof.                  = LMM dimers from different 
layers;        = titin molecules.  
 
~27.9nm (16.6 grid units)
~27.9nm (16.6 grid units)
13,0nm (8.67 grid units) 
a.) 
b.) 
c.) 
23.10nm (15.4 grid units)
23.10nm (15.4 grid units) 
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IV.3.2.2. Position of cMyBPC on the “expanded” thick filament backbone 
 
Following the addition of titin dimers to the proposed model of the quaternary structure of the 
“expanded” thick filament backbone, cMyBPC was integrated into this model. In order to allow the 
positioning of cMyBPC on the “expanded” thick filament backbone, several factors had to be taken 
into account. The interactions between the C10 domain of cMyBPC and LMM (Okagaki et al., 
1993; Miyamoto et al., 1999; Welikson and Fischman, 2002), as well as that between the C9 and/or 
C10 domain(s) of cMyBPC and titin (Freiburg and Gautel, 1996), were considered to be constitutive, 
irrespective of the phosphorylation state of cMyBPC, as these interactions are responsible for the C-
zone localisation and anchoring of cMyBPC (section IV.7). If the “tight collar” arrangement of 
cMyBPC, depicted in figure IV.7b, is accepted to be correct, it would allow the positioning of the 
C10 domain on the “expanded” thick filament backbone in such a way that it would retain interaction 
with the same two LMM dimers as in the “compact” conformation (figure IV.11). Additionally, if 
titin dimers are arranged on the “expanded” thick filament backbone, as depicted in figure IV.10b, 
the C10:titin interaction would be retained (figure IV.11). 
 
Following the expansion of the thick filament backbone, the portion of the cMyBPC N-terminal of 
the C10 domain could assume two possible conformations. Firstly, it is possible that the collar would 
be completely abrogated and that cMyBPC would extend into the interfilament space, where its N-
terminal portion could interact with other sarcomeric components. Alternatively, the trimeric collar 
conformation of cMyBPC might not be lost, but may assume a looser conformation. To investigate 
the latter scenario, scale drawings were constructed in which cMyBPC would form a trimeric, 
predominantly single layer, “loose collar” around the thick filament backbone (figure IV.11b). From 
these scale drawings, the diameter of the thick filament backbone, including both titin and cMyBPC, 
was estimated at being about 27.9nm, a value that is compatible with the values calculated for the
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diameter of the “expanded” thick filament backbone of about 29.6nm to 30.6nm (box 2) (Weisberg 
and Winegrad, 1996; Weisberg and Winegrad, 1998).  
 
It appeared from these scale drawings that, in this model of the “expanded” thick filament, the C10 
domain of cMyBPC would be juxtaposed to the C3 domain in the “loose collar” conformation. It 
was, therefore, postulated that if the cMyBPC trimeric single layer “loose collar” could form around 
the thick filament backbone (figure IV.11b), it may be stabilised by an interaction between these two 
cMyBPC domains. In order to test this proposal, Y2H candidate-ligand assays were performed. 
These assays clearly showed that the C3 domain of cMyBPC specifically interacted with the C10 
domain of cMyBPC, whereas domains C2 and C5 did not (figure III.44 and section III.3.4.5)*. This 
finding, combined with the fact the arrangement of cMyBPC depicted in figure IV.11b produces an 
“expanded” thick filament with a diameter that is in step with the measurements of Weisberg and 
Winegrad (1996 and 1998), suggests that cMyBPC is likely to form a trimeric single layer “loose 
collar” around the “expanded thick” filament backbone. However, the possibility that the cMyBPC 
collar conformation may be completely abrogated under certain circumstances cannot be excluded by 
this study. 
 
                                                 
* Subsequent experiments showed that a frame-shift mutation occurred in the pGBKT7-C3 bait construct used in these 
experiments. These results should, therefore, be considered preliminary until tested. 
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Figure IV.11. Proposed arrangement of cMyBPC “loose collar” around the “expanded” thick filament backbone 
Scale drawings depicting transverse sections of the thick filament backbone in its a) “compact” and b) “expanded” state, showing the arrangement of 
LMM and titin dimers, as well as cMyBPC, within the thick filament backbone.               molecules = three consecutive partial cMyBPC molecules 
trimerising to form a) a “tight”, double layer and b) a loose, predominantly single layer, collar around the thick filament backbone;                 = LMM 
dimers from different layers;      = titin molecules. The N-terminal regions of cMyBPC molecules (domains C0 to C3 in a) and domains C0 to C2 in b)) 
are not indicated in the figure and are predicted to extend into the interfilament space. 
~27.9nm (16.6 grid units) 
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IV.3.3. PHYSIOLOGICAL EFFECT(S) OF cMyBPC MEDIATED EXPANSION OF THE 
THICK FILAMENT BACKBONE 
 
Expansion of the thick filament backbone (transition of thick filaments from a “tight” to a “loose” 
structure), following the PKA-dependent phosphorylation of cMyBPC, results in crossbridges being 
brought into closer proximity to the thin filament, thereby favouring the formation of weak 
interactions between thick and thin filaments (Weisberg and Winegrad, 1996; Weisberg and 
Winegrad, 1998; Levine et al., 2001). The formation of these weak interactions potentiates the 
contractile apparatus, resulting in an increase in force production, in actomyosin ATPase activity and 
in crossbridge cycling rates during systole (Weisberg and Winegrad, 1996; Weisberg and Winegrad, 
1998; Levine et al., 2001). This view is in step with the findings of England (1975) and Solaro et al., 
(1976), who showed that β-adrenergic stimulation of intact cardiac muscle results in a marked 
increase in contractile force, of up to 70%, which is likely to be the result of the PKA-dependent 
phosphorylation of cMyBPC (sections I.4, I.5, I.6 and I.7.7) (McClellan et al., 1994). The increase in 
the number of crossbridges forming weak interactions with the thin filament may, however, impair 
relaxation, ventricular filling and diastolic function during periods of β-adrenergic stimulation.  
 
The models of thick filament and cMyBPC quaternary structure in its “compact” and “expanded” 
state have important implications concerning the regulatory functions of cMyBPC, by suggesting a 
mechanism through which cMyBPC might regulate the dimensions of the thick filament backbone 
(Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; Levine et al., 2001). Offer et al., 
(1973) found that the addition of purified skeletal MyBPC reduced actomyosin ATPase activity of 
isolated myosin and F-actin by about 50% in a Ca2+-independent fashion, indicating that MyBPC 
plays an inhibitory, rather than an activatory, role (Offer et al., 1973). In the light of this finding, it is 
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likely that the increase in actomyosin activity, observed following the phosphorylation of cMyBPC, 
may abolish the inhibitory effect of MyBPC on actomyosin activity. The phosphorylation-dependent 
abolition of this inhibitory effect of cMyBPC is likely to happen in two stages. Firstly, the release of 
myosin S2 from the MyBPC-motif, following phosphorylation of site B in the MyBPC-motif by 
MyBPC-associated kinase, results in alterations in crossbridge structure (Gruen et al., 1999; Kunst et 
al., 2000), leading to an increase in actomyosin ATPase activity. Secondly, the PKA-dependent 
phosphorylation of sites A and C in the MyBPC-motif would result in the release of the cMyBPC 
“tight collar”, causing expansion of the thick filament backbone to a diameter of about 28nm, 
thereby bringing crossbridges into closer proximity to thin filaments, resulting in an increase in 
actomyosin ATPase activity (Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; Levine 
et al., 2001). From these findings, it may be concluded that, in the absence of MyBPC, thick 
filaments are more likely to take on an “expanded,” rather than a “tight”, conformation. 
 
In conclusion, therefore, data generated in this and other studies was used to construct detailed 
integrated models of the quaternary structure of the A-band thick filament backbone both in the 
presence, and absence, of phosphorylation of cMyBPC by PKA. These models provide new insights 
into the mechanisms through which phosphorylation of cMyBPC by PKA results in increased 
actomyosin ATPase activity. Furthermore, these models have assigned either experimental or 
putative functions to several domains of cMyBPC to which no function was previously ascribed. As 
HCM-causing missense mutations are found in several of these domains, the models proposed in this 
study may be invaluable in gaining an understanding of how these mutations may have their 
pathogenic effect (section IV.5). 
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IV.4. Y2H-ANALYSIS OF THE N-TERMINAL REGION OF cMyBPC 
 
The exon 7 SaS +1 g>a splicing mutation is postulated to result in the generation of a truncated 
peptide consisting of only the C0 domain, the PA-region, a partial C1 domain and 90 novel amino 
acids (section IV.1.2.2). Based on the hypothesis that truncated cMyBPC peptides are likely to act as 
“poison peptides”, rather than through haploinsufficiency (sections I.1.1.1 and I.7.8.2), it was 
proposed that this region of the protein (C0C1) contained, as yet, unidentified protein binding-site(s), 
allowing this peptide to be incorporated into the sarcomeric A-band. This hypothesis is supported by 
the finding that C0C1 is incorporated specifically into the sarcomeric A-band (Flavigny et al., 1999), 
suggesting that the C0C1 region of cMyBPC contains an A-band specific binding-site. In order to 
test this hypothesis, the C0C1 region of cMyBPC and the C0 domain of cMyBPC were used in Y2H 
library-assays.  
 
IV.4.1. Y2H LIBRARY-ASSAYS IN WHICH THE C0C1 REGION OF cMyBPC WERE 
USED AS BAIT 
 
In the first of these assays, the C0C1 region of cMyBPC was used to screen a cardiac cDNA library, 
using the MATCHMAKER GAL4 Two-Hybrid System 2 (BD Biosciences, Clontech, Palo Alto, 
CA, USA) (cMyBPC C0C1 Y2H library-assay (1)). This assay allowed the identification of human 
Jun coactivator (COP9 subunit 5) (two independent clones) and human homeobox protein MOX-1 
(one clone) as putative ligands of the C0C1 region of cMyBPC. Neither of these proteins was, 
however, considered a plausible ligand of cMyBPC, as they both are reported to have a nuclear 
localisation. As this library-assay failed to identify any plausible ligands of the C0C1 region of 
cMyBPC, this library screen was subsequently repeated using the MATCHMAKER GAL4 Two-
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Hybrid System 3 (BD Biosciences, Clontech, Palo Alto, CA, USA), that only became available 
during this study.  
 
The MATCHMAKER GAL4 Two-Hybrid System 3 (hereafter referred to as system 3), was used in 
this and other Y2H library-assays, as it had several advantages over the MATCHMAKER GAL4 
Two-Hybrid System 2 (hereafter referred to as system 2). Firstly, in addition to the HIS3, ADE2 and 
lacZ reporter genes provided by yeast strain PJ69 2A used in system 2, yeast strain AH109, used in 
system 3, also provides the MEL1 reporter gene, thus allowing further elimination of false positive 
interactions by means of X-α-gal assays (MATCHMAKER GAL4 Two-Hybrid System 3 & libraries 
user manual, BD Biosciences, Clontech, Palo Alto, CA, USA). Secondly, in the bait-vector used in 
system 3 (pGBKT7), the T7 RNA polymerase promoter, rather than the ADH1 promotor sequence 
contained in the bait-vector used in system 2 (pAS2.1), facilitates high-level bait fusion-protein 
expression, thus allowing the detection of weak interactions (MATCHMAKER GAL4 Two-Hybrid 
System 3 & libraries user manual, BD Biosciences, Clontech, Palo Alto, CA, USA). Thirdly, as the 
bait and prey-vectors used in system 3 contain different antibiotic resistance genes (kanamycin and 
ampicillin, respectively) (a feature not present in system 2), the isolation and purification of prey-
vectors encoding putative interactor peptides was greatly simplified (MATCHMAKER GAL4 Two-
Hybrid System 3 & libraries user manual, BD Biosciences, Clontech, Palo Alto, CA, USA). Finally, 
bait and prey fusion-proteins, expressed by vectors used in system 3, contained different epitope tags 
(c-Myc and hemagglutinin, respectively), allowing the isolation and use of fusion-peptides in CoIP 
assays (MATCHMAKER GAL4 Two-Hybrid System 3 & libraries user manual, BD Biosciences, 
Clontech, Palo Alto, CA, USA). 
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The second Y2H library-assay (cMyBPC C0C1 Y2H library-assay (2)) identified the C-terminal 
region of human titin (six independent clones), human multiple PDZ domain protein (two 
independent clones) and human cytochrome c oxidase subunit I (three independent clones) as 
putative ligands of the C0C1 region of cMyBPC. Based on its cellular localisation in the 
mitochondrial inner membrane, cytochrome c oxidase subunit I was not considered a plausible ligand 
of cMyBPC.  
 
Additionally, as multiple PDZ domain protein, a “scaffolding” protein, is predominantly a nuclear 
protein, it was not considered to be of specific significance to the present study. However, as minor 
fractions of this protein are found in the cytoplasm and cytoskeletal lattice (localisation according to 
PSORT II, available at: http://psort.ims.u-tokyo.ac.jp/cgi-bin/runpsort.pl), it is possible that multiple 
PDZ domain protein may facilitate the crosslinking of the N-terminal region of cMyBPC and other 
ligands, and may, therefore, require further investigation. Based on its sarcomeric localisation, titin 
was, however, considered a plausible ligand of cMyBPC and was, therefore, investigated further in 
Y2H candidate-ligand assays (section IV.4.3.1). 
 
IV.4.2. Y2H LIBRARY-ASSAY IN WHICH THE C0 DOMAIN OF cMyBPC WAS USED AS 
BAIT 
 
The Y2H library-assay in which the C0 domain of cMyBPC was used as bait was performed using 
Y2H system 3 (BD Biosciences, Clontech, Palo Alto, CA, USA). This assay identified human 
sarcoglycan (delta subunit) (one clone), human tousled–like kinase 1 (also known as protein kinase 
U) (one clone), the beta-1 chain of human sodium/potassium-transporting ATPase (one clone) and 
human Ran binding protein 9 (two independent clones) as putative ligands of the C0 domain of 
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cMyBPC. Interaction-specificity tests, however, showed that the sarcoglycan delta subunit, tousled-
like kinase 1, the sodium/potassium-transporting ATPase and RAN binding protein 9 all led to 
activation of reporter gene transcription in the presence of heterologous baits (table III.13). These 
proteins were, therefore, not considered to be specific ligands of the C0 domain of cMyBPC.  
 
Additionally, eight putative interactor clones contained portions of human clone RP4-614C10 from 
chromosome 2. Analysis of the sequences contained in these clones, as well as the specific portion, 
and the region 5’, of human clone RP4-614C10 to which they mapped, revealed the absence of any 
known genes, or any open reading frames of any significant length. Based on this finding, it was 
concluded that these clones do not encode plausible binding partners of the C0 domain of cMyBPC. 
 
It is interesting to note that there was no overlap between putative interactor clones identified in the 
C0 and C0C1 library screens. One possible explanation for this apparent discrepancy is that the 
tertiary/quaternary structure of the C0C1 region may sterically hinder the association between the C0 
domain and peptides identified as spuriously interacting with it in the C0 library-assay. 
 
IV.4.3. Y2H CANDIDATE-LIGAND ASSAYS IN WHICH THE N-TERMINAL DOMAINS 
OF cMyBPC WERE USED AS BAIT 
 
IV.4.3.1. C-zone titin as a candidate-ligand of the N-terminal region of cMyBPC 
 
Six of the interactor clones identified in the cMyBPC C0C1 Y2H library-assay (2) encoded portions 
of the C-terminal region of titin, which varied in size from 34 to 69 amino acids in length (sections 
III.2.2, IV.4.1 and table III.9). As the region of titin encoded by these clones would be embedded in 
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the M-line in the intact sarcomere, while cMyBPC is found in the C-zone, the region encoded by 
these clones was not considered to be a plausible ligand of cMyBPC (figure III.39). The shortest of 
these peptides were, however, virtually identical to the 35 amino acid peptide that was identified as 
an informative ligand in the C7 Y2H library-assay. As this 35 amino acid peptide was shown to share 
the highest homology to the first IgC2 domain of each of the eleven-domain super-repeats of C-zone 
titin (sections I.6.3.2, III.3.3; figures I.9, III.39, III.40 and table III.16), these titin domains were 
considered plausible ligands of the C0C1 region of cMyBPC.  
 
The candidacy of C-zone titin as a ligand of the C0C1 region of MyBPC is supported by the findings 
of Flavigny et al., (1999), who showed that truncated cMyBPC peptides consisting only of the C0C1 
region, were incorporated specifically into the sarcomeric A-band. Bennett et al., (1986 and 1999), 
however, showed that antibodies directed against either the N- or C-terminal regions of MyBPC 
labelled two distinct lines about 15-20nm apart. This finding largely excluded the possibility that the 
C0C1 region of cMyBPC would interact with the first IgC2 domain of the eleven-domain super-
repeat of C-zone titin, as the C-terminal region of cMyBPC would be bound to these domains. Based 
on this finding, combined with the fact that the C0C1 region of cMyBPC is able to interact with a 
partial IgC2 domain (domain M10 of titin) (sections III.2.2 and IV.4.1), it was postulated that the 
C0C1 region may interact with IgC2 domains in C-zone titin, other than the first domain of the 
eleven-domain super-repeat.  
 
As the N-terminal region of cMyBPC was shown to be located about 15-20nm closer to the Z-disk 
than the C-terminal of cMyBPC, it was postulated that the C0C1 (N-terminal) region of cMyBPC 
may interact with the third IgC2 domain of the previous eleven-domain super-repeat of C-zone titin 
(figures III.39 and IV.11). If this were so, it would be expected that the N- and C-termini of cMyBPC 
would be separated by about 12 to 14nm. This predicted distance is slightly less than, but compatible 
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with, the measurements of Bennett et al., (1986 and 1999). Furthermore, it was postulated that the 
presence of an interaction between the N-terminal region of cMyBPC and C-zone titin may also 
allow the formation of thick filaments with a “disordered” structure observed when cMyBPC is 
unphosphorylated (Weisberg and Winegrad, 1996; Weisberg and Winegrad, 1998; Levine et al., 
2001), as some crossbridges may be pulled towards the thick filament backbone (figure IV.12). 
 
As C-zone titin was not expected to be represented in the cardiac cDNA library that was screened, 
due to the gigantic size of titin transcript (>27kb) (section II.16.2.1), Y2H candidate-ligand assays 
were performed to test whether the C0C1 region of cMyBPC did indeed interact with IgC2 domains 
of C-zone titin. In these assays, the third IgC2 domain of the seventh eleven-domain super-repeat of 
A-band titin (domain A116 of titin) was used as candidate prey in Y2H candidate-ligand assays 
(figure III.39). Additionally, other constructs, representing the first (domain A43 and A109 of titin) 
and second (domain A112 of titin) IgC2 domains of the first and seventh eleven-domain super-
repeat, as well as a construct representing the first four domains of the seventh eleven-domain super-
repeat of titin, were used as candidate-ligands in Y2H candidate-ligand assays (figure III.39). These 
assays, however, showed that the C0C1 region of cMyBPC did not interact with any of the IgC2 
domains of C-zone titin, indicating that the orientation of the N-terminal region of cMyBPC depicted 
in figure IV.12 is unlikely.  
 
IV.4.3.2. N-terminal domains of cMyBPC as candidate-ligands of the N-terminal region of 
cMyBPC 
 
Based on the findings of Flavigny et al., (1999), which showed that truncated cMyBPC peptides, 
consisting only of the C0C1 region, were incorporated specifically into the sarcomeric A-band, it 
was postulated that the C0C1 region of cMyBPC interacts with an A-band specific ligand. In the 
light of this finding, it was postulated that this region of cMyBPC may be able to interact with other 
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Figure IV.12. Proposed orientation of the N-terminal portion of cMyBPC 
Side-on view of the “compact” thick filament in the C-zone, depicting the positions of crossbridges, cMyBPC 
and titin. cMyBPC is depicted in its unphosphorylated state in which the C-terminal domains trimerise to 
form a “tight collar” around the thick filament backbone, the MyBPC-motif interacting with myosin S2 and 
the C0C1 (N-terminal) region interacting with the third IgC2 domain of the previous eleven-domain super-
repeat of C-zone titin (adjacent eleven-domain super-repeat towards the Z-disk). The relative positions 
of the N-terminal region of cMyBPC and crossbridges in the absence of an interaction between the C0C1 
region of cMyBPC and C-zone titin are also depicted as shaded white structures. In the interest of clarity, 
only crossbridges from every third crown are shown.            molecules = cMyBPC molecules;     = Fn3 
domains of C-zone titin;     = IgC2 domains of C-zone titin;     structures = myosin molecules, of which LMM 
forms the body of the thick filament backbone. The second (fn3) and eleventh (IgC2) domains of one of the C-
zone titin eleven-domain super-repeat is labled in the figure, while the arrows labled M and Z indicate the 
directions in which the M-line and Z-disk is located, respectively. 
2             11 
Z M
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N-terminal domains of cMyBPC itself. As the N-terminal region of cMyBPC was not expected to be 
represented in the cardiac cDNA libraries that were screened, due to the size of cMyBPC transcript 
(>4.1kb) (section II.16.2.1), Y2H candidate-ligand assays were performed to test whether the C0C1 
region of cMyBPC did indeed interact with other domains/regions in the N-terminal region of 
cMyBPC. In these assays, the C0, C0C1 and C0C2 domains/regions of cMyBPC were used as baits, 
while the C1, C2 and C1C2 domains/regions of cMyBPC were used as preys. No interactions 
between any of these domains/regions were detected in these assays, indicating the absence of any 
inter-molecular or intra-molecular interactions between domains/regions in the N-terminal portion of 
cMyBPC. 
 
IV.4.3.3. Cardiac actin as a candidate-ligand of the N-terminal region of cMyBPC 
 
As the C0 domain of cMyBPC was shown to interact with cardiac actin monomers in in vitro 
binding-assays (Kulikovskaya et al., 2003), combined with the proposal by Squire et al., (2003) that 
the PA-region of cMyBPC may interact with cardiac F-actin (sections I.7.3.5 and I.7.7.3), cardiac 
actin was considered a candidate ligand of the C0C1 region of cMyBPC. Cardiac actin was, 
however, not identified as a candidate ligand of this region of cMyBPC in the cMyBPC C0 Y2H 
library-assay (sections III.3.2.3and IV.4.2) or either the Y2H library-assays in which the C0C1 
region of cMyBPC was used as bait (sections III.3.2.1, III.3.2.2 and IV.4.1). This finding was 
surprising due to the fact that, firstly, a high level of cardiac actin expression is expected in cardiac 
tissue, indicating that multiple cardiac actin clones should be present in the cardiac cDNA libraries 
screened. Secondly, due to the relatively small size of the cardiac actin transcript (1.5kb), it was 
anticipated that full-length cardiac actin clones would be present in the cardiac cDNA libraries 
screened. 
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The presence of cardiac actin clones in the cardiac cDNA libraries that were screened in this study 
was subsequently confirmed when cardiac actin was identified as a putative ligand of the tri-
phosphomimic C1C2 region of cMyBPC in a Y2H library-assay in which an identical cardiac cDNA 
library was used (personal communication Dr Hanlie Moolman-Smook, 10 April 2003). In addition 
to the Y2H library-assays in which the C0 and C0C1 regions of cMyBPC were used as bait, these 
regions were also used as bait in candidate-ligand Y2H-assays in which cardiac actin clones, 
identified as putative ligands of the C1C2 region, were used as preys. These candidate-ligand Y2H 
assays, however, failed to show any interaction between this region of cMyBPC and cardiac actin.  
 
There may be several explanations as to why the interaction between the C0C1 region of cMyBPC 
and cardiac actin remained undetected in Y2H assays. Firstly, it is possible that the N-terminal 
region of cardiac actin, absent from the clones used as prey in the candidate-ligand-assays, is 
essential for its interaction with the N-terminal region of cMyBPC. However, full-length cardiac 
actin transcripts are expected to have been in abundance in the cardiac cDNA libraries screened, 
using the N-terminal region of cMyBPC as bait. Secondly, it is possible that the position of the 
GAL4-AD that is part of the actin prey fusion-peptide may sterically hinder the binding of the 
cardiac actin fusion-peptide to the C0C1 region of cMyBPC. If this is the case, it would be 
impossible to detect an interaction between cardiac actin and the C0C1 region of cMyBPC using 
Y2H-assays. However, the GAL4-AD did not hinder the interaction between actin clones and the 
C1C2 region of cMyBPC in a Y2H library-assay. Thirdly, it is possible that, even though 
Kulikovskaya et al., (2003) showed binding between the C0 domain of cMyBPC and cardiac actin in 
vitro, such an interaction does not occur in an in situ environment. In order to establish whether the 
latter scenario is plausible, the results obtained by Kulikovskaya et al., (2003) in in situ experiments 
were re-interpreted. 
 318
In these experiments by Kulikovskaya et al., (2003), skinned cardiac trabeculae were soaked in a 
relaxing solution containing low concentrations of either C0C1, C1C2, or C0C2 cMyBPC fragments. 
It was shown that in trabeculae in which cMyBPC was predominantly unphosphorylated, C1C2 
cMyBPC fragments were not bound to the trabeculae, but that C0C1 and C0C2 cMyBPC fragments 
did bind to the trabeculae. The authors interpreted these results as suggesting that all cMyBPC 
binding-sites on myosin S2 are occupied by endogenous cMyBPC (through the MyBPC-motif), thus 
not allowing the binding of exogenous C1C2 cMyBPC fragments. The fact that C0C1 and C0C2 
cMyBPC fragments were bound to these trabeculae was interpreted as suggesting that cMyBPC 
binding-sites on F-actin would be free of endogenous cMyBPC, therefore, allowing interaction with 
exogenous C0C1 and C0C2 cMyBPC fragments. Conversely, in trabeculae with a high degree of 
phosphorylation, C0C1 cMyBPC fragments were not bound to the trabeculae, while C1C2 and C0C2 
cMyBPC fragments did bind to the trabeculae (Kolikovskaya et al., 2003).  
 
These results suggested that, in cases where MyBPC were predominantly phosphorylated, and the 
MyBPC-motif was not bound to myosin S2 (Gruen et al., 1999; Kunst et al., 2000), the cMyBPC 
binding-sites on F-actin would be occupied by endogenous cMyBPC, thus not allowing exogenous 
C0-containing cMyBPC fragments to bind to actin. Exogenous cMyBPC fragments in which the 
MyBPC-motif was present (C0C2 and C1C2) would, however, be able to bind to trabeculae through 
interaction with myosin S2 (Kolikovskaya et al., 2003). It was, therefore, suggested that these 
interactions of the N-terminal region of cMyBPC were competitive and that the phosphorylation 
status of cMyBPC would determine whether the MyBPC-motif would interact with myosin S2 
(Kunst et al., 2000), or the C0 domain would interact with F-actin (Kolikovskaya et al., 2003). 
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This hypothesis is, however, implausible due to the fact that myosin S2 is not restricted to the C-
zone, and, even in the C-zone, the molar ratio of cMyBPC to myosin S2 is 1:3, suggesting that 
sufficient S2 binding-sites would remain available for exogenous C1C2 fragments independent of the 
endogenous cMyBPC phosphorylation status in these trabeculae. Furthermore, it can be assumed that 
each actin monomer in F-actin, of which only a small fraction would interact with the endogenous 
cMyBPC, would contain a cMyBPC C0 binding-site, and would, therefore, be able to interact with 
exogenous C0-containing cMyBPC fragments, irrespective of the phosphorylation status of 
endogenous cMyBPC. Additionally, the interaction originally described by Moos and coworkers, 
was between skeletal MyBPC and F-actin (Moos et al., 1978; Moos, 1981). As the skeletal MyBPC 
isoforms lack the C0 domain (Carrier et al., 1997), the F-actin binding-site cannot be located in this 
domain only, if indeed such an interaction occurs in vivo. 
 
An alternative interpretation of the results obtained by Kolikovskaya et al. (2003) may be that the C0 
domain of cMyBPC competitively interacts with a specific, as yet unidentified, ligand, restricted 
only to positions in the C-zone. C-zone specific candidate ligands include domains of cMyBPC, or 
C-zone specific domains of titin. This interpretation would explain why exogenous C0C1 cMyBPC 
fragments were able to bind to trabeculae with a low degree of endogenous cMyBPC 
phosphorylation, but not to trabeculae with a high degree of cMyBPC phosphorylation. The reason 
why C1C2 cMyBPC fragments were not able to bind to trabeculae with a low degree of endogenous 
cMyBPC phosphorylation, however, remains inexplicable. 
 
In summary, therefore, even though the in vitro binding assays performed by Kolikovskaya et al., 
(2003) provide compelling evidence that the C0 domain of cMyBPC can interact with F-actin in 
vitro, the evidence provided for this interaction taking place in situ and in vivo seems less 
convincing. The data obtained from skinned trabeculae studies performed by Kolikovskaya et al., 
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(2003), however, provides new insights into the functioning of the N-terminal region of cMyBPC, 
and suggests that the C0 domain interacts with an, as yet, unidentified C-zone specific ligand, when 
cMyBPC is phosphorylated. 
 
IV.5. EFFECT OF HCM-CAUSING MYBPC3 MUTATIONS ON cMyBPC 
QUATERNARY STRUCTURE 
 
The identification of ligands of specific domains of cMyBPC, during the course of this study, has led 
to the assignment of novel function to the C3, C7 and C10 domains of cMyBPC (sections III.3.2.4, 
III.3.4.1, III.3.4.2, III.3.4.5, IV.2.1 and IV.2.2). Additionally, the identification the C8 domain of 
cMyBPC as the ligand of the C5 domain (Moolman-Smook et al., 2002) has led to novel functions 
being assigned to these two domains of cMyBPC (table IV.1). In conjunction, this data was used in 
the establishment of models of cMyBPC quaternary structure in both the “compact” and “expanded” 
thick filaments. As the C6 and C9 domains of cMyBPC are juxtapositioned in the cMyBPC “tight 
collar” model (cMyBPC unphosphorylated, thick filaments in the “compact” conformation) (section 
IV.6.1.3 and figure IV.7), it is possible that these domains could also interact, thus assigning putative 
function to these two domains (table IV.1). The presence of an interaction between the C6 and C9 
domains (both Fn3 domains) of cMyBPC was, however, not tested experimentally in this study, as 
Fn3 domains are known to be inherently “sticky” molecules that often form homophilic interaction 
with other Fn3 domains (Nave et al., 1989; Price and Gomers, 1993; Labeit and Kolmerer, 1995). 
 
As the cMyBPC trimeric “tight collar” is proposed to be stabilised by the C5:C8 interaction, the 
C7:C10 interaction, the C7:titin interaction, and possibly also the C6:C9 interaction (section 
IV.6.1.3, figure IV.7 and table IV.4), it was postulated that HCM-causing missense mutations in 
these domains may be pathogenic by adversely affecting these interactions. In a study by Moolman- 
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Table IV.1. Functions assigned to specific domains/regions of cMyBPC 
cMyBPC 
domain/region 
Known function  Novel function Status  Ref  
 
C0  
 
Interaction with F-actin 
 
- 
 
Exp  
 
1-3 
PA-region Interaction with F-actin - Put 4 
C1 - - - - 
MyBPC-motif Contains phosphorylation sites 
Interaction with myosin S2 
- 
 
Exp  
Exp 
5 
6-8 
C2 - - - - 
C3 - Interaction with C10 domain of cMyBPC Exp 9 
C4 - - - - 
C5 Interaction with C8 domain of cMyBPC - Exp 10 
C6 - Interaction with C9 domain of cMyBPC Put 9,10 
C7 - Interactions with C10 domain of cMyBPC, and with C-
zone titin 
Exp 9 
C8 Interaction with C5 domain of cMyBPC - Exp 10 
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cMyBPC 
domain/region 
Known function  Novel function Status  Ref  
 
C9 
 
Interaction with C-zone titin 
 
 
Interaction with C6 domain of cMyBPC 
 
Exp* 
Put 
 
11 
9-10 
C10 Interaction with LMM 
Interaction with C-zone titin 
 
 
Interactions with C7 domain of cMyBPC in the “compact” 
thick filament 
Interactions with C3 domain of cMyBPC in the 
“expanded” thick filament 
Exp 
Exp* 
Exp 
 
Exp 
12,13 
11 
9 
 
9 
Status refers to whether the function assigned to a specific cMyBPC domain or region has been shown experimentally or is a proposed/putative 
function. Exp = shown experimentally; Known function = functions previously reported; Novel function = function assigned in the present study; Put 
= proposed/putative function that has not been confirmed by experimental data; Ref = reference; 1 = Moos et al., 1978; 2 = Moos, 1981; 3 = 
Kulikovskaya et al., 2003; 4 = Squire et al., 2003; 5 = Gautel et al., 1995; 6 = Gruen and Gautel, 1999; 7 = Gruen et al., 1999; 8 = Kunst et al., 
2000; 9 = present study; 10 = Moolman-Smook et al., 2002; 11 = Freiburg and Gautel, 1996; 12 = Okagaki et al., 1993; 13 = Welikson and 
Fischman, 2002; * = binding-site located in the C9 and/or C10 domain(s); - = no known/putative function assigned to a particular domain. 
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Smook et al., (2002), it was shown that the R654H and N755K HCM-causing missense mutations in 
the C5 domain of cMyBPC (Moolman-Smook et al., 1998; Yu et al., 1998) both significantly 
decrease the affinity of the C5 domain for the C8 domain of cMyBPC (Moolman-Smook et al., 
2002). These findings indicate that these HCM-causing missense mutations in the C5 domain may 
result in a destabilisation of the cMyBPC “tight collar” conformation, and may allow expansion of 
the thick filament backbone in the absence of PKA-mediated phosphorylation of cMyBPC.  
 
In order to establish whether V896M, which was until recently considered to be an HCM-causing 
mutation (Moolman-Smook et al., 1999), acts in a similar fashion by destabilising the cMyBPC 
trimeric “tight collar”, as a result of a weakening of either the C7:10 or C7:titin interactions, 
quantitative β-galactosidase Y2H-assays were performed. These assays indicated that V896M 
significantly strengthened the C7:C10 interaction, without having any effect on the C7:titin 
interaction (section III.3.4.3 and figure III.43). This result was surprising, as it suggested that V896M 
would result in a strengthening, rather than a weakening, of the cMyBPC “tight collar” and might 
prevent the expansion of the thick filament backbone following PKA-mediated phosphorylation of 
cMyBPC, while HCM-causing missense mutations in the C5 domain had the opposite effect. 
Subsequently, however, CoIP studies have shown that the presence of V896M in the C7 domain 
decreases the strength of both the C7:C10 and C7:titin interactions (personal communication Dr 
Hanlie Moolman-Smook, 12 September 2003), suggesting that V896M may indeed act similarly to 
mutations in the C5 domain by destabilising the cMyBPC “tight collar”.  
 
The discrepancy in the findings of CoIP analysis and quantitative β-galactosidase Y2H-assays, 
however, casts doubt over the accuracy and usefulness of quantitative β-galactosidase Y2H-assays. 
Similar discrepancies were also found when the effect of the R654H and N755K HCM-causing 
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missense mutations on the C5:C8 interaction was assessed by quantitative β-galactosidase Y2H-
assays and BIAcore experiments. Both these mutations were shown to significantly strengthen the 
C5:C8 interaction as assessed by quantitative β-galactosidase Y2H-assays, while BIAcore 
experiments showed that these mutations significantly weakened this interaction (personal 
communication Dr Hanlie Moolman-Smook, 20 January 2002; Moolman-Smook et al., 2002). It can, 
therefore, be concluded that quantitative data obtained from β-galactosidase Y2H-assays should be 
treated with some suspicion, and that results obtained from these assays should be confirmed by at 
least one independent biochemical assay such as CoIP or BIAcore. 
 
Subsequent to V896M being described as an HCM-causing mutation (Moolman-Smook et al., 1999), 
V896M was also described in HCM-affected populations in several other studies (Jaaskelainen et al., 
2002; Morner et al., 2003; Richard et al., 2003). In these studies, however, V896M was described as 
either a polymorphism (Jaaskelainen et al., 2002; Morner et al., 2003), or a disease-modifying factor 
(Richard et al., 2003), based on the finding that it was also present in HCM-unaffected control 
populations. The finding that V896M results in a weakening in the strength of the C7:C10 and 
C7:titin interactions, both of which are predicted to destabilise the cMyBPC trimeric “tight collar”, 
suggests that V896M may indeed be of functional, if not pathological, relevance. V896M may result 
in the formation of thick filaments with a “loose” structure being favoured in the absence of PKA-
mediated phosphorylation of cMyBPC. As this effect is similar to the proposed pathogenic effect of 
the R654H and N755K HCM-causing missense mutations in the C5 domain of cMyBPC, it is 
plausible that V896M may act as a disease-modifying factor in individuals carrying other HCM-
causing mutations. 
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As the R654H and N755K HCM-causing missense mutations and the V896M putative disease-
modifying factor were all found to weaken interactions stabilising the cMyBPC trimeric “tight 
collar” conformation, it could be postulated that other HCM-causing missense mutations may act in a 
similar fashion. A destabilisation of the cMyBPC trimeric “tight collar” would favour the formation 
of thick filaments with a “loose” structure in the absence of PKA-mediated phosphorylation of 
cMyBPC. As domains C5, C6, C7, C8 and C9 are all involved in interdomain interactions that 
stabilise the cMyBPC “tight collar” conformation (C5:C8, C6:C9, C7:C10 and C7:titin interactions) 
(section IV.3), it can be proposed that missense mutations in any of these domains would weaken 
these stabilising interdomain interactions. Conversely, as the interaction between the C3 and C10 
domain of cMyBPC is likely to stabilise the cMyBPC “loose collar” conformation, it is possible that 
missense mutations in the C3 domain of cMyBPC would lead to a strengthening of this interaction, 
thus also favouring the formation of thick filaments with a “loose” conformation. According to this 
hypothesis, missense mutations in the C10 domain of cMyBPC could either lead to a strengthening 
of the C3:C10, interaction or a weakening of the C7:C10 interaction. Missense mutations in these 
domains may affect these interactions by either altering specific binding surfaces on a domain, or by 
destabilising the structure of the domain as a whole. The possibility that some missense mutations 
may cause a strengthening of interactions stabilising the cMyBPC “tight collar” conformation can, 
however, not be excluded by this study. The former scenario, in which missense mutations in 
cMyBPC favours the formation of thick filaments with a “loose” structure is, however, favoured by 
this author as it would provide a unifying mechanism through which HCM-causing missense 
mutations cause disease. 
 
Additionally, it is plausible that HCM-causing mutations, resulting in the truncation of cMyBPC, 
may also favour the formation of thick filaments with a “loose” conformation, irrespective of 
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whether they function through a mechanism of haploinsufficiency, or act as “poison peptides” 
(sections I.1.1.1 and I.7.8.2). If MYBPC3 truncation mutations act through a mechanism of 
haploinsufficiency, it is likely that this would prevent the formation of the cMyBPC trimeric “tight” 
and “loose collar” structures, due to a stoichiometric deficiency in cMyBPC, resulting in the loss of 
regulation of thick filament structure by cMyBPC. The subsequent loss of the cMyBPC trimeric 
“tight collar” may result in thick filaments taking on a “loose”, rather than a “tight”, conformation 
(section IV.3.3). Similarly, if truncated MyBPC peptides act as “poison peptides,” (sections I.1.1.1 
and I.7.8.2), these truncated peptides may be incorporated into the sarcomere, where they would 
compete with full length cMyBPC for the respective sarcomeric binding-sites. As these truncated 
cMyBPC peptides lack varying portions of their C-terminal regions (figure I.23 and table I.6), 
necessary for forming the cMyBPC “tight collar”, it is likely that the presence of these truncated 
peptides in the A-band would prevent the formation of the cMyBPC “tight collar” conformation, 
resulting in the formation of thick filaments with a “loose” conformation (section IV.3.3).  
 
The hypothesis that HCM-causing missense mutations in the C3, C5, C6, C7, C8, C9 and C10 
domains of cMyBPC, and cMyBPC truncation mutations, may share a common disease pathogenesis 
by favouring the formation of thick filaments with a “loose” structure has several important 
implications. Firstly, as thick filaments in the “loose” conformation are more likely to form weak 
interactions with thin filaments, it is possible that the relaxation of cardiac muscle may be impaired, 
leading to diastolic dysfunction, a feature commonly caused by HCM-causing mutations (section 
I.1.1.1, table I.2 and references therein). Secondly, the formation of a larger number of weak 
interactions between thick and thin filaments, resulting from thick filaments being in the “loose” 
conformation, would potentiate the contractile apparatus, resulting in an increase in actomyosin 
ATPase activity. This increase in actomyosin ATPase activity would result in increased ATP usage, 
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which may lead to ATP depletion, specifically during periods of β-adrenergic stimulation, or during 
strenuous exercise when ATP demand is increased. The finding that ATP depletion may be a 
hallmark of all HCM-causing mutations (section I.1.1.2 and references therein) supports this 
hypothesis. Additionally, ATP depletion, in turn, may impair the function of SERCA2a, thus 
resulting in alterations in Ca2+ homeostasis in the cardiomyocyte, which has been associated with 
HCM (section I.1.1.1, table I.2 and references therein). 
 
If indeed destabilisation of the trimeric cMyBPC “tight collar” conformation, or a strengthening of 
the “loose” cMyBPC collar conformation, is a hallmark of cMyBPC HCM-causing missense 
mutations, it would be possible that HCM-causing missense mutations in domains stabilising these 
conformations would be found in clusters on specific binding surfaces. In order to investigate this 
possibility, the positions of cMyBPC missense mutations in the C3, C5, C6, C7*, C8, C9 and C10 
domains were mapped on the three-dimensional structures of chain A of telokin, in the case of IgC2 
domains, or the Fn3 consensus sequence, in the case of Fn3 domains (figures IV.12 to IV.20).  
 
IV.5.1. POSITION OF HCM-CAUSING MISSENSE MUTATIONS IN THE C3 DOMAIN OF 
cMyBPC 
 
The identification of an interaction between the C3 and C10 domains of cMyBPC has led to the 
hypothesis that HCM-causing missense mutations in the C3 domain of cMyBPC may strengthen this 
interaction (section IV.5 and table IV.1). It was, therefore, postulated that missense mutations in the 
C3 domain may be clustered on a specific β-sheet of this domain, indicative of the position of the 
binding surface. 
                                                 
* V896M putative disease-modifying factor. 
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The mapping of the positions of HCM-causing missense mutations in the C3 domain of cMyBPC 
revealed that the R502Q, R502W and ∆K504 HCM-causing missense mutations (Niimura et al., 
1998; Richard et al., 2003) all occur in β-strand D of this IgC2 domain, while the G507R HCM-
causing mutation (sections III.1.2.5 and IV.1.5) (Erdmann et al., 2001) occurs in β-strand E of this 
domain (figure IV.13). As these four mutations all cluster in a small portion of the four-stranded β-
sheet, consisting of β-strands A, B, D and E (ABDE-β-sheet), it can be assumed that these four 
mutations may affect the same binding surface, which may be involved in the C3:C10 interaction.  
 
The G523W and E542Q HCM-causing mutations (Carrier et al., 1997; Erdmann et al., 2003) were, 
however, found to be located in the F and G β-strands, respectively (figure IV.13). As the F and G β-
strands, together with the β-strand C, form the three-stranded β-sheet (CFG-β-sheet) in IgC2 
domains, it is unlikely that the G523W and E542Q HCM-causing mutations would affect the same 
protein binding-site as the R502Q, R502W, ∆K504 and G507R mutations (figure IV.13). As the 
G523W and E542Q mutations are also in close proximity to each other, the possibility that the C10 
binding-site is located on the CFG-β-sheet cannot be excluded.  
 
The R495Q HCM-causing missense mutation (Niimura et al., 1998) was found to be located in the 
loop region that separates the C and D β-strands and is unlikely to directly affect protein binding-
sites. This mutation may, however, have its pathogenic effect by disrupting the overall structure of 
the C3 IgC2 domain. 
 
In summary, therefore, most of the missense mutations in the C3 domain of cMyBPC were found in 
one of two clusters on the ABDE- and CFG-β-sheets, indicating that both these β-sheets may be 
involved in protein:protein interactions. In this study, the C10 domain of cMyBPC was identified as 
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a ligand of the C3 domain in candidate-ligand Y2H-assays, while the identity of a putative second 
ligand, binding to the second binding-site, was not determined. It is also not possible to predict 
which of the two β-sheets contains the C10 binding-site. 
 
 
 
 
 
 
 
 
 
 
Figure IV.13. Relative positions of HCM-causing missense mutations in the C3 IgC2 domain of cMyBPC 
Structure of chain A of telokin, on which the positions corresponding to the positions of HCM-causing 
missense mutations occurring in the C3 domain of cMyBPC have been indicated. The seven β-strands 
(indicated as broad purple arrows) constituting an IgC2 domain are labeled A to G, and the N- and C-termini 
of the domain indicated by N(A) and C(A), respectively (three-dimensional modeling performed using Cn3D 
version 4.1, available at http://www.ncbi.nih.gov). 
 
IV.5.2. POSITION OF HCM-CAUSING MISSENSE MUTATIONS IN THE C5 DOMAIN OF 
cMyBPC 
 
Moolman-Smook et al., (2002) have shown an interaction between the C5 and C8 domains of 
cMyBPC, which is affected by the presence of the R654H and N755K HCM-causing mutations in 
the C5 domain (section IV.5 and table IV.1). It was, therefore, postulated that missense mutations in 
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the C5 domain may be clustered on a specific β-sheet of this domain, indicative of the position of the 
binding surface. 
 
The mapping of the positions of HCM-causing missense mutations in the C5 domain of cMyBPC 
revealed that the R668P, and R668H HCM-causing missense mutations (Erdmann et al., 2003; 
Morner et al., 2003) occur in β-strand B of this IgC2 domain, while the R654H HCM-causing 
mutation (Moolman-Smook et al., 1998) occurs in β-strand A of this domain (figure IV.14). As these 
three mutations all cluster in the four-stranded β-sheet, consisting of β-strands A, B, D and E 
(ABDE-β-sheet) (figure IV.14) (three-dimensional modeling performed using Cn3D version 4.1, 
available at: http://www.ncbi.nih.gov), it can be speculated that this β-sheet contains the binding 
surface for the C8 domain of cMyBPC, as the R654H HCM-causing mutation was shown to decrease 
the affinity of the C5 domain for the C8 domain (Moolman-Smook et al., 2002). The N755K HCM-
causing missense mutation (Yu et al., 1998), which was shown to have an even more pronounced 
effect on the C5:C8 interaction (Moolman-Smook et al., 2002), was, however, found to be located in 
β-strand F, which together with β-strands C and G form the three-stranded β-sheet (CFG-β-sheet) 
(figures IV.13 and IV.14b).  
 
Structural NMR spectroscopical analysis of the C5 domain of cMyBPC by Idowu et al., (2003), 
however, indicated that in this domain of cMyBPC, the A β-strand that was predicted to form part of 
the ABDE-β-sheet may, in fact, be shorter than predicted by Cn3D version 4.1 (figure IV.15). 
Additionally, Idowu et al., (2003) predicted that β-strand A may, in fact, together with β-strands C, F 
and G, form a β-sheet (ACFG-β-sheet), while β-strands B, D and E would form a three-stranded β-
sheet (BDE-β-sheet) that would form the opposite surface of the domain (figure IV.14).
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Figure IV.14. Relative positions of HCM-causing missense mutations in the C5 IgC2 domain of cMyBPC 
Structure of chain A of telokin, on which the positions corresponding to the positions of HCM-causing 
missense mutations occurring in the C5 domain of cMyBPC have been indicated. The seven β-strands 
(indicated as broad purple arrows) constituting an IgC2 domain are labeled A to G, and the N- and C-termini 
of the domain indicated by N(A) and C(A), respectively (three-dimensional modeling performed using Cn3D 
version 4.1, available at http://www.ncbi.nih.gov). 
 
In this conformation of the C5 domain, the R654H HCM-causing missense mutation would be 
located in the region N-terminal of β-strand A, on, or near to, the ACFG-β-sheet (figure IV.15a) 
(Idowu et al., 2003). In this arrangement, the R654H and N755K HCM-causing missense mutations 
would both be located on the ACFG-β-sheet, while the R668P and R668H mutations would be on the 
BDE-β-sheet, indicating two possible binding surfaces of the C8 domain (figure IV.15a).  
 
Idowu et al., (2003), however, also showed that the N755K HCM-causing missense mutation results 
in a total destabilisation of the C5 domain, indicating that this mutation may have a deleterious 
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effect, without directly affecting the C8 binding-surface. It is intriguing to note that if, indeed, the 
three-dimensional structure of the C5 domain as predicted using Cn3D version 4.1, rather than that 
predicted by Idowu et al., (2003), is correct, the R668P, R668H and R654H HCM-causing missense 
mutations would all be located on the surface of the ABDE-β-sheet, which may contain the C8 
binding-site (figures IV.13 and Iv.14b). This scenario would provide an elegant mechanism through 
which missense mutations in domain C5 could affect the binding of the C8 domain, as R668P, 
R668H and R654H could all directly alter the C8 binding-surface, while the N755K mutation could 
affect the C5:C8 interaction by destabilising the C5 domain.  
 
 
Figure IV.15. Proposed three-dimensional structures of domain C5 of cMyBPC 
a) Three-dimensional structure of the C5 domain of cMyBPC as predicted by Idowu et al., (2003); b) three-
dimensional structure of the C5 domain of cMyBPC based on the structure of chain A of telokin by Cn3D 
version 4.1. The relative positions of HCM-causing missense mutations in the C5 domain of cMyBPC are 
shown in both figures. Broad arrows = β-strands; a) from Idowu et al., 2003); b) three-dimensional modeling 
performed using Cn3D version 4.1, available at http://www.ncbi.nih.gov. 
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IV.5.3. POSITION OF HCM-CAUSING MISSENSE MUTATIONS IN THE C6 DOMAIN OF 
cMyBPC 
 
Based on the cMyBPC trimeric “tight collar” model, it was speculated that the C6 domain of 
cMyBPC may interact with the C9 domain of cMyBPC (section IV.5 and table IV.1). Furthermore, it 
was postulated that missense mutations in the C6 domain may be clustered on a specific β-sheet of 
this domain, which may be indicative of the position of the binding surface. 
 
The mapping of the positions of HCM-causing missense mutations in the C6 domain of cMyBPC 
revealed that the R811K and ∆K812 HCM-causing mutations (Jaaskelainen et al., 2002; Richard et 
al., 2003) both occur in β-strand D of this Fn3 domain, while the R820Q HCM-causing mutation 
(Konno et al., 2003) occurs in β-strand E of this domain (figure IV.16). As β-strands D, E and G 
form a three-stranded β-sheet (DEG-β-sheet) in Fn3 domains, it is possible that these mutations may 
share a pathological effect by affecting a ligand-binding surface located on this β- sheet. 
 
The A833V and A833T HCM-causing missense mutations (Richard et al., 2003; Erdmann et al., 
2003; Morner et al., 2003) are located in β-strand F, which together with β-strands B and C, form the 
second three-stranded β-sheet (BCF) in Fn3 domains (figure IV.16). It is, therefore, also possible that 
the BCF-β-sheet may contain a protein binding surface. As the mutations in the C6 domain do not 
cluster in one specific β-sheet which may constitute a binding surface, it is not possible to speculate 
which of these two β-sheets contain the putative C9-binding surface. 
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Figure IV.16. Relative positions of HCM-causing missense mutations in the C6 Fn3 domain of cMyBPC 
Structure of the consensus sequence of Fn3 domains, on which the positions corresponding to the positions of 
HCM-causing missense mutations occurring in the C6 domain of cMyBPC have been indicated. The nine β-
strands (indicated as broad purple arrows) constituting a Fn3 domain are labeled A to H, and the C-terminus 
of the domain indicated by C (three-dimensional modeling performed using Cn3D version 4.1, available at 
http://www.ncbi.nih.gov). 
 
IV.5.4 POSITION OF THE V896M PUTATIVE DISEASE-MODIFYING FACTOR IN THE 
C7 DOMAIN OF cMyBPC 
 
Based on the finding that the V896M putative disease-modifying factor affects the C7:C10 and 
C7:titin interactions, it was postulated that the position of this mutation may facilitate the 
identification of the binding surfaces of these two ligands of the C7 domain (sections III.3.4.3, IV.5 
and figure III.43). 
 
The V896M putative disease-modifying factor (Moolman-Smook et al., 1999; Jaaskelainen et al., 
2002; Morner et al., 2003; Richard et al., 2003) was, however, found to be located in the loop 
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separating the C and D β-strands in the C7 Fn3 domain (figure IV.17). It is, therefore, postulated that 
V896M would affect the overall structure of this domain, thereby altering its interaction with both 
C10 and titin, rather than affecting a specific binding surface, a finding that is supported by CoIP 
analysis that showed that the presence of V896M in the C7 domain significantly weakens its 
interactions with both C10 and titin. 
 
 
 
 
 
 
 
 
 
 
Figure IV.17. Relative positions of the V896M putative disease-modifying factor in the C7 Fn3 domain of 
cMyBPC 
Structure of the consensus sequence of Fn3 domains, on which the position corresponding to position 896 in 
domain C7 of cMyBPC, affected by the V896M putative disease-modifying factor, has been indicated. The 
nine β-strands (indicated as broad purple arrows) constituting a Fn3 domain are labeled A to H, and the C-
terminus of the domain indicated by C (three-dimensional modeling performed using Cn3D version 4.1, 
available at http://www.ncbi.nih.gov). 
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IV.5.5 POSITION OF HCM-CAUSING MISSENSE MUTATIONS IN THE C8 DOMAIN OF 
cMyBPC 
 
Moolman-Smook et al., (2002) have shown an interaction between the C5 and C8 domains of 
cMyBPC, which was affected by the presence of the R654H and N755K HCM-causing mutations in 
the C5 domain (section IV.5 and table IV.1). It was, therefore, postulated that missense mutations in 
the C8 domain may be clustered on a specific β-sheet of this domain, indicative of the position of the 
C5 domain binding surface. 
 
The mapping of the positions of HCM-causing missense mutations in the C8 domain of cMyBPC 
revealed that the R1002Q and E1017K HCM-causing mutations (Niimura et al., 2002; Barr et al., 
unpublished data available at: http://genetics.med.harvard.edu/~seidman/cg3/muts/MYBPC3_ 
mutations_TOC.html) occur in the loops connecting β-strands B and C, and β-strands C and D, 
respectively (figure IV.18). As neither of these mutations occur in either the three- or four-stranded 
β-sheets, it is likely that they would affect the overall structure of the C8 IgC2 domain, rather than 
specifically affecting the C5 binding surface. 
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Figure IV.18. Relative positions of HCM-causing missense mutations in the C8 IgC2 domain of cMyBPC 
Structure of chain A of telokin, on which the positions corresponding to the positions of HCM-causing 
missense mutations occurring in the C8 domain of cMyBPC have been indicated. The seven β-strands 
(indicated as broad purple arrows) constituting an IgC2 domain are labeled A to G, and the N- and C-termini 
of the domain indicated by N(A) and C(A), respectively (three-dimensional modeling performed using Cn3D 
version 4.1, available at http://www.ncbi.nih.gov). 
 
IV.5.6 POSITION OF THE V1115I HCM-CAUSING MISSENSE MUTATION IN THE C9 
DOMAIN OF cMyBPC 
 
Based on the cMyBPC trimeric “tight collar” model, it was speculated that the C6 domain of 
cMyBPC may interact with the C9 domain of cMyBPC (section IV.5 and table IV.1). Furthermore, it 
was postulated that the position of the V1115I (Erdmann et al., 2001) HCM-causing missense 
mutation in the C9 domain may be indicative of the position of the C6 binding-site. 
 
The mapping of the position of the V1115H HCM-causing missense mutation (Erdmann et al., 2001) 
in the C9 domain of cMyBPC revealed that this mutation was located in β-strand E, which, together 
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with β-strands D and G, forms the three-stranded EDG-β-sheets of Fn3 domains (figure IV.19). Even 
though it is tempting to speculate that this finding may be indicative of the position of the C6 
binding-site on the EDG β-sheet, caution should be taken, as this assumption is made based solely on 
the position of a single HCM-causing missense mutation. 
 
 
 
 
 
 
 
 
 
Figure IV.19. Relative position of the V1115I HCM-causing missense mutation in the C9 Fn3 domain of 
cMyBPC 
Structure of the consensus sequence of Fn3 domains, on which the position corresponding to position 1115 in 
the C9 Fn3 domain of cMyBPC, at which the V1115I HCM-causing missense mutation occurs, has been 
indicated. The nine β-strands (indicated as broad purple arrows) constituting a Fn3 domain are labeled A to 
H, and the C-terminus of the domain indicated by C (three-dimensional modeling performed using Cn3D 
version 4.1, available at http://www.ncbi.nih.gov).  
 
IV.5.7 POSITION OF HCM-CAUSING MISSENSE MUTATIONS IN THE C10 DOMAIN 
OF cMyBPC 
 
Previous studies have shown that the C10 domain of cMyBPC interacts with LMM (Okagaki et al., 
1993; Miyamoto et al., 1999; Welikson and Fischman, 2002) and it has also been implicated in the 
binding of C-zone titin (Freiburg and Gautel, 1996). 
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Additionally, it was found that this domain of cMyBPC is also able to interact with the C7 domain in 
the cMyBPC “tight collar” conformation and with domain C3 in the cMyBPC “loose” collar 
conformation. It was postulated that the positions of HCM-causing missense mutations in this 
domain may allow insights into the positions of the binding-sites of these ligands on the C10 domain, 
as they may disrupt ligand-binding. 
 
The mapping of the positions of HCM-causing missense mutations in the C10 domain of cMyBPC 
revealed that the A1194T HCM-causing missense mutation (Richard et al., 2003) is located in the 
loop connecting β-strands A and B (figure IV.20). The A1255T HCM-causing missense mutation 
(Richard et al., 2003) was found to be located in β-strand F, which, together with β-strands C and G, 
form the three-stranded CFG-β-sheet in IgC2 domains (figure IV.20). 
 
As A1194T is located in a loop connecting β-strands A and B, both of which form part of the four-
stranded ABDE-β-sheet in IgC2 domains, it is possible that this mutation could alter the structure of 
this β-sheet, thus disrupting the binding-site of one of the ligands of the C10 domain which may be 
located on this β-sheet. The finding that the A1255T mutation is located in the three-stranded CFG-
β-sheet may indicate that this β-sheet may also be involved in ligand-binding.  
 
In order to establish which of the β-sheets of the C10 domain is most likely to contain the binding-
site of the C7 domain, the relative position of the 39 amino acid residue partial C10 peptide, 
identified as the ligand of the C7 domain of cMyBPC in the C7 Y2H library-assay (sections III.3.2.4 
and IV.2), was mapped on the three-dimensional structure of chain A of telokin (figure IV.21). This 
revealed that the partial C10 peptide which was found to interact with domain C7, consisted of β-
strands E, F and G. β-strands F and G, together with β-strand C, constitute the three-stranded CFG-β-
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sheet, while β-strand E forms part of the four-stranded ABDE-β-sheet in IgC2 domains. As two 
strands (F and G) of the three-stranded CFG-β-sheet were present in the partial C10 peptide, 
combined with the fact that its tertiary structure may be stabilised by the presence of β-strand E, it 
was postulated that the C7 binding-site was likely to be located on the three-stranded CFG-β-sheet 
(figures IV.19 and IV.20). It is, therefore, possible that the A1255T mutation in β-strand F may 
adversely affect the C7:C10 interaction. 
 
 
 
 
 
 
 
 
 
 
 
Figure IV.20. Relative positions of HCM-causing missense mutations in the C10 IgC2 domain of cMyBPC 
Structure of chain A of telokin, on which the positions corresponding to the positions of HCM-causing 
missense mutations occurring in the C10 domain of cMyBPC have been indicated. The seven β-strands 
(indicated as broad purple arrows) constituting an IgC2 domain are labeled A to G, and the N- and C-termini 
of the domain indicated by N(A) and C(A), respectively (three-dimensional modeling performed using Cn3D 
version 4.1, available at http://www.ncbi.nih.gov). 
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Figure IV.21. Proposed structure of the partial C10 domain identified as the ligand of the C7 domain 
Structure of chain A of telokin, on which the position corresponding to the 39 amino acid residue partial C10 
peptide, identified as the ligand of the C7 domain of cMyBPC in the C7 Y2H library-assay, has been 
highlighted in yellow. The seven β-strands (indicated as broad purple arrows) constituting an IgC2 domain 
are labeled A to G, and the N- and C-termini of the domain indicated by N(A) and C(A), respectively (three-
dimensional modeling performed using Cn3D version 4.1, available at http://www.ncbi.nih.gov). 
 
IV.6. CONCLUDING REMARKS 
 
The screening of MYBPC3 in a South African HCM-affected population led to the identification of 
two novel putative disease-causing mutations that result in the truncation of cMyBPC (∆c13255 and 
ex7 SaS+1 g>a), as well as two missense mutations, previously described as being HCM-causing 
(G278E and G507R) (Erdmann et al., 2001; Richard et al., 2003). The data generated in the present 
study, in combination with that presented by Erdmann et al., (2001), suggests that G507R is indeed 
an HCM-causing mutation, and that this mutation may be associated with early-onset HCM, 
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pronounced LVH and an increased risk of SCD. The finding that G278E occurred at a significant 
frequency in a control population, however, suggests that it is, in all likelihood, a disease-modifying 
factor, rather than a main-locus HCM-causing mutation. Similarly, V896M, which was described as 
a putative HCM-causing mutation in the present study (Moolman-Smook et al., 1999), was 
subsequently found in control populations in other studies (Jaaskelaien et al., 2002; Morner et al., 
2003; Richard et al., 2003), indicating that V896M may also be either a polymorphism or a disease-
modifying factor, rather than a main-locus HCM-causing mutation.  
 
Based on the identification of V896M in the C7 domain of cMyBPC, combined with the fact that 
previous studies have implicated this domain as being functionally important (section I.7.3.3), it was 
postulated that this domain of cMyBPC may be involved in, as yet unidentified, protein:protein 
interactions. Subsequent Y2H-assays allowed the identification of the C10 domain of cMyBPC and 
specific domains of C-zone titin as ligands of this domain. This finding, in combination with Y2H 
results generated by Dr Hanlie Moolman-Smook in our laboratory, allowed the development of a 
novel model of cMyBPC quaternary structure in which cMyBPC trimerises to form a “tight collar” 
around the thick filament backbone, when cMyBPC is in its unphosphorylated state. This model has 
allowed new insights into the functioning of this protein in both in health and disease (Moolman-
Smook et al., 2002). This model was subsequently refined to include not only the quaternary 
structure of cMyBPC, but an integrated model of thick filament quaternary structure based on the 
curved crystalline layer model of the myosin filament. 
 
Additionally, the identification of the G507R putative HCM-causing mutation in the C3 domain of 
cMyBPC indicated that this domain, to which no function had previously been ascribed, may also be 
of functional importance. The subsequent identification of the C10 domain of cMyBPC as a ligand of 
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the C3 domain in Y2H-assays allowed the development of a novel integrated model of cMyBPC and 
thick filament quaternary structure. In this model, cMyBPC forms a trimeric “loose collar” around 
the thick filament backbone following PKA-dependent phosphorylation of cMyBPC.  
 
Together, the development of these models of cMyBPC quaternary structures has allowed new 
insights into the mechanisms through which cMyBPC regulates thick filament structure and cardiac 
contractility, following β-adrenergic stimulation. Additionally, it was found that HCM-causing 
mutations in the C5 domain of cMyBPC (Moolman-Smook et al., 2002), and the V896M putative 
disease-modifying factor in the C7 domain, weaken interactions that are thought to stabilise the 
cMyBPC trimeric “tight collar” conformation. These findings have led to the development of a 
unifying hypothesis, namely, that cMyBPC HCM-causing mutations and disease-modifying factors, 
whether missense or truncation, result in the destabilisation of the cMyBPC “tight collar” 
conformation, thus favouring the formation of “expanded” thick filaments in the absence of β-
adrenergic stimulation. The preferential formation of “expanded” thick filaments in cMyBPC 
mutation carriers, in turn, may result in altered cardiac contractility, impaired diastolic function, ATP 
wastage and altered Ca2+ homeostasis, features which are all associated with HCM.  
 
In order to test this hypothesis, future biochemical studies are required to establish the effect of 
HCM-causing mutations on interactions that are postulated to stabilise the cMyBPC “tight” and 
“loose collar” conformations. 
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“I was grading exams, and a student referred to the components of a two hybrid screen as 
“bait” and “pray”.” David Stillman 
 
Having worked with the yeast two-hybrid system for the last four years, it is my opinion that not 
only does this student deserve full marks for the answer, but deserves bonus marks for insights far 
beyond his/her experience! 
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APPENDIX A 
 
1. DNA EXTRACTION SOLUTIONS 
 
Cell lysis buffer 
Sucrose (Merck)     0.32M 
Triton X-100 (Merck)     1% 
MgCl2 (Merck)      5mM 
Tris-HCl pH 8.0 (Biorad)    10mM 
ddH2O to 1 litre 
 
3M NaAc 
NaAc.3H2O (Merck)     40.81g 
ddH2O       50ml 
Adjust pH to 5.2 with glacial acetic acid (Merck) and adjust volume to 100ml with ddH2O. 
 
Na-EDTA solution 
NaCl (Merck)      18.75ml of 4M stock solution 
EDTA (B&M Scientific)    250ml of a 100mM stock solution 
Mix well. 
Phenol/Chloroform 
Phenol (saturated with 1x TE) (Merck)   50ml 
Chloroform (Merck)     48ml 
8-Hydroxiquinoline (Merck)    2ml 
Mix well, store at 4oC. 
 
Chloroform/octanol (24:1) 
Chloroform (Merck)     96ml 
Octanol (Merck)     4ml 
Mix well, store at 4oC. 
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10x TE stock solution 
Tris-HCl (Biorad)     0.1M (pH 8.0) 
EDTA (Biorad)      0.01M (pH 8.0) 
 
2. RNA EXTRACTION SOLUTIONS 
 
0.2% DEPC water (RNase treatment of surfaces and equipment) 
Diethylpyrocarbonate (DEPC)    2ml 
ddH2O to a final volume of 1 litre 
 
0.2% DEPC water (reaction use) 
Diethylpyrocarbonate (DEPC)    2ml 
ddH2O to a final volume of 1 litre 
Autoclave to inactivate DEPC 
 
PBS buffer 
NaCl       8.0g 
KCl       0.2g 
Na2HPO4.2H2O      1.42g 
KH2PO4      0.2g 
ddH2O to a final volume of 1 litre 
 
RNA-Denaturing Solution 
Guanidinium Thiocyanate     250g 
ddH2O       293ml 
0.75M Sodium Citrate     17.6ml 
10% Sodium Sarcosyl     26.4ml 
This stock solution was stored in the dark for up to three months, 360 μl β-mercaptoethanol per 50ml stock 
solution should be added just prior to use 
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3. BACTERIAL PLASMID PURIFICATION SOLUTIONS:  
 
Cell Resuspension Solution: 
50mM Tris-HCL, pH 7.5   2.5ml 1M Tris 
10mM EDTA  1ml 0.5M EDTA 
ddH2O to a final volume of 50ml 
 
Cell Lysis solution: 
0.2M NaOH  2.5ml 4M NaOH 
1% SDS  5ml 
ddH2O to a final volume of 50ml 
 
Neutralization solution 
1.32M KOAc, pH 4.8  13.2ml 5M KOAc 
ddH2O to a final volume of 50ml 
 
4. YEAST PLASMID PURIFICATION SOLUTIONS: 
 
Yeast lysis buffer 
SDS       1% 
Triton X-100       2% 
NaCl       100mM 
Tris (pH 8)      10mM 
EDTA (pH 8)      1mM 
 
5. ELECTROPHORESIS STOCK SOLUTIONS  
 
10% Ammonium persulphate 
Ammonium persulphate (Merck)   10g 
ddH2O       10ml 
Mix well and store at 4oC 
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10x TBE stock solution 
Tris base (Biorad)     108g 
Boric Acid (Merck)     58g  
Na2EDTA (Merck)     9.3g 
ddH2O to a final volume of 1 litre 
 
50x TAE stock solution 
Tris base      242g 
Acetic acid (glacial)     57.1ml 
Na2EDTA      37.2g 
ddH2O to a final volume of 1 litre 
 
Ethidium bromide 
Ethidium bromide (Sigma)    500mg 
ddH2O       50ml 
Stir well on magnetic stirrer for 4h, store in dark container at 4oC. 
 
Bromophenol blue loading dye 
Bromophenol blue     0.1% (w/v) 
ddH2O to a final volume of 100ml 
store in dark at 4oC 
 
SSCP loading dye 
Bromophenol blue      0.1% (w/v) 
Xylene cyanol       0.1% (w/v) 
Formamide       95% (v/v)  
NaOH        10mM (w/v)  
EDTA        20mM (w/v) 
ddH2O to a final volume of 100ml 
store in dark at 4oC 
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6. MOLECULAR SIZE MARKERS 
 
λPst molecular size marker 
Bacteriophage Lambda genomic DNA   200µl 
PstI Restriction enzyme     3µl (30U) 
Promega buffer H     30µl 
ddH2O to a final volume of 300µl 
 
Incubate at 37oC for 3h, heat inactivate enzyme at 65oC for 10min. Use 1µl of digestion product on 
polyacrylamide gels, or 3µl on ethidium bromide stained agarose gels. 
Fragment Sizes: 
11497bp, 5077bp, 4507bp, 2838bp, 2560bp, 2459bp, 2443bp, 2140bp, 1986bp, 1700bp, 1159bp, 1093bp, 
805bp, 514bp, 468bp, 448bp, 339bp, 264bp, 247bp, 211bp, 200bp, 164bp, 150bp, 94bp, 87bp, 72bp 
 
7. PCR BUFFER 
 
10x NH4 PCR Reaction Buffer (Bioline, UK) 
(NH4)2SO4      160mM 
Tris-HCl       670mM pH 8.8(25°C),  
Tween 20      0.1% 
 
7. SILVER STAINING SOLUTIONS 
 
0.1% AgNO3  
AgNO3       1g 
ddH2O to a final volume of 1 litre 
 
Developing solution 
BaBH4        0.1g 
NaOH       15g 
Formaldehyde      4ml 
ddH2O to a final volume of 1 litre 
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8. SOLUTIONS USED FOR THE ESTABLISHMENT OF EBV TRANSFORMED CELL LINES 
 
EBV-medium 
RPMI 1640 
FCS   15% 
 
9. SOLUTIONS USED FOR THE ESTABLISHMENT BACTERIAL COMPETENT CELLS 
 
CAP-buffer 
CaCl2        2.21g 
Glycerol       37.5ml 
PIPES        0.76g 
ddH2O to a final volume of 250ml 
Adjust pH to 7.0, store at 4oC 
 
10. SSCP SOLUTIONS AND METHODOLOGY 
 
Solutions 
 
8% Mildly denaturing SSCP gel 
40% Acrylamide-bisacrylamide (37.5:1) stock solution   32ml [8% (v/v)] 
Urea         24g [15% (w/v)] 
Glycerol        8ml [5% (v/v)] 
10xTBE buffer stock solution     8ml [1x (v/v)] 
ddH2O        92ml 
Ammonium persulphate      1.6ml [0.1% (w/v)] 
TEMED        160μl [0.01% (v/v)]  
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10% Mildly denaturing SSCP gel 
40% Acrylamide-bisacrylamide (37.5:1) stock solution   40ml [8% (v/v)] 
Urea         24g [15% (w/v)] 
Glycerol        8ml [5% (v/v)] 
10xTBE buffer stock solution     8ml [1x (v/v)] 
ddH2O        81ml 
Ammonium persulphate      1.6ml [0.1% (w/v)] 
TEMED        160μl [0.01% (v/v)]  
 
Methodology 
 
Glass plates were prepared by carefully and meticulously washing both plates with detergent. Any traces of 
detergent were subsequently removed by wiping the plates with 70% ethanol, and drying them thoroughly. 
The notched plate was then silinised with Wynn’s C-thru windshield rain dispersant (Wynn Oil S.A. Ptd Ltd, 
SA) to allow the gel to remain stuck to the large plate upon dismantling after electrophoresis. More 70% 
ethanol was then sprayed on the inner surface of the large glass plate. A sheet of GelbondTM (BMA, Rockland, 
ME, USA), cut to the same size as the large glass plate, was placed, hydrophobic side down, on this plate, 
taking care not to remove the protective sheet of paper from the hydrophilic side of the GelbondTM membrane 
(BMA, Rockland, ME, USA). Air bubbles trapped between the GelbondTM and the glass were removed by 
careful rubbing over the protective sheet of paper with a piece of paper towel. Subsequently this sheet of paper 
was removed from the GelbondTM membrane and spacers of 1mm thickness were placed lengthwise at the 
edges of the large plate, and the notched plate placed silanised side-down on top of the spacers. This assembly 
was subsequently sealed with the use of a rubber boot (S2 casting boot, LifeTM Technologies) and gel poured 
with the glass assembly slanted at a slight angle. The glass assembly was subsequently layed down 
horizontally and a square-tooth well-forming comb inserted. The gel was allowed to set for 1-2 hours. 
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11. POLYACRYLAMIDE SEQUENCING GELS SOLUTIONS AND METHODOLOGY 
 
Solutions 
 
5% Denaturing polyacrylamide gel solution 
30% Acrylamide stock solution    8.1ml 
10x TBE stock solution     6ml 
Urea       26.64g 
H2O       15.45ml 
Stir well with a magnetic stirrer until all the urea is dissolved, prior to the addition of: 
10% ammonium persulphate    500μl 
TEMED      50μl 
 
Methodology 
 
Glass plates were prepared by carefully and meticulously washing both plates with detergent. Any traces of 
detergent was subsequently removed by wiping the plates with 70% ethanol, and drying them thoroughly. The 
notched plate was then silinised with Wynn’s C-thru windshield rain dispersant (Wynn Oil S.A. Ptd Ltd, SA) 
to allow the gel to remain stuck to the large plate upon dismantling after electrophoresis. Spacers of 0.4mm 
thickness were placed lengthwise at the edges of the large plate, and the notched plate placed silanised side-
down on top of the spacers. This assembly was subsequently sealed with the use of a rubber boot (S2 casting 
boot, LifeTM Technologies) and gel poured with the glass assembly slanted at a slight angle. The glass 
assembly was subsequently layed down horizontally and the loading front formed with a top spacer of 
identical thickness to the lengthwise spacers. The gel was allowed to set for 1-2 hours, whereupon the top 
spacer was removed and replaced by a sharktooth comb to separate wells for loading samples. 
 
12. BACTERIAL MEDIA 
 
LB-media 
Bacto tryptone       5g 
Yeast extract      2.5g 
NaCl       5g 
ddH2O to a final volume of 500ml 
Autoclave and add appropriate antibiotic to media when a temperature of >55oC is reached (Amp 
25mg/l or Kan 5mg/l).
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LB-agar plates 
Bacto tryptone       5g 
Yeast extract      2.5g 
NaCl       5g 
Bacto agar      8g 
ddH2O to a final volume of 500ml 
Autoclave and add appropriate antibiotic to media when a temperature of >55oC is reached (Amp 25mg/l or 
Kan 5mg/l), prior to pouring ~20, 90mm plates. These plates were subsequently allowed to set for 2-5h and 
stored at room temperature for up to three weeks. 
 
M9 agar plates 
5x M9 salts      200ml 
20% glucose      20ml 
Bacto agar      8g 
SD-L amino acid supplement    0.67g 
ddH2O to a final volume of 1 litre 
Autoclave and add Amp 25mg to media when a temperature of >55oC is reached, prior to pouring ~20, 90mm 
plates. These plates were subsequently allowed to set for 2-5h and stored at room temperature for up to three 
weeks. 
 
5x M9 salt solution 
Na2HPO4·7H2O      64g 
KH2PO4      15g 
NaCl       2.5g 
NH4Cl       5g 
ddH2O to a final volume of 1 litre 
 
13. YEAST MEDIA 
 
YPDA media 
Difco peptone       10g 
Yeast extract      10g 
Glucose      10g 
L-adenine hemisulpate (0.2% stock solution)  7.5ml 
ddH2O to a final volume of 500ml 
Adjust pH to 5.8 and autoclave at 121oC for 15min. 
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YPDA agar plates 
Difco peptone       10g 
Yeast extract      10g 
Glucose      10g 
Bacto agar      10g 
L-adenine hemisulpate (0.2% stock solution)  7.5ml 
ddH2O to a final volume of 500ml 
Adjust pH to 5.8, autoclave at 121oC for 15min and allow to cool to a temperature of ~55oC is reached, prior 
to pouring ~20, 90mm plates. These plates were subsequently allowed to set for 2-5h and stored at room 
temperature for up to three weeks. 
 
SD-W media 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-W amino acid supplement    0.4g 
0.2% adenine hemisulfate    9ml 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8 and autoclave at 121oC for 15min. 
 
SD-W agar plates 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-W amino acid supplement    0.4g 
Bacto agar      12g 
0.2% adenine hemisulfate    9ml 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8, autoclave at 121oC for 15min and allow to cool to a temperature of ~55oC is reached, prior 
to pouring ~20, 90mm plates. These plates were subsequently allowed to set for 2-5h and stored at room 
temperature for up to three weeks. 
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SD-L media 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L amino acid supplement    0.4g 
0.2% adenine hemisulfate    9ml 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8 and autoclave at 121oC for 15min. 
 
SD-L agar plates 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L amino acid supplement    0.4g 
Bacto agar      12g 
0.2% adenine hemisulfate    9ml 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8, autoclave at 121oC for 15min and allow to cool to a temperature of ~55oC is reached, prior 
to pouring ~20, 90mm plates. These plates were subsequently allowed to set for 2-5h and stored at room 
temperature for up to three weeks. 
 
SD-L-W media 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W amino acid supplement    0.4g 
0.2% adenine hemisulfate    9ml 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8 and autoclave at 121oC for 15min. 
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SD-L-W agar plates 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W amino acid supplement    0.4g 
Bacto agar      12g 
0.2% adenine hemisulfate    9ml 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8, autoclave at 121oC for 15min and allow to cool to a temperature of ~55oC is reached, prior 
to pouring ~20, 90mm plates. These plates were subsequently allowed to set for 2-5h and stored at room 
temperature for up to three weeks. 
 
TDO media 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W-H amino acid supplement    0.4g 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8 and autoclave at 121oC for 15min. 
 
TDO agar plates 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W-H amino acid supplement    0.4g 
Bacto agar      12g 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8, autoclave at 121oC for 15min and allow to cool to a temperature of ~55oC is reached, prior 
to pouring ~20, 90mm plates or ~5, 150mm plates. These plates were subsequently allowed to set for 2-5h and 
stored at room temperature for up to three weeks. 
 
QDO media 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W-H-Ade amino acid supplement   0.4g 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8 and autoclave at 121oC for 15min. 
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QDO agar plates 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W-H-Ade amino acid supplement   0.4g 
Bacto agar      12g 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8, autoclave at 121oC for 15min, allow to cool to a temperature of ~55oC is reached, prior to 
pouring ~20, 90mm plates. These plates were subsequently allowed to set for 2-5h and stored at room 
temperature for up to three weeks. 
 
SD-H-W agar plates 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W-H amino acid supplement    0.4g 
Leucine supplement     0.04g 
Bacto agar      12g 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8, autoclave at 121oC for 15min and allow to cool to a temperature of ~55oC is reached, prior 
to pouring ~20, 90mm plates or ~5, 150mm plates. These plates were subsequently allowed to set for 2-5h and 
stored at room temperature for up to three weeks. 
 
SD-L-H agar plates 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W-H amino acid supplement    0.4g 
Tryptophan supplement     0.04g 
Bacto agar      12g 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8, autoclave at 121oC for 15min and allow to cool to a temperature of ~55oC is reached, prior 
to pouring ~20, 90mm plates or ~5, 150mm plates. These plates were subsequently allowed to set for 2-5h and 
stored at room temperature for up to three weeks. 
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SD-W-H-Ade agar plates 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W-H-Ade amino acid supplement   0.4g 
Leucine supplement     0.04g 
Bacto agar      12g 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8, autoclave at 121oC for 15min, allow to cool to a temperature of ~55oC is reached, prior to 
pouring ~20, 90mm plates. These plates were subsequently allowed to set for 2-5h and stored at room 
temperature for up to three weeks. 
 
SD-L-H-Ade agar plates 
Glucose      12g 
Yeast nitrogen base without amino acids   4g 
SD-L-W-H-Ade amino acid supplement   0.4g 
Tryptophan suppliment     0.04g 
Bacto agar      12g 
ddH2O to a final volume of 600ml 
Adjust pH to 5.8, autoclave at 121oC for 15min, allow to cool to a temperature of ~55oC is reached, prior to 
pouring ~20, 90mm plates. These plates were subsequently allowed to set for 2-5h and stored at room 
temperature for up to three weeks. 
 
14. ONPG QUANTITATIVE ß-GALACTOSIDASE ASSAY SOLUTIONS: 
 
Z-buffer 
Na2HPO4.7H2O     16.1g 
NaH2PO4.H2O     5.5g 
KCl     0.75g 
MgSO4.7H2O     0.246g 
ddH2O to a final volume of 50ml 
Adjust to pH 7.0, autoclave and store at room temperature. 
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Z-buffer/ß-mercapto-ethanol 
Add 0.27ml ß-mercapto-ethanol per 100ml of Z-buffer 
 
ONPG/Z-buffer 
Add 4mg o-nitrophenyl β-D-galactopyranoside (ONPG) per 1ml of Z-buffer.  
Adjust pH to 7 and mix well. 
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APPENDIX B 
 
BACTERIAL STRAIN PHENOTYPES 
 
E.coli strain DH5α 
φ 80d lacZΔM15 recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 deoR Δ(lacZYA-argF)U169 
 
E.coli strain KC8 
hsdR, leuB600, trpC9830, pyrF::Tn5, hisB463, lacDX74, strA, galU, K (3) 
 
YEAST STRAIN PHENOTYPES 
 
Yeast strain PJ69-2A  
MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-
GAL2TATA-ADE2 
(James et al., 1996) 
 
Yeast strain AH109  
MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-
GAL2TATA-ADE2, URA3::MEL1UAS-MEL1TATA-lacZ  
(James et al., 1996) 
 
Yeast strain Y187  
MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4Δ, met-, gal80Δ, URA3::GAL1UAS-GAL1TATA-
lacZ  
(Harper et al., 1993) 
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APPENDIX C 
 
CALCULATIONS 
 
Mating efficiencies 
Count # of colonies on all plates with 30-300 colonies after 4 days. 
 
#cfu/ml =        cfux 1000ul/ml   
     volume plated (ul) x dilution factor 
 
1. #cfu/ml on SD-Leu plates = viability of prey partner 
2. #cfu/ml on SD-Trp plates = viability of bait partner 
3. #cfu/ml on SD –L-W plates = viability of diploids 
 
4. Lowest #cfu/ml of SD-Leu or SD-Trp indicate limiting partner. 
 
5. Mating efficiency = #cfu/ml of diploids x 100 
#cfu/ml of limiting partner 
 
Library titre 
Count # of colonies on all plates with 30-300 colonies after 4 days 
#cfu/ml =   # colonies   
          plating volume (ml) x dilution factor 
 
Number of clones screened 
# cfu/ml of diploids x final resuspension volume 
 
Calculation of β-gal units 
β-gal units = 1 000 x OD420/(t x V x OD600) 
where  
t = elapsed time for colour to develop 
V = 0.1ml x concentration factor (i.e. 100ul x 5 in this case) 
OD600 = either the absorption at A600 for 1ml taken from the post-5hr YPDA culture 
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